Bridging the gap between the distinct regulatory frameworks of international trade law and UN human rights law: Access to medicines by LOWRI, DAVIES
 
 
Bridging the gap between the distinct regulatory 
frameworks of international trade law and UN 
human rights law: Access to medicines 
 
VOLUME I of II 
 
 
 
 
 
 
Lowri Elizabeth Gwyn Davies LLB (Hons), LLM, PGDip, AFHEA 
 
 
 
 
Submitted to Swansea University in fulfilment of the requirements for the 
Degree of Doctor of Philosophy 
 
Swansea University 
2020 
 
 
 
 
Abstract 
This research is focused on the complexity of two distinct legal frameworks, the World 
Trade Organization and the United Nations human rights systems, which converge on the 
issue of enhancing effective access to medicines for all.  This research explores the 
intellectual property rules specifically in relation to patents, set out in the Agreement on 
Trade-Related Aspects of Intellectual Property Rights, administered by the World Trade 
Organization, for the purpose of understanding how these legal norms impact upon 
securing access to medicines.  Measures intended to enhance access to medicines within 
this framework will also be explored in order to evaluate their effectiveness.   
This research also explores whether the issue of access to medicines can be 
considered within the context of a human right, through an examination of the UN human 
right systems, specifically in relation to the right to the highest attainable standard of 
physical and mental health under Article 12 of the International Covenant on Economic, 
Social and Cultural Rights.  An analysis of the interpretation of this right will be 
undertaken, and an examination of the work of the UN human rights bodies to advance 
access to medicines will also be explored, in order to further understanding on the status 
of access to medicines within this framework.   
The purpose of this research is to highlight factors which may impede access to 
medicines and also potential factors for consideration when proposing solutions to this 
global concern.  In order to further understanding of specific issues that impact on 
patients, two country case studies are also undertaken, to examine whether key themes 
emanating from earlier chapters are evident, and to provide insights into the challenges 
experienced at national level, as well as good practices that could help to inform policy 
at international level, for the purpose of enhancing access to medicines for all. 
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Chapter 1: Introduction 
 
Securing effective access to medicines for all is a global public health concern.  The 
World Health Organization estimates that nearly two billion people do not have access to 
basic medicines1.  Two related considerations operate to limit sufficient access.  First, the 
intellectual property rights protection, particularly in the form of patents, afforded to 
pharmaceutical companies. These rights can lead to a monopoly in the market, resulting 
in less competition and higher prices of medicines, putting them out of reach for many 
people.   Secondly, the physical accessibility of medicines stemming from the lack of 
research and development of medicines to treat diseases that are prevalent in developing 
countries, or so-called ‘neglected’ diseases.  Justifications for the monopoly rights are 
that pharmaceutical companies need to recoup the substantial research and development 
costs involved in creating new medicines, so patent protection acts as an incentive to 
investment and innovation in developing new medicines.  However this creates an 
incentive to invest in research and development in commercially valuable medicines 
rather than medicines necessary to treat diseases predominantly in developing countries.  
These issues negatively impact on patients’ access to medicines and create tensions with 
international human rights law, which protects the human right to the highest attainable 
standard of physical and mental health2. 
This issue is examined in the context of international trade and intellectual 
property (IP) law and United Nations (UN) human rights law. The growth of technology 
and emergence of new industries has increased the demand for intellectual property 
protection3 and seen the incorporation of intellectual property law into the World Trade 
Organization framework through the adoption of the Agreement on Trade-Related 
Aspects of Intellectual Property Rights4 (TRIPS) as part of the Agreement Establishing 
the World Trade Organization5 (WTO).  This has had important consequences, changing 
                                                            
1 World Health Organization, ‘Ten Years in Public Health 2007-2017: Report by Dr Margaret Chan, 
Director-General, World Health Organization’ (World Health Organization 2017), P.14,  
<https://www.who.int/publications/10-year-review/medicines/en/> (accessed 27/04/2020) 
2 See Article 12, International Covenant on Economic, Social and Cultural Rights (adopted 16 December 
1966, entered into force 3 January 1976) UNGA res 2200A (XXI). The link between access to medicines 
and the Article 12 right to the highest attainable standard of health is discussed in Chapter 3. 
3 L Helfer and G Austin, Human Rights and Intellectual Property: Mapping the Global Interface, 
(Cambridge University Press, Cambridge 2011), P.2 
4 Agreement on Trade-Related Aspects of Intellectual Property Rights (15 April 1994) LT/UR/A-1C/IP/1 
[hereinafter the TRIPS Agreement] 
5 Agreement Establishing the World Trade Organization (15 April 1994) LT/UR/A/2 
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the way in which IP rights are protected and enforced.  As the first multilateral treaty on 
IP rights, TRIPS requires WTO Members to implement a minimum standard of IP rights 
protection into national law, which requires all WTO Members to implement patent laws 
which protect IP rights in pharmaceuticals. Tensions exist where the cost of medicines 
resulting from the monopoly rights afforded through IP rights becomes prohibitive, and 
this negatively impacts upon the health of patients who cannot afford the medicines they 
need. 
 The UN human rights system has also expanded in recent decades, with near-
universal ratification of the International Covenant on Economic, Social and Cultural 
Rights6 (ICESCR). This has led to increased recognition of economic and social rights 
including the right to health, as well as the work of the UN human rights bodies7 on 
elaborating and clarifying the content of such rights and the obligations of states under 
international human rights law.  Globalisation has contributed to the expansion of trade 
regulation into the area of IP and leading to intersections between trade and human rights 
that had not previously been contemplated.8  Examples of these intersections include the 
impact of farming subsidies on the right to food, addressing environmental concerns such 
as pollution and sustainable energy, as well as public health concerns have received 
increasing attention in academic literature.9 Despite the robust nature of the TRIPS rules 
                                                            
6 International Covenant on Economic, Social and Cultural Rights (n 2); See also UN Office of the High 
Commissioner for Human Rights, ‘Status of Ratifications’ <http://indicators.ohchr.org/> (accessed 
27/04/2020).  
7 The UN Human Rights law framework comprises UN Human Rights Charter-based Bodies and the 
relevant UN Human Rights Treaty Monitoring Bodies. The UN Human Rights Charter bodies include the 
Special Procedures mechanism and the Universal Periodic Review. The Special Procedures mechanism 
allows the Human Rights Council to address specific issues in a particular State or to address thematic 
issues globally, involving experts acting in a personal capacity as either an individual Special Rapporteur, 
or as a Working Group. The UPR is a State-driven process of review of the human rights records of all UN 
Member States. Under the UN Human Rights Treaty Monitoring system there are ten human rights 
treaty bodies that monitor implementation of the core international human rights treaties.  The UN 
Human Rights Treaty Monitoring body relevant to this thesis is the Committee on Economic Social and 
Cultural Rights, which monitors the implementation of the ICESCR. See also United Nations Office of the 
High Commissioner for Human Rights, ‘Human Rights Bodies’ 
<http://www.ohchr.org/EN/HRBodies/Pages/HumanRightsBodies.aspx> (accessed 27/04/2020) 
8 T Cottier, J Pauwelyn and E Bürgi, ‘Linking Trade Regulation and Human Rights in International Law: An 
Overview’ in T Cottier, J Pauwelyn and E Bürgi (eds), Human Rights and International Trade, (Oxford 
University Press, Oxford, 2005), 2 
9 See examples: O De Schutter and KY Cordes (eds), Accounting for Hunger: The Right to Food in the Era 
of Globalisation, (Hart Publishing, Oregon 2011); Helfer and Austin (n 3); P Menell and S Tran (eds), 
Intellectual Property, Innovation and the Environment, (Edward Elgar 2014); W Benedek, K De Feyter and 
F Marrella (eds), Economic Globalisation and Human Rights, (Cambridge University Press, New York 
2007); P Yu, ‘Intellectual Property and Human Rights 2.0’ (2019) 53(4) University of Richmond Law 
Review 1375 
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and the near-universal ratification of UN core instruments, there are still problems for 
states to adopt domestic patent rules which do not act as a barrier to access to medicines, 
while also appropriately protecting the interests of pharmaceutical manufacturers.  This 
can have negative human rights consequences as a lack of access to medicines can raise 
issues in relation to states’ international human rights obligations in relation to public 
health.  This thesis explores the challenges raised by the applicability of the TRIPS and 
the UN human rights framework, as distinct legal systems, to the issue of access to 
medicines, as well as responses to these challenges. 
 
a) Access to medicines against the backdrop of public international law 
The issue of access to medicines is an example of the interaction between international 
intellectual property law, international trade law and international human rights law, in 
the context of patent protection for medicines and the right to health. Therefore it is 
pertinent for this issue to be considered against the backdrop of international law.  
International law does not have a central law-making body, with the main sources of 
international law being treaties, customary international law and general principles of 
law, as outlined in Article 38(1) Statute of the International Court of Justice (ICJ).10 As 
international law is decentralised, specialised regimes have evolved, such as World Trade 
Law, Human Rights Law, Environmental Law, within the international legal order.  These 
specialised regimes have developed independently of one another as each regime has its 
own distinct law-making process, which has facilitated the evolution of norms within the 
regimes11.  The diversification of these regimes is highlighted by some regimes having 
developed adjudicative bodies which contribute to the development of the legal norms 
and the regulation of the regimes12, such as the WTO dispute resolution mechanism.  
Despite the differing histories of the evolution of WTO trade law and UN human rights 
law, the TRIPS Agreement and the ICESCR are treaties that exist as part of a larger body 
of public international law.  This is of relevance to this thesis as it presents the issue of 
                                                            
10 Statute of the International Court of Justice, annexed to the Charter of the United Nations, 24 October 
1945, 1 UNTS XVI [hereinafter ICJ Statute] 
11 T Cottier ‘Trade and Human Rights: A Relationship to Discover’ (2002) 5(1) JIEL 111, 119; PM Dupuy, 
‘The Danger of Fragmentation or Unification of the International Legal System and the International 
Court of Justice’ (1999) 31 International Law and Politics 791, 791-2; M Koskenniemi and P Leino 
‘Fragmentation of International Law? Postmodern Anxieties’ (2002) 15 LJIL 553, 557 
12 J Pauwelyn, Conflict of Norms In Public International Law: How WTO Law Relates to other Rules of 
International Law (Cambridge University Press, Cambridge 2003), 16 
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whether there is a tension between the World Trade and UN human rights regimes, when 
the obligations under these regimes intersect in relation to access to medicines.  
International law scholars have paid increasing attention to the ‘fragmentation’ of 
international law13, including the impact of the rules emanating from the specialised 
regimes in international law, given that they pursue diverse objectives and may develop 
differing interpretations of the law14. The issue of fragmentation was given prominence 
by the International Law Commission (ILC) report on the Fragmentation of International 
Law15.  The ILC report highlighted that the growth in multilateral treaties in the last fifty 
years has made it increasingly probable that multiple rules of international law will apply 
in a particular circumstance16, so determining the relationship between them is 
increasingly important, due to the complications which may arise where more than one 
international law rule applies to a particular situation. It is recognised that specialised 
regimes are not fully self-contained17 and therefore there is scope for some overlap as the 
distinct regimes have expanded.  This can lead to some fragmentation as the principles of 
general international law evolve. Further, that there being no hierarchy between these 
distinct laws presents the problem of conflicting jurisdictions and uncertainty over 
interpretation of international legal norms18, with concerns that the specialised regimes 
could lead to the breaking up of the international legal order, affecting the unity of 
                                                            
13 See examples PM Dupuy, ‘The Danger of Fragmentation or Unification of the International Legal 
System and the International Court of Justice’ (n 11); A Fischer-Lescano and G Teubner ‘Regime 
Collisions: The Vain Search for Legal Unity in the Fragmentation of Global Law’ (2004) 25 Michigan 
Journal of International Law 999; E Benvenisti and G Downs, ‘The Empire's New Clothes: Political 
Economy and the Fragmentation of International Law’ (2007) 60 Stan. L. Rev. 595; G Hafner ‘Pros and 
Cons Ensuing from Fragmentation of International Law’ (2004) 25 Mich. J. Int'l L. 849 
14 Pauwelyn (n 12) 12, 16; Koskenniemi and Leino (n 11); G Abi-Saab, ‘Fragmentation or Unification: 
Some Concluding Remarks’ (1999) 31 N.Y.U. J.Int'l L. & Pol. 919 
15 International Law Commission, ‘Fragmentation of International Law: Difficulties arising from the 
diversification and expansion of international law’, Report of the Study Group of the International Law 
Commission. Finalized by Martti Koskenniemi (13 April 2006) UN Doc A/CN.4/L.682 
16 ibid para 7 
17 See ILC Fragmentation Report (ibid) which refers to examples from WTO and Human rights as 
examples in support of this theme. See also Pauwelyn (n 12) 460; A Peters, ‘The refinement of 
international law: From fragmentation to regime interaction and politicization’ (2017) 15 (3) Int J 
Constitutional Law 671, 696; PM Dupuy ‘A Doctrinal Debate in the Globalization Era: On the 
Fragmentation of International Law’(2007) 1 Eur. J. Legal Stud. 25, 26 
18 See I Brownlie 'The Rights of Peoples in Modern International Law' in Crawford J (ed), The Rights of 
Peoples (Clarendon Press Oxford 1988), 15; W Jenks, ‘Conflict of Law-Making Treaties’ (1953) 30 British 
Yearbook of International Law 401, 405; Abi-Saab (n 14) 926; Benvenisti and Downs (n 13); Peters (n 17); 
Dupuy (n 11) 792 
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international law19, and ultimately undermining its legitimacy20.  Positive aspects of 
fragmentation have also been debated in the literature, including that fragmentation 
creates more diversity in international law, and that the widening of the context of 
international law can lead to a more sophisticated body of law.21 Other academics 
consider that fragmentation is beyond legal conflicts but about political differences, and 
fragmentation is inevitable because it is an expression of political diversity 
internationally.22  Instead, the focus should be on finding compatibility between 
fragments23.  These are compelling arguments as although sophisticated specialised 
regimes have developed and continue to evolve in international law, there has not been a 
collapse of the public international law system. Instead the depth and complexities of the 
evolving international legal order can be seen as a natural consequence of the expansion 
of the specialised regimes, and not unlike the specialisms in national law.  With growing 
specialisations and advancement of experts in policy and law making within the 
specialised regimes, States may perceive that their individual position is better respected 
and therefore could be more likely to comply with the rules of the regime24. By placing 
the focus on finding coherence within the international legal order, and to ensure 
continued coherence among specialised regimes, work of the distinct specialised regimes 
which a specific situation may fall within should be understood and respected.  This has 
been described as ‘convergence’ instead of fragmentation25, to reflect how states and 
adjudicative bodies find ways to interact coherently.  This is of particular relevance to 
this thesis. Although the focus of this research is not on fragmentation and convergence 
in international law, this thesis will address the challenges which arise when international 
trade law rules and UN human rights law converge in relation to access to medicines. 
                                                            
19 G Guillaume, ‘The Future of International Judicial Institutions’(1995) 44 Int'l & Comp. L.Q. 848, 862;  
Hafner (n 13) 854 
20 Peters (n 17); Abi-Saab (n 14); Benvenisti and Downs (n 13)  
21 R Higgins, ‘A Babel of Judicial Voices? Ruminations from the Bench’, (2006) 55 Int’l & Comp. L. Q. 791; 
B Simma, ‘Universality of International Law from the Perspective of a Practitioner’ (2009) 20 (2) Eur J Int 
Law 265;  J Crawford, ‘Chance, Order, Change: The Course of International Law, General Course on 
Public International Law’, 365 (2013) Hague Academy Int’l L. 228, 394 
22 Koskenniemi and Leino (n 11); Fischer-Lescano and Teubner (n 13) 
23 Koskenniemi and Leino (n 11); Fischer-Lescano and Teubner (n 13) 
24 Hafner (n 13) 859  
25 P Webb, ‘Factors influencing fragmentation and convergence in international courts’ in M Andenas & 
E Bjorge (eds), A Farewell to Fragmentation: Reassertion and Convergence in International Law 
(Cambridge University Press, 2015), 146; Dupuy (n 17) 30-31 ; C Greenwood ‘Unity and Diversity in 
International Law’ in in M Andenas & E Bjorge (eds), A Farewell to Fragmentation: Reassertion and 
Convergence in International Law (Cambridge University Press, 2015) 
 6 
 
This thesis will also address how states are to resolve situations where their obligations 
under international trade law rules come into conflict with their human rights obligations. 
This thesis focuses on the relationship between the patent provisions in the TRIPS 
Agreement and the provisions of the ICESCR protecting access to medicines and will 
consider if a conflict exists between the respective treaties.  In considering whether a 
conflict exists between international trade law and international human rights law, it is 
important to consider the question of what is a conflict.  The ILC report recognised that 
conflict can be interpreted narrowly and broadly.26 The narrow definition of conflict first 
articulated by Jenks is that a conflict only arises where a party to two treaties cannot 
comply with its obligations under both treaties simultaneously27. Under this definition it 
can be said that there is no conflict between TRIPS and the ICESCR as compliance with 
one of the treaties does not violate the other. There are flexibilities in TRIPS relating to 
the implementation of IP law which can be utilised for the protection of public health28, 
so there is no direct incompatibility between them.  However, Pauwelyn argues that this 
view ignores the complexities of the interactions between norms29. He gives a 
hypothetical example of a treaty between two states in which they grant each other 
permission to trade in slaves, highlighting that under Jenks’ narrow definition of conflict, 
there would not be a conflict between this treaty and the jus cogens prohibition of slavery, 
as only if a treaty obliges trade in slaves would there be a conflict.30  Instead, Pauwelyn 
outlines a broader definition, that a conflict will arise where one norm has led to, or may 
lead to the breach of another norm31, equating a conflict with a breach of norm. Pauwelyn 
argues that an advantage of this approach is that “conflict becomes an ‘objective’ 
question, based on the rights and obligations set out in the norms in question, to be 
determined by normal rules on, for, example, treaty interpretation”32, rather than the 
subjective intentions of the states involved33.   
                                                            
26 ILC Fragmentation Report (n 15) paras 21-26 
27 Jenks (n 18) 426.  Pauwelyn discusses strict definitions of conflict in doctrinal writings, in Pauwelyn (n 
12) 166 
28 For example Articles 7 and 8 of TRIPS as well as the Preamble which reflect the need to balance IP 
rights with public health objectives. This is discussed further in Chapter 2. 
29 Pauwelyn (n 12) 171 
30 ibid 174 
31 ibid 175-6 
32 ibid 176 
33 ibid 
 7 
 
The ILC report also adopts a broad definition of conflict to include where two 
rules suggest different ways of dealing with a situation34.  This position proposes that 
regimes cannot be truly isolated as completely autonomous regimes, and rather than a 
conflict, the interaction between international intellectual property law and international 
human rights law could be seen as a tension, where one treaty may encumber the 
objectives of another in relation to the issue of access to medicines.  While it is noted 
above that there is no direct conflict between TRIPS and the ICESCR under the narrow 
definition of conflict, taking the broader definition of conflict there could be a tension 
between the treaties in terms of different approaches could be taken under both treaties to 
address access to medicines.  This thesis adopts the broader definition of conflict. A key 
objective of this thesis is to explore how a potential conflict may be resolved in a manner 
that is consistent with States’ obligations under the respective treaty regimes. 
The ILC report has emphasised that the complexity of fragmentation has not 
undermined the coherence and systemic integrity of the international legal system, and 
considered how existing legal norms respond to conflicts between applicable norms35. 
The ILC report considered the lex superior rule, where a superior norm prevails over an 
inferior norm; lex posterior, where a later rule prevails over an earlier rule, and lex 
specialis, where a specialist norm prevails over a generalist norm36. However the ILC and 
academics have conceded that the principles are of limited utility in resolving conflict, as 
the lex specialis rule is not always helpful where the norms are within different specialised 
regimes37 such as the WTO and UN human rights law frameworks, while it is difficult to 
argue that the norms within the respective frameworks are superior or inferior and the 
fragmented nature of international law means that the value of the lex posterior rule is 
reduced38.   
The ILC report also discusses particular norms that should be given effect in cases 
of conflict, despite the horizontal nature of international law and lack of a formal 
hierarchy of norms or treaties39.  Specifically the report discusses Article 103 of the 
                                                            
34 ILC Fragmentation Report (n 15) para 24 
35 ILC Fragmentation Report (n 15) Section C, P.30 and Section D, P.122 
36 ibid 
37 See ILC Fragmentation Report (n 15) para 488; HG Ruse-Khan, ‘Conflict-of-laws approach to competing 
rationalities in international law: The case of plain packaging between intellectual property, trade, 
investment and health’ (2013) 9(2) Journal of Private International Law 309, 320-321; R Harris and G 
Moon, ‘GATT Article XX and human Rights: What Do We Know From the First 20 Years?’ (2015) 15 
Melbourne Journal of International Law, 14-15 
38 ILC Fragmentation Report (n 15) para 243; Ruse-Khan (n 37)  310; Pauwelyn (n 12) 97 
39 ILC Fragmentation Report (n 15)  paras 324-327 
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United Nations Charter, the concepts of peremptory norms (jus cogens) and obligations 
erga omnes40.  Although Article 103 UN Charter gives priority to obligations set out in 
the UN Charter, it does not give priority to human rights treaty obligations or non-binding 
resolutions of human rights bodies41.  Despite criticism42, it is accepted that jus cogens 
norms are peremptory norms which are accepted as such by the international community 
and cannot be derogated from43, while obligations erga omnes are obligations owed by 
states to the international community as a whole44. Currently there is no evidence to 
suggest that the right to health or trade rules are universally recognised as jus cogens or 
obligations erga omnes within international law45.  Therefore these rules also have limited 
utility in reconciling conflicts between international trade and international human rights 
law in relation to access to medicines, and will not be the focus of this thesis.   
The limited applicability of the above principles led the ILC to conclude that 
harmonisation can be achieved between norms of specialised regimes through 
interpretative techniques, in light of the general principles of treaty interpretation set out 
in Article 31(3)(c) of the Vienna Convention on the Law of Treaties (VCLT).46  Article 
31(3)(c) states that any relevant rules of international law applicable in the relations 
between the parties shall be taken into account in the context of treaty interpretation.47. 
The report outlines that the VCLT provides the normative basis for dealing with 
fragmentation48, as treaties are part of the international legal system and therefore should 
                                                            
40 ibid para 327 
41 See H Charlesworth and C Chinkin ‘The Gender of Jus Cogens’ (1993) 15 Human Rights Quarterly 63, 
63-64; P Weil, ‘Towards Relative Normativity in International Law?’ (1983) 77 American Journal of 
International Law 413; ILC Fragmentation Report (n 15) paras 331, 374-6. 
42 Weil (n 41) 
43 See B Simma and P Alston ‘The Sources of Human Rights Law: Custom, Jus Cogens, and General 
Principles’ (1988)12 Aust. YBIL 82; C Chinkin ‘The Challenge of Soft Law: Development and Change in 
International Law’ (1989) 38 Int'l & Comp. L.Q. 850, 856; J Pauwelyn ‘The Role of Public International 
Law in the WTO: How Far Can We Go’ (2001) 95 Am. J. Int'l L. 535, 537; R Higgins, Problems and Process: 
International Law and How We Use It, (Oxford University Press 1994), P.21, R Baker ‘Customary 
international law in the 21st century: old challenges and new debates’ (2010) 21(1) E.J.I.L. 173, 177 
44 See Baker (n 43) 177; H Thirlway ‘Human rights in customary law: an attempt to define some of the 
issues’ (2015) 28(3) L.J.I.L. 495, 499; A Cassimatis ‘International Trade and Human Rights--Which Human 
Rights’ (2001) 6 Int'l. Trade & Bus. L. Ann. 19, 48 
45 L Forman, ‘An Elementary Consideration of Humanity? Linking Trade-Related Intellectual Property 
Rights to the Human Rights to Health in International Law’ (2011) 14(2) JWIPO 155, 157; Cottier (n 11) 
5(1) 114; Cassimatis (n 44) 46 
46 ILC Fragmentation Report (n 15) 410 
47 Vienna Convention on the Law of Treaties (23 May 1969) 1155 UNTS 331, entered into force 27 
January 1980, Article 31 
48 ILC Fragmentation Report (n 15) 250 
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be interpreted in light of the general principles of international law49. The question of 
determining the most appropriate legal rule to be applied and to ensure greater coherence 
between the international regimes can be addressed through treaty interpretation, and 
therefore is a principal way of avoiding conflicts between treaties50.  Of the various 
techniques discussed in the ILC report, this thesis will pay closest attention to Article 31 
VCLT to determine whether a conflict between TRIPS and the ICESCR can be avoided 
by interpreting TRIPS in a manner conducive to promoting human rights, particularly the 
right to health and to enhance access to medicines. 
 
b) International Trade and Human Rights Law 
There is a considerable body of academic literature on the interaction of international 
trade and human rights law, including in relation to development, public health and 
environment51.  This literature has explored the issue at a conceptual level, examining the 
legal foundations of the relationship between trade law and human rights law and has 
discussed the existence of a qualitative difference between trade and human rights 
norms52, whether human rights are of a higher normative level than trade law53 and 
therefore whether the regimes could interact successfully.  The Preamble of the WTO 
agreement sets out the purposes of the WTO system being that trade should be conducted 
with a view to increasing standards of living, employment, expanding the production of 
and trade in goods and services, while stressing the importance of the objective of 
                                                            
49 C McLachlan ‘The Principle of Systemic Integration and Article 31(3)(c) of the Vienna Convention 
(2005) 54 International and Comparative Law Quarterly 279, 280 
50 ibid; Pauwelyn (n 12) 244; Peters (n 17) 693; Forman (n 45) 163 
51 Illustrative examples include T Cottier, J Pauwelyn, and E Bürgi (eds), Human Rights and International 
Trade, (Oxford University Press, Oxford 2005); F Abbott, C Breining-Kaufmann, T Cottier 
(eds),International Trade and Human Rights: Foundations and Conceptual Issues, (University of Michigan 
Press, Michigan, 2006); D Kinley, Civilising Globalisation: Human Rights and the Global Economy, 
(Cambridge University Press, Cambridge, 2009); EU Petersmann, ‘The WTO Constitution and Human 
Rights’ (2000) 3 JIEL 19; Benedek, De Feyter and Marrella (n 9); J Trachtman ‘Legal Aspects of a Poverty 
Agenda at the WTO: Trade Law and ‘Global Apartheid’’ (2003) 6(1) JIEL 3; G Moon, ‘Fair in form, but 
discriminatory in operation—WTO Law’s discriminatory effects on human rights in developing countries’ 
(2011) 14(3) JIEL 553 
52 D McRae, ‘International Economic Law and Public International Law: The Past and The Future’, (2014) 
17 (3) Journal of International Economic Law 627, 633; Cottier (n 11); EU Petersmann, ‘Human Rights 
and International Economic Law in the 21st Century—The Need to Clarify their Interrelationships’ (2001) 
4 (1) JIEL 3; C Breining-Kaufmann ‘The Legal Matrix of Human Rights and Trade Law: State Obligations 
versus Private Rights and Obligations’ in T Cottier, J Pauwelyn, and E Bürgi (eds), Human Rights and 
International Trade, (Oxford University Press, Oxford 2005); A Lang, ‘Re-Thinking Trade and Human 
Rights’ (2007) 15 Tul. J. Int'l & Comp. L.335  
53 United Nations Commission on Human Rights, ‘The impact of the Agreement on Trade-Related 
Aspects of Intellectual Property Rights on human rights: Report of the High Commissioner’ (27 June 
2001) UN Doc. E/CN.4/Sub.2/2001/13, para 22 
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sustainable development, and of the integration of developing countries. The Preamble 
states that these objectives are to be achieved through the progressive reduction in barriers 
to trade and elimination of discrimination54.  The objectives set out in the WTO Preamble 
are not contradictory to the obligations under the ICESCR outlined in Article 2, and 
Howse argues that the progressive fulfilment of economic and social rights can be 
achieved with the advancement of the goals stated in the WTO Preamble55. Article XX 
of the General Agreement on Tariffs and Trade (GATT) also provides that WTO 
Members may be exempted from trade rules where necessary for the protection of human 
health56.  The lack of inherent conflict is also evidenced by the inclusion in WTO treaties 
of exceptions or limitations clauses which allow states to depart from trade rules for the 
realisation of fundamental norms, including the TRIPS agreement which includes 
exception clauses to be utilised for the benefit of public health57.  The WTO Appellate 
Body in EC - Asbestos58 suggested that WTO law must be interpreted and applied in light 
of the notion that the preservation of human life and health is a vital and important value59, 
although it should be noted that the Appellate Body did not articulate this with reference 
to human rights context.  However, academics have raised the question of whether more 
could be done to recognise the importance of the protection and promotion of human 
rights within the international trade system60, with the interpretation of such provisions 
presenting challenges in consistent implementation of the rules to promote human 
rights61. This thesis will explore the challenges in interpreting the patent provisions in 
                                                            
54 Agreement Establishing the World Trade Organization (n 5) Preamble 
55 R Howse and R Teitel ‘Beyond the divide: the International Covenant on Economic, Social and Cultural 
Rights and the World Trade Organization’ in S Joseph, D Kinley and J Waincymer (eds) The World Trade 
Organization and Human Rights: Interdisciplinary Perspectives (Edward Elgar, Cheltenham 2009), P.42-
43 
56 General Agreement on Tariffs and Trade, Oct. 30, 1947, 61 Stat. A-11, 55 U.N.T.S. 194 [hereinafter 
GATT], Article XX 
57 Agreement on Trade-Related Aspects of Intellectual Property Rights (n 4) Articles 30 and 31. The Doha 
Declaration on TRIPS and Public Health also provides an authoritative legal interpretation of TRIPS, and 
is discussed below and in Chapter 2. 
58 European Communities – Measures Affecting Asbestos and Asbestos-Containing Products, 
WT/DS135/AB/R (5 April 2001), (EC – Asbestos) 
59 ibid 172 
60 Howse and Teitel (n 55); J Harrison, The Human Rights Impact of the World Trade Organization (Hart, 
Oxford 2007) P.36; J Harrison and A Goller, 'Trade and Human Rights: What Does Impact Assessment 
Have to Offer' (2008) 8 Hum Rts L Rev 587, 591; EU Petersmann, 'Human Rights and International 
Economic Law' (2012) 4 Trade L & Dev 283, 301; Lang (n 52); H Haugen, 'Human Rights and TRIPS 
Exclusion and Exception Provisions' (2008) 11 J World Intell Prop 345; EU Petersmann ‘Human Rights 
and International Trade Law: Defining and Constructing the Two Fields’ in T Cottier, J Pauwelyn and E 
Burgi, Human Rights and International Trade (Oxford University Press, Oxford 2005), 42 
61 C Kaufmann and L Meyer, 'Trade and Human Rights' (2007) 1 Hum Rts & Int'l Legal Discourse 61; P 
Cullet, 'Human Rights and Intellectual Property Protection in the TRIPS Era' (2007) 29 Hum Rts Q 403; W 
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TRIPS in the light of human rights, and the importance of taking full account of the right 
to health, including within the WTO legal order, to promote access to medicines.  While 
not an inherent conflict, this thesis will explore interpretational challenges where the 
WTO and UN human rights regimes converge on the issue of access to medicines, and 
how such challenges could be resolved by giving full consideration of the right to health.  
The WTO is not a self-contained regime and has to take other international law into 
account, including human rights, although there are also limits to the WTO mandate in 
terms of the promotion and protection of human rights. This has been considered in 
academic literature which has discussed methodologies by which consistency between 
trade norms and human rights norms could be achieved. 
Some academics have discussed the integration of human rights and WTO norms 
to resolve conflicts, most notably in the exchange between Petersmann and Alston62, 
where Alston described Petersmann’s theory of coordinating human rights and trade law 
under an international constitutional structure as hijacking international human rights 
law63.  While these are important debates, this thesis focuses on reconciling tensions 
between treaties within the international human rights law regime and WTO law regime 
through treaty interpretation.  Other academics have taken a more functional perspective, 
examining how human rights questions may be addressed in the WTO dispute settlement 
mechanism, with differing views as to how human rights norms can be brought in to the 
WTO mechanism.  Pauwelyn proposed a rather expansive view that the jurisdiction of a 
WTO panel, and the applicable law before that panel, are distinct concepts64. While 
jurisdiction is limited to claims under the WTO covered agreements, the applicable law 
when assessing these claims comprises not only WTO law, but also the broader corpus of 
                                                            
Benedek ‘The World Trade Organization and Human Rights’ in W Benedek, K de Feyter and F Marrella, 
Economic Globalisation and Human Rights (Cambridge University Press, New York 2010) 155; D Ovett, 
‘Making Trade Policies More Accountable and Human Rights-Consistent: A NGO Perspective of Using 
Human Rights Instruments in the case of Access to Medicines’, in W Benedek, Koen De Feyter and F 
Marrella (eds), Economic Globalisation and Human Rights (Cambridge University Press, New York 2010) 
62 EU Petersmann, ‘Time for a United Nations “Global Compact” for Integrating Human Rights into the 
Law of Worldwide Organizations: Lessons from European Integration’ (2002) 13(3) European Journal of 
International Law 621; P Alston, ‘Resisting the Merger and Acquisition of Human Rights by Trade Law: A 
Reply to Petersmann’ (2002) 13(4) European Journal of International Law 815; EU Petersmann, ‘Taking 
Human Rights, Poverty and Empowerment of Individuals More Seriously: Rejoinder to Alston’ (2002) 13 
European Journal of International Law 845; R Howse ‘Human Rights in the WTO: Whose Rights, What 
Humanity? Comment on Petersmann’ (2002) 13 EJIL 651 
63 Alston (n 62) 816 
64 J Pauwelyn ‘Human Rights in WTO Dispute Settlement’ in T Cottier, J Pauwelyn, and E Bürgi (eds) 
Human Rights and International Trade (Oxford University Press, Oxford 2005) 215 
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public international law65. His main argument is that the WTO Dispute Settlement 
Understanding does not explicitly state that the applicable law is limited to WTO law66.  
This is a contentious point as it proposes that human rights norms could apply over WTO 
norms in dispute settlement within the WTO.  Trachtman takes a narrower view, and does 
not accept that there is a distinction between the law on which a claim must be based, and 
the applicable law.67  Other academics have also taken a more moderate view, outlining 
that trade and human rights law are separate principles, and that there is no normative 
foundation for the position that human rights law should outrank WTO law, but that they 
can be interpreted in the light of the general rules of treaty interpretation in Articles 31-
32 VCLT68. This view is the most widely accepted and is convincing as it proposes that 
regimes cannot be truly isolated as completely autonomous regimes, and rather than a 
direct normative conflict, the interaction between international trade law and international 
human rights law could be seen as a tension, where one treaty may encumber the 
objectives of another.  To mitigate the effects of the convergence of the distinct norms 
and avoid tensions between the state obligations in the respective treaties, this can be dealt 
with through treaty interpretation69. This view may also provide some assistance to States 
seeking to reconcile their obligations under the respective specialised regimes at national 
level.  This speaks to an objective of this thesis which is to explore how might the potential 
conflicts be resolved in a manner that is consistent with States’ obligations under the 
respective treaty regimes, in relation to the issue of access to medicines. 
 
c) International Intellectual Property Law and Medicines 
TRIPS requires all WTO Members to implement national laws which protect the IP rights 
of owners of IP.  There has been some debate in the literature about the impact of IP law 
on medicines, specifically how patent law can impede access to medicines, particularly 
                                                            
65 Pauwelyn (n 43) 577 
66 Pauwelyn (n 64) 215 
67 J Trachtman, ‘Conflict of Norms in Public International Law: How WTO Law Relates to Other Rules of 
International Law by Joost Pauwelyn, (Review)’ (2004) 98 American Journal of International Law 855, 
855-861 
68 See for example, Trachtman (n 67); G Marceau, ‘WTO dispute settlement and human rights’ (2002) 
13(4) EJIL 753; L Bartels, ‘Applicable Law in WTO Dispute Settlement Proceedings’, (2001) 35 Journal of 
World Trade 499; A Cassimatis, Human Rights Related Trade Measures Under International Law: The 
Legality of Trade Measures Imposed in Response to Violations of Human Rights Obligations under 
General International Law (Brill/Nijhoff 2007) 
69 Marceau (n 68); Bartels (n 68) 
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in developing States70.  The key issue discussed in this literature is how patent protection 
protects innovation, giving the owner an incentive and reward in the form of a monopoly 
right, leading to less competition in the market and therefore higher pricing of medicines, 
putting them out of reach for poorer patients71.  A related concern is that patents create an 
incentive to innovate in commercially valuable medicines, leading to lack of physical 
accessibility to medicines for ‘neglected’ diseases72.  There has also been some debate in 
the literature about how prohibitive costs of medicines might be addressed through 
competition law principles, including by addressing anti-competitive practices such as 
patent tying arrangements and pay-for-delay agreements between branded 
pharmaceutical companies and generic competitors73. While competition law 
undoubtedly is an important tool to combat anti-competitive pricing, this thesis focuses 
on how these challenges might be addressed in a human rights context, given the absence 
of a global competition law framework. Threats of sanctions for anti-competitive pricing 
may not be most effective for developing States as not all states have a national 
competition law framework74.  There is a difference between a developed state imposing 
                                                            
70 Examples include F Abbott, ‘The TRIPS Agreement, Access to Medicines, and the WTO Doha 
Ministerial Conference’ (2002) 5 J. World Intell. Prop. 15, 15-16; B Mercurio ‘TRIPs, Patents, and Access 
To Life-Saving Drugs In The Developing World’ (2004) 8 Intellectual Property L. Rev. 211, 211; F Abbott 
and J Reichman, ‘The Doha Round's public health legacy: strategies for the production and diffusion of 
patented medicines under the amended TRIPS provisions’ (2007) 10(4) JIEL 921, 928 
71 C Correa ‘Public Health and Patent Legislation in Developing Countries’ (2001) 3 Tul. J. Tech. & Intell. 
Prop. 1, 3; Forman (n 45) 156; Cullet (n 61) 416 
72 D Matthews ‘WTO Decision on Implementation of Paragraph 6 of the Doha Declaration on the TRIPS 
Agreement and Public Health: A Solution to the Access to Essential Medicines Problem?’ (2004) 7(1) JIEL 
73, 74; A Chapman ‘The Human Rights implications of Intellectual Property Protection’ (2002) 5(4) JIEL 
861, 877-878; H Hestermeyer, Human Rights and the WTO: The Case of Patents and Access to Medicines 
(Oxford University Press Oxford 2007), 162. Neglected diseases are defined as ‘Diseases for which there 
is a lack of sufficient medical innovation, resulting in inadequate, ineffective or non-existent means to 
prevent, diagnose and treat them. The lack of sufficient medical innovation is often rooted in an 
absence of market incentives owing to the low purchasing power of the populations disproportionately 
affected by such conditions’ in United Nations Secretary-General’s High-Level Panel on Access to 
Medicines, Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines: 
Promoting Innovation and Access to Health Technologies, September 2016, 
<http://www.unsgaccessmeds.org/final-report> (accessed 27/04/2020), P.5 
73 F Abbott ‘The ‘Rule of Reason’ and the Right to Health: Integrating Human Rights and Competition 
Principles in the Context of TRIPS’ in T Cottier, J Pauwelyn, and E Bürgi (eds), Human Rights and 
International Trade, (Oxford University Press, Oxford 2005); S Musungu ‘The Right to Health, Intellectual 
property and Competition Principles’ in T Cottier, J Pauwelyn, and E Bürgi (eds), Human Rights and 
International Trade, (Oxford University Press, Oxford 2005); G Pitruzzella and L Arnaudo ‘On vaccines, 
pharmaceutical markets, and a role for competition law in protecting (also) human rights’  (2017) 38(8) 
E.C.L.R. 347; O Gurgula ‘Anti-competitive patent acquisitions in the pharmaceutical industry’ (2017) 
38(1) E.C.L.R. 35 
74 R Anderson and H Wager ‘Human Rights, Development, and the WTO: The Cases of Intellectual 
Property and Competition Policy (2006) 9 (3) J Int Economic Law 707, 734 
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a sanction, and a developing state imposing a sanction, on the basis that the sanctioned 
company must retain access to the developed country market but could relinquish access 
to the smaller developing country market.75 Developing states often have a smaller 
number of competitors and therefore may be more vulnerable to anti-competitive 
practices76.  Additionally, competition law may not be the most effective tool in 
addressing the challenge of incentivising innovation in neglected diseases77, which is a 
key challenge in the access to medicines debate in terms of securing physical accessibility 
to medicines, in addition to economic accessibility in terms of affordable pricing.  
Addressing the challenge of enhancing access to medicines in a rights-based context 
means that the challenges can be addressed in the context of States’ obligations to 
promote and protect the rights of individuals, regardless of the level of development of 
the State.  Competition law will only go so far, in terms of its applicability to state actors. 
Given the absence of a universal competition law framework and the universal nature of 
human rights, this thesis will explore how states can effectively meet their obligations to 
secure effective access to medicines for patients in a human rights context. 
 There has also been some discussion in the literature of IP law and access to 
medicines in a rights-based context, particularly in relation to whether the patent 
provisions in TRIPS are in conflict with the realisation of economic and social rights or 
whether they are essentially compatible78. Specific focus has been on the rights within the 
ICESCR, and in particular the right of everyone to the enjoyment of the highest attainable 
standard of physical and mental health set out in Article 12.  The debate on normative 
conflicts in international law79 can facilitate a greater understanding of the interaction 
between TRIPS and the ICESCR, with the recognition that the obligations under TRIPS 
have to be interpreted in light of all other international law.  As discussed above, Article 
31(3)(c) VCLT has been significant in the discussion on the fragmentation of 
international law, forming the basis for arguments promoting harmonisation between 
                                                            
75 U Aydin and T Buthe ‘Competition Law and Policy in Developing Countries: Explaining Variations in 
Outcomes; Exploring Possibilities and Limits’ (2016) 79 Law and Contemporary Problems 1, 24 
76 Abbott (n 73) 290 
77 D Matthews and O Gurgula ‘Patent Strategies and Competition Law in the Pharmaceutical Sector: 
Implications for Access to Medicines’ (2016) 38(11) E.I.P.R. 661, 666 
78 UN Sub-Commission on Human Rights Resolution 2000/7, ‘Intellectual Property Rights and Human 
Rights’ (17 August 2000) UN Doc. E/CN.4/Sub.2/Res/2000/7, Preamble; Hestermeyer (n 72) 169; L Helfer 
‘Human Rights and Intellectual Property: Conflict or Coexistence?’ (2003) 5 Minn. Intell. Prop. Rev. 47, 
54 
79 See discussion on fragmentation above. 
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specialised regimes.80  Marceau, for example, argues that “a good faith interpretation of 
the relevant WTO and human rights provisions should lead to a reading of WTO law 
coherent with human rights law”81, so that an interpretation of TRIPS consistent with 
international law will resolve tensions with UN human rights law under the ICESCR in 
relation to access to medicines.  This principle has been applied by the WTO to treaty 
regimes other than UN human rights law, as the WTO Appellate Body referred to sources 
of environmental law from other international legal regimes in US-Shrimp Turtle82  to 
assist its interpretation of terms in Article XX of GATT83. The WTO Appellate Body also 
confirmed in US-Gasoline84 that WTO law should be interpreted according to customary 
rules of treaty interpretation being Article 31 and 32 VCLT85.  Given that there is a 
presumption against conflict in international law86, and that resolving normative conflicts 
can be achieved through interpretation87, a key question is whether the patent law 
provisions under TRIPS can be interpreted so as to enhance access to medicines.  The 
present thesis will consider whether potential tensions between TRIPS and the ICESCR 
can be resolved through interpretation of TRIPS in light of the right to health set out in 
Article 12 of the ICESCR, for the purpose of enhancing access to medicines.   
States parties have obligations under TRIPS and the ICESCR respectively, which 
include interpreting and implementing their respective obligations at national level in 
order to comply with their international commitments. This poses the question of how 
States can resolve situations in which measures to protect intellectual property rights in 
medicines could conflict with obligations to protect human rights, specifically in relation 
to health, and how those situations can be resolved in a manner consistent with States 
parties obligations under TRIPS and the ICESCR. This research aims to fill gaps in the 
                                                            
80 McLachlan (n 49); J Crawford, Brownlie’s Principles of Public International Law, 8th ed (Oxford 
University Press, Oxford 2012) 
81 Marceau (n 68) 755 
82 United States - Import Prohibition of certain Shrimp and Shrimp Products, WT/DS58/AB/R, adopted 12 
October 1998, 129-130 
83 General Agreement on Tariffs and Trade (n 56) 
84 United States – Standard for Reformulated and Conventional Gasoline (US – Gasoline), adopted 20 
May 1996, WT/DS2/AB/R 
85 ibid 17. Article 3.2 of the Dispute Settlement Understanding requires interpretation “in accordance 
with customary rules of interpretation of public international law”. See Art 3(2) Understanding on Rules 
and Procedures Governing the Settlement of Disputes, Annex 2 to Marrakesh Agreement establishing 
the World Trade Organization ("DSU'), in World Trade Organization, The Legal Texts: the Results of the 
Uruguay Round of Multilateral Trade Negotiations (Cambridge University Press, Cambridge 1999) 354, 
355 
86 ILC Fragmentation Report (n 15) para 37 
87 ibid para 43 
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literature on how States might reconcile these competing obligations at national level, by 
exploring how States could implement their international commitments under TRIPS in 
light of wider societal interests such as public health and access to medicines, and how 
measures taken by States at national level may, or may not, address or resolve tensions.  
This thesis will address these questions by undertaking two country case studies, to 
explore how the issue of enhancing access to medicines can be addressed at national as 
well as international level.  The case studies will be valuable in terms of offering insights 
into whether States appreciate the interaction between IP and human rights in relation to 
access to medicines at national level, and their ability to address possible tensions in order 
to meet their obligations simultaneously under TRIPS and ICESCR.  The outcomes of the 
studies could also offer examples of good practice to other states on effectively meeting 
their obligations under the respective treaties so that the treaties can be implemented 
coherently at national level to enhance access to medicines globally.  The studies will also 
explore how State practice at national level might inform understanding of key issues on 
reconciling obligations under TRIPS and the ICESCR and promoting access to medicines 
at international level.  
 
Scope and objectives 
 
a) Sources of Law 
In exploring how TRIPS might be interpreted consistently with the right to health under 
the ICESCR, it is necessary to understand the content of the state obligations under the 
treaties.  Therefore, it is important to consider the sources of law that will assist in 
interpreting the treaties. Article 38(1)(a)-(c) of the ICJ Statute provides that treaties, 
customary international law and general principles of international law are formal sources 
of international law. TRIPS, as an annex to the Agreement Establishing the World Trade 
Organization88, which is the main source of WTO law, and the ICESCR, a core UN treaty 
on social and economic rights which contains the right to health, are treaties under Article 
38(1)(a).  These are the relevant treaties considered for the purpose of this research.  The 
treaties are binding on all states which are parties to that treaty.  Customary international 
law is binding on all states, and a norm will become a rule of customary international law 
                                                            
88 Agreement Establishing the World Trade Organization (n 5) 
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if it reflects state practice and is accepted as law89.  There is no hierarchy between these 
sources, except for jus cogens norms which have superior status90.  Article 38(1)(d) ICJ 
Statute states that the Court can apply judicial decisions and doctrine as subsidiary means 
for the determination of rules of law, and the sources under Article 38(1)(d) can be used 
to understand the sources under Article 38(1)(a)-(c).    
Reports of the WTO panels and the Appellate Body are also considered, as 
although they only bind the parties to the dispute, they have value in interpreting and 
clarifying WTO law91.  The Doha Declaration on the TRIPS Agreement and Public 
Health92 is also a non-binding WTO instrument but its significance is evident from the 
fact that the requisite number of WTO Members have agreed to amend TRIPS as a result 
of paragraph 6 of the Doha Declaration.93 The amendment waives the requirement under 
Article 31(f) that production under a compulsory licence had to be predominantly for the 
domestic market, which limited states from importing cheaper generic medicines from 
states where medicines were patented94. The purpose of the waiver is to make it easier for 
states to import generic medicines, and the waiver took effect on 23 January 201795, so 
paragraph 6 of the Doha Declaration can now be said to have binding force.  The WTO 
Panel in the Plain Packaging96 case considered that the Doha Declaration amounted to a 
subsequent agreement of WTO Members within the meaning of Article 31(3)(a) VCLT.97  
The Panel stated that it confirms the manner in which each provision of TRIPS must be 
interpreted98, underlining the importance of the Doha Declaration on the interpretation of 
the provisions within TRIPS, and also its significance to this research.   
                                                            
89 Higgins (n 43) 
90 Weil (n 41) 421 
91 Pauwelyn (n 12) 110 
92 Declaration on the TRIPS Agreement and Public Health (14 November 2001) WT/MIN(01)/DEC/2. 
(Herein referred to as the Doha Declaration) 
93 World Trade Organization, ‘2017 news items: WTO IP rules amended to ease poor countries’ access to 
affordable medicines’ 23 January 2017, 
<https://www.wto.org/english/news_e/news17_e/trip_23jan17_e.htm> (accessed 27/04/2020) 
94 World Trade Organization ‘Decision removes final patent obstacle to cheap drug imports’ 
<https://www.wto.org/english/news_e/pres03_e/pr350_e.htm> (accessed 27/04/2020) 
95 World Trade Organization ‘Amendment of the TRIPS Agreement’ 
<https://www.wto.org/english/tratop_e/trips_e/amendment_e.htm> (accessed 27/04/2020)  
96 Australia — Certain Measures Concerning Trademarks, Geographical Indications and Other Plain 
Packaging Requirements Applicable to Tobacco Products and Packaging (28 June 2018) WT/DS435/R, 
WT/DS441/R, WT/DS458/R, WT/DS467/R 
97 ibid paras 7.2409-7.2410 
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The UN, with near universal membership provides a clear central point for state 
practice99, providing a good reason to look to UN practice for the direction of 
development of human rights in international law.  Achieving access to affordable 
essential medicines for all is also one of the Sustainable Development Goals agreement 
by the Member States of the UN, highlighting the significance of the issue, and the 
commitments by states to address this.100  The UN Charter101 and Treaty Monitoring 
bodies102 provide guidance to states on their obligations to protect human rights. The 
reports of the UN human rights bodies provide an authoritative interpretation of the 
content of the rights and the obligations they impose on States103 and therefore provide 
valuable interpretative insights. Specifically the reports of UN human rights bodies in 
relation to the right to the highest attainable standard of health under Article 12 ICESCR, 
and the relationship between TRIPS and human rights in relation to access to medicines 
will be considered.  The Committee on Economic, Social and Cultural Rights (CESCR), 
the treaty monitoring body of the ICESCR has issued General Comments providing 
guidance on the normative content of the ICESCR.    The General Comments are non-
binding but they are important for the setting of standards that States should meet in order 
to comply with their obligations under Article 12.  For example, Chinkin notes that the 
ICJ has stated that the opinion of the Human Rights Committee, the treaty monitoring 
body of the International Covenant on Civil and Political Rights (ICCPR), should be 
given ‘great weight’, because it is an independent body established under a binding treaty 
with a specific remit as to its interpretation104.  Similar considerations would apply in 
respect of the CESCR by the same reasoning of the Court. Further, the work of the treaty 
bodies and the responses of the States Party to it, generate subsequent practice within the 
                                                            
99 Higgins (n 43) 23 
100 United Nations, ‘Sustainable Development Goals’, Goal 3.8 
<https://sustainabledevelopment.un.org/?menu=1300> (accessed 27/04/2020) 
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Human Rights Law, (Oxford University Press, Oxford 2014), 90 
 19 
 
meaning of Article 31(3)(b) VCLT105. It demonstrates the significance of the work of 
these in terms of the interpretation of States’ human rights obligations. 
In addition to the UN Human Rights Treaty system, the UN Charter-based 
system106 undertakes Universal Periodic Review of all UN Member States.107 This applies 
regardless of whether they have ratified a UN human rights treaty and provides an 
important measure of accountability.  Contributions to the UPR process also present 
examples of state practice108, which must be taken into account under Article 31(3)(b) if 
it establishes the agreement of the parties regarding the interpretation of specific human 
rights109. Even if the state practice does not establish agreement under Article 31(3)(b), 
the state practice will still be relevant under Article 32 as a supplementary means of 
interpretation110.  The reports of the Special Rapporteur on the right to the highest 
attainable standard of physical and mental health111, who has a mandate to monitor the 
situation of the right to health globally and engage in discourse with States on alleged 
violations of the right112 will also be considered.  The Special Rapporteur is an 
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the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of 
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independent expert so the reports provide a unique insight into the situation in relation to 
the right to health globally, and in specific states if a country visit is undertaken. The 
reports are not binding but are valuable to UN human rights bodies. For example, the 
reports of Special Rapporteurs can be used in review of the human rights situation of the 
State subject to UPR, and also provide authoritative guidance on interpretation of issues 
within its mandate. 
In addition, the resolutions and declarations of the Human Rights Council and the 
General Assembly can have considerable effect on creating norms, particularly where a 
large majority has supported their adoption or where they have influenced the practice of 
states113. The resolutions can be standard setting, and can reflect the aspirations of the UN 
human rights regime for States. They can also impact on the formation of customary 
international law. An example of this is the role of the Universal Declaration of Human 
Rights adopted by General Assembly resolution which contributed to the formation of 
customary international law, inter alia, concerning the prohibition on torture.114  The 
resolutions may also exert pressure on states to address human rights concerns, 
unanimous resolutions are highly persuasive and if subsequently endorsed can be 
evidence of state practice, and form the basis for binding norms.115  Therefore although 
the resolutions of the General Assembly are considered to be soft law, they can influence 
State behaviour and can, in some instances, lead to the codification or progressive 
development of customary international law.  These instruments can also have practical 
advantages as they may provide states with flexibility in implementation, and have also 
been achieved through a degree of consensus by states.116   
Weil was critical of resolutions of international organisations being considered as 
part of international law as it was not straightforward to work out their normative force, 
and while they may be a stage in the development of new norms, they do not constitute a 
                                                            
Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and 
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formal source of new norms117. In other words, if states wanted to be bound by these 
instruments they could have chosen to be so.   However, scholars including Higgins argue 
that soft law can be considered a source of law, to have legal effect and not be binding118, 
so while not being a substitute for legal custom, forms of soft law do have legal relevance 
in the creation of legal norms, as legal consequences can flow from non-binding acts119. 
Higgins also argues that the repeated practice of a UN human rights body in interpreting 
a human rights treaty may establish a practice that is of probative value as customary 
law120.  Chinkin asserts that soft law provides the space for the shaping of values and the 
creation of expectations as to the limits States will accept on their actions, and that they 
will seek to impose on others121, proposing that the consent of states to these instruments 
has a legitimising effect. Mendelson deftly articulates the controversy around the sources 
of international law as a failure to perceive the different observational standpoints, where 
persons performing different functions may adopt different attitudes to sources of law, 
and giving the example of a judge who has to apply the law impartially to the facts, 
contrasted with a government legal adviser who considers how a rule might develop and 
how they might assist this.122 Mendelson argues that while it perhaps does not matter 
which standpoint is taken by legal commentators, it is important to appreciate that there 
is a spectrum and that different positions on it are possible123.  So while forms of soft law 
are not directly enforceable, soft law does have a significant role in developing best 
practices and interpreting binding obligations of states under the UN human rights 
framework, with the Nicaragua124 case a recognised example of a General Assembly 
resolution being utilised to interpret and apply the UN Charter125.  Therefore, soft law is 
important for assisting with the interpretation of States obligations and the normative 
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content of the right to health under the ICESCR. In undertaking country case studies, 
relevant national legislation, policy documents and related case law have been reviewed. 
 
b) Definitions 
For the purposes of this research, ‘access to medicines’ refers to ‘access to essential 
medicines’.  The term ‘essential medicines’ refers to the definition given by the World 
Health Organization, which defines essential medicines as “those that satisfy the priority 
health care needs of the population… [E]ssential medicines are intended to be available 
within the context of functioning health systems at all times in adequate amounts, in the 
appropriate dosage forms, with assured quality, and at a price the individual and the 
community can afford.”126 The question of whether access to essential medicines forms 
part of the right to health under Article 12 ICESCR is discussed in Chapter 3.  The earlier 
reports of the Special Rapporteur on the highest attainable standard of physical and mental 
health include the terminology ‘access to essential medicines’127 while the more recent 
reports refer to ‘access to medicines’128. There is also evidence of both terms being used 
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the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of 
physical and mental health, Anand Grover:  Addendum:  Mission to Azerbaijan (16–23 May 2012)’ (3 
May 2013) UN Doc A/HRC/23/41/Add.1 
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in Reports of the Working Group on the Universal Periodic Review129, as well as 
Concluding Observations of the CESCR130, raising the question of whether there has been 
a shift in the discourse from whether access to essential medicines is part of the right to 
health, to whether access to non-essential medicines is also part of the right to health. 
However, it is evident that where the term ‘access to medicines’ is used, the medicines 
being referred to are predominantly to treat HIV/AIDS and tuberculosis, and are the same 
kinds of medicines as those commonly referred to as ‘essential medicines’131. Therefore, 
this thesis would suggest that, this seems to indicate that ‘access to essential medicines’ 
is the intended meaning where the term ‘access to medicines’ is used.  The issue of 
availability and accessibility of essential medicines encompasses a range of 
communicable and non-communicable diseases such as malaria, leukaemia, tuberculosis 
and other epidemics. Such concerns escalated during the HIV/AIDS pandemic across 
Africa during the late twentieth century.  In 2016 it was estimated that 36.8 million adults 
and children were living with HIV, with approximately 25.6 million of those people living 
                                                            
129 See examples from the first cycle of ‘access to medicines’ used in relation to HIV/AIDS in UN Human 
Rights Council ‘Universal Periodic Review, Report of the Working Group on the Universal Periodic 
Review, South Africa’ (23 May 2008) UN Doc A/HRC/8/32; UNHRC ‘Universal Periodic Review, Report of 
the Working Group on the Universal Periodic Review, Brazil’ (22 May 2008) UN Doc A/HRC/8/27; UNHRC 
‘Universal Periodic Review, Report of the Working Group on the Universal Periodic Review, Swaziland’ 
(12 December 2011) UN Doc A/HRC/19/6; UN Doc A/HRC/8/32; UNHRC ‘Universal Periodic Review, 
Report of the Working Group on the Universal Periodic Review, Uganda’ (22 December 2011) UN Doc 
A/HRC/19/16; UNHRC ‘Universal Periodic Review, Report of the Working Group on the Universal 
Periodic Review, Cameroon’ (12 October 2009) UN Doc A/HRC/11/21. The UPR report for Cameroon also 
refers to ‘access to medicines’ in relation to tuberculosis. In the second cycle the reports of Zambia, 
Jamaica and Dominican Republic use the term ‘access to medicines’ in relation to HIV/AIDS, the report 
of Trinidad and Tobago uses the term ‘essential medicines’ in the context of HIV and the UPR report of 
Venezuela includes reference to ‘access to essential medicines’ and ‘access to medicines’ but no 
distinction between the terms is presented. UNHRC ‘Universal Periodic Review, Report of the Working 
Group on the Universal Periodic Review, Zambia’ (31 December 2012) UN Doc A/HRC/22/13; UNHRC 
‘Universal Periodic Review, Report of the Working Group on the Universal Periodic Review, Jamaica’ (20 
July 2015) UN Doc A/HRC/30/15; UNHRC ‘Universal Periodic Review, Report of the Working Group on 
the Universal Periodic Review, Dominican Republic’ (4 April 2014) UN Doc A/HRC/26/15; UNHRC 
‘Universal Periodic Review, Report of the Working Group on the Universal Periodic Review, Trinidad and 
Tobago’ (15 July 2016) UN Doc A/HRC/33/15; UNHRC ‘Universal Periodic Review, Report of the Working 
Group on the Universal Periodic Review, Bolivarian Republic of Venezuela’ (27 December 2016) UN Doc 
A/HRC/34/6. 
130 Examples of the term ‘essential medicines’ in UNCESCR ‘Concluding observations of the Committee 
on Economic, Social and Cultural Rights; Republic of the Congo’ (23 May 2000) UN Doc E/C.12/1/Add.45; 
UNCESCR ‘Concluding observations of the Committee on Economic, Social and Cultural Rights: Peru’ (30 
May 2012) UN Doc E/C.12/PER/CO/2-4. Examples of ‘access to medicines’ in the context of HIV/AIDS in 
UNCESCR ‘Concluding observations of the Committee on Economic, Social and Cultural Rights; Sudan’ (1 
September 2000) UN Doc E/C.12/1/Add.48; UNCESCR ‘Concluding observations of the Committee on 
Economic, Social and Cultural Rights: Jamaica’  (6 December 2001) UN Doc E/C.12/1/Add.75 
131 Medicines to treat HIV/AIDS, tuberculosis and malaria all appear on the WHO Model List of Essential 
Medicines (n 126) 19, 16 
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in Africa132.  There is presently no cure or vaccine for HIV/AIDS, with the current most 
effective treatment being a combination of antiretroviral drugs.  While HIV/AIDS and 
tuberculosis are prominent concerns when discussing access to medicines, the issue of 
access to medicines is not limited to these diseases, and this is reflected in the WHO 
Model List of Essential Medicines, which also includes medicines for treatment of 
diseases including malaria, measles and others133. Therefore this thesis is not focused on 
exploring access to medicines to treat HIV/AIDS and tuberculosis specifically, but will 
include references to diseases such as HIV/AIDS as a specific example of challenges in 
relation to access to medicines. 
The term ‘pharmaceuticals’ is referred to in this research where the academic 
literature under discussion uses this term134.  The term is also used in cases relating to 
patent law in this thesis, for example by WTO panels and Appellate Body135.  Where this 
term is used in the literature and a definition is not outlined, this thesis will take the term 
‘pharmaceuticals’ to mean ‘medicines’ for definitional purposes in this research.136 
The term ‘right to health’ used in this research is a shortened reference to the right 
of everyone to the enjoyment of the highest attainable standard of physical and mental 
health set out in Article 12 of the ICESCR. This is defined by the UN Committee on 
Economic, Social and Cultural Rights in General Comment 14 as “not confined to the 
right to health care.  On the contrary, the drafting history and the express wording of 
article 12.2 acknowledge that the right to health embraces a wide range of socio economic 
factors that promote conditions in which people can lead a healthy life, and extends to the 
underlying determinants of health, such as food and nutrition, housing, access to safe and 
potable water and adequate sanitation, safe and healthy working conditions, and a healthy 
environment.”137  It is important to note that the “highest attainable” standard will vary 
                                                            
132 World Health Organization, ‘Global Health Observatory Map Gallery’ 
<http://gamapserver.who.int/mapLibrary/app/searchResults.aspx> (accessed 27/04/2020) 
133 See the WHO Model List of Essential Medicines (n 126) 
134 See examples in J Reichman "Compulsory Licensing of Patented Pharmaceutical Inventions: 
Evaluating the Options’ (2009) 32(2) Journal of Law and Medicine Ethics 10; A Sykes ‘TRIPS, 
Pharmaceuticals, Developing Countries, and the Doha “Solution”’ (2002) 3 CJlL 47; R Beall and R Kuhn 
‘Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis’ 
(2012) 9 PLoS Med 1 
135 See examples in Canada – Patent Protection for Pharmaceutical Products, WT/DS114/R, adopted  7 
April 2000; Canada-Term of Patent Protection, WT/DS170/AB/R, adopted 12 October 2000; Canada-
Term of Patent Protection, WT/DS170/R, final report circulated 5 May 2000 
136 Pharmaceuticals are defined as a ‘medicinal drug’. See Oxford English Dictionary, ‘Pharmaceutical’ 
<https://www.oed.com/view/Entry/142229?redirectedFrom=pharmaceutical#eid> (accessed 
27/04/2020) 
137 General Comment No. 14 (n 112) 4 
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from state to state, as the highest attainable standard of health in a developed state will 
likely be higher than that of a developing state.  Therefore the ‘highest attainable standard’ 
means the highest attainable standard within the state concerned.138 
 
c) Towards improving access to medicines within states 
One question addressed in this thesis is how states can interpret and apply their 
international IP and human rights obligations at national level in a manner that enhances 
effective access to medicines for patients.  The interaction between patent protection 
afforded to pharmaceutical manufacturers and the right to health under the ICESCR is 
examined at international and national level, since TRIPS came into force in 1995.  A key 
theme is whether TRIPS is more to the benefit of states which are creators of IP than 
states which are users of IP, presenting an asymmetry within TRIPS. Another key theme 
is whether IP protection can be seen, in one sense, as a trade impediment, but in another 
sense as facilitative of trade.  The key tensions within TRIPS are traced, including 
extension of the term of patent protection. The success of measures aimed at promoting 
public health is also evaluated, including the only amendment to TRIPS following the 
Doha Declaration, which had the objective of making it easier for developing countries 
without manufacturing capacity to import medicines.  Drawing on the object and purpose 
of the agreement, this thesis proposes that TRIPS is not fundamentally in conflict with 
UN human rights law. The work of the UN human rights bodies in clarifying the content 
of the right to health and the obligations of states parties to the ICESCR is also examined, 
to make the case that the right to health includes access to medicines.  Therefore, states 
have obligations to implement measures into national law to protect and promote access 
to medicines, and that TRIPS can be interpreted in the context of the right to health to 
promote access to medicines.   
The argument as to whether IP rights can amount to a human right under the 
ICESCR is also evaluated, to examine whether a conflict exists between state obligations 
towards creators of medicines and patients requiring medicines in international human 
rights law.  Recent developments in the UN human rights framework are also analysed to 
evaluate their contribution to advancing access to medicines and how this discourse can 
assist states in meeting their concurrent obligations to protect the right to health and under 
IP law. The thesis then moves to undertaking two country case studies to provide insights 
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into how the selected states have implemented TRIPS and to identify significant problems 
as well as possible solutions to key challenges in relation to complying concurrently with 
human rights law. The studies will draw upon illustrative examples from national law, 
policy and jurisprudence to examine the implications of the issue of access to medicines 
at national level, and assess whether states have found solutions which could be 
implemented in other states. In addition, how state practice could inform understanding 
of the key challenges at international level is also considered.  The thesis concludes by 
proposing factors for consideration at national and international level for resolving 
tensions between the WTO and UN human rights frameworks in relation to access to 
medicines in a manner that promotes the rights of all to secure effective access to 
medicines. 
 Chapter 2 critically evaluates the rationale for intellectual property protection and 
the reasoning for the implementation of TRIPS as an international standard for intellectual 
property rights.  This includes exploring the tensions with patent law and access to 
medicines, by analysing the terms on patents in TRIPS, the minimum standards for 
protection and how they have been interpreted, and challenges including the 
implementation of a higher standard of intellectual property protection by some WTO 
Members.  Exceptions to patent rights under Article 30 and Article 31 of TRIPS will also 
be explored to analyse whether these exceptions are practicable. The difficulties in 
satisfying the compulsory licensing requirements under Article 31 has been addressed by 
Doha Declaration in November 2001, which led to an amendment of Article 31.  The 
chapter does not provide a detailed historical analysis of IP rights, focusing instead on 
key developments in the law and providing context to the challenges in interpreting 
TRIPS in a manner that is consistent with securing access to medicines. 
 Chapter 3 undertakes a systematic review of the reports of the UN Human Rights 
Charter-based Bodies and the relevant UN Human Rights Treaty Monitoring body to 
explore the status of access to medicines in the context of international human rights law, 
and to explore the value of the interpretative guidance provided by these instruments.  The 
purpose of this is to explore whether access to medicines can be considered as forming 
part of the human right to health in international human rights law, specifically under 
Article 12 of the ICESCR. The review of the Charter-based system involves a systematic 
analysis of the Universal Periodic Review (UPR) documentation with a view to 
ascertaining recommendations made to states in relation to medicines, to analyse state 
views on their human rights obligations and how improving access to medicines fits with 
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those obligations.  A review of the reports of the Special Rapporteur on the highest 
attainable standard of physical and mental health to December 2019 is also undertaken, 
as the Special Rapporteur has a specific mandate to report on health matters and to provide 
guidance to states on their obligations under the right to health. 
In relation to the UN Treaty Monitoring Bodies, the chapter also includes a 
systematic review of the reports on the concluding observations of the Committee on 
Economic, Social and Cultural Rights (CESCR) to December 2019, as the ICESCR 
includes the right to highest attainable standard of physical and mental health under 
Article 12, to understand the key concerns in relation to this right.  The General 
Comments on the treaties are also informative and are considered as they provide 
guidance on the interpretation of the States parties’ obligations.  The purpose of this 
review is to explore how access to medicines is considered as part of the human right to 
health by the UN human rights bodies, identify concerns over barriers to access which 
prevent the fulfilment of the right to health. Also, how the UN human rights instruments 
can be instructive to states in interpreting and implementing their obligations under the 
ICESCR to enhance access to medicines while concurrently complying with their 
obligations under TRIPS.  
Chapter 4 explores the question of whether IP rights could be considered as human 
rights also, specifically under Article 15 ICESCR.  This includes a review of the content 
of Article 15 and the UN guidance on Article 15, including the relevant General 
Comments, to examine how IP rights fit into the UN human rights framework, to evaluate 
measures to advance this right within this framework, and the significance of this right 
internationally and domestically within states. The chapter then goes on to explore key 
recent developments in the UN that seek to enhance access to medicines in this rights-
based context.  Such developments include the expert consultation on access to medicines 
convened by the Office of the High Commissioner for Human Rights (OHCHR), and the 
UN Secretary-General’s High-Level Panel on Access to Medicines139, which outlined 
                                                            
139 The Panel comprised fourteen members and two co-chairs from developed and developing countries, 
The co-chairs were Ruth Dreifuss, former Chairperson of the Commission on Intellectual Property Rights, 
Innovation, and Public Health, and Festus Gontebanye Mogae, former President of the Republic of 
Botswana and Chairman of Champions for a HIV Free Generation. The membership of the Panel 
included Andrew Witty, former CEO of GlaxoSmithKline; Stephen Lewis, the UN Secretary-General’s 
Special Envoy for HIV/AIDS in Africa (2001-06);,Deputy Executive Director of UNICEF (1995 -1999), and 
he served as Canada’s Ambassador to the UN (1984-1988); Malebona Precious Matsoso, former Director 
at the World Health Organisation (WHO) responsible for the implementation of the Global Strategy and 
Plan of Action; Michael Kirby, a retired Justice of the High Court of Australia,  he served as the Special 
Representative of the United Nations Secretary-General for Human Rights in Cambodia between 1993 
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problems in terms of innovation and in terms of physical accessibility, and made a series 
of recommendations to address key challenges identified by the Panel.  The chapter will 
evaluate the outcomes of these developments to assess the utility and efficacy of the 
recommendations made in helping states to interpret and implement their obligations 
under TRIPS and the ICESCR to enhance access to medicines.  The chapter will also 
evaluate whether states parties can be bound to fulfil such recommendations, through 
monitoring and accountability mechanisms, and whether this would have a positive 
impact to enhance access to medicines and in influencing state behaviour. 
Chapters 5 and 6 of this thesis will focus on country case studies, for the purpose 
of providing an examination of how the States are interpreting and implementing their 
TRIPS and ICESCR obligations in to national law, and to further understand how these 
issues impact upon patients within the States. Chapter 5 focuses on Canada as the first 
country case study and Chapter 6 focuses on Peru. The methodology of selecting these 
states is outlined in the introductory paragraphs of Chapters 5 and 6.  The reasoning for 
selecting one developed state and one developing state is to analyse whether 
recommendations emanating from the international frameworks on how states should 
interpret their obligations under TRIPS and the ICESCR, are recognising the varied 
factors which can have an impact on states’ abilities to comply with their international 
obligations on medicines.  The purpose is to offer insights into the States’ experience and 
to further understanding on how to develop the discourse on access to medicines at 
national and international level.  National legislation on intellectual property will be 
explored in the studies, including national policy and available data in relation to the 
national pharmaceutical industry, as well as whether the studied State recognises access 
to medicines within their legislative system, and if so, the legal status and consequences.   
The studies also outline illustrative examples of how the tensions identified 
between the states obligations within the international trade and human rights systems at 
international level, translate to domestic level, to highlight how such tension manifests at 
national level.  Examples of good practice in the States is also highlighted, to evaluate 
whether such practices could be adopted in other states, and to further understanding on 
how to develop the discourse on access to medicines at national and international level. 
                                                            
and 1996,  From 2010 to 2012, he served as Commissioner on the Global Commission on HIV and the 
Law and co-chaired the Commission’s Technical Advisory Group. In May 2013 he was appointed by the 
United Nations Human Rights Council to lead a Commission of Inquiry into human rights abuses in North 
Korea. United Nations Secretary-General’s High-Level Panel on Access to Medicines, ‘The Panel’, 
<http://www.unsgaccessmeds.org/new-page/> (accessed 27/04/2020) 
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Important issues identified include physical accessibility of medicines, pricing and 
research and development (R&D) costs, data exclusivity and development of local 
generic medicines, and national constitutional measures impacting upon access to 
medicines.  Specific challenges faced by the State’s indigenous peoples are also explored, 
including how broader concerns such as access to culturally appropriate services, and the 
protection of traditional medicines, can impact on their access to medicines.  This analysis 
fills gaps in understanding of how the complexities around enhancing access to medicines 
impact upon minority groups, the specific challenges that such groups face, which need 
to form part of the discourse on enhancing access to medicines for everyone. 
The final chapter evaluates the outcomes of the research undertaken in each of the 
earlier chapters, for the purpose of raising questions relating to states’ policy and 
measures on medicines and also to suggest possible actions to improve the position.  The 
chapter will take a thematic approach to outline several factors for consideration for states 
to address the wide-ranging issues affecting access to medicines, and to comply with their 
international commitments.   This chapter will outline the utility of the research not only 
at the national level but also to help inform initiatives at the intergovernmental or 
international level to promote effective access to medicines, for the benefit of patients 
across all states. 
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Chapter 2: Trade, Intellectual Property and the TRIPS Agreement  
 
Introduction 
 
The objective of this chapter is to provide an analysis of the terms in the TRIPS 
Agreement140 that are relevant to medicines, to further understanding of where tension 
exists between compliance with TRIPS provisions and access to medicines. The chapter 
will critically examine the purpose of intellectual property law, and identify and analyse 
factors affecting access to medicines in the context of trade and intellectual property law. 
The TRIPS agreement, administered by the WTO, was the first multilateral trade 
agreement pertaining specifically to IP rights and sets minimum standards of IP protection 
which WTO Members are required to implement into national law.  The chapter will 
provide an overview of how TRIPS came to be agreed by WTO Members, and the 
obligations the Agreement placed on Members.  A key theme discussed in this chapter is 
whether TRIPS is more to the benefit of states which are creators of IP than states which 
are users of IP. Another key theme is whether IP protection can be seen, in one sense, as 
a trade impediment, but in another sense as facilitative of trade. The chapter will also 
consider the implementation of TRIPS specifically in relation to patents and access to 
medicines, and explore why some terms create challenges in securing access to essential 
medicines, to analyse where tensions exist between implementing patent law and 
promoting public health objectives.   
A key question is whether potential tension between the WTO and UN human 
rights regimes can be resolved through interpretation, in particular whether TRIPS can be 
interpreted to serve public health interests such as enhancing access to medicines.  An 
analysis of the exceptions to the patent rights afforded by TRIPS under Articles 30 and 
31 and the effectiveness of their application in practice will be undertaken, as well as 
whether these provisions can be interpreted in a manner which promotes access to 
essential medicines.  An evaluation of the current legal position will also be undertaken, 
including how the Doha Declaration was intended to address the public health concerns 
arising from TRIPS and whether this was successful.  The chapter will also consider the 
effect of the implementation of IP provisions in bilateral trade agreements that are stricter 
than those set out in TRIPS. An evaluation of the literature surrounding this issue will 
                                                            
140 TRIPS Agreement (n 4). The TRIPS Agreement came into force on 1 January 1995. 
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assist the discussion, and demonstrate how the issue of securing effective access to 
medicines is of key importance in a global context beyond the trade platform. 
  
I. The evolution of IP in trade law 
 
Since the TRIPS agreement came into force in 1995, as part of the agreement that 
established the WTO, the perspective on access to essential medicines has altered 
significantly.  Prior to the implementation of TRIPS the absence of a standardised IP law 
resulted in varying types and standards of protection in different jurisdictions.  The World 
Intellectual Property Organization (WIPO) administered various treaties141 relating to IP 
rights which delivered a mechanism for protecting IP rights globally without the 
requirement for harmonisation.142  However no cohesive system with a legitimate process 
for dispute resolution existed.  TRIPS recognised the increasing relevance of trade in 
knowledge and creative ideas, with the outcome being that trade in intangible goods as 
well as tangible goods could be regulated within the same platform, harmonising IP law 
with trade law. 
 Prior to the creation of the WTO, the General Agreement on Tariffs and Trade 
(GATT) administered international trade in goods with the intention to reduce tariff duties 
between the contracting states.  Although the general GATT provisions applied to IP143, 
issues relating specifically to IP protection were left to the competency of contracting 
states, and territorial IP rights developed as a result.144  As new Contracting Parties, 
including developing countries with more diverse interests joined the GATT system, 
dissatisfaction emerged as to the adequacy of the GATT system to address trade 
                                                            
141 The Paris Convention (Industrial Property) and the Berne Convention (Literary and Artistic Works) 
referred to protection of IP rights, although IP rights were not included in GATT, the multilateral trade 
agreement which preceded TRIPS. 
142 P Drahos, 'Developing Countries and International Intellectual Property Standard-Setting' (2002) 5 J 
World Intell Prop 765, 768-769; M Blakeney ‘Intellectual property in world trade: The Failure of the 
Ancien Régime of Intellectual Property Protection’ (1995) 1(3) Int. T.L.R. 76, 76-77; M Elsmore, 
‘Comparing regulatory treatment of intellectual property at WTO and EU level’ in S Gaines, B Olsen and 
K Sørensen (eds), Liberalising Trade in the EU and the WTO (Cambridge University Press, Cambridge 
2014), 419; Helfer and Austin (n 3) 37-38 
143 D Gervais, The TRIPS Agreement: Drafting Analysis and History (4th ed Sweet and Maxwell, London 
2012), [1.08] 
144 J Reichman, 'Intellectual Property in International Trade: Opportunities and Risks of a GATT 
Connection' (1989) 22 Vand J Transnat'l L 747, 756-757; P Geller ‘Intellectual Property in the Global 
Marketplace: Impact of TRIPS Dispute Settlements?’ (1995) 29 Int'l Law 99, 106; Elsmore (n 13) 418; D 
Gervais ‘The TRIPs Agreement: interpretation and implementation’ (1999) 21(3) E.I.P.R. 156, 156 
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imbalances.145 Therefore there was an inclination for reform of the international trading 
system. 
The Uruguay Round of trade negotiations between the Contracting Parties began 
in 1986 and comprised new areas of trade regulation including trade in IP, with pressure 
to resolve the issue of trade in pirated and counterfeit goods.146 The US in particular 
advocated the introduction of strict IP protection, and a Report to Selected Congressional 
Subcommittees by the US Accounting Office147 outlined the US government efforts to 
combat counterfeiting and piracy by encouraging other states to implement stronger 
national IP rights.148  Although the Uruguay Round began with concerns over counterfeit 
goods, the limited mandate evolved into a far-reaching agreement on IP protection.149  
During the negotiations it was evident that while the focus was on the protection and 
enforcement of IP rights, there was a lack of consensus on how these norms may be 
realised. For example, the US position was that the GATT articles on IP were inadequate 
to address distortions to trade and sought to establish enforcement mechanisms150, while 
a Swiss proposal favoured the establishment of general normative principles including 
the avoidance of trade distortions caused by insufficient IP rights protection, to be 
enforced by the existing GATT procedures.151   
Furthermore, submissions by several developing countries during the negotiations 
reflected a position in contrast to that of developed countries, and expressed concerns 
about a high level of IP protection obstructing technology transfer and affecting costs of 
                                                            
145 R Dreyfuss and A Lowenfeld, 'Two Achievements of the Uruguay Round: Putting TRIPS and Dispute 
Settlement Together' (1997) 37 Va J Int'l L 275, 277; P Gallagher, The First Ten Years of the WTO: 1995-
2005 (Cambridge University Press, Cambridge 2005), 3; Reichman (n 144) 765-766; C Wadlow ‘"Including 
trade in counterfeit goods": the origin of TRIPS as a GATT anti-counterfeiting code’ (2007) 3 I.P.Q. 350, 
350 
146 A Taubman, H Wager and J Watal (eds), A Handbook on the WTO TRIPS Agreement (Cambridge 
University Press, Cambridge 2012), 4; Wadlow (n 145) 351-352; Gervais (n 143) P.8-9 
147 US General Accounting Office, ‘International Trade: Strengthening Worldwide Protection of 
Intellectual Property Rights’, GAO/NSIAD-87-65 (1987) <http://archive.gao.gov/d2t4/132699.pdf> 
(accessed 27/04/2020) 
148 ibid 8 
149 C Arup, The New World Trade Organization Agreements: Globalizing Law Through Services and 
Intellectual Property (Cambridge University Press, Cambridge 2000), 64; S Joseph ‘Democratic Deficit, 
participation and the WTO’ in S Joseph, D Kinley and J Waincymer (eds) The World Trade Organization 
and Human Rights (Edward Elgar, Cheltenham 2009), P.317; Blakeney (n 142) 80-81; F Abbott, 'The WTO 
Trips Agreement and Global Economic Development' (1996) 72 Chi-Kent L Rev 385, 390 
150 Group of Negotiations on Goods (GATT) Negotiating Group on Trade-Related Aspects of Intellectual 
Property Rights, including Trade in Counterfeit Goods , Statement by United States at Meeting of 25 
March 1987, (3 April 1987) MTN.GNG/NG11/W/2, 4 
151 Group of Negotiations on Goods (GATT) Negotiating Group on Trade-Related Aspects of Intellectual 
Property Rights, including Trade in Counterfeit Goods , Proposal by Switzerland, (21 June 1988) 
MTN.GNG/NG11/W/25, 3 
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medicines.  In a statement to the Negotiating Group, Thailand highlighted developing 
countries’ concerns over the scope of discussions, asserting that the objectives of some 
countries in proposing wider international standards of IP protection went beyond the 
intentions of the Round.152  The State argued that enforcement procedures should further 
trade liberalisation and not lead to excessive protection which obstructed technology 
transfer.153 It was also stated that the two fundamental aims pursued by governments when 
granting IP protection are the stimulation of intellectual creativity and appropriate 
protection of the public interest, and it “goes without saying that the former must not put 
undue burden on the latter.”154  These statements illustrated the competing interests of the 
developed and developing countries during the negotiations, with developing countries’ 
concerns over how higher IP would limit the transfer of knowledge and development 
goals.   
A statement from Peru also reiterated the balance between protecting creativity 
and furthering the development agenda155 and stated that pharmaceutical products should 
be excluded from patentability, and provisions to ensure that patents further technology 
transfer should be included.156 This underlined that the issue of access to essential 
medicines was a concern for a developing country before TRIPS was agreed, however 
through the negotiations the issue did not appear to have been adopted as a prominent 
concern.  Submissions by Brazil noted that the discussions had been focussed on the IP 
owner, while there was a need to consider the IP user also, emphasising that the IP owner 
had not only rights but obligations, including to provide access to technological 
innovations.157 The submissions by Brazil also demonstrated concerns of developing 
countries, emphasising that the mandate of the Negotiating Group was to discuss trade 
related aspects of IP rights in the broader context of promotion of growth and 
                                                            
152 Group of Negotiations on Goods (GATT) Negotiating Group on Trade-Related Aspects of Intellectual 
Property Rights, including Trade in Counterfeit Goods, Statement by Thailand at the meeting of 12-14 
September 1988, (21 September 1988) MTN.GNG/NG11/W/27, 1 
153 ibid 2 
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155 Group of Negotiations on Goods (GATT) Negotiating Group on Trade-Related Aspects of Intellectual 
Property Rights, including Trade in Counterfeit Goods, Guidelines for negotiations that strike a balance 
between intellectual property rights and development objectives – Communication from Peru, (27 
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157 Group of Negotiations on Goods (GATT) Negotiating Group on Trade-Related Aspects of Intellectual 
Property Rights, including Trade in Counterfeit Goods, Submission from Brazil, (31 October 1988) 
MTN.GNG/NG11/W/30, 3 
 34 
 
development158, rather than in the context of enforcement of IP rights, including non-trade 
related rights. 
Negotiating IP rights in WIPO was favoured by developing countries in order to 
consider the impact of IP rights on a wider scale outside of the trade forum159, raising the 
question of why the developing countries participated in the discussions of IP right within 
the GATT given their fears over the impact of higher IP rights protection.  However 
participation in the negotiations in GATT was perceived as beneficial due to potential 
gains in other areas of trade.160  Developing countries had the opportunity to secure 
compromises on other trade matters such as textiles and agriculture, as part of the 
agreement that included IP rights, by having such discussions within the GATT 
mechanism rather than WIPO.161  The development of a multilateral framework for 
enforcement and dispute resolution to address IP rights infringement was also preferable 
to “guarantee security against the power politics of aggressive unilateralism and bilateral 
bargaining” by developed countries.162 Developing countries, including those with 
growing pharmaceutical industries, were granted greater access to developed markets for 
manufactured goods as well as assurances from developed countries to refrain from 
imposing unilateral sanctions for perceived inadequate IP protection.163 
 
II. The TRIPS Agreement 
 
  An outcome of the Uruguay Round was the creation of a new trade organisation, the 
WTO, which would replace the GATT in administering trade relations between its 
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Members.  Against this background the obligations TRIPS imposes on WTO Members 
in relation to medicines will be considered.  A key theme is whether TRIPS is more to the 
benefit of states which are creators of IP than states which are users of IP, presenting an 
asymmetry within TRIPS. Another key theme is whether IP protection can be seen, in 
one sense, as facilitative of trade, but in another sense as a trade impediment.  A wealth 
of literature explores the scope of the international trade system and how it increasingly 
impacts upon other areas of law, and society164.  There is recognition of the fact that 
decisions taken within the WTO legal framework have significant impacts on non-trade 
issues, including environmental concerns, labour standards, and health.  Much of the 
academic literature discusses whether there is conflict between WTO trade law and other 
objectives where the distinct legal norms converge in international law, and has been 
framed in the context of promoting trade liberalisation against competing social values165, 
providing an example of the problem of fragmentation in international law.  However this 
assessment has been contested in academic literature which takes the view that trade 
liberalisation through the WTO has been shaped by its overarching purpose, including 
the contribution that trade makes to global welfare, and the problems that it was 
implemented to resolve166.  Lang argues that the debate should be reframed, to instead 
analyse the norms and values that the trade regime is to pursue, and how the trade system 
contributes to broader social goals167.  This view explores that the trade regime is 
complementary to the human rights regime as the trade regime protects economic 
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freedoms and development, and is underpinned by the freedoms associated with human 
rights168.  Article XX GATT provides foundation for the consideration of human rights 
law within the WTO framework, and TRIPS recognises the significance of public health 
under Article 8.  The terminology within the WTO Preamble, as well as Article XX 
GATT, are not precise or unambiguous and are therefore open to interpretation. Therefore 
there is scope for the interpretation of TRIPS in light of human rights objectives, including 
the right to health.  However the question is the extent to which this can be achieved.  The 
WTO Preamble states the objectives of the WTO are the reduction of barriers and 
discrimination in trade to promote economic development and improve standards of 
living, in particular sustainable development and with regard to the needs of developing 
states169. Academic literature has considered the extent to which the WTO expanded the 
nature of the trading regime to development, economic and welfare gain170. While it is 
reasonable to propose that an aim of the WTO is to promote development through trade 
liberalisation171, the Preamble does not outline specific goals for achieving this, and the 
wording does not indicate that there is an unlimited extent to which social considerations 
can be considered when seeking to reduce trade barriers.  The Preamble does not outline 
the degree to which social and welfare considerations are to be taken into account, or 
given that there is not stated to be a hierarchy of objectives within the Preamble, whether 
the position is that these considerations are to be taken into account to the extent that they 
impact on trade.   
As an instrument managed within the WTO, TRIPS has the objective of ensuring 
adequate protection of IP rights, while ensuring that enforcement of IP rights do not 
themselves create distortions and impediments to international trade172.  IP rights are 
private rights which create positive obligations in the public international trade law 
system, and therefore a relevant issue is whether TRIPS is trade liberalising, facilitating 
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international trade through a common standard of rights. TRIPS requires WTO Members 
to provide regulation and enforcement procedures for IP in national law that allow foreign 
owners to establish and protect IP rights.  For numerous states the effect is to require that 
their domestic industries pay to use the IP when previously their national laws permitted 
free and unrestricted use.173 International IP standards may address disparities between 
international trading partners and promote trading relationships. The effect of reducing 
tariff barriers generally results in reciprocal benefits for trading partners. However, in 
dealing with this non-tariff trade issue, states, usually developing countries using IP to 
further development of national industries, now have to incur licensing fees for authorised 
use of IP. Therefore they do not receive a reciprocal benefit from this trade agreement.174  
This suggests a conflict between trade liberalisation and IP rights as the monopoly rights 
gained by the IP holders does not facilitate trade liberalisation for the benefit of all WTO 
Members, and states with little IP cannot achieve the gains that IP holders would benefit 
from. Therefore TRIPS may not be beneficial for states oriented to use of IP rather than 
creation of IP. 
 An argument in support of TRIPS as an instrument of trade liberalisation is that 
such protection provides a global benefit through encouraging innovation and creativity, 
by providing the inventor or holder of the idea to be entitled to an exclusive property right 
in the creation. This will in turn encourage investment in developing knowledge and 
ideas, which will then lead to the creation of new products to be introduced to the global 
market.  However, the creation of new products only benefits the global economy if the 
new product is sought after.175 It could be argued that IP does not promote creativity as 
this presumes that creators only create if they can profit from their creations, and therefore 
a more accurate assessment is that IP encourages commercially valuable research and 
development. This is particularly evident in the pharmaceuticals industry where the 
protection of such creations in the form of patents can impede trade in generic medicines, 
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as to authorise use of the creation would present unwanted generic competition in the 
market176. 
Where IP protection is strict and right holders can receive remuneration in 
exchange for authorised use of the protected idea or creation, this protects the value of 
the IP to the holder.  This standard also furthers trade liberalisation because the 
information that is the subject of an IP right is traded and shared with both parties 
benefitting from the trading arrangement.  The right holder receives payment in exchange 
for licensing the information for use and the licensee can use the information for the 
purpose of creating a valuable product.  However, for this standard to continually occur, 
this could impact upon social and cultural interests, particularly the right to health 
articulated within Article 12 of the International Covenant on Economic, Social and 
Cultural Rights.177 Article 12 provides that states which are parties to the Covenant are to 
take steps necessary to realise the right to health, including “creating conditions which 
would assure to all medical service and medical attention in the event of sickness.”178  
However, if IP rights effectively cause the escalation of costs of essential medicines, and 
disincentivise research into treatments for diseases common to developing and least 
developed countries, then states may not be fully realising their obligations under Article 
12 ICESCR. This point is raised only briefly here, with an analysis of the human rights 
implications of the effect of IP law, particularly in relation to patents, to be explored in 
more depth in subsequent chapters. 
 Since coming into effect in 1995 there has been debate over whether TRIPS may 
be too restrictive to meet the needs of developing countries in relation to access to 
medicines179, and that TRIPS in effect creates a barrier to access to essential medicines 
for developing countries.   
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Specific concerns include the cost of medicines, particularly as these are generally set by 
pharmaceutical companies, which are private entities and therefore are not bound by the 
same obligations under international law as states are under TRIPS and the ICESCR.  
Also, the availability of newer, more effective medicines to treat people in need and the 
cost of these new products is an additional concern.  A particular problem is that although 
IP rights are considered to encourage the creation of new products, they can act as a 
barrier to existing medicines that are essential for sufferers of diseases which, without 
adequate treatment, can be life limiting or fatal.  Therefore, securing physical access to 
new medicines and promoting innovation in developing new medicines to treat growing 
public health concerns is also a key challenge for states. 
 
III. Patent law and essential medicines 
 
Many factors can impede access to medicines for the poorest populations in developed 
and developing countries, including insufficient research in development of new 
medicines for new diseases, delays in obtaining regulatory approval and decreased 
production of unprofitable medicines.180 A specific challenge resulting from TRIPS 
standards of protection has been the effect of the patent protection provisions set out in 
Section 5, Articles 27-34 on access to essential medicines including antiretroviral drugs.  
This challenge exists particularly in relation to pharmaceutical patents.  IP rights reward 
the innovative process of the creation of new medicines by allowing the creator to control 
and restrict the use of the new creation, most commonly in the form of a patent.181 Patented 
medicines are protected from being copied to produce generic copies for the duration of 
the patent. Generic manufacturers can copy existing medicines at much cheaper cost 
because they do not have to invest in research and development where a medicine is 
already in existence, merely needing to demonstrate the generic medicine’s 
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‘bioequivalence’ to the patented medicine.182 Therefore the IP rights given under the 
patent are extremely valuable to pharmaceutical companies so that the newly created 
medicines can be commercially exploited.  The legal protection afforded by a patent can 
be an incentive to pharmaceutical companies to invest in the creation of new medicines, 
which can increase the availability of specific medicines needed during public health 
crises. Patents essentially create a monopoly right over the creation which protects the 
creator’s investment and knowledge in the product, but the prices set by pharmaceutical 
companies which have the monopoly on trade in these medicines while they are under 
patent have been criticised183 for creating a barrier to access.  
 Hestermeyer argues that although patents are territorial and the 
comprehensiveness of rights granted by national legislation varies, the lack of patent 
protection in a particular country does not necessarily mean that a company is suffering 
loss because of a lack of a licensing regime in that territory.184  For example, the product 
may not be as successful in that particular market.  The absence of patent protection in 
some developing markets is detrimental to pharmaceutical companies. Without patent 
protection, there is the potential for pharmaceutical manufacturers in that country, if such 
capacity exists, to reverse engineer the pharmaceutical products on the market in order to 
manufacture copies.  There is a further risk that the copies could be exported to other 
markets in countries with weak or no IP regimes, and sold at a cheaper cost than the 
original.  This would provide direct competition for the original manufacturer in various 
international markets.  This would be objectionable to the original manufacturer because 
the copier is profiting from the original company’s investment in the product by 
undercutting the cost of its own product. Lack of patent protection in a territory may also 
dissuade investment in research and development of medicines, as the return on such 
investment may be at risk due to the lack of security and legal protection over the invented 
product.  The potential growth of the domestic pharmaceutical industry in a territory could 
therefore be detrimentally affected, which could have implications on social and 
economic development. 
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Reichman argues that pharmaceutical companies avoid differential pricing in least 
developed countries because those companies will maximise their profits by selling their 
products at a high cost to the most affluent members of society.185  They can do so because 
their patents afford a monopoly right and the lack of market competition allows them to 
set high prices.  However the effect is to price poor countries out of purchasing essential 
medicines for the members of society who are most in need, and presents a barrier to 
access to such medicines.  Consequently the trade in essential medicines can result in 
access to such medicines being unobtainable, particularly for developing countries which 
cannot commit the necessary expenditure to purchase such medicines at the market value, 
while they lack sufficient manufacturing capacity to invest in the research and 
development of medicines that their populations need.  
If IP rights effectively cause the escalation of costs of essential medicines, and 
disincentivise research into treatments for diseases common to developing and least 
developed countries, then states may not be fully realising their obligations under Article 
12 ICESCR. This point is raised only briefly here, with an analysis of the human rights 
implications of the effect of IP law, particularly in relation to patents, to be explored in 
more depth in subsequent chapters.  If states are not fully complying with their obligations 
under Article 12 ICESCR then this provides an example of the challenges for states where 
two international legal orders converge and also the question of how to resolve tensions 
between the regimes so that states can meet their obligations effectively under the 
respective regimes. Therefore the question is whether potential tension between these 
legal regimes can be resolved through interpretation. In particular, can TRIPS be 
interpreted to serve public health interests, specifically enhancing access to medicines. 
 
IV. Interpreting the TRIPS provisions on patents 
 
TRIPS provides a high level of patent protection under Article 28186, providing exclusive 
rights of use by the patent holder and prohibiting unauthorised use and manufacture of 
the patented product.  This protection is limited to a period of 20 years187.  It is important 
to consider how these provisions have been implemented by WTO Members in national 
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law, as this will demonstrate the effect of such protection on patent holders as well as 
those who wish to utilise the patented product.  
The term of protection is an important provision because a greater term will 
provide stronger protection to the patent holder, as this will provide a longer period of 
market exclusivity for the patented product.  This was highlighted in the decision of the 
WTO Appellate Body in Canada-Term of Patent Protection.188  This case related to the 
implementation of TRIPS, and the issue in dispute was whether Canada was required to 
extend the term of protection for patents which were granted for a lesser term under the 
national law before TRIPS was implemented. Prior to TRIPS coming into effect, under 
Section 45 of Canada’s Patent Act, patents were granted for a maximum term of 17 
years.189 Canada appealed the Panel’s conclusion190 that this provision violated Article 33 
of TRIPS, arguing that Article 28 VCLT191 which establishes a non-retroactivity principle 
in respect of treaties was applicable. The Appellate Body considered that the non-
retroactivity rule under Article 28 only applied to any situation which ceased to exist 
before the date that a treaty entered into force.192 The Appellate Body interpreted that this 
provision established that treaty obligations would apply to any situation which continued 
to exist when that treaty entered into force.193  Therefore patents existing at the time that 
TRIPS entered into force were subject to the obligation under TRIPS.  Canada also argued 
that as its national patent office regularly took approximately five years to grant a patent, 
this period should be added to the term of protection.194 However the Appellate Body 
rejected this argument as the wording of Article 33 is clear, and to interpret it in the way 
in which Canada proposed would lead to inconsistencies with the implementation of the 
provision.195 
 This case demonstrates that where a patent exists at the date of entry into force of 
TRIPS, the patent obligations under TRIPS will apply to those patents196. This has 
important implications as the owners of patents that were granted in Canada prior to 
TRIPS being in force will benefit from the additional patent protection provided. The 
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decision also set a precedent for the term of patent protection to be incorporated in 
national legislation of other WTO Members.  The patent holder will benefit from an 
extension of the monopoly rights provided by the patent even though this obligation was 
not in force when the patent was granted.  Therefore a larger number of patents will be 
subject to the term of patent protection set out in TRIPS, which indicates that this decision 
favours the interests of the patent holders. However, extending the term of patent 
protection means that generic competitors are prevented from entering the market for a 
further period, which fails to promote access to essential medicines, and the furtherance 
of public health needs. 
Although TRIPS provides extensive rights for patent holders in Section 5, two 
categories of permitted exceptions to the exclusive rights under Article 28 are found under 
Articles 30 and 31197. The exceptions to patent rights within TRIPS could potentially be 
significant provisions in securing improved access to essential medicines for all.  It is 
important to evaluate the interpretation and application of these exceptions in order to 
determine whether they can be used effectively to promote access to medicines. 
 
IV(i). Article 30 
 
Article 30 of TRIPS states: 
 
“Exceptions to Rights Conferred 
 
Members may provide limited exceptions to the exclusive rights conferred by a patent, 
provided that such exceptions do not unreasonably conflict with a normal exploitation of 
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the patent and do not unreasonably prejudice the legitimate interests of the patent owner, 
taking account of the legitimate interests of third parties.” 
 
Article 30 permits WTO Members to provide limited exceptions to patent rights. The 
broad drafting of the provision could be construed to permit exceptions to patent rights in 
the legitimate interest of improving global health, allowing the patented product to be 
used or manufactured without the authorisation of the patent holder. However, Article 30 
has not been widely relied upon198 by WTO Members.  A WTO Panel has, as of March 
2020, undertaken an analysis of Article 30 in only one case, Canada – Patent Protection 
for Pharmaceutical Products199. The Panel’s interpretation of Article 30 has been 
criticised as failing to give full effect to Articles 7 and 8 when interpreting the 
exception200, and therefore failing to fully take into account public health measures such 
as improving access to medicines as legitimate interests under Article 30. 
The case concerned Canada’s Patent Act, specifically Section 55.2(1) and 
55.2(2)201. Section 55.2(1) permitted generic manufacturers of pharmaceutical products 
to conduct testing of patented pharmaceuticals and obtain marketing approval for generic 
copies of the product before the expiration of the patent, with the aim of marketing the 
generic drug immediately upon expiry of the patent.202 Section 55.2(2) permitted generic 
producers to make generic medicines and to stockpile them six months prior to the 
expiration of the patent, so that they would have a supply of generic medicines which 
could be sold immediately upon expiration of the patent.203 
The Panel found that the regulatory review provision under Section 55.2(1) of 
Canada’s Patent Act was legitimate, confirming that generic copies could be tested while 
the patented drug was still under patent protection, for the purpose of preparing the 
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generic medicines to be marketed as soon as the patent expired204.  However, the Panel 
concluded that the stockpiling of generic medicines in anticipation of the expiration of 
the patent was not consistent with Article 30205.  In the course of reaching its decision the 
Panel established that Article 30 had three requirements which must all be satisfied in 
order to qualify as a permitted exception; (1) the exception must be limited; (2) the 
exception must not unreasonably conflict with normal exploitation of the patent; (3) the 
exception must not unreasonably prejudice the legitimate interests of the patent holder, 
taking into account the legitimate interests of third parties.206 
 
(i) ‘Limited’ exception 
 
The Panel found that the regulatory review exception was a ‘limited exception’ as it was 
“confined to conduct needed to comply with the requirements of the regulatory review 
process”207 and would amount to a “narrow curtailment”208 of the legal rights of the patent 
holder. The reasoning for the Panel’s decision was that to prohibit all manufacturing and 
use of the patented product would amount to an extension of the period of the patent 
holders’ exclusivity beyond the 20 year period to the time after the patent expired that 
competitors could place their generic product on the market209.  Conversely, although the 
stockpiling provision was only available to non-right holders who had also invoked the 
regulatory review provision, and was only permitted during the last six months of the 
patent term, the Panel concluded that this provision was not a ‘limited exception’.210  The 
reasoning for this decision was that the stockpiling provision did not set any limitations 
on the quantity of the product, and as a result this would significantly restrict the patent 
holder’s benefit of extended market exclusivity after the patent had expired211. The Panel 
considered it unnecessary to determine whether the stockpiling provision satisfied the 
second and third requirements of Article 30 as it had failed to satisfy the first 
requirement.212 
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Hestermeyer reasons that the Panel adopted a narrow interpretation of the term 
‘limited’ by finding that an exception is by characterisation narrow, and the inclusion of 
‘limited’ further restricts the scope of the exception213.  However, this narrow 
interpretation has been criticised as being too narrow as the Panel should have taken into 
account the objectives and principles of TRIPS documented in Articles 7 and 8214.  The 
Panel confirmed that the WTO Dispute Settlement Body has to follow the customary rules 
of interpretation set out in Articles 31 and 32 VCLT when interpreting WTO agreements, 
including TRIPS, stating that “[T]he rules that govern the interpretation of WTO 
agreements are the rules of treaty interpretation stated in Articles 31 and 32 of the Vienna 
Convention”.215 Articles 7 and 8 of TRIPS are part of the context of Article 30 and also 
speak to the object and purpose of the agreement.  Articles 7 and 8 recognise that a 
balancing of interests is required when interpreting TRIPS and that Members may adopt 
measures necessary to protect public health, so limited exceptions should be permitted if 
they pursue purposes set out in Articles 7 and 8216. Therefore, by failing to fully apply 
Articles 7 and 8 the Panel’s approach fails to consider fully why an exception may be 
required under TRIPS, such as to ensure access to essential medicines, and so does not 
appropriately balance those competing interests as required under Article 7. The Panel’s 
interpretation also contradicts the conclusion of the Appellate Body in EC-Hormones217 
that the characterisation of a provision as an exception does not by itself justify a stricter 
interpretation of that provision218.  The Panel’s approach reversed the burden of proof to 
requiring the respondent to demonstrate that the exception does fall within Article 30 
instead of the claimant being required to demonstrate prima facie that the exception does 
not fall within Article 30219.  This directly contradicts the Appellate Body’s decision in 
EC-Hormones220 which states that the general rule in dispute settlement proceedings that 
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the burden of proof lies with the claimant to establish a prima facie breach of a provision 
“is not avoided by simply describing that same provision as an “exception.””221 
  A further argument relating to the inconsistencies in the Panel’s interpretation of 
Article 30 is that, in considering the patent holder’s market exclusivity when finding that 
the stockpiling provision did not amount to a limited exception, the Panel did address the 
economic impact of the first requirement, even though it had in the course of its decision 
stated that this was not intended to be addressed by this requirement.222  This further 
highlights a potential ambiguity as to the application and interpretation of the ‘limited 
exception’ requirement.  
 
(ii)  Do not unreasonably conflict with normal exploitation of the patent 
 
The Panel defined the normal approach to exploitation by patent holders as having the 
right to “exclude all forms of competition that could detract significantly from the 
economic returns anticipated from a patent’s grant of market exclusivity.”223 The Panel 
also considered that the period of market exclusivity which existed after the patent had 
expired was ‘normal’.  This indicates the Panel’s emphasis on protecting patent rights, by 
failing to balance this interest with the social interest of protecting public health by 
promoting better access to essential medicines. This position highlights that it is likely 
that the stockpiling provision would have been found to be inconsistent with this 
requirement of Article 30, as having an unlimited stockpile which could be marketed 
immediately upon expiry of the patent would inhibit the patent holder’s market 
exclusivity.  However, the Panel acknowledged that pharmaceuticals are subject to the 
government’s regulatory review process, which can be a rigorous and lengthy process to 
ensure the safety and effectiveness of the product, and this form of regulatory review is 
not usually applicable to other types of patented products224.  Therefore this extended 
period of market exclusivity for pharmaceuticals was considered to give “a greater than 
normal period of market exclusivity to the enforcement of certain patent rights”225 and the 
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regulatory review provision did not unreasonably conflict with normal exploitation of the 
patent. 
 
(iii) Not unreasonably prejudice the legitimate interests of the patent holder, taking into 
account the legitimate interests of third parties 
 
The specific wording of this requirement implies a need to balance the interests of the 
patent holder with competing third party interests, with scope to present the argument that 
public health is a legitimate third party interest, with reference to Article 8(1)226.  The 
Panel considered that the regulatory review provision did not unreasonably conflict with 
the patent holder’s legitimate interests227.  However the basis of its decision was that the 
“effective period of market exclusivity had been reduced by delays in marketing approval 
was neither so compelling nor so widely recognized that it could be regarded as a 
"legitimate interest" within the meaning of Article 30 of the TRIPS Agreement”228.  This 
highlights that the Panel prioritised the patent holder’s interests over any balancing with 
competing third party interests, despite the explicit language of Article 30.   
The Panel’s emphasis on the legitimate economic interests of the rights holders is 
evident in its statement that “the weight of legitimate third party interests cannot be fully 
appraised until the legitimacy and weight of the patent owner's legitimate interests, if any, 
are defined”229.  Howse argues that by doing so “one can silence competing social and 
economic interests entirely by starting off with defining the rights holder’s interests as so 
weighty or fundamental that other legitimate interests cannot possibly outweigh the 
prejudice to rights holder’s interests.”230  This seems to suggest an imbalance, with the 
Panel’s focus on the interests of the patent holder.  In considering how else the Panel 
could balance this third stage of the test under Article 30, a comparison could be drawn 
with EU law, specifically the Court of Justice decision in Schmidberger v Austria231.  The 
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Court decided that free movement of goods and the right to assembly under the ECHR 
were both legitimate interests, were not absolute, and were competing rights of equal 
weight to be weighed with regard to all circumstances to ensure a fair balancing232.  Were 
the Panel to follow this approach, this would involve recognising the right to health under 
Article 12 ICESCR as a legitimate interest of third parties to be balanced with the 
legitimate interests of the patent holder under TRIPS, and applying the balancing test so 
as to consider not only the patent’s holder’s economic interests, but the right to health 
under Article 12 ICESCR.  Therefore, applying the balancing test and giving equal weight 
to the competing interests.   
However, a distinction may be drawn in that the Schmidberger233 case outlines 
the recognition in EU law that the EU must respect fundamental rights as an integral part 
of the general principles of law and the significance the ECHR in this respect234, so it is 
reasonable to propose that human rights norms of the ECHR are integrated in EU law. In 
comparing this position to WTO law, the Article 12 ICESCR right to health is an external 
norm, it is not as integrated into the WTO trade law system in contrast to the position in 
relation to ECHR norms in EU law, so it is difficult to argue that this level of engagement 
can apply in the context of WTO dispute settlement.  The Schmidberger235 case 
demonstrates engagement with a human rights norm as a general principle of law236, and 
as Article 38(1) ICJ Statute outlines, ‘general principles of law of civilized nations’237 are 
sources of international law.  Article 31(3)(c) VCLT states that any relevant rules of 
international law applicable in the relations between the parties shall be taken into account 
in treaty interpretation238.  Article 31(3)(c) VCLT covers Article 38(1) ICJ Statute239 so 
that, when interpreting a TRIPS provision, Article 12 can be taken into account if it has 
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reached the threshold of a general principle of international law240.  Article 12 ICESCR 
could be brought into the interpretative process even where it is not yet a general principle 
of international law, as a supplementary means of interpretation under Article 32 
VCLT241.  The rules of treaty interpretation can be utilised to allow external norms to be 
taken into account in the WTO framework to an extent, although perhaps not to the same 
extent as the level of integration of ECHR norms in EU law as outlined in 
Schmidberger242. 
The starting point for the Panel in Canada – Patent Protection for Pharmaceutical 
Products when interpreting TRIPS provisions is Article 31(1) VCLT which states: "A 
treaty is to be interpreted in good faith in accordance with the ordinary meaning to be 
given to the terms of the treaty in their context and in the light of its object and 
purpose."243  The provisions of a treaty are to be given their ordinary meaning in their 
context, which is to be informed by the object and purpose of the treaty. These are not 
hierarchical tests, as confirmed by the ILC244, and should be viewed as a rule of 
interpretation.  Therefore TRIPS must be interpreted in good faith and in light of its 
ordinary meaning taking into account its objectives and purpose, which are embodied in 
Articles 7 and 8.  Articles 7 and 8 are directly about interpreting TRIPS, and are therefore 
treaty interpretation provisions internal to TRIPS, which the Panel should have referred 
to in interpreting Article 30.  The relevance of Articles 7 and 8 to the interpretation of 
TRIPS provisions was recognised in this case, with the Panel stating that they must be 
“borne in mind”245 when interpreting Article 30. However this does not go far enough.  
Article 30 is a permitted exception to patent rules so is qualified, but its object and purpose 
and Articles 7 and 8 must be considered when interpreting the provision. This requires a 
balancing of these standards but it is questionable if the Panel got the balance right 
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because it did not provide an appropriate analysis of Articles 7 and 8.  The Panel’s 
position indicates a missed opportunity to adopt an interpretation of Article 30 in line 
with the objectives of TRIPS Articles 7 and 8, in order to set a precedent in dispute 
resolution proceedings that the protection of public health is a legitimate exception to 
patent protection.  The narrow interpretation of this requirement and the focus on the 
potential economic losses of the patent holder failed to adequately identify when a 
legitimate interest of third parties can justify an exception to patent protection for 
pharmaceuticals under Article 30.  The regulatory review and stockpiling measures have 
been described as “incidental measures”246, which suggests that if these provisions are 
considered narrowly then other, more significant provisions introduced to reduce the price 
of patented medicines may be held to be inconsistent with TRIPS obligations.   
Rights holders are likely to take the view that Article 30 as an exception should 
be interpreted narrowly. However, academics have expressed a lack of support for this 
view247.  Academic literature has highlighted that the Panel appears to indicate that the 
individual provisions in TRIPS, such as Article 30, which set minimum standards of IP 
rights protection already reflect the intended balance outlined in the Preamble248 and so 
Articles 7 and 8 need not be considered249.  Frankel and Slade argue that this is not what 
Article 31 VCLT suggests is correct treaty interpretation as this would mean that Articles 
7 and 8 have no meaning250. This does not seem to be the correct approach as it cannot 
be the intentions of the parties to TRIPS for Articles 7 and 8 to have no practical effect.   
Yu points out the importance of Articles 7 and 8 to developing countries in terms of 
establishing that IP rights are intended to benefit society as a whole251. Therefore it is 
important to give due weight to Articles 7 and 8 in accordance with general rules of treaty 
interpretation so that a proper balancing is carried out.  Discussions in the literature have 
further proposed that Articles 7 and 8 could be used to define a maximum standard of IP 
protection252, although this approach could go too far in having a limiting effect on the 
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flexibilities within TRIPS and the flexibility of Members to implement the most 
appropriate IP standards in national law. While this view may be a little too expansive in 
terms of the intentions of the parties to the agreement, the Panel should consider the value 
of Articles 7 and 8 for interpretive purposes when interpreting Article 30. 
When discussing the three-stage test, The Panel referred to legitimate interests as 
those that are justifiable in that they “are supported by relevant public policies or other 
social norms”253. Therefore interpreting a ‘legitimate interest’ to include wider social 
interests such as public health and the objectives in Articles 7 and 8 would indicate a more 
balanced test.  The Panel should have broadened discussion of the interpretation of 
‘legitimate interest’ with reference to Articles 7 and 8, and then the issue of access to 
medicines as balanced with the interests of the right holder254.  By considering all of the 
relevant circumstances including not only the patent holder’s economic interests, but the 
interests of the users of the patented medicines, and wider societal interests in relation to 
promoting public health, this could have led to a more even balancing under the three-
stage test.  However, the Panel primarily considered the potential economic loss to the 
right holder,255 and in doing so interpreted the patent provisions of TRIPS from the 
perspective of the patent holder, failing to carry out an appropriate balancing provided for 
in the objectives and purpose of TRIPS in Articles 7 and 8, and failing to interpret TRIPS 
in light of the customary rules of treaty interpretation under Article 31 VCLT.  Therefore 
the Panel decision did not adequately consider the issue of access to essential medicines 
as a serious public health concern, and reduced “considerably the range of regulatory 
diversity permitted under TRIPS”256.  The failure to balance social interests and economic 
interests, despite this balancing of obligations being a stated purpose within TRIPS 
Articles 7 and 8 brings into question the efficacy of the scope of the Article 30 exception 
in improving access to cheaper generic medicines.  Therefore reliance upon this provision 
by WTO Members is unlikely, and if the exception cannot be utilised then its purpose is 
undermined. 
 
(iv) Implications resulting from the Panel decision 
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Following this decision it is difficult to be optimistic as to whether the WTO Dispute 
Settlement Body (DSB) will take full account of the right to health under Article 12 
ICESCR in its interpretation and implementation of Article 30 TRIPS, as the Panel in this 
case did not pay due attention to the provisions in TRIPS to assist in its interpretation.  
However, Frankel argues this is exactly the analysis that the object and purpose of the 
TRIPS Agreement requires a Panel to do, and the failure to apply Article 31 VCLT 
interpretation to its fullest extent and then having recourse to Article 32 leaves the Panel 
decision open to criticism257. This analysis suggests that, had the Panel fully applied the 
customary rules of interpretation in VCLT, and the internal interpretive provisions in 
Articles 7 and 8, the outcome in relation to the stockpiling provisions could have been 
decided differently, which would have been a positive outcome in relation to enhancing 
access to medicines. 
Although the Panel did not pronounce on the interpretation of Articles 7 and 8 in 
relation to Article 30, a positive perspective is that the Appellate Body can do so in future 
cases. The Appellate Body did not pronounce on Articles 7 and 8 in Canada – Term of 
Patent Protection, stating that they still await appropriate interpretation258, but in light of 
the criticism of the Panel decision in Canada-Patent Protection for Pharmaceutical 
Products259 the Appellate Body might take the view of providing some clarification in 
future.  Going forward, the Doha Declaration provides an authoritative interpretation of 
TRIPS, and gives more weight to the need for a proper balancing and consideration of 
Articles 7 and 8 for the purpose of public health. Paragraph 5 of the Doha Declaration 
confirms the need to interpret TRIPS provisions in light of its object and purpose outlined 
in Articles 7 and 8260. The Doha Declaration is a ‘subsequent agreement’ under Article 
31(3)(a) VCLT261, and therefore should be taken into account when interpreting TRIPS.  
The Doha Declaration also confirmed that TRIPS should be interpreted in a manner 
supportive of WTO Members’ right to protect public health, in particular to promote 
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access to medicines262.  A further cause for optimism is the Panel decision in the recent 
Plain Packaging263 case, where, in relation to the interpretation of an exception to 
trademark protection under Article 20, the Panel affirmed that TRIPS is to be interpreted 
in light of the provision in Article 8 that Members may adopt measures to protect public 
health264. The Panel also found that the Doha Declaration was a subsequent agreement 
under Article 31(3)(a) VCLT and TRIPS must therefore be interpreted in light of 
paragraph 5 of the Declaration265.  Therefore, this decision could have an important 
impact in future cases relating to Article 30 TRIPS in terms of the appropriate 
interpretation of the exception to give due weight to Article 8 and Members’ public health 
objectives, including to improve access to medicines. 
 
IV(ii). Article 31 
 
Article 31 details the circumstances where other use of a patented product can be 
permitted without the authorisation of the patent holder, provided that the conditions in 
Article 31(a)-(l) are satisfied. Article 31 states: 
 
“Other Use Without Authorization of the Right Holder 
 
Where the law of a Member allows for other use of the subject matter of a patent without 
the authorization of the right holder, including use by the government or third parties 
authorized by the government, the following provisions shall be respected: 
 
(a) authorization of such use shall be considered on its individual merits; 
 
(b) such use may only be permitted if, prior to such use, the proposed user has made 
efforts to obtain authorization from the right holder on reasonable commercial terms and 
conditions and that such efforts have not been successful within a reasonable period of 
time.  This requirement may be waived by a Member in the case of national emergency 
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or other circumstances of extreme urgency or in cases of public non-commercial use.  In 
situations of national emergency or other circumstances of extreme urgency, the right 
holder shall, nevertheless, be notified as soon as reasonably practicable.  In the case of 
public non-commercial use, where the government or contractor, without making a patent 
search, knows or has demonstrable grounds to know that a valid patent is or will be used 
by or for the government, the right holder shall be informed promptly; 
 
(c) the scope and duration of such use shall be limited to the purpose for which it was 
authorized, and in the case of semi-conductor technology shall only be for public non-
commercial use or to remedy a practice determined after judicial or administrative 
process to be anti-competitive; 
 
(d) such use shall be non-exclusive; 
 
(e) such use shall be non-assignable, except with that part of the enterprise or 
goodwill which enjoys such use; 
 
(f) any such use shall be authorized predominantly for the supply of the domestic 
market of the Member authorizing such use; 
 
(g) authorization for such use shall be liable, subject to adequate protection of the 
legitimate interests of the persons so authorized, to be terminated if and when the 
circumstances which led to it cease to exist and are unlikely to recur.  The competent 
authority shall have the authority to review, upon motivated request, the continued 
existence of these circumstances; 
 
(h) the right holder shall be paid adequate remuneration in the circumstances of each 
case, taking into account the economic value of the authorization; 
 
(i) the legal validity of any decision relating to the authorization of such use shall be 
subject to judicial review or other independent review by a distinct higher authority in 
that Member; 
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(j) any decision relating to the remuneration provided in respect of such use shall be 
subject to judicial review or other independent review by a distinct higher authority in 
that Member; 
 
(k) Members are not obliged to apply the conditions set forth in subparagraphs (b) 
and (f) where such use is permitted to remedy a practice determined after judicial or 
administrative process to be anti-competitive.  The need to correct anti-competitive 
practices may be taken into account in determining the amount of remuneration in such 
cases.  Competent authorities shall have the authority to refuse termination of 
authorization if and when the conditions which led to such authorization are likely to 
recur; 
 
(l) where such use is authorized to permit the exploitation of a patent ("the second 
patent") which cannot be exploited without infringing another patent ("the first patent"), 
the following additional conditions shall apply: 
 
(i) the invention claimed in the second patent shall involve an important 
technical advance of considerable economic significance in relation to the 
invention claimed in the first patent; 
 
(ii) the owner of the first patent shall be entitled to a cross-licence on 
reasonable terms to use the invention claimed in the second patent;  and 
 
(iii) the use authorized in respect of the first patent shall be non-assignable 
except with the assignment of the second patent.” 
 
 
Although not explicitly stated, this provision applies to the practice of compulsory 
licensing.266  Compulsory licensing under TRIPS has been utilised in relation to medicines 
where a WTO Member that has implemented TRIPS into national legislation, grants a 
licence to a generic manufacturer to produce a medicine that is under patent in that 
Member state at cheaper cost. This licence is granted without the patent holder’s 
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authorisation irrespective of the holder’s exclusive rights over the patented medicine. 
Compulsory licences can be issued by governments and such licences are not restricted 
to the manufacturer which holds the patent, but can also be issued to other pharmaceutical 
manufacturers. Multiple manufacturers producing generic copies of the patented 
medicine can increase competition in the market leading to lower prices.  Increased 
production of such medicine will also lead to an increased supply, with the aim of 
ensuring that essential medicines are available at an affordable cost during public health 
emergencies.  The construction of Article 31 indicates that the provision does not 
explicitly set limitations on the grounds upon which compulsory licenses can be granted 
but merely states the conditions that WTO Members should observe, although all 
conditions are mandatory.267  Therefore, WTO Members have flexibility as to how to 
utilise this provision, in theory assisting WTO Members in developing better access to 
essential medicines by allowing WTO Members to circumvent a patent in order to make 
available medicines to treat public health crises.  If the WTO Members clearly outlined 
the circumstances in which compulsory licences may be requested, this could add an 
additional impediment for WTO Members aiming to use Article 31. While the WTO 
Members have the flexibility to implement compulsory licensing provisions to satisfy 
domestic requirements, the additional structural and legislative burden before a 
compulsory licence could be granted may result in less flexibility and deter some WTO 
Members from engaging in the process. This flexibility gives Members scope to use this 
provision for public health purposes, however Members, in particular developing 
countries have faced challenges is using this provision to enhance access to medicines. 
Matthews argues that this challenge existed because the exception provision under 
Article 31 was too onerous for developing countries to use, due to the requirements within 
Article 31 (a)-(l) above, which must be respected before a compulsory licence could 
validly be issued268.  Developing countries may lack the bargaining power by which to 
attempt to negotiate a voluntary licence in the first instance, as is required under Article 
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31(b). It is also unclear as to what would amount to a ‘reasonable’ period of time in which 
to negotiate before it is permissible to pursue a compulsory licence.  Article 31(h) does 
not explicitly state what amounts to ‘adequate remuneration’ which was to be paid to the 
patent holder whose patent was circumvented by the compulsory licence. If ‘adequate’ 
remuneration was required to be almost the present market value, then the issuing of the 
compulsory licence would be futile.   
A particular problem with the provisions under Article 31 has related to Article 
31(f), which required that the medicines for which a compulsory licence was issued had 
to be predominantly for the domestic use of the WTO Member which issued that licence.  
This was problematic for WTO Members, particularly developing and least developed 
states that do not have the requisite manufacturing capacity to produce the necessary 
medicines for domestic use, and therefore relied on imports 269.  There is a clearly held 
view in the academic literature that Article 31 has failed to assist least developed and 
developing countries, which need the most support as these countries have little or no 
manufacturing capacity and therefore could not rely on the compulsory licensing 
provision270. This provision also prevented developing countries from importing essential 
medicines from countries with the necessary manufacturing capacity.  WHO observed 
that compulsory licensing “is useful for the small group of developing countries (such as 
Brazil, India, and South Africa) that have a high-quality generics sector with the know-
how and capacity to produce for the home market”271. However this provision is of little 
use to those countries lacking the capacity to produce pharmaceuticals domestically and 
therefore must import medicines which are under patent.  Developing and developed 
countries with manufacturing capacity could not export because of this requirement, 
demonstrating an impediment to access and availability because they could not meet the 
non-domestic demand for essential medicines.  States with the manufacturing capacity 
risked litigation from the patent holders if they misinterpreted the TRIPS flexibilities and 
scope.   
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A number of disputes relating to compulsory licensing brought the debate to the 
fore272. In 1998 thirty-nine pharmaceutical companies challenged the South African 
government in its constitutional court over its national legislation relating to compulsory 
licensing and parallel imports of medicines patented in South Africa.  However the 
negative reaction to this action and subsequent bad publicity caused the action to be 
withdrawn.273  In 2001 the US government took an action to the WTO against Brazil, 
which had issued compulsory licences for medicines owned by US pharmaceutical 
companies that were patented in, but had not been produced in Brazil.  This action was 
also settled.274 Also in 2001, following 9/11, USA and Canada were subject to anthrax 
threats, and used the threat of issuing a compulsory licence to negotiate a voluntary 
licence with the German pharmaceutical company Bayer for the production of its patented 
drug for the treatment of anthrax.275 This action appeared as a double standard following 
the US approach to Brazil.  Abbott argues that “no responsible government with a choice 
would place the public health of its citizens below the interests of a few patent holders”276, 
but in reality it is difficult for developing countries to use the threat of issuing a 
compulsory licence as an inducement in negotiations for a voluntary licence, because of 
their generally weaker position in the global market.  There is a risk for developing 
countries that in making such threats, they will bear consequences in future trade 
negotiations, and will lose any goodwill with the patent holder companies.277 For example, 
in 2007 Thailand was subjected to international political pressure, as a result of issuing a 
compulsory licence for Kaletra, a medicine used to treat HIV owned by Abbott 
Laboratories in the US.278  Such pressure came from US and EU despite that fact that the 
compulsory licence was legitimately issued.  Following the issue of the compulsory 
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licence, the patent holding company decided to withdraw applications for regulatory 
approval of several other medicines from Thailand.  Although in this case the Thai 
government had not attempted to negotiate a voluntary licence on this occasion279, the 
reaction of the patent holder company demonstrates that a compulsory licence can be a 
hostile device and may result in retaliatory measures.  Therefore the threat of a 
compulsory licence may be ineffective as well as counterproductive for developing 
countries. 
 
V. Doha Declaration 
 
The Doha Declaration280 sought to address the challenges of Members lacking 
manufacturing capacity to make use of the compulsory licensing provision under Article 
31. The Declaration affirmed that “the Agreement can and should be interpreted and 
implemented in a manner supportive of WTO members' right to protect public health and, 
in particular, to promote access to medicines for all.”281 The Declaration provided explicit 
clarification that TRIPS can and should be interpreted by WTO Members in such manner 
as necessary to promote public health and to combat public health crises, and is a 
significant statement on the interpretation of TRIPS. This also supports the objective set 
out in Article 8, adding further clarity to the existing interpretative framework of TRIPS. 
Paragraph 5 also confirms that Members have discretion as to the grounds and 
circumstances as to when a compulsory licence can be granted, confirming that Article 
31 does not limit the grounds for the grant of a compulsory licence282. Paragraph 5 also 
provides clarity with regard to the discretion of Members to determine a ‘national 
emergency’, and recognises that public health crises can be a national emergency, 
justifying the grant of a compulsory licence without prior negotiation on a voluntary 
licence283.  As discussed in Chapter 1, the Declaration amounts to a subsequent agreement 
under Article 31 VCLT and is therefore an important tool for the interpretation of TRIPS 
in light of public health objectives including access to medicines. 
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The route to the Doha Declaration was driven by global health crises, primarily 
the HIV/AIDS pandemic.  The access to medicines debate was placed on the agenda of 
the General Council meeting in 2001 by African nations284, with the developing countries 
sending “a clear signal that they were determined to reverse the unbalanced outcome of 
the Uruguay Round in the future new round of multilateral trade negotiations”285 by 
requesting clarification on the interpretation and application of the flexibilities within 
TRIPS, specifically in relation to access to medicines.  The result was the adoption of the 
Doha Declaration by the WTO Ministerial Conference on 14 November 2001.   
 
The Declaration included a clear statement in paragraph 6 that: 
 
 “[W]e recognize that WTO members with insufficient or no manufacturing capacities in 
the pharmaceutical sector could face difficulties in making effective use of compulsory 
licensing under the TRIPS Agreement. We instruct the Council for TRIPS to find an 
expeditious solution to this problem and to report to the General Council before the end 
of 2002.”286 
 
The Implementation Decision287 of TRIPS Council on 30 August 2003, in satisfaction of 
paragraph 6 of the Doha Declaration, stated that:   
 
“The obligations of an exporting Member under Article 31(f) of the TRIPS Agreement 
shall be waived with respect to the grant by it of a compulsory licence to the extent 
necessary for the purposes of production of a pharmaceutical product(s) and its export 
to an eligible importing Member(s) in accordance with the terms set out below in this 
paragraph:”288  
 
This amounted to a waiver of the obligation on exporting WTO Members under Article 
31(f) to allow export of medicines to countries without sufficient manufacturing capacity.  
Also agreed was a waiver of the domestic use obligation under Article 31(h) for importing 
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countries to provide adequate remuneration where the exporting country has already paid 
the remuneration for the same product.289  The reference to ‘pharmaceutical products’ also 
demonstrates that the Decision was not limited to medicines only, permitting a wider 
scope for the type of products which may be imported. 
The Implementation Decision was a significant development from the Doha 
Declaration, as developing countries were permitted to import medicines under a 
compulsory licence with the General Council agreeing a temporary waiver of the 
domestic use requirement under Article 31(f),290 referred to as the ‘paragraph 6 waiver’.  
This meant that the exporting WTO Member was not required to produce the 
pharmaceuticals predominantly for domestic use, and could produce the quantity of 
necessary medicines to meet the demand of a developing WTO Member.  This provision 
was intended to make the compulsory licensing provision in TRIPS more effective, as 
developing and least developed countries with the inability to manufacture the medicines 
domestically were unable to utilise this TRIPS provision. However discussion in the 
literature reflects the view that the Declaration and Implementation Decision did not 
eliminate all of the problems generated by TRIPS, and related concerns including that 
economic pressures would dissuade developing countries from utilising the waiver.291  
This raises the question of how effective the Implementation Decision has been in 
improving access to medicines. 
As noted in Chapter 1, the General Council Ministerial Decision on 6 December 
2005292 provided for an amendment to TRIPS to insert Article 31(bis). This amendment 
incorporates the TRIPS Council Decision on the implementation of paragraph 6 of the 
Doha Declaration into TRIPS, ensuring that the waiver of the domestic use requirement 
under Article 31(f) becomes permanent. This is the only amendment to TRIPS, which it 
could be argued demonstrates that the agreement itself is working appropriately.  The 
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amendment was approved by the requisite number of WTO Members on 23 January 
2017293, eleven years after it was approved by the General Council. 
 
VI. After Doha 
 
An objective of the Implementation Decision was to ensure that newer medicines reached 
individuals in need more rapidly294, by clarifying that WTO Members had the freedom to 
realise national public health objectives by using the harmonised IP provisions under 
TRIPS. However, the Implementation Decision was another compromise between the 
competing interests of the needs of developing and least developed countries seeking 
greater clarity on the flexibilities of TRIPS in respect of manufacturing patented 
medicines to treat health emergencies, and those WTO Members with large 
pharmaceutical manufacturing industries that wanted to preserve strict IP protection.   An 
example of the compromise is evident in the requirements that must be satisfied in order 
to take advantage of the paragraph 6 waiver. In particular, the requirements that the 
exported product must be clearly labelled and distinguishable from the patented version 
in terms of shape, colour and packaging demonstrates a compromise between ensuring 
that compulsory licensing could be used effectively for the furtherance of global public 
health aims, and the developed Members’ concerns over trade diversion of the exported 
product.  A United Nations Development Programme (UNDP) Discussion Paper295 
reviewing the implications of the Doha Declaration over a ten year period noted that the 
Doha Declaration was a significant achievement as it recognised the severity of the public 
health problems in developing and least developed countries. It also acknowledged the 
issue of cost of medicines and the effect of TRIPS on medicine prices, and emphasised 
that governments have a duty to interpret TRIPS as necessary to achieve public health 
goals.   
This Discussion Paper specifically addressed the tensions between the Doha 
Declaration and the right to health, noting the conflict, in certain contexts, between IP as 
an incentive to stimulate innovation and the international human right to health.296  The 
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Paper also considered the extent to which the Doha Declaration has contributed to 
achieving its main objective, being confirmation of the right of any WTO Member to use 
the TRIPS flexibilities to promote access to medicines. It concluded that while the Doha 
Declaration “has had a clear impact on the international discourse relating to IPRs and 
access to medicines”,297 it “has not been sufficient to prevent TRIPS-plus demands, 
concession and commitments in FTAs and other bilateral agreements that may negatively 
affect access to medicines.”298 The Paper places the review of the Doha Declaration in a 
human rights context and emphasises the urgent need to find a solution to impediments 
to access and availability.299 However the Paper’s conclusion on the success of the Doha 
Declaration in achieving its objective demonstrates that while it succeeded in bringing to 
an international platform the debate on affordability and access to medicines, it has so far 
not been successful in achieving improvements to access to essential medicines for all. 
Matthews argues that the ineffectiveness of the Doha Declaration is that the 
compulsory licensing process resulting from the Implementation Decision is burdensome 
and arduous to use300. Both the importing and exporting countries have to issue 
compulsory licences and the importing country has to demonstrate insufficient 
manufacturing capacity.  The Decision does not prescribe a specific method of 
establishing insufficient manufacturing capacity,301 which may cause uncertainty as to 
which countries may rely on this provision.  Administrative requirements must also be 
complied with, including issuing notice to the WTO. The information required includes 
the quantities required by the importing country, and the use for the drug and requires 
detailed information from the importing country at the outset. Information on the specific 
labelling and marking of the drug is required to counteract the risk of parallel importation. 
This requirement can be costly for the exporting country, and as a result this may act as a 
disincentive to generic manufacturers to engage in exporting medicines to developing and 
least developed countries. Another issue is that the process “fails to take into account that 
flexibility and rapidity of response to ever-changing circumstances are vital”302, 
highlighting that these onerous requirements must be satisfied before the compulsory 
licence can be issued.  This also reflects that access to medicines in emergencies during 
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public health crises requires immediate action, which may be difficult to respond to under 
the current compulsory licensing requirements. 
The paragraph 6 waiver resulting from the Implementation Decision amounted to 
an exception to the domestic use restriction under Article 31(f). This exception amounts 
to a waiver of the restriction on exports of pharmaceuticals, allowing any WTO member 
to export pharmaceutical products, produced under compulsory licensing, to countries 
with no manufacturing capacity in the pharmaceutical industry.  Difficulties in the 
application of this mechanism can be evidenced by the fact that there has been only one 
case where this has been relied upon in over ten years since the waiver was agreed.  In 
2007 the Canadian and Rwandan governments issued compulsory licences for Canadian 
generic manufacturer Apotex to supply Rwanda with antiretroviral drug Apo-Triavir to 
treat HIV/AIDS.  In accordance with the requirements of the Implementation Decision303  
Rwanda as the importing WTO Member had to notify the TRIPS Council of its need.  
Then it was required to specify the names and expected quantities of the product(s) 
needed; to confirm that it had insufficient or no manufacturing capacity in the 
pharmaceutical sector;304 and to confirm that it had granted or intended to grant a 
compulsory licence in relation to the required product.  Canada as the exporting Member 
had to issue a compulsory licence upon the conditions that only the quantity of 
pharmaceutical products necessary to meet Rwanda’s needs was to be manufactured and 
exported, the pharmaceutical products produced under the licence were to be clearly 
distinguishable from the patented product. Prior to exporting the product manufactured 
under the licence, the information relating to the quantity and distinguishing features of 
the product was posted on the WTO website. 
This transaction was only completed on one occasion, with a single supply of the 
required medicines being provided to the importing country.  Apotex was critical of the 
process, arguing that the “fact that countries cannot place a simple order or extend a tender 
for a specific product but have to initiate what is perceived to be a ‘political’ or legal 
process is in itself intimidating.”305  This supports the assertion that the administrative 
requirements are demanding, particularly as the need is a public health need which should 
be managed expeditiously.  The company also commented that the “process is, for the 
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most part, invisible to most agencies in countries that would access it.”306 This suggests 
that developing WTO Members are not taking advantage of the paragraph 6 waiver 
because the relevant governments are unaware or uninformed of the availability of this 
process.  It may be contended that greater support from developed WTO Members is 
needed for importing Members during the application process, instead of a focus on 
protection of the patent holder’s product.  Developed Members which have sufficient 
expertise could provide technical assistance which may help to make this mechanism 
more effective.  This further indicates that support from developed WTO Members could 
be valuable in apprising developing Members of the process. 
Apotex, as of March 2020 the only pharmaceutical manufacturer to have been 
through the complete process of using the paragraph 6 waiver to supply generic 
antiretroviral drugs, has not repeated the process. The company’s experience highlights 
why developing countries are unlikely to rely on the paragraph 6 waiver to import generic 
medicines.  If the manufacturing industries within developed WTO Member countries 
considered that it was difficult to satisfy the export requirements under the mechanism 
then it is unlikely that they would continue to use it.  If developing WTO Members cannot 
engage a developed Member with sufficient manufacturing capacity with the process then 
the problem of providing an adequate supply of medicines to the population is not 
resolved.   
Academics have proposed several reasons for the lack of use of the waiver, 
including that the cost of the medicines imported by Rwanda was still higher than the cost 
of comparable Indian generic medicines307.  This suggests that in addition to the process 
being burdensome, it was also not cost-effective and does not achieve the purpose of 
promoting the use of compulsory licensing for pharmaceuticals to treat pandemics and 
life limiting diseases.  A further issue is that the waiver fails to allow developing countries 
to take advantage of cheaper generic medicines through economies of scale.308 This is 
problematic in terms of encouraging generic manufacturers to invest in producing 
medicines under the Canadian regime, as the limitations on the quantities of medicines 
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would make it difficult to recoup the development costs. It is a significant challenge as 
although the Canadian regime was implemented for the purpose of promoting access to 
medicines, it is the pharmaceutical companies which manufacture the generic medicines 
to be ordered under the regime, and as commercial enterprises they are unlikely to enter 
into a commercial arrangement where they stand to make a loss. 
Another suggested reason is that the lack of dedication in supporting developing 
countries to take the opportunity to utilise the waiver demonstrates that developed WTO 
Members are not willing to share in the transfer of technology to developing countries, 
which could assist them in developing production capacity to meet the needs of their own 
population.309  Under Article 67 of TRIPS, developed Members have an obligation to 
provide financial and technical cooperation to developing and least developed Members 
for the purpose of implementing TRIPS.  This suggests that TRIPS has not supported 
developing countries in their development because they are still reliant upon developed 
Members for imports, and have not benefitted from transfer of technology in order to 
develop domestic production. It questions the effectiveness of the Implementation 
Decision. It is clear that the aim of the Implementation Decision in providing greater 
accessibility to essential medicines for developing countries has so far not been achieved, 
and may indicate that developed countries have focused on the protection of intellectual 
property afforded by TRIPS rather than the dissemination of knowledge and technology 
transfer to developing countries which the agreement can support. 
In contrast, Sykes argues that the Doha Declaration could lead to the erosion of 
patent protection of pharmaceuticals in developing countries.310 Specific concern related 
to the compulsory licensing provision in Article 31(f) which provided that a country could 
issue a compulsory licence in a national emergency without notice to or negotiation with 
the patent holder.311 Sykes argues that strong patent rights for pharmaceuticals are 
necessary for international trade which in turn will benefit developing countries in the 
long term as the strong patent rights will encourage innovation, which will benefit 
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developing countries in the long term.312  It is important to note that patent holders are 
entitled to challenge a compulsory licence on particular grounds, for example, non-
compliance with the legal requirements,313 which may undermine this argument. While 
innovation is necessary to advance medical technologies in order to improve treatment 
for those in need, this position does not address the issue that developing countries are 
still reliant on the exporting country to issue a compulsory licence under the waiver. This 
in turn demonstrates that the developing countries are dependent on other countries to 
provide the particular medicines needed.  This position also does not support the 
development of developing and least developed countries in assisting them to establish 
the capabilities to increase and improve their own manufacturing capacities, to 
manufacture the medicines that are needed domestically. 
 
VII. Implications for public health 
 
The experience of the participants in the Canadian regime suggests that there are 
significant public health concerns resulting from the provisions in TRIPS, and these have 
not successfully been addressed by the Doha Declaration.  The Doha Declaration, and 
subsequent Implementation Decision, was a positive development in terms of promoting 
public health as it was a response to addressing the immediate problem of access to 
medicines. However, the challenges experienced by the participants in the Canadian 
regime in utilising the waiver, coupled with the fact that no other states have attempted 
to utilise the waiver, shows that this mechanism has not been effective in achieving its 
aim of promoting access to medicines314.  It is important to acknowledge that the issue of 
global access to essential medicines requires a response which is much broader than 
simply amending intellectual property protection. Inadequate domestic health care 
systems, lack of infrastructure to distribute medicines in developing and least developed 
countries, and procedural and legislative problems involved in issuing compulsory 
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licences are all contributing factors.  While the Implementation Decision may have 
provided clarification on the flexibilities in TRIPS, and provides an important 
interpretative tool in the analysis of Article 31(f) of TRIPS, it alone cannot provide the 
answer to the problem of improving accessibility and availability of essential medicines.  
Abbott and Reichman also point out that the restrictive administrative requirements of 
Article 31(bis) suggested that the provision resulted as a compromise with the 
pharmaceutical industry, and that it would be difficult to foresee further negotiations on 
the issue within the WTO315. This would indicate a further series of compromises, as well 
as highlighting that pressure from the pharmaceutical industry on pricing is also a 
significant issue for states.  However, as the paragraph 6 waiver is a measure which was 
specifically implemented to improve access to medicines and has not successfully 
achieved this, it is important to explore whether the waiver could be utilised more 
effectively in order to achieve its aim of securing access to medicines for developing 
states. 
In 2015 the WTO produced a working paper316 analysing the impact of the 
paragraph 6 waiver and the ways in which it has been implemented by WTO Members.  
The paper surveyed the methods of implementation, finding that as of July 2015, 51 WTO 
Members had adopted specific implementation provisions at varying levels of detail.317 It 
suggests that the system may be a useful tool for encouraging generic manufacturers to 
participate in the provision of medicines to developing countries, which could stimulate 
competition between creator and generic companies. The paper also found that the system 
“has the potential to serve as a significant procurement tool for access to medicines by 
expanding the base of trade opportunities to meet demand for medicines”318.  Such 
opportunities may include the manufacturing of generic medicines leading to increased 
competition in the market, and promoting favourable trading relationships between 
importing and exporting Members.  However, little use has been made of this so far.  The 
paper was also critical of the annual review mechanism of the paragraph 6 system 
included in the Implementation Decision, which confirmed that the implementation and 
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efficacy of the paragraph 6 system was to be reviewed on an annual basis by the TRIPS 
Council and reported on to the General Council.319 The Paper found that the annual review 
mechanism was not a useful indication of whether the system was functioning properly, 
and that a substantive review was needed. 
In evaluating the system, the paper proposed that there may be a need to simplify 
national measures, and also to encourage suppliers and industry to participate more 
actively by making the process more sustainable and cost effective.320 This proposal could 
go some way to addressing the challenges experienced by the participants under the 
Canadian regime, however it does not fully address the argument in academic literature 
that the waiver itself is too burdensome to be effective321.  The paper also suggested a 
need to review whether the TRIPS-plus provisions under bilateral trade agreements has 
affected prospective use of the system.322  The paper also suggests that political pressures 
may explain the limited use of the system, and a definitive statement is needed to clarify 
that allowing compulsory licensing for the export of medicines under the paragraph 6 
system is a positive advance.323  The paper also aimed to promote discussion within the 
WTO with the aim of ensuring that the paragraph 6 waiver can be used as a “practical 
procurement tool”324 which actively contributes to improving trade in essential medicines 
between exporting countries and importing countries in need. This evaluation indicates 
that there is a need for closer collaboration between Members and the pharmaceutical 
industry in order to make effective use of the paragraph 6 system, and also suggests that 
the cost of medicines is still a barrier to access.  Further, although the system was intended 
to clarify that TRIPS was to be interpreted in a manner supportive of public health 
interests, the fact that clarification is still required on this point suggests that Members 
remain concerned about potential consequences if they were to issue compulsory licenses 
to export medicines. The system was also intended to extend the scope in which 
compulsory licenses could be granted, and the extremely limited use of the compulsory 
licensing provisions in the twelve years between the Implementation Decision and the 
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Paper highlights the ineffectiveness of the system in securing access to medicines for all.  
Therefore the paragraph 6 system cannot be considered to be successful in achieving its 
aim. 
The paragraph 6 waiver does not add considerably beyond TRIPS in terms of 
actually implementing processes to improve access to medicines. It was noted that 
although the difficulties of least developed countries in accessing essential medicines was 
explicitly considered in paragraph 7 of the Doha Declaration, this did not actually provide 
a significant improvement, and further consideration of the issues specifically 
experienced by least developed countries would need to be addressed by the WTO325. 
Paragraph 7 confirmed the commitment of developed countries to assist least developed 
countries by promoting and encouraging technology transfer.  However there is little 
evidence of such commitment being fulfilled in relation to the pharmaceutical industry, 
and particularly in the development of essential medicines needed to treat diseases which 
are prevalent in least developed countries326. While paragraph 7 emphasised the 
commitment of developed countries, it did not explicitly set out the ways in which 
developed Members should fulfil this commitment or a mechanism by which to monitor 
the steps taken to fulfil this commitment.  This suggests that the Doha Declaration did not 
provide assistance to least developed countries, and that further focus on the needs of 
least developed countries by the WTO is needed is order to effectively address the 
accessibility of essential medicines for these countries.  This point further highlights that 
the compromises encountered due to a single system for all WTO Members regardless of 
development may not have been efficacious. 
 
VIII. TRIPS-plus provisions 
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Another key challenge to improving access to medicines is that WTO Members can 
increase the IP protection standards under TRIPS through free trade agreements (FTAs), 
known as ‘TRIPS-plus’ agreements. TRIPS-plus agreements may go beyond TRIPS 
minimum standards in the case of patenting of medicines in several ways, including 
effectively extending the term of patent protection and restricting the use of compulsory 
licensing.327  Matthews argues that developing countries may be subject to pressure to 
agree to TRIPS-plus standards into national law, for fear of otherwise damaging trading 
relationships with developed WTO Members. 328  Therefore, such bilateral pressure could 
add to existing challenges for developing states to balance their obligations under TRIPS 
with their public health goals in relation to enhancing access to medicines. 
 Correa contends that the TRIPS-plus agreements formalised in FTAs have a 
negative impact on development, arguing that it should not be assumed that strict IP 
protection will always promote innovation, and that “the higher the level of protection, 
the better for all trade partners”,329 because the social and economic conditions will also 
have relevance. Social and economic conditions including public health do not always 
benefit from strict IP protection.  There is comparably little research into vaccines and 
treatments for malaria, leprosy and other tropical parasitic diseases330 most commonly 
affecting poorer countries, with the contention that poor countries only benefit from 
research and development when rich countries suffer from a particular disease.331   This 
indicates that IP rights promote research which is commercially valuable and lucrative. It 
also suggests that a harmonised IP regime internationally does not best serve the 
developing countries, particularly in relation to pharmaceutical patents.  Frankel argues 
that although the nature of IP rights is to restrict other parties from using the IP, this 
argument does not justify the restrictions that TRIPS-plus agreements place on 
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developing countries, particularly those countries which depend on using foreign IP for 
development.332 Where the effect of IP protection is to restrict and control innovation, 
then it is difficult to justify having an even higher standard of IP protection than TRIPS 
already affords, through the formation of FTAs. 
The Doha Declaration and paragraph 6 waiver are important measures in the 
interpretation and implementation of TRIPS in light of public health objectives, however 
the measures have not resolved the difficulties experienced in relation to TRIPS-plus 
provisions being included in bilateral free trade agreements, particularly favoured by the 
US and other developed states333. A clearly held view in the academic literature is that 
such agreements further negate the efficacy of the Doha Declaration as they are trade-
focused and reduce the capacity of states to secure access to medicines nationally334.  
Although there are advantages for developing countries to entering into such agreements 
in the form of increased access to the US market, it has been observed that negotiations 
on such agreements are usually confidential, which is inappropriate for taking into 
consideration the interests of all participating states.335  Correa argues that these 
agreements produce only a minor benefit for pharmaceutical companies contrasted with 
the major potential detriment to the poorer countries, and such agreements “give priority 
to narrow commercial interests rather than to improving the lives of people and 
development prospects around the world.”336  This type of agreement could be seen to 
conflict with the principles of TRIPS and the Implementation Decision, as WTO 
Members have agreed that these instruments may be interpreted in a way which promotes 
public health.  Therefore developing countries should not be deterred from granting 
compulsory licences because of a potential risk of consequences on trade relationships 
with developed countries.  However, it was noted that the USA entered into FTAs with a 
                                                            
332 S Frankel, ‘Trade-offs and transparency’(2013) 44(8) IIC 913, 914 
333 P Li and P Lim, ‘A precautionary approach to compulsory licensing of medicines: tempering data 
exclusivity as an obstacle to access’ (2014) 3 IPQ 241, 247 
334 Matthews (n 197); C Correa ‘Implications of Bilateral Free Trade Agreements on Access to Medicines’ 
(2006) 84(5) Bulletin of the World Health Organization 399; F Abbott ‘The Doha Declaration on the TRIPS 
Agreement and Public Health and the Contradictory Trend in Bilateral and Regional Free Trade 
Agreements’ Quaker United Nations Office (Geneva) (QUNO), Occasional Paper No. 14, April 2004; 
Musungu and Oh (n 197); WTO, WIPO, WHO, ‘Promoting Access to Medical Technologies and 
Innovation: Intersections between public health, intellectual property and trade’ (World Trade 
Organization, Geneva 2012) WTO ISBN 978-92-870-3839-5 
335 S Flynn, B Baker, M Kaminski and J Koo, ‘The U.S. Proposal for an Intellectual Property Chapter in the 
Trans-Pacific Partnership Agreement’ (2012) 28 Am. U. Int'l L. Rev. 105, 114-115 
336 C Correa, ‘Bilateralism in Intellectual Property: Defeating the WTO System for Access to Medicines’ 
(2004) 36 Case W. Res. J. Int’l. L. 79, 94 
 74 
 
number of developing countries which amounted to “favourable trading deals in exchange 
for agreement not to issue compulsory licences”337, and that this may be a potential reason 
for the lack of use of the paragraph 6 system under the Implementation Decision. 
FTAs also allow developed countries to restrict the production of generic 
medicines through data exclusivity provisions.  Data exclusivity has the effect of 
preventing the generic manufacturers from using the original data of the patented drug to 
obtain regulatory approval for the generic copy.338  Therefore generic manufacturers have 
to produce their own data on the safety and effectiveness of the generic copy, making the 
production of generics more costly and time consuming, which will have the effect of 
increasing in the cost. TRIPS does not provide for data exclusivity under Article 39.3, 
and the academic literature outlines the view that the US in particular is using the 
negotiation of FTAs to implement TRIPS-plus provisions that it was unsuccessful in 
securing under TRIPS.339 
The Trans-Pacific Partnership (TPP) was signed on 4 February 2016340 with the 
objective of liberalising trade in the Asia-Pacific through tariff reduction.341 The TPP was 
a free trade agreement originally between twelve states, Australia, Brunei, Canada, Chile, 
Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, USA and Vietnam342, and was 
renamed the Comprehensive and Progressive Agreement for Trans-Pacific Partnership 
(CPTPP)343 in 2018, following the withdrawal of the US on 30 January 2017344.  The 
intellectual property chapter proved controversial because it intended to introduce 
intellectual property standards which went far beyond TRIPS345,  including “the most 
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aggressive pharmaceutical intellectual property provisions to date”346, due to proposals to 
grant a mandatory extension of five years to the term of patent protection, to introduce 
patent linkages, as well as increased data exclusivity provisions347.  Significantly, in 
November 2017 it was announced that several of the IP provisions in the agreement had 
been suspended348, including the requirement to adjust the term of patent protection if 
there are unreasonable delays in the patent being issued349, and the requirement for five 
years of protection for test or other data submitted to a regulatory authority for the 
purposes of obtaining regulatory approval to market a pharmaceutical product, or a 
biologic pharmaceutical product350. These provisions were considered to be too extensive 
and far-reaching because they could have had a detrimental effect on medicines prices351 
so the suspension of the provisions is a positive step. However, as they are merely 
suspended, and not withdrawn or redrafted, there remains the possibility that these 
provisions could be restored to the agreement.   The agreement came into force on 30 
December 2018352.  The success or failure of TPP will have implications on future trade 
agreements, and could lead to a change in forum for discussion on issues including the 
achievement of global public health objectives. 
An objective of TRIPS was the harmonising of IP law, introducing uniformity and 
continuity in the scope of rights available to IP owners.  However, bilateral trade 
agreements contradict this intention by supporting the implementation of diverging 
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standards between the parties, contrasted with the international legislative standards set 
out in TRIPS. As these agreements are free trade agreements, it could be argued that 
public health issues are not given sufficient prominence, and therefore responses to global 
health emergencies cannot be adequately comprehended within FTAs.  It could also be 
argued that in agreeing stricter IP provisions as part of FTAs, developing and least 
developed countries will not have an equal opportunity to further development and 
participate in global free trade. Such provisions also raise IP rights protection standards 
globally making international agreements on IP standards redundant. 
 
IX. IP and public health 
 
With the ineffectiveness of the Doha Declaration in significantly improving access to 
medicines for developing countries, as well as the implementation of stricter IP standards 
in FTAs, it may be pertinent to consider other approaches to addressing what is a critical 
global public health concern.  This is highlighted by the actions of intergovernmental 
organisations353 and stakeholders to promote global public health, and including 
multilateral cooperation between the WTO, WHO and WIPO.  In 2010 the WTO, WHO 
and WIPO held the first of a series of joint technical symposia on access to medicines354.  
This collaborative approach also provides an opportunity for policy coherence across the 
organisations on how to promote access to medicines, which is reflected in efforts to build 
on the trilateral study through joint technical symposia including the 2018 symposium 
looking at how innovative technologies can help to achieve the UN Sustainable 
Development Goals related to health355.  However, it is states that have agreed to be 
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subject to obligations under TRIPS, and states also have obligations in relation to 
promoting public health under UN human rights law. 
The right to health is an international human right356, while Article 12 of the 
ICESCR recognises the right of everyone to the enjoyment of the highest attainable 
standard of physical and mental health357.  This right imposes obligations on states to 
uphold this right for the benefit of individuals.  The monopoly rights derived from patent 
protection conflict with human rights “if the product is essential for the enjoyment of 
human rights yet it becomes inaccessible to poor people.”358 Patents conflict with this 
right if the cost of such medicines, based on the manufacturer’s monopoly in the global 
market, makes them inaccessible.  Therefore, taking full account of states obligations in 
relation to the right to health in Article 12 ICESCR could help in interpreting TRIPS in a 
manner conducive to public health goals including enhancing access to medicines.  
However it is also pertinent to highlight that the rights of creators are protected under 
Article 15 of the ICESCR359, while patents form part of the human right to protection of 
property under the European Convention on Human Rights (ECHR)360.  Therefore it is 
also important to consider the rights that patent holders have in their creations, and the 
legal obligations that such rights create in favour of the protection of the rights of creators 
in their creations, such as new medicines. 
While it is important to ensure that essential medicines are made available to 
countries that do not have the capacity to produce them domestically, it is also important 
to support the distribution of medicines to the population of such countries.  Other barriers 
to medicines exist in developing countries, including lack of adequate health care systems 
and health insurance provisions, lack of access to education, and weak infrastructure to 
reach the poorest populations who are most in need.  While the arguments in support of 
patent protection include the stimulation of creativity and innovation, this is not always 
the case, as many new patented medicines are minor modifications to existing medicines 
which provide little additional benefit.361  This highlights that an issue relating to access 
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to medicines is that treatments must exist in order to be accessible.  It emphasises that 
accessibility does not just relate to the affordability of medicines, but also the availability 
of medicines so that they can be physically accessed, and also indicates the complex 
issues in addition to IP rules which impact upon access to medicines. 
 
X. Conclusion 
 
It is evident that IP is a valuable form of property for creators, and its protection in the 
form of legally enforceable rights for the owners is beneficial and potentially lucrative.  
IP rights protect investment in creativity which is important in order to further 
development.  Developed and developing countries came into the TRIPS negotiations 
with diverging views on whether IP rights should be concentrated on protecting inventors 
or whether such rights should be balanced with advancing public interests.  The TRIPS 
Preamble and Articles 7 and 8 provide its objectives to be a balance of rights and 
obligations including the promotion of technological innovation and dissemination of 
technology in a manner conducive to social and economic welfare, and reflect that IP 
rights protection is not an end in itself.  However, TRIPS is a trade agreement and the 
promotion of access to medicines was not a main objective when the agreement was 
negotiated.  Since TRIPS came into force there have been increasing concerns over access 
to medicines as TRIPS requires a minimum standard of IP rights protection to be 
implemented by Members, including in relation to medicines.  Particular problems have 
arisen from the length and exclusivity of patent rights, and the interpretation and 
implementation of such protection effectively creating a barrier to access to medicines. 
This chapter has explored ways in which TRIPS can be interpreted and 
implemented in light of the promotion of public health objectives.  The Doha Declaration 
has provided additional interpretative guidance for the purpose of helping Members 
promote access to medicines, and TRIPS includes exception to patent protection to allow 
Members to adopt measures to enhance access to medicines, balanced with the interests 
of patent holders, at national level. These provisions alone have not had the effect of 
removing barriers to medicines created by IP law, specifically in relation to patents.  A 
key finding is that public health concerns, specifically access to medicines, is not being 
given sufficient prominence in the interpretation and implementation of TRIPS patent 
standards, even where there is scope to do so under TRIPS.  Members have experienced 
challenges in relying upon the exceptions to patent protection under Articles 30 and 31, 
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and although Members have agreed to a permanent amendment of Article 31 for the 
purpose of making it easier for states without manufacturing capacity improve access to 
medicines, there are limitations as to the effectiveness of the amendment.  In Canada – 
Patent Protection for Pharmaceutical Products, the failure of the WTO Panel to provide 
an appropriate analysis of Articles 7 and 8 of TRIPS, in line with the rules of treaty 
interpretation under Articles 31 and 32 VCLT, also raises the question of whether the 
Panel struck an appropriate balance between Articles 7 and 8, and Article 30 TRIPS. The 
narrow interpretation of Article 30 failed to fully take into account public health measures 
such as improving access to medicines as legitimate interests, and had a negative impact 
on access to generic medicines in this case. The utility of the exceptions to patent 
protection in TRIPS in enhancing access to medicines will be determined by the manner 
in which they can be implemented by Members. Therefore it is important that they are 
interpreted and implemented more effectively, so that Members can improve access to 
medicines nationally while meeting their obligations towards patent holders under the 
agreement. 
A further concern is the increase of FTAs incorporating stricter IP protection, as 
such agreements do not appear to give due consideration to public health issues, such as 
access medicines.  Other, wider, factors also impact upon access to medicines, including 
the lack of adequate health care systems and poor infrastructure in developing countries.  
Access to medicines is a serious public health issue due to the cost of essential medicines, 
as the most effective medicines remain under patent and are therefore too costly to be 
obtainable for the poorest populations.  The complexity of the issue of access to essential 
medicines is demonstrated by the human rights implications that arise from lack of access 
to life-saving or life-prolonging medicines.  Therefore it is pertinent to consider whether 
a rights-based approach could assist states in developing new strategies for securing 
access to essential medicines for all. 
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Chapter 3: Status of access to medicines in International Human Rights Law 
 
Introduction 
 
Helfer and Austin argue that the twenty-first century has seen “increasingly high profile 
and contentious debates over legal and political issues that arise at the interface of human 
rights and intellectual property”362. Access to medicines has been a significant matter for 
such debate.  Chapters 1 and 2 discussed the issue of access to essential medicines and 
the relevance of this issue within international trade platforms as medicines are a 
commercially valuable and tradable product.  This chapter will explore how the issue of 
access to medicines has been addressed within an international human rights framework. 
This chapter will explore whether there is a human right to medicines, and the scope of 
such a right. The obligations of states with respect to the right will also be analysed, which 
will assist in assessing the nature and scope of any potential conflict with the obligations 
under TRIPS. The position of the UN bodies with regard to reconciling the State’s 
obligations in relation the right of access to medicines and State obligations under TRIPS 
will also be examined. The purpose of this is to explore whether these bodies have 
provided guidance on ensuring effective enjoyment of the right to medicines and whether 
there is guidance on how States could meet their human rights obligations and their 
obligations under TRIPS. 
 This chapter will review the work of bodies under the UN Charter-based system 
and the UN Treaty Monitoring Bodies system.  The UN Charter-based system emanates 
from the UN Charter which applies to all UN Member States.363 Two core features of this 
system include the Human Rights Council and Special Procedures. The Human Rights 
Council is an intergovernmental body made up of representatives from UN Member 
States, and a key function is the Universal Periodic Review (UPR).364 The UPR is a 
process which involves a review of the human rights records of all UN Member States. 
The Special Procedures are independent experts with a mandate to report on human rights 
in a thematic context, undertake country visits, receive communications on potential 
violations, and have an important role in clarifying the scope and implementation of 
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human rights.365  The significance of the work of these bodies will be discussed later in 
the chapter, but it is important to note that they provide authoritative interpretations on 
the scope of state obligations, and proposals for how states can meet their obligations.366 
The Treaty Monitoring Bodies (TMB) system has developed extemporaneously since the 
inception of the UN, and applies to States that have ratified one or more of the nine core 
international human rights treaties and therefore have agreed to engage with the 
monitoring system under that treaty.367  The relevant treaty to this research is the 
International Covenant on Economic, Social and Cultural Rights (ICESCR), which is a 
legally binding treaty and includes the right to health under Article 12.368  The TMB 
promote and monitor compliance with the respective treaty, and therefore can provide 
important insights into the nature and scope of obligations on access to medicines, and 
how states can best discharge their obligations. 
This chapter will undertake a systematic analysis of a series of original 
documents.  The UPR is an important source as the review is cyclical, and the reports are 
produced by Member States, UN bodies and relevant stakeholders.369  All available 
documents of the first and second cycles are reviewed. The third cycle is currently 
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369 The review is based on three sets of documents; the National Report, the Compilation of UN 
Information and the Summary of Stakeholders Information. The review involves an interactive dialogue 
in a Working Group of the Council which comprises other Member States. Non-member States may also 
participate. States can make recommendations to the reviewed State which may be accepted or 
rejected. The Report of the Working Group on the Universal Periodic Review for the State concerned is 
then adopted by the Council. See also: <www.ohchr.org/EN/HRBodies/UPR/Pages/UPRMain.aspx>  
(accessed 27/04/2020) 
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ongoing and so all available documents up to December 2019 are reviewed. The system 
of Special Procedures is also reviewed, most notably the reports of the Special Rapporteur 
on the highest attainable standard of physical and mental health to December 2019, due 
to the direct relationship to the topic of this research.  The relevant treaty monitoring body 
to the ICESCR is the Committee on Economic, Social and Cultural Rights (CESCR) 370, 
and the chapter also includes a systematic review of the reports on the concluding 
observations and General Comments of the CESCR, to December 2019.   
This chapter will focus predominantly on original documents to analyse how these 
bodies are addressing the provisions. The chapter will also draw on relevant academic 
literature in the analysis of the findings from this research.  The chapter will begin with 
discussion of the Human Rights Council, with focus on the UPR to explore whether an 
authoritative interpretation of the scope of state obligations with regards to access to 
medicines is identifiable, and whether any proposals are made for states to meet their 
obligations.  The documents of the Special Procedures will be reviewed, specifically the 
Special Rapporteur on the highest attainable standard of physical and mental health, to 
analyse whether the Special Rapporteur provides clarification on whether medicines form 
part of the right to health. The chapter will then move to discussion of the TMB system, 
to analyse how the reports of the CESCR assist in interpreting the scope of the Article 12 
right to health and the scope of State obligations in relation to this right.  The chapter will 
conclude with the findings from this research, including whether there is a right to access 
to medicines, and if so, what medicines are covered by this right. Findings will also 
include the nature of obligations of States, in relation to those residing within and outside 
of their jurisdiction, as well as what the work of the UN bodies adds to the understanding 
of the relationship of the UN human rights framework and TRIPS in relation to enhancing 
access to medicines. 
 
I. The United Nations Human Rights System: Some Preliminary Considerations 
 
                                                            
370 Under the UN Treaty Monitoring Bodies system, when a state ratifies a core UN human rights treaty, 
that states agrees to engage with the monitoring system under that treaty. States submit a report to the 
relevant treaty monitoring body and the treaty body will offer concluding observations on the report. 
See: United Nations Office of the High Commissioner for Human Rights, ‘Monitoring the Core 
International Human Rights Treaties’ <http://www.ohchr.org/EN/HRBodies/Pages/WhatTBDo.aspx> 
(accessed 27/04/2020) 
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The UN human rights system is important to this research for several reasons.  The work 
of the UN bodies is important in terms of clarifying the nature and scope of obligations 
under UN treaties. One question to be explored in this chapter is whether access to 
medicines forms part of the right to health under Article 12 ICESCR. Clarifying the scope 
of Article 12 is of key relevance to this research as it is a legally binding treaty obligation.  
The UN human rights bodies also provide authoritative interpretations on the content and 
scope of human rights obligations, even though their reports are not legally binding, and 
provide insights on the application of human rights norms.371 Therefore, they are of 
importance in addressing the question of the State’s obligations in relation to access to 
medicines.   
Even though some of the work of the UN bodies is soft law, there is a value to 
this as it is not always the case that legal obligations effect changes in state behaviour.372 
For example, the UPR has encouraged some states, including Viet Nam, to submit 
overdue state reports to TMBs, highlighting that the UPR has led to states re-engaging 
with their legally binding treaty obligations.373 There is also a body of academic literature 
which recognises that soft law can make a significant contribution to the development of 
international law.374  Examples include monitoring mechanisms which document 
violations, and creating expectations as to future behaviour of states.375  Although there 
may not be direct legal sanctions for non-compliance, states may be subject to incidental 
effects such as moral and political pressure, which in practice can be an important 
enforcement mechanism in international law. 376 
It is also important to distinguish between the existence of obligations and the 
monitoring of compliance with those obligations.  Clearly, Article 12 imposes legally 
binding obligations.  However, in terms of enforcement there is no international human 
                                                            
371 H Quane ‘Legal Pluralism and International Human Rights Law: Inherently Incompatible, Mutually 
Reinforcing or Something in Between?’ (2013) 33 (4) Oxford J Legal Studies 675, 693 
372 K Roth ‘Defending Economic, Social and Cultural Rights: Practical Issues Faced by and International 
Human Rights Organization’ (2004) 26(1) Human Rights Quarterly, 63; D Etone ‘African States: Themes 
Emerging from the Human Rights Council's Universal Periodic Review’ (2018) 62 (2) Journal of African 
Law 201, 202-3 
373 H Quane ‘The Significance of an Evolving Relationship: ASEAN States and the Global Human Rights 
Mechanisms’ (2015) 15(2) HRLR 283, 288 
374 This literature is discussed in Chapter 1.  Examples include: Chinkin (n 43) 866; D Shelton, 
'Compliance with International Human Rights Soft Law' (1997) 29 Stud Transnat'l Legal Pol'y 119, 140-
141; Higgins (n 43) 24; D Cassel, 'Does International Human Rights Law Make a Difference' (2001) 2 Chi J 
Int'l L 121; Boyle (n 115) 123 
375 Chinkin (n 43) 859 & 862 
376 H Hillgenberg ‘A fresh look at soft law’ (1999) 10 EJIL 3 499, 511 
 84 
 
rights court, and this is not viable due to significant resistance from Member States.377  In 
the absence of a court, the work of independent experts, who have a treaty-based mandate, 
provide authoritative interpretations and guidance through their reports. The TMB are 
bodies established by treaties to promote and monitor human rights, so their 
interpretations, in concluding observations and General Comments, are authoritative, 
even though they are not legally binding. Intergovernmental mechanisms also provide 
authoritative interpretations on from those to whom the norm is addressed.  The Human 
Rights Council is an intergovernmental body378.  The value of the UPR is that it is the 
states themselves that are clarifying how they are interpreting their legal obligations. The 
UPR reports also include whether the state under review accepts, or rejects a 
recommendation, and their reasons for doing so.  Therefore, it is a useful source in relation 
to how states view their obligations, and in terms of how they interpret how they should 
implement these obligations. 
The UN human rights system is also important in terms of the extent to which 
these fora provide subsequent practice in relation to the rules of treaty interpretation under 
the VCLT.  When exploring the questions of whether there is a right to medicines and the 
obligations of states in relation to this right, the interpretation of the ICESCR is a key 
focus in this chapter.  Article 31 VCLT provides that treaties are to be interpreted in light 
of several factors, being the ordinary meaning of the treaty, its context and purpose, 
subsequent agreement and practice379.  A literal interpretation of Article 12 ICESCR 
would result in a finding that access to medicines does not form part of the right to health. 
The position is less clear in relation to a contextual interpretation by reference to the 
Preamble of the treaty380. However, the treaty can be interpreted in light of subsequent 
practice of states381, so the importance of the Human Rights Council as an 
intergovernmental body is relevant in terms of the important insights it provides in 
                                                            
377 P Alston ‘Against a World Court for Human Rights’ (2014) 28(2) Ethics & International Affairs 197; S 
Trechsel ‘A World Court for Human Rights?’ (2003) 1 Northwestern University Journal of International 
Human Rights 3, 15; A Cassese ‘A Plea for a Global Community Grounded in a Core of Human Rights’ in A 
Cassese (ed) Realizing Utopia: The Future of International Law (Oxford University Press, Oxford 2012), 
136, 141. This is symptomatic of international human rights law generally, as it is only the ECHR which is 
exclusively judicial. 
378 For further discussion of the Human Rights Council, see Bantekas and Oette (n 363) Chapter 4 
379 VCLT (n 47) Article 31 
380 J Tobin, 'Seeking to Persuade: A Constructive Approach to Human Rights Treaty Interpretation' (2010) 
23 Harv Hum Rts J 1, 18; International Covenant on Economic, Social and Cultural Rights (n 2) Preamble 
381 Hillgenberg (n 376) 513 
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subsequent interpretation of the treaty obligations.  Therefore, while non-binding the 
work of this body is valuable in relation to interpretation of the ICESCR.382 
 
II. Human Rights Council 
 
The Human Rights Council set up in 2006 to replace the Commission on Human Rights, 
is an intergovernmental body comprised of representatives of 47 elected Member States 
which serve three year terms383.  It has an extensive human rights mandate including 
setting human rights standards and issuing resolutions on any human rights concern.384 
The resolutions passed may confirm human rights principles or censure the human rights 
performance of a particular state385, and are persuasive in promoting compliance by those 
states.  The Human Rights Council also submits annual reports to the UN General 
Assembly386, which are instructive in the policy-making of the UN General Assembly, 
and also reaffirm the rights of individuals where there is concern that such rights are not 
being upheld.   
The 2010 annual report referenced the Human Rights Council’s resolution on the 
protection of human rights in the context of HIV/AIDS387.  It highlights that access to 
medicines is a fundamental element in achieving the full realisation of the right of 
everyone to the enjoyment of the highest attainable standard of physical and mental 
health, and that it is the responsibility of States to ensure access to medicines for all. The 
                                                            
382 Mechlem (n 105) 919-920 
383 Bantekas and Oette (n 363) Chapter 4 
384 ibid 
385 ibid 
386 In the annual report to the UN General Assembly, the Human Rights Council can make 
recommendations, make requests of the UN Security Council and other bodies, and highlight issues that 
it believes need urgent consideration and action. See United Nations Office of the High Commissioner 
for Human Rights, ‘United Nations Human Rights Council‘ 
<http://www.ohchr.org/EN/HRBodies/HRC/Pages/AboutCouncil.aspx> (accessed 27/04/2020) 
387 United Nations Human Rights Council Resolution 12/27 ‘The protection of human rights in the 
context of human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS)’ (22 
October 2009) UN Doc. A/HRC/RES/12/27. See also United Nations General Assembly, Report of the 
Human Rights Council (United Nations New York 2010) UN Doc A/65/53, 100 
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draft resolution was introduced by Brazil388 and was adopted without a vote389.  
Significantly, the resolution reaffirms the responsibility of States to make full use of the 
TRIPS flexibilities to promote access to medicines for all.  The issue of access to 
medicines is an important thematic issue for the Human Rights Council, which it reports 
upon to the General Assembly. The 2013 annual report refers to the Human Rights 
Council’s resolution on access to medicines, in which it invited the Special Rapporteur 
on the right of everyone to the enjoyment of the highest attainable standard of physical 
and mental health to continue to focus on the issue of access to medicines.390   
 
Universal Periodic Review 
 
UPR has a significant role to play in assisting the promotion and protection of human 
rights, and in clarifying the content of human rights norms.391  The UPR involves a review 
of the human rights records of each Member State, following which a report is issued 
including recommendations on the satisfaction of their obligations392.  It is a cooperative 
process of peer review which every UN Member State must undergo every four and a 
half years.  The review is driven by Member States and entails interactive dialogue among 
Member States on all human rights.393  The utility of the UPR has been questioned by 
                                                            
388 The draft resolution A/HRC/12/L.24 was introduced by Brazil at the thirty-second meeting on 2 
October 2009 sponsored by Brazil and co-sponsored by Argentina, Bolivia (Plurinational State of), Bosnia 
and Herzegovina, Chile, Colombia, Guatemala, Mexico, Mozambique, Nicaragua, Panama, Paraguay, 
Peru, South Africa, Uruguay and Venezuela (Bolivarian Republic of). Subsequently, Angola, Armenia, 
Congo, Cuba, El Salvador, Guatemala, Montenegro, Senegal, Serbia and Thailand joined the sponsors. 
(UNHRC ‘Report of the Human Rights Council on its twelfth session’ (25 February 2010), UN Doc 
A/HRC/12/50, 172) 
389 At the thirty-second meeting the representative of Brazil orally revised the draft resolution, the 
representative of France made general comments and representatives of Egypt and Indonesia made 
statements. The draft resolution, as orally revised, was adopted without a vote. (UNHRC ‘Report of the 
Human Rights Council on its twelfth session’ (25 February 2010), UN Doc A/HRC/12/50, 173-174) 
390 United Nations Human Rights Council Resolution 23/14 ‘Access to medicines in the context of the 
right of everyone to the enjoyment of the highest attainable standard of physical and mental health’ (24 
June 2013) UN Doc A/HRC/RES/23/14, See Also United Nations General Assembly, Report of the Human 
Rights Council UN Doc A/68/53 (United Nations New York 2013), 164 
391 Quane (n 373) 294; L Richardson ‘Economic, Social and Cultural Rights (and Beyond) in the UN Human 
Rights Council’ (2015) 15(3) HRLR 409, 427; E Domınguez Redondo ‘The Universal Periodic Review of the 
UN Human Rights Council: An Assessment of the First Session’ (2008) 7(3) Chinese JIL 721, 733  
392 United Nations Office of the High Commissioner for Human Rights, ‘Universal Periodic Review’ 
<http://www.ohchr.org/EN/HRBodies/UPR/Pages/UPRMain.aspx> (accessed 27/04/2020) 
393 M e Silva, 'The United Nations Human Rights Council: Six Years On' (2013) 18 SUR - Int'l J on Hum Rts 
97, 106; J Duggan-Larkin, 'Can an Intergovernmental Mechanism Increase the Protection of Human 
Rights? The Potential of Universal Periodic Review in Relation to the Realisation of Economic, Social and 
Cultural Rights' (2010) 28 Neth Q Hum Rts 548, 549; A Abebe, 'Of Shaming and Bargaining: African States 
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some academics due to the non-binding nature of the process.394  The States are free to 
accept or reject the recommendations generated through this non-confrontational 
interactive dialogue.  In practice, it appears that states are generally receptive to the 
recommendations, as during the first cycle 74 percent of the recommendations had been 
accepted.395  This reflects the general acceptance of states obligations to engage with the 
process and highlights the utility of cooperative monitoring  mechanisms396, particularly 
in light of the unfeasibility of a UN human rights court. The cyclical nature of the review 
also allows scrutiny of the measures taken to meet recommendations of previous cycles 
and to evaluate progress towards full realisation of human rights.397  Further, the UPR is 
also valuable in terms of influencing State behaviour, such as enhancing implementation 
of human rights at national level, promoting international cooperation and assistance 
among states and leading to increases in the ratification of core human rights treaties.398 
Therefore, UPR is important to this research in terms of providing valuable guidance to 
States on the interpretation of human rights norms in relation to medicines, as well as on 
the implementation of these norms.   
It is pertinent to undertake a systematic evaluation of the available UPR reports 
of the first399, second400 and third401 cycles. The review will explore whether states are 
making recommendations in relation to enhancing access to medicines, the types of 
                                                            
and the Universal Periodic Review of the United Nations Human Rights Council' (2009) 9 Hum Rts L Rev 
1, 11 
394 O de Frouville ‘Building a Universal System for the Protection of Human Rights’ in M.Cherif Bassouni 
and William A Schabas (eds), New Challenges for the UN Human Rights Machinery: What Future for the 
UN Treaty Body System and the Human Rights Council Procedures? (Intersentia, 2011) at 253-266; H 
Charlesworth and Emma Larking (eds) Human Rights and the Universal Periodic Review: Rituals and 
Ritualism (Cambridge University Press, Cambridge 2015); Etone (n 372) 202 
395 Bantekas and Oette (n 363) 167 
396 Etone (n 372) 202; T Opsahl ‘Instruments of Implementation of Human Rights’ (1989) 10(2) Human 
Rights Law Journal 13, 31-32; Roth (n 372) 63; C Careniero and Dominique Elden, ‘Economic Sanctions, 
Leadership survival and human rights’ (2009) 30(3) University of Pennsylvania Journal of International 
Law, 969; Abebe (n 393) 8 
397 Duggan-Larkin (n 393) 557; Quane (n 373) 299 & 303 
398 N Pillay ‘ Strengthening the United Nations human rights treaty body system A report by the United 
Nations High Commissioner for Human Rights’ (June 2012), 17 
<https://www2.ohchr.org/english/bodies/HRTD/docs/HCReportTBStrengthening.pdf> (accessed 
27/04/2020) 
399 The documents of the first cycle of UPR which were reviewed are found in Annex I, part A) of the 
thesis. 
400 The documents of the second cycle of UPR which were reviewed are found in Annex I, part B) of the 
thesis. 
401 The documents of the third cycle of UPR which were reviewed are found in Annex I, part C) of the 
thesis. As the third cycle has not yet been completed, the documents were reviewed up to December 
2019. 
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medicines being discussed and whether states are accepting the recommendations. The 
purpose of this review is to analyse the role of the UPR in clarifying the scope of state 
obligations with regards to access to medicines, and whether any proposals are made for 
states concerning the implementation of their obligations. 
 
(a) Review of the reports 
Of the 192 states reviewed in the first cycle, 11.5 percent of the national reports made 
reference to provisions for medicines domestically402. 4.2 percent of the national reports 
referred to access to medicines as of right in terms of forming part of the right to health. 
Only one of these national reports was that of a developed state403. Of the 193 states 
reviewed during the second cycle, 18.1 percent of the national reports made reference to 
provision of medicines, with only one of the states being a developed state404.  1 percent 
of national reports reporting on access to medicines as forming part of the right to health, 
with all being developing states which were net importers of pharmaceuticals405.  This 
may suggest that more states had implemented provisions to increase access to medicines 
since the first cycle, although fewer were discussing medicines in terms of a right.  
However, none of the national reports indicated any objections to referencing medicines 
in the form of a right, so perhaps the lack of reference to medicines as a right may be 
because the states had generally accepted the Article 12 right included access to 
medicines. 
8.9 percent of the reports of the Working Group from the first cycle, and 7.3 
percent from the second cycle did include reference to medicines in some form, such as 
through recommendations on improving access to medicines in a particular state, or by 
recognising the measures taken by the state to improve access406.  This demonstrates a 
lower scale of reporting on medicines compared to the national reports, and it is 
particularly interesting to note that only four of the reports of the Working Group 
                                                            
402 22 out of the 192 States included in Annex I, part A), comprising 21 developing States and 1 
developed State.  
403 As at 2014. Classification of developed and developing countries taken from United Nations, World 
Economic Situation and Prospects 2014, (United Nations, New York 2014), ISBN 978-92-1-109168-7, 
Statistical Annex, Country Classification, P.145 
<http://unctad.org/en/PublicationsLibrary/wesp2014_en.pdf> (accessed 27/04/2020). 
404 35 out of the 193 States included in Annex I, part B), comprising 34 developing States and 1 
developed State. 
405 The two States were Eritrea and Georgia.  See also Annex I, part B) (n 400) 
406 Reports of the Working Group for 17 States in the first cycle and 14 States in the second cycle.  See 
also Annex I, part A) (n 399) and Annex I, part B) (n 400) 
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contained reference to cost as hindering access to medicines across the first and second 
cycles and those reports were on developing states that were net importers of 
pharmaceuticals.  It is encouraging to note that there was an increase, from 5.7 percent 
during the first cycle to 12.4 percent during the second cycle, in the number of states 
reporting on steps taken by their governments to address enhancing access to medicines 
domestically407.  However, just one of the states which reported on this point was a 
developed state, further highlighting that the UPR has shown that improving access to 
medicines was predominantly a concern for developing states. 
 
(b) Recommendations on enhancing access to medicines 
Of the 192 states reviewed in the first cycle, 2.6 percent of the reports of the Working 
Group from the first cycle included recommendations relating to enhancing access to 
medicines. Five recommendations were made by four states; Azerbaijan, Switzerland, the 
Holy See and Egypt408. The recommendations by Azerbaijan to Mauritius, and by 
Switzerland to Mozambique related to improving access to medicines generally.409 The 
recommendations by the Holy See to Swaziland and Uganda were to improve access to 
HIV/AIDS medicines.410 The recommendation by Egypt to Malawi was to seek 
international assistance to address HIV/AIDS, in particular to ensure supply of HIV/AIDS 
medicines.411 All states except Mozambique accepted the recommendations. Only 
Mozambique rejected its recommendation, on the basis that its Ministry of Health had a 
large budget deficit412. 
                                                            
407 An increase from 11 States during the first cycle to 24 States during the second cycle. See also Annex 
I, part A) (n 330) and Annex I, part B) (n 400) 
408 See recommendations in the following reports: UNHRC ‘Report of the Working Group on the 
Universal Periodic Review: Mauritius’ (3 March 2009) UN Doc A/HRC/11/28; UNHRC ‘Report of the 
Working Group on the Universal Periodic Review: Mozambique’ (28 March 2011) UN Doc A/HRC/17/16; 
UNHRC ‘Report of the Working Group on the Universal Periodic Review: Malawi’ (4 January 2011) UN 
Doc A/HRC/16/4, 102.63; UNHRC ‘Report of the Working Group on the Universal Periodic Review: 
Swaziland’ (12 December 2011) UN Doc A/HRC/19/6, 76.55;  
409 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Mauritius’ (3 March 2009) 
UN Doc A/HRC/11/28, 56; UNHRC ‘Report of the Working Group on the Universal Periodic Review: 
Mozambique’ (28 March 2011) UN Doc A/HRC/17/16, 91.10 
410 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Swaziland’ (12 December 
2011) UN Doc A/HRC/19/6, 76.55; UNHRC ‘Report of the Working Group on the Universal Periodic 
Review: Uganda’ (22 December 2011) UN Doc A/HRC/19/16, 111.87 
411 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Malawi’ (4 January 2011) UN 
Doc A/HRC/16/4, 102.63 
412 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Mozambique: Addendum’ 
(31 May 2011) UN Doc A/HRC/17/16/Add.1, 45 
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 Of the 193 states reviewed during the second cycle, 3.6 percent of the reports of 
the Working Group included recommendations relating to enhancing access to medicines, 
a slight increase from the first cycle.  Seven states made recommendations relating to 
enhancing access to medicines; Ukraine, Pakistan, Sierra Leone, Belarus, El Salvador, 
Canada and Colombia.413  The third cycle of review is currently ongoing and will be 
completed in 2021.  Of the 84 states reviewed up to December 2019, 9.5 percent of the 
reports of the Working Group include recommendations relating to enhancing access to 
medicines. The cycle is not yet complete, and so this figure should be treated with caution 
when drawing comparisons with earlier cycles.  However, it is notable that already the 
number of recommendations has exceeded the first and second cycles. Eight 
recommendations have been made, states that have made the recommendations are: 
Equatorial Guinea, Syrian Arab Republic, Saudi Arabia, Serbia, Algeria, Indonesia, 
Australia and Iran.414   
A qualitative change in the recommendations made during the second and third 
cycles compared with the first cycle is that two recommendations explicitly referred to 
access to medicines as part of the right to health. During the second cycle, Colombia 
recommended that Trinidad and Tobago ensure the right to health of persons living with 
HIV through the establishment of programmes to make available essential medicines.415  
During the third cycle, Indonesia recommended that Uruguay strengthen efforts to 
provide affordable access to all medicines to ensure the right to health.416  Both of these 
recommendations were accepted by the reviewed states.  
                                                            
413 See the recommendations in the following reports: UNHRC ‘Report of the Working Group on the 
Universal Periodic Review: Trinidad and Tobago’ (15 July 2016) UN Doc A/HRC/33/15, 106.57; UNHRC 
‘Report of the Working Group on the Universal Periodic Review: Bolivarian Republic of Venezuela’ (27 
December 2016) UN Doc A/HRC/34/6, 133.238 & 133.240; UNHRC ‘Report of the Working Group on the 
Universal Periodic Review: Democratic People’s Republic of Korea’ (2 July 2014) UN Doc A/HRC/27/10, 
124.164; UNHRC ‘Report of the Working Group on the Universal Periodic Review: Cuba’ (8 July 2013) UN 
Doc A/HRC/24/16, 170.254; UNHRC ‘Report of the Working Group on the Universal Periodic Review: 
Malaysia’ (4 December 2013) UN Doc A/HRC/25/10, 146.180 
414 See the recommendations in the following reports: UNHRC ‘Report of the Working Group on the 
Universal Periodic Review: Uruguay’ (18 April 2019) UN Doc A/HRC/41/8; UNHRC ‘Report of the Working 
Group on the Universal Periodic Review: Turkmenistan’ (6 July 2018) UN Doc A/HRC/39/3, 114.62; 
UNHRC ‘Report of the Working Group on the Universal Periodic Review: Pakistan’ (29 December 2017) 
UN Doc A/HRC/37/13, 152.213; UNHRC ‘Report of the Working Group on the Universal Periodic Review: 
Yemen’ (17 April 2019) UN Doc A/HRC/41/9, 123.83, 124.65 
415 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Trinidad and Tobago’ (15 July 
2016) UN Doc A/HRC/33/15, 106.57 
416 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Uruguay’ (18 April 2019) UN 
Doc A/HRC/41/8, 118.06 
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During the second cycle, two recommendations related to seeking international 
assistance.  Canada recommended that Venezuela ensure immediate and urgent provision 
of essential medicines, including by deploying necessary resources and accepting 
international assistance and cooperation.417  El Salvador also recommended that 
Venezuela continue developing relevant international cooperation agreements to ensure 
universal access to medicines.418  These recommendations were accepted.  Other 
recommendations made during the second and third cycles related to ensuring the 
affordability and availability of medicines.  Belarus made a recommendation that the 
Democratic Peoples’ Republic of Korea consider further spending on health services, 
including access to essential medicines.419 Saudi Arabia recommended that Turkmenistan 
implement a strategy for development of production of medicines.420  Ukraine made a 
recommendation to Cuba to develop programmes to further expand availability of 
medicines to the elderly.421 Syrian Arab Republic recommended that Pakistan ensure 
availability of good quality medicines at an appropriate price, especially for the 
disadvantaged.422  Several of the recommendations relating to access to medicines were 
of a general nature, and did not elaborate on how states might implement the 
recommendations. Pakistan’s recommendation to Malaysia and Equatorial Guinea’s 
recommendation to Djibouti were to ensure that medicines were affordable.423  Algeria 
made a general recommendation that the Central African Republic take steps to ensure 
the availability of medicines, and Serbia recommended that Turkmenistan address the 
lack of medicines in the state.424  These recommendations were accepted. 
The UPR recommendations are only useful if they are translated into practice by 
states. Of the 17 recommendations that were accepted, only three states have followed up 
                                                            
417 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Bolivarian Republic of 
Venezuela’ (27 December 2016) UN Doc A/HRC/34/6, 133.238 
418 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Bolivarian Republic of 
Venezuela’ (27 December 2016) UN Doc A/HRC/34/6, 133.240 
419 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Democratic People’s 
Republic of Korea’ (2 July 2014) UN Doc A/HRC/27/10, 124.164 
420 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Turkmenistan’ (6 July 2018) 
UN Doc A/HRC/39/3, 114.62 
421 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Cuba’ (8 July 2013) UN Doc 
A/HRC/24/16, 170.254 
422 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Pakistan’ (29 December 
2017) UN Doc A/HRC/37/13, 152.213 
423 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Malaysia’ (4 December 2013) 
UN Doc A/HRC/25/10, 146.180 
424 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Turkmenistan’ (6 July 2018) 
UN Doc A/HRC/39/3, 114.63 
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on the extent to which they had implemented the recommendations. It is important to 
highlight that as the third cycle is ongoing, states that received recommendations could 
still follow-up on their implementation, either in interim reports or during the next UPR 
cycle.  Swaziland outlined that it had improved the provision of free antiretroviral 
medicines in an interim report.425  Uganda and the Democratic Republic of Korea reported 
on measures taken to improve access to medicines in their national reports in the 
subsequent UPR cycles.426 The lack of effective follow-up on these recommendations is 
a weakness in the UPR system, which is a criticism of the UPR in the academic 
literature.427   
Two recommendations made during the second and third cycles were rejected. In 
the second cycle, Sierra Leone made a recommendation that Malaysia consider the 
comments of the Special Rapporteur on the right to health of the negative impact of the 
Trans-Pacific Partnership on access to medicines, which was rejected because TPP 
negotiations were still ongoing at the time.428 During the third cycle, Yemen received 
recommendations from Australia and Iran to facilitate the delivery of medicines to all 
Yemenis, in light of the conflict in the reviewed state.429 Yemen rejected Iran’s 
recommendation without explanation, but accepted Australia’s recommendation.430 
Although these recommendations were rejected, it is notable that they were not rejected 
on the basis that states did not accept that access to medicines forms part of a human 
rights norm.   
Given the very low number of recommendations which have been made in relation 
to access to medicines, it is not possible to draw definitive conclusions. This is perhaps 
understandable as the UPR has a broad scope and covers a range of human rights431. 
However, the UPR process provides some tentative insights.  First, where access to 
                                                            
425 UNHRC ‘First Cycle Mid-Term Report: Swaziland’ (April-May 2016) 
426 UNHRC ‘National report submitted in accordance with paragraph 5 of the annex to Human Rights 
Council resolution 16/21: Uganda’ (3 October 2016) UN Doc A/HRC/WG.6/26/UGA/1, 50; UNHRC 
‘National report submitted in accordance with paragraph 5 of the annex to Human Rights Council 
resolution 16/21: Democratic People’s Republic of Korea’ (20 February 2019) UN Doc 
A/HRC/WG.6/33/PRK/1, 39 
427 Etone (n 372) 220; e Silva (n 393) 107  
428 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Malaysia’ (4 December 2013) 
UN Doc A/HRC/25/10, 146.174; UNHRC ‘Report of the Working Group on the Universal Periodic Review: 
Malaysia: Addendum’ (4 March 2014) UN Doc A/HRC/25/10/Add.1, 6 
429 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Yemen’ (17 April 2019) UN 
Doc A/HRC/41/9, 123.83, 124.65 
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medicines has been discussed in the context of a right, the focus has been on the right to 
health rather than, for example, the right to life. Second, there is a lack of precision as to 
the definition of the types of ‘medicines’ being referred to. Any conclusions on what 
states consider to be the definition of ‘medicines’ should be treated with caution because 
of the limited data, which is open to interpretation. It appears that as a minimum, 
HIV/AIDS medicines could be considered as essential medicines.  However, this is a 
tentative conclusion and reflects the challenge in clarifying the definition of ‘medicines’ 
discussed in Chapter 1.  Third, there is some recognition that trade agreements can raise 
issues in relation to human rights and specifically access to medicines. 
 
Special Procedures 
 
The Special Procedures mechanism involves experts acting in an independent capacity, 
as either an individual Special Rapporteur or as a Working Group, to carry out country 
missions, address communications to States and then prepare reports to the Human Rights 
Council432. Academics have taken the view that the reports and recommendations provide 
valuable information for UN bodies in developing strategies to address human rights 
concerns, as well as placing public pressure on governments.433  In addition to providing 
information, Special Procedures promote human rights through the recommendations to 
address human rights issues within states.  Subedi argues that the Special Procedures not 
only have a monitoring function, but have also influenced the interpretation and 
implementation of human rights norms.434  This is because the process seeks collaboration 
and engagement with national governments, and this constructive dialogue is key to the 
promotion and protection of human rights under the UN human rights framework.  A 
criticism of the Special Procedures is the lack of follow-up on the recommendations, so 
they cannot be enforced, while states cannot be obliged to cooperate with the process.435  
Freedman argues that as the reports are made public, States’ weaknesses in complying 
                                                            
432 N Rodley, ‘United Nations Human Rights Treaty Bodies and Special Procedures of the Commission on 
Human Rights – Complementary or Competition?’ (2003) 25(4) HRQ 882, 883 
433 M Kirby, 'UN Special Procedures - Reflections on the Office of UN Special Representative for Human 
Rights in Cambodia' (2010) 11 Melb J Int'l L 491, 505; Subedi (n 111) 223-224; Ovett (n 61) 202 
434 Subedi (n 111) 223-224 
435 PS Pinheiro ‘Being a special rapporteur: a delicate balancing act’ (2011) 15(2) IJHR 162, 169; Subedi (n 
111) 223-224; J Gutter ‘Special Procedures and the Human Rights Council: Achievements and Challenges 
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with human rights are publicly exposed.436  The reports are important to the 
implementation of human rights norms, as publicised criticism of a State practice 
following a State visit may be politically embarrassing.  Therefore, the work of the 
Special Procedures has the potential to make an important contribution to the clarification 
of the scope of the right to health and access to medicines, and to the implementation of 
the right. There are a number of Special Procedures which have an impact on advancing 
access to medicines437, and the most pertinent are discussed below. 
 
a) Special Rapporteur on the right of everyone to the enjoyment of the highest attainable 
standard of physical and mental health 
 
In 2002, the first Special Rapporteur on the right of everyone to the enjoyment of the 
highest attainable standard of physical and mental health was appointed with the mandate 
to report annually on the status of the right to health globally and to make 
recommendations on the promotion and protection of the right438. Therefore, given the 
significance of the right to health to this research, the reports of the Special Rapporteur 
on the right to health439 will be examined, to evaluate their contribution to clarifying the 
scope of the right to health in relation to access to medicines, and how the 
recommendations of the Special Rapporteur further the implementation of the right440. 
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Protection of the Rights of All Migrant Workers and Members of their Families; The Convention on the 
Rights of Persons with Disabilities and The United Nations Declaration on the Rights of Indigenous 
Peoples  
438 United Nations Commission on Human Rights Resolution 2002/31 (22 April 2002) UN Doc. 
E/CN.4/RES/2002/31, 4 
439 It is pertinent to note that there have been three different Special Rapporteurs on health (Dainius 
Pūras since August 2014; Anand Grover, August 2008-July 2014; and Paul Hunt, August 2002-July 2008) 
and as such there is potential for each to take different approaches to key challenges relating to health.  
See also United Nations Office of the High Commission for Human Rights, ‘Special Rapporteur on the 
right of everyone to the enjoyment of the highest attainable standard of physical and mental health’ 
<https://www.ohchr.org/EN/Issues/Health/Pages/SRRightHealthIndex.aspx> (accessed 27/04/2020) 
440 It is pertinent to undertake a systematic review of the following annual reports of the Special 
Rapporteur, as well as reports generated as a result of country visits, up to July 2019; Annual Reports: 
Dainius Pūras (2014-present): (2019) A/74/174, A/HRC/41/34; (2018) A/73/216, A/HRC/38/36; (2017) 
A/72/137, A/HRC/35/21; (2016) A/71/304, A/HRC/32/32, A/HRC/32/33; (2015) A/70/213, A/HRC/29/33. 
Anand Grover (2008-2014): (2014) A/69/299, A/HRC/26/31; (2013) A/68/297, A/HRC/23/41, 
A/HRC/23/42, A/HRC/23/51; (2012) A/67/302, A/HRC/20/15; (2011) A/66/254, A/HRC/18/37, 
A/HRC/17/43, A/HRC/17/25, A/HRC/17/25/Add.1; (2010) A/65/255, A/HRC/14/20, A/HRC/14/20/Add 
1/Corr.1; (2009) A/64/272, A/HRC/11/12, A/HRC/11/12/Add.1. Paul Hunt (2002-2008): (2008) A/63/263, 
A/HRC/7/11, A/HRC/7/11/Add.1, (2007) A/HRC/4/28, A/HRC/4/28/Add.1, A/62/214; (2006) 
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The 2004 report of the Special Rapporteur Paul Hunt specifically outlined that the 
right to health was made up of elements including access to essential medicines441. The 
2006 report442 highlighted that although the right to health is a right which is subject to 
progressive realisation, Member States have immediate obligations with regard to 
elements of the right443.  A Member State has a core obligation of immediate effect to 
make essential medicines available and accessible throughout its jurisdiction.444  This 
interpretation of the right to health is in line with the interpretation of the CESCR445 and 
provides important clarification of the scope of the right to health.  The Special 
Rapporteur Anand Grover’s 2009 report to the Human Rights Council also clarified that 
access to essential medicines is a key element of the right to health,446 He also explicitly 
                                                            
E/CN.4/2006/48, E/CN.4/2006/48/Add.1, A/61/338; (2005) E/CN.4/2005/51, E/CN.4/2005/51/Add.1, 
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November 2012) A/HRC/23/41/Add.3, Visit to Ghana (May 2011)A/HRC/20/15/Add.1, Visit to Viet Nam 
(November-December 2011) A/HRC/20/15/Add.2, 2011 Visit to Guatemala (May 2010) 
A/HRC/17/25/Add.2, Visit to the Syrian Arab Republic (November 2010) A/HRC/17/25/Add.3,Visit to 
Australia (November 2009) A/HRC/14/20/Add.4, Visit to Poland (May 2009) A/HRC/14/20/Add.3, Visit to 
India (November 2007) A/HRC/14/20/Add.2, Visit to Glaxo Smith Kline (June 2008) A/HRC/11/12/Add.2.  
Paul Hunt (2002-2008): India (November-December 2007)Preliminary notes A/HRC/7/11/Add.4, Ecuador 
(May 2007) and Colombia (September 2007) Preliminary notes A/HRC/7/11/Add.3, Uganda (joint report 
with visit to the World Bank and the International Monetary Fund) (February 2007) A/HRC/7/11/Add.2, 
The World Bank, the International Monetary Fund (joint report with visit to Uganda) (October 2006) 
A/HRC/7/11/Add.2, Sweden (January 2006) A/HRC/4/28/Add.2, Lebanon and Israel (September 2006) 
Joint visit with the Special Rapporteur on extrajudicial, summary or arbitrary executions; the Special 
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persons and the and the Special Rapporteur on adequate housing as a component of the right to an 
adequate standard of living, Miloon Kothari. A/HRC/2/7, Uganda (March 2005) 
E/CN.4/2006/48/Add.2,Mozambique (December 2003) E/CN.4/2005/51/Add.2, Peru (June 2004) 
E/CN.4/2005/51/Add.3, Romania (August 2004) E/CN.4/2005/51/Add.4, World Trade Organization (16 
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441 UNGA ‘Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest 
attainable standard of physical and mental health’ (8 October 2004) UN Doc A/59/422, 16 
442 UNGA ‘Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest 
attainable standard of physical and mental health’ (13 September 2006) UN Doc A/61/338 
443 ibid 56 
444 ibid 58 
445 General Comment No. 14 (n 112) 
446 UNHRC ‘Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest 
attainable standard of physical and mental health’ (31 March 2009) UN Doc A/HRC/11/12, 94 
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stated that access to essential medicines is a core obligation of the right to health447.  This 
interpretation is consistent with the previous Special Rapporteur’s analysis of the right, 
providing consensus on the scope of the right. The Human Rights Council noted the 
content of Special Rapporteur Anand Grover’s 2011 report, and stated that access to 
medicines is one of the fundamental elements in progressively achieving the right to 
health448, highlighting the agreement of the Human Rights Council, and hence States, on 
the scope of the right. 
 Special Rapporteur Paul Hunt also addressed the issue of neglected diseases and 
concluded that access to medicines to treat neglected diseases fell within the scope of the 
right.  During the 2005 visit to Uganda, the Special Rapporteur had the opportunity to 
examine the national circumstances on research and development, noting that the 
international community should give a higher priority to health research and 
development449, in particular for neglected diseases prevalent in the State.  The Special 
Rapporteur stated that IP regimes should not constrain access to essential medicines and 
suggested the development of new IP frameworks in order to encourage research and 
development into medicines to treat neglected diseases as well as essential medicines.450  
However, the report did not elaborate on the type of frameworks that the State may need 
to implement, or give an indication of the substantive content of such frameworks. The 
Special Rapporteurs have also made recommendations on how states can meet their 
obligations under this right, which provide guidance on how states can implement this 
right. Trends in the recommendations relate to promoting compulsory licensing, concern 
over the impact of TRIPS-plus provisions on access to medicines, and states obligations 
in relation to the actions of pharmaceutical companies. 
 
(i) Promoting use of compulsory licensing 
 
                                                            
447 UNHRC ‘Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest 
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Special Rapporteur Paul Hunt visited the WTO in 2003 and his subsequent report451 
discussed in detail access to medicines as an element of the human right to health452.  The 
report provided advice to Member States in promoting access to affordable medicines in 
compliance with their trade obligations by utilising the TRIPS flexibilities, including 
compulsory licensing, and also recommending that Member States place such provisions 
within national legislation in order to safeguard access to medicines453. It recognised that 
the WTO had taken positive steps to address the issue within the trade forum with the 
Doha Declaration.  
The outcomes of the visit to the WTO included a number of recommendations 
aimed at numerous stakeholders.  Recommendations to the Commission on Human 
Rights, predecessor of the Human Rights Council, included requesting a report on the 
relationship between trade, poverty and human rights and requesting the preparation of 
guidelines to assist treaty bodies to raise trade issues454. It was also recommended that 
special rapporteurs and treaty bodies consider the impact of trade policies and rules when 
carrying out their responsibilities455.  Recommendations for the WTO Member States 
included promoting access to affordable medicines by incorporating the TRIPS 
flexibilities into national legislation456.  This highlights the importance of addressing the 
barriers to using the TRIPS flexibilities addressed elsewhere in the thesis.  
Recommendations also included establishing mechanisms to enhance policy coherence 
between trade, human rights and health457 and promoting intellectual property legislation 
that is consistent with their human rights obligations458.  International organisations 
including the WTO, WIPO and WHO were also encouraged to promote the use of TRIPS 
flexibilities through technical assistance459 and all stakeholders were recommended to 
identify measures to address the human rights concern of neglected diseases460.  These 
recommendations highlight that there is no zero-sum conflict between trade law and the 
                                                            
451 UNCHR ‘The right of everyone to the enjoyment of the highest attainable standard of physical and 
mental health Report of the Special Rapporteur, Paul Hunt, Addendum, Mission to the World Trade 
Organization’ (1 March 2004) E/CN.4/2004/49/Add.1 
452 ibid 43 
453 ibid 81 
454 ibid 72-76 
455 ibid 77-78 
456 ibid 81 
457 ibid 79 
458 ibid 82 
459 ibid 88 
460 ibid 89 
 98 
 
right to health.  Ovett argues that the Special Rapporteur’s decision to visit the WTO for 
his first mission was evidence of the importance of cooperation with the WTO.461  The 
visit opened a dialogue with the WTO and other stakeholders, and did result in 
recommendations that invited constructive and collaborative engagement with the WTO 
and states. 
 
(ii) TRIPS-plus provisions 
 
Numerous reports of the Special Rapporteur have identified concerns over the agreeing 
of TRIPS-plus provisions in FTAs.  Following visits to Peru in 2004462 Special Rapporteur 
Paul Hunt expressed concern that some of the terms of the bilateral trade agreement being 
negotiated with the United States were inconsistent with the Member State’s human rights 
obligations, and would “significantly impede access to affordable medicines for some 
individuals and groups”463.  The report recommended that Peru assessed the likely impact 
on access to medicines prior to finalising the agreement, and also impressed upon the 
United States that as part of its human rights responsibilities it should not exert pressure 
on Peru to agree to TRIPS-plus terms that would be inconsistent with its human rights 
obligations.464  This highlights that all Member States must consider the human rights 
impact of FTAs in the negotiating state also, outlining an extraterritorial obligation on 
Member States. 
The 2009 report also elucidated that TRIPS and FTAs can have an adverse impact 
on access465, highlighting that although there was not considered to be a fundamental 
conflict between TRIPS and access to medicines, the use of FTAs to increase the 
minimum standards of IP protection set out in TRIPS was a significant risk to securing 
access.  There was criticism of the implementation of paragraph 6 of the Doha Declaration 
and a call for a simpler mechanism to be devised466, indicating the challenges posed by 
the current provisions.  The report also found that States need to take advantage of the 
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flexibilities inherent in TRIPS, and also to ensure that national patent law standards were 
flexible to allow exceptions to further promote compulsory licensing and access to 
medicines.467   
In the 2009 report following his visit to Guatemala468, Special Rapporteur Anand 
Grover stated that major government policies combined with the IP provisions of the 
Central America-Dominican Republic-United States Free Trade Agreement had 
negatively impacted on access to medicines.469  Furthermore, he recommended the 
elimination of barriers to procurement of generic medicines as well as utilising the TRIPS 
flexibilities and not entering into FTAs with TRIPS-plus provisions470.  Special 
Rapporteur Anand Grover also expressed concern regarding Viet Nam’s decision-making 
as part of the TPP negotiations, and its failure to involve stakeholders as part of the 
process471, suggesting that there was a risk of TRIPS-plus provisions being agreed which 
would be detrimental to the accessibility of medicines in the Member State.  The Special 
Rapporteurs’ analysis of the right to health in these reports is significant as agreeing of 
TRIPS-plus standards in FTAs could amount to an infringement of the right, and failure 
by states to discharge their obligations under the right. 
 
(iii) State obligations in relation to the actions of pharmaceutical companies 
 
Special Rapporteur Paul Hunt’s 2006 report noted that the business sector, including 
pharmaceutical companies, have some human rights responsibilities472.  However, it must 
be emphasised that the business sector, including the pharmaceutical industry, is not 
currently bound by the UN human rights system, so it is difficult to enforce such 
responsibilities473. The report does note that ‘naming and shaming’ of businesses that fail 
to uphold human rights, as well as bringing them before the national courts, is an 
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rights and transnational corporations and other business enterprises, discussed below. 
 100 
 
important role in realising the rights to health, in particular access to medicines.474 This 
suggests that despite a lack of enforcement mechanism within the UN system, States and 
private actors can face negative consequences for failing to uphold human rights. 
In his last thematic report, Special Rapporteur Paul Hunt observed that he had 
frequently engaged with states regarding their responsibilities in relation to access to 
medicines, which he described as a “vital component of the right to the highest attainable 
standard of health”475.  However, he noted that a common argument made by States was 
that the policies and practices of some pharmaceutical companies created obstacles with 
regard to their implementation of the right.476  In response, the Special Rapporteur drafted 
guidelines for pharmaceutical companies477, annexed to his 2008 report, to encourage 
collective responsibility for the enhancement of access to medicines for all.  These 
guidelines include provisions that pharmaceutical companies should arrange differential 
pricing478, issue voluntary licences with a view to increasing access to medicines479, adopt 
anti-corruption policies and anti-counterfeiting measures480, and should establish 
independent monitoring and accountability mechanisms to assess the impact of the 
company’s activities on access to medicines481. 
This report encourages various states and non-state actors to appreciate that there 
is a collective responsibility to promote access to medicines globally, and some 
pharmaceutical companies do have corporate responsibility policies which indicate a 
commitment to promoting access to adequate health care including medicines482.  
However, the non-binding nature of the guidelines means that the lack of enforceability 
may be detrimental to their effectiveness.  Grover et al acknowledged that the guidelines 
marked a first attempt to articulate responsibilities for pharmaceutical companies, but 
argued that they did not go far enough in creating direct legal obligations on 
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pharmaceutical companies under the right to health.483  Grover et al commented that the 
guidelines were not mandatory, did not provide for a real accountability mechanism and 
did not provide an effective remedy to those individuals whose rights had been infringed 
by the behaviour of pharmaceutical companies.484  Grover et al also asserted that it is 
evident that the international intellectual property regime “must be modified and that 
reasonable constraints be placed on the behaviour of pharmaceutical companies in order 
to allow for adequate levels of industry competition.”485  Although this demonstrates the 
influence of pharmaceutical companies on securing access to medicines, it also highlights 
that private businesses and companies are not directly bound by the conclusions of the 
human rights regime, which is increasingly problematic in terms of making progress to 
secure improved access to essential medicines worldwide. 
The visit to GlaxoSmithKline undertaken by Special Rapporteur Paul Hunt in 
2009486 demonstrated his view that there is a need for an independent mechanism to 
monitor compliance of pharmaceutical companies with their corporate social 
responsibilities487.  His reasoning for pharmaceutical companies having such 
responsibilities is that “[h]aving developed a life-saving medicine, the company has a 
human rights responsibility to take all reasonable steps to make the medicine as accessible 
as possible, as soon as possible, to all those in need”488.  This suggests that if those 
companies undertake the responsibility of manufacturing essential medicines, there is an 
attached responsibility, shared with Member States, to ensure that the essential medicines 
are used for the purpose for which they were developed.  This aligns with the UN Guiding 
Principles on Business and Human Rights489, which sets out the responsibility of 
businesses to mitigate adverse human right impacts of their activities. Through the 
implementation of monitoring mechanisms, States could impose legal obligations on 
pharmaceutical companies at national level to comply with corporate social responsibility 
goals. 
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The 2013 report490 of Special Rapporteur Anand Grover focused specifically on 
access to medicines and examined various factors, including those linked to production 
and pricing. To promote affordability, the report also recommended encouragement of 
local production of medicines, the establishment of an essential medicines list which is 
based on national need and irrespective of cost, and a recommendation that States adopt 
competition laws and policies to prevent pharmaceutical companies from indulging in 
anti-competitive practices and promote competitive pricing of medicines together with 
strong enforcement.491  This recommendation demonstrates that the Special Rapporteur 
is pursuing devices to indirectly enforce responsibilities upon pharmaceutical companies 
by placing responsibility upon the State Members, which do have obligations under UN 
treaties to promote the right to health, to try to regulate the pricing of medicines set by 
pharmaceutical companies to promote access for all.  States also have positive obligations 
to protect the right to health.  However, it is problematic that the reports are not binding, 
and therefore enforcing state compliance with such recommendations is difficult.  The 
Special Rapporteur noted that there was a gap between the formulation and 
implementation of health policies, which had a negative effect on a number of the 
elements of the right to health, including medicines492.  Therefore, states have obligations 
to ensure the effective implementation of policies to enhance access to medicines as part 
of the right to health. 
 
b) Working Group on the issue of human rights and transnational corporations and other 
business enterprises 
 
The Working Group on the issue of human rights and transnational corporations and other 
business enterprises also has a thematic mandate under the Special Procedures. The 
Working Group examines the developing standards relating to the responsibilities of 
business enterprises with respect to human rights and, like the Special Rapporteur on the 
right to health, reports to the Human Rights Council.493 One of the main functions of the 
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Working Group is to promote the dissemination and implementation of the UN Guiding 
Principles on Business and Human Rights 494.  The Guiding Principles were developed by 
the Special Representative of the Secretary-General on human rights and transnational 
corporations and other business enterprises495, John Ruggie, appointed in 2005.  The 
Guiding Principles provide a framework for addressing the issue of human rights harms 
caused by business enterprises which is based on three central pillars. The first pillar is 
the State duty to protect against human rights abuses by third parties, including business 
enterprises. The second is the corporate responsibility to respect human rights. The third 
is effective access to remedies.  The Guiding Principles were adopted unanimously496, 
which is significant as it reflects the states’ consensus on their utility.  A key challenge in 
relation to enhancing access to medicines is the high pricing of medicines by 
pharmaceutical companies which make them unaffordable to many patients.  Business 
enterprises do not have obligations under international human rights law, and the Guiding 
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Principles were developed to address the adverse impacts that can be caused by 
businesses. Therefore, Guiding Principles and the work of the Working Group is 
important to this research in terms of the potential for delivering legally binding 
obligations for pharmaceutical companies in relation to the right to health and access to 
medicines.  
A criticism of the Guiding Principles is that while the Guiding Principles have 
received a high level of endorsement by a range of stakeholders, including from the 
Human Rights Council and the UN Global Compact, the focus on ‘responsibilities’ rather 
than obligations and the absence of an effective remedy for failing to comply, means that 
the Guiding Principles do not go far enough to address business conduct which is harmful 
to human rights.497 However, an alternative view is that the Guiding Principles were not 
intended to create legal obligations or to be a regulatory regime in itself, but a platform 
of guidelines by which stakeholders including states may define their own regulatory 
regimes, to promote policy coherence between states’ human rights obligations and their 
actions in relation to business and commercial entities.498  The fact that the Guiding 
Principles are non-binding could present challenges in persuading States and private 
enterprises of the need for enforceable norms to implement regulatory regimes for 
businesses where human rights concerns arise. However, the level of endorsement of the 
Guiding Principles reflects that there is a desire at the international level for guidance on 
how to address actions of corporations that harm human rights.  The flexibility for States 
to develop their own national regulatory regimes could also encourage enhanced 
compliance with human rights norms.  A challenge for States will be how to effectively 
address situations where business enterprises do not cooperate with the implementation 
of the Guiding Principles, although strategies could include ‘naming and shaming’ of 
infringing companies, withdrawal of government funding, should the company benefit 
from such funding, or imposition of sanctions.499 
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The work of the Working Group provides an important source of information on 
experiences and lessons learned by states.500  The Working Group encourages States to 
produce National Action Plans on business and human rights as part of their responsibility 
to implement of the Guiding Principles and has produced guidance in order to help States 
to do so501.  The Guiding Principles have gained support from States and the private 
sector502, and Member States including the UK, Spain and Colombia503 have adopted 
National Action Plans as part of the State responsibility to implement the UN Guiding 
Principles nationally504. This illustrates that action is being taken by governments at 
national level to implement the Guiding Principles and operationalise the framework.   
The Working Group created by the Human Rights Council in its resolution 17/4505 
in 2011 was originally established for a period of three years.  In 2014 the Human Rights 
Council decided to establish an open-ended intergovernmental Working Group with a 
mandate to establish a legally binding instrument on human rights, transnational 
corporations and other business enterprises506.  The instrument is currently in the drafting 
stage, with emphasis on building upon the Guiding Principles.507  If the instrument does 
come into force, it could have significant implications for businesses, as it is likely that 
they will be held accountable for failing to respect human rights, through the introduction 
of stricter regulatory mechanisms by States bound by the proposed instrument. 
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Following the development of the Guiding Principles, the CESCR issued its 
General Comment 24508 in 2017 to clarify the obligations of States parties to the ICESCR 
with a view to addressing adverse effects of business activities on human rights.  General 
Comment 24 highlights that States parties have a responsibility to regulate transnational 
corporations as part of their human rights obligations under the ICESCR.509  General 
Comment 24 also highlights that States parties have extraterritorial obligations founded 
in Article 2 ICESCR510 to take steps to prevent and remedy infringements of ICESCR 
rights that occur outside their territories due to the activities of business entities over 
which they can exercise control.511  This guidance is significant in terms of clarifying the 
scope of States’ parties obligations in relation to access to medicines and the right to 
health under Article 12 ICESCR, as it illustrates that States parties have obligations under 
the ICESCR to regulate pharmaceutical companies under their control, where the price of 
medicines could infringe the right to health. This obligation extends to the extraterritorial 
actions of those companies, such as setting high prices for medicines in other territories 
which could infringe the right to health of patients. 
 
UN High Commissioner for Human Rights 
 
In 2001, the UN High Commissioner for Human Rights also produced a report examining 
the links between human rights and TRIPS, with a focus on the right to health.512  The 
report declared that when considering the operation of IP systems with regard to access 
to medicines the starting point is that access to essential medicines is a human right.513  
This is a significant statement from the UN High Commissioner that access to essential 
medicines forms part of the rights in the UN system. However, there is no clear guidance 
on where the issue of access to essential medicines fits in to the system, and on whether 
access to essential medicines should form a distinct human right, or whether it is an aspect 
of an existing human right. Article 31(1) VCLT provides the general rule of interpretation 
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being that a treaty is interpreted in good faith in accordance with its ordinary meaning in 
light of its object and purpose514.  Furthermore, Article 38 of the ICJ Statute515 provides 
that when deciding disputes in accordance with international law, the ICJ shall apply 
international conventions establishing rules expressly recognised by the contesting States, 
international customs and general principles of law, and does not expressly state that 
human rights principles must be given prominence.   
The report also specifically addressed the impact of IP systems on access to 
medicines, observing that while protecting IP rights can enhance technology transfer to 
developing countries, such protection can also lead to higher pricing which can restrict 
access to medicines for the poor.516  The report noted the potential links between human 
rights and the objective of promoting social and economic welfare under Article 7 
TRIPS517, but that “recognizing the links between the standards in the TRIPS Agreement 
and the promotion and protection of human rights is not the same as saying that the TRIPS 
Agreement takes a human rights approach to intellectual property protection.”518  The 
guidance from the High Commissioner’s report included that states should prevent abuses 
of IP rights that lead to violations of the right to health, such as restrictive licensing 
practices or the setting of high prices for essential medicines.519  The report encouraged 
states to implement the compulsory licensing provisions under Article 31 TRIPS in 
national legislation as safeguards to protect access to essential medicines as a component 
of the right to health.520 The report also recommended that developing countries be 
cautious about enacting ‘TRIPS-plus’ legislation without first understanding the impact 
of such legislation on the protection of human rights521.  
The report provides useful guidance on the scope of the right to health includes 
access to essential medicines. The report also outlines the scope of states obligations, 
including that states should implement TRIPS in light of their obligations under the right 
to health and should utilise compulsory licensing to promote affordable access to 
medicines. While the statements in the UN High Commissioner’s report are non-binding, 
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the report has been considered as a useful contribution to the discourse on the impact of 
economic globalisation on the enjoyment of human rights, because it outlines that the 
international trade system can work for the promotion and protection of human rights, 
and discusses how states can balance their obligations.522 The guidance in the report 
considers how states could address potential tensions between their human rights 
obligations and their obligations under TRIPS, illustrating that the High Commissioner 
did not find that TRIPS was inherently compatible with human rights. However, the report 
did outline that the implementation of TRIPS-plus standards of IP rights protection could 
be inconsistent with states’ human rights obligations. 
 
III. United Nations Human Rights Treaty Monitoring Bodies 
 
In addition to the Charter-based bodies, the bodies within the Treaty Monitoring system 
also have a remit with regard to the advancement of the right to health.  Although the 
decisions of the Treaty Monitoring Bodies system are not legally binding they are 
considered to be authoritative523. The main role of the treaty bodies is to receive State 
parties’ reports on the implementation of the rights within the specific treaty and to adopt 
concluding observations, which are valuable as an interpretative tool for the treaties.524  
Therefore, the work of the treaty bodies have significant interpretative value for this 
research in relation to the normative content of the right to health.   
The findings of the treaty bodies are also relevant to domestic courts, with the 
International Law Association stating that national courts have recognised that the treaty 
bodies’ interpretations deserve to be given considerable weight in determining the 
meaning of a relevant right and the existence of a violation.525  This is significant in 
relation to the monitoring and accountability of state obligations at national level, as it 
demonstrates how domestic courts utilise the treaty bodies’ reports to inform their 
interpretation of statutory or constitutional human rights provisions.526  This suggests that 
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the treaty bodies have an influential role in terms of guidance to State parties on how they 
should meet their obligations under the treaties, rather than a mandate of enforcement. 
The Treaty Monitoring Body system does face some challenges, including the 
non-binding nature of recommendations, the issue of effective follow-up action and non-
submission of state reports.527 The formulation of concluding observations is intended to 
be a process of interactive dialogue with the state, not a process of adjudication as in the 
case of court proceedings528, but following up on the implementation of the 
recommendations made during the process could add to the utility of the concluding 
observations.  Alston argues that although there are problems, difficulties in changing the 
system include reluctance from states as well as decreasing UN resources.529  Various 
proposals for reform have been advanced, most notably the 2012 report of the then High 
Commissioner for Human Rights, Navi Pillay, which outlined proposals on simplifying 
reporting procedures and strengthening the expertise of treaty body members.530 As yet, 
these have not been taken forward. 
 There are currently nine core international human rights treaties, with individual 
monitoring bodies in the form of Committees to promote and monitor state compliance 
with their obligations in the treaties.531  The Committee on Economic, Social and Cultural 
Rights (CESCR) monitors the ICESCR.  For the purposes of this chapter, the ICESCR is 
particularly significant due to the nature of the social and cultural rights contained in this 
treaty, including the right to the highest attainable standard of health under Article 12.532  
As at 31 March 2020, 170 states are states parties to the ICESCR, including Canada, Peru 
and EU Member States.533 The US is one of four states that is a signatory but has not 
ratified the ICESCR.534  The Committees overseeing the respective treaties may also 
publish General Comments on thematic issues, which provide authoritative interpretative 
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guidance on the obligations of the State parties under the relevant treaty.535  General 
Comments can also provide guidance in formulating concluding observations. 
Article 2 of the ICESCR outlines States parties’ obligations under the Covenant 
in general, stating that States are obligated to take steps to progressively realise the rights 
in the Covenant.  This suggests that the States parties have a wide discretion in terms of 
the period of time in which to realise their responsibilities, although there are also 
immediate obligations such as non-discrimination. The CESCR issued General Comment 
3536, which clarifies that Article 2 recognises that some States will not be able to achieve 
full realisation of all of the Covenant rights in a short period of time, although they are 
required to immediately take steps to begin the full realisation of the rights.537  Therefore 
the States must actively demonstrate that they have implemented processes in order to 
achieve full realisation of the rights in the Covenant. 
 
(a) ICESCR Article 12 
 
The ICESCR is the most significant treaty with regard to health rights, originally provided 
for in Article 25 of the Universal Declaration on Human rights (UDHR) as part of an 
adequate standard of living538, and since enshrined in Article 12 of the ICESCR539 which 
states: 
 
“1. The States Parties to the present Covenant recognize the right of everyone to the 
enjoyment of the highest attainable standard of physical and mental health. 
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2. The steps to be taken by the States Parties to the present Covenant to achieve the full 
realization of this right shall include those necessary for: (a) The provision for the 
reduction of the stillbirth-rate and of infant mortality and for the healthy development of 
the child; (b) The improvement of all aspects of environmental and industrial hygiene; 
(c) The prevention, treatment and control of epidemic, endemic, occupational and other 
diseases; (d) The creation of conditions which would assure to all medical service and 
medical attention in the event of sickness.” 
 
The obligations of the States parties in Article 12 are widely drafted, as the term “all steps 
necessary” is open to be interpreted differently by different State parties.  While this 
flexibility may be an advantage to countries which do not have the resources to make the 
same provisions to realise the right as more developed countries, there is potential for 
uncertainty as to the limits of the States parties’ obligations.   
 
(b) National obligations of States parties under the ICESCR 
 
There is no reference to medicines in the drafting history of the ICESCR540, so it is 
important to consider the content and interpretation of the right in order to understand 
whether the right has been interpreted to include access to medicines.  In 2000 the CESCR 
issued its General Comment 14 in order to provide guidance on interpreting Article 12.541  
General Comment 14 clarifies that Article 12 affords the right to equality of opportunity 
to enjoy the highest attainable standard of health542. General Comment 14 also clarifies 
that the essential elements of the right include availability of essential medicines and 
accessibility of such medicines, although does not define what amounts to ‘essential’ 
medicines.  This is an example of the lack of clarity on terminology previously discussed 
in Chapter 1.  General Comment 14 also provides that the right to health facilities in 
Article 12(2)(d) includes the provision of essential medicines.  Accessibility is considered 
in economic terms rather than geographical or physical terms and therefore means that 
health facilities, goods and services must be affordable for all.543  Therefore the right of 
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access to essential medicines is specifically adopted as part of the ICESCR through 
General Comment 14.544  
The specific legal obligations on Member States include obligations to respect, 
protect and fulfil the right to health545.  The obligation to respect includes an obligation 
on Member States to refrain from marketing unsafe medicines546, obligations to protect 
involve duties on Member States to enact legislation or national policies to secure equal 
access to health care and services provided by third parties, including to control the 
marketing of medicines and ensuring that third parties do not limit access to health-related 
services547.  General Comment 14 clarifies that availability of affordable essential 
medicines is a critical component of the right to the highest attainable standard of health, 
by outlining that access to essential medicines is a core obligation of states.548  ‘While this 
is an important clarification, there is no elaboration on how this obligation is to be 
realised.  Given that states’ ability to ensure availability of medicines, and therefore meet 
this obligation, is linked to resource availability, developing states may be unable to fully 
realise this right due to resource constraints. However, General Comment 3 does address 
such a situation, providing that a state has to show that they have made every effort to use 
all available resources to satisfy those minimum core obligations.549 
 
(c) International obligations of States parties under ICESCR Article 12 
 
General Comment 14 provides guidance on the actions to be taken by States parties.  This 
includes defining the actions under Article 12(2)(c) regarding control of diseases as States 
parties individual and joint efforts to make available relevant technologies550, which may 
be relevant in terms of new medicines under patent and generic production, and highlights 
the extraterritorial responsibility to cooperate with other States.  The General Comment 
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also clarifies that the right to health includes accessibility of health facilities, goods and 
services without discrimination, and ensuring that health expenses do not 
disproportionately burden the poor in comparison to the wealthier sector of the 
population.551 Therefore, states have an obligation to promote affordable essential 
medicines for all, not just those who are able to pay the current costs for the provision of 
health goods and services.  
The international obligations of States also include the obligation to respect the 
right to health in other countries and to prevent third parties, such as companies, from 
violating the right in other territories as far as possible552.  States are also required to 
facilitate access to health facilities, goods and services in other countries, have an 
obligation to ensure that their actions as members of international organisations take due 
account of the right to health, and should refrain at all times from imposing embargoes or 
similar measures restricting the supply to another State of adequate medicines553. 
However this is not an absolute requirement as States are only required to do so as far as 
it is possible for them to do so, which may be difficult to monitor, particularly in relation 
to developing countries that have resource constraints.  Coomans argues that the CESCR 
has not provided an in-depth clarification of the international obligations of states, and 
this has led to the use of different terms and weak language on the nature of states’ 
commitments554. The lack of clarity on the notion of international obligations could 
present uncertainties for states if the extent of their obligations is not clearly defined. It is 
also difficult to see how States could be held accountable for failing to meet such 
obligations. However, this reflects that States parties have to recognise the importance of 
international assistance among a range of stakeholders in achieving full realisation of the 
right to health, and access to medicines. 
The extraterritoriality of State obligations under the ICESCR are evident in 
General Comment 3555 which elaborates on Article 2(1)556, emphasising that international 
cooperation for the realisation of the rights enshrined in the ICESCR is an obligation of 
all States, and without international cooperation and assistance the full realisation of these 
                                                            
551 ibid 12 
552 ibid 39 
553 ibid 39-41 
554 F Coomans, 'The Extraterritorial Scope of the International Covenant on Economic, Social and Cultural 
Rights in the Work of the United Nations Committee on Economic, Social and Cultural Rights' (2011) 11 
Hum Rts L Rev 1, 34 
555 General Comment No. 3 (n 536) 
556 International Covenant on Economic, Social and Cultural Rights (n 2) Article 2(1) 
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rights will not be attainable for all Member States557.  General Comment 14 also clarified 
that States are bound by their obligations under the ICESCR when acting as a member of 
an international organisation558.  Not only must States have due regard to their human 
rights obligations in the negotiation of international agreements, but they also have to 
respect the enjoyment of the right to health in other countries, and to prevent third parties 
from violating the right in other countries, as far as they are able to do so.  This proposes 
that WTO Member States are required to consider their human rights obligations in the 
negotiation of trade agreements and must therefore consider how such agreements affect 
the right to health including access to medicines, and also suggests that Member States 
are obliged to take positive actions for furtherance of the right to health in other countries.  
Such obligations are particularly pertinent in relation to access to medicines, and ensuring 
that the related rights of all individuals in all states are upheld. 
 
The utility of Concluding Observations559 
                                                            
557 General Comment No. 3 (n 536) 14 
558 General Comment No. 14 (n 112) 39 
559 A systematic, chronological review of the Concluding Observations of the CESCR has been 
undertaken, in consideration of their relevance to accessing medicines: Luxembourg E/1991/23, Tunisia 
E/1980/WG.1/SR.5, United Republic of Tanzania E/1980/WG.1/SR.5, Ecuador E/1980/WG.1/SR.4, 
Ecuador E/1980/WG.1/SR.5, Norway, E/1980/WG.1/SR.5, Romania E/1980/WG.1/SR.7, Mongolia 
E/1980/WG.1/SR.7, Chile E/1980/WG.1/SR.9, Hungary E/1980/WG.1/SR.7, Finland E/1980/WG.1/SR.6, 
Tunisia E/1980/WG.1/SR.6, Germany E/1980/WG.1/SR.8, Chile E/1980/WG.1/SR.8, Philippines 
E/1980/WG.1/SR.11, Australia E/1980/WG.1/SR.12, Bulgaria E/1980/WG.1/SR.12, Germany 
E/1980/WG.1/SR.10, Denmark E/1980/WG.1/SR.10, Australia E/1980/WG.1/SR.13, Cyprus 
E/1980/WG.1/SR.17, Colombia E/1980/WG.1/SR.15, Russian Federation E/1980/WG.1/SR.14, Sweden 
E/1980/WG.1/SR.15, Ukraine E/1980/WG.1/SR.18, Poland E/1980/WG.1/SR.18, Romania 
E/1980/WG.1/SR.16,  Belarus E/1980/WG.1/SR.16, Jamaica E/1980/WG.1/SR.20, Spain 
E/1980/WG.1/SR.20, Poland E/1980/WG.1/SR.19, United Kingdom of Great Britain and Northern Ireland 
E/1980/WG.1/SR.19, Madagascar E/1981/WG.1/SR.2, Syrian Arab Republic E/1981/WG.1/SR.4, 
Germany E/1981/WG.1/SR.8, Germany E/1981/WG.1/SR.10, Austria E/1981/WG.1/SR.8, Iraq 
E/1981/WG.1/SR.12, Senegal E/1981/WG.1/SR.11, United Kingdom of Great Britain and Northern 
Ireland E/1981/WG.1/SR.16, United Kingdom of Great Britain and Northern Ireland, 
E/1981/WG.1/SR.17, Canada E/1982/WG.1/SR.1, Italy E/1982/WG.1/SR.3, Italy E/1982/WG.1/SR.4, 
Panama E/1982/WG.1/SR.5, Barbados E/1982/WG.1/SR.3, Canada E/1982/WG.1/SR.2, Japan 
E/1982/WG.1/SR.12,  Japan E/1982/WG.1/SR.13, Mexico E/1982/WG.1/SR.14, Mexico 
E/1982/WG.1/SR.15, Libya E/1983/WG.1/SR.16, Libya E/1983/WG.1/SR.17, India E/1984/WG.1/SR.6, 
India E/1984/WG.1/SR.8, Venezuela (Bolivarian Republic of) E/1984/WG.1/SR.7, Venezuela  Bolivarian 
Republic of) E/1984/WG.1/SR.8, Russian Federation E/1984/WG.1/SR.9, Venezuela (Bolivarian Republic 
of) E/1984/WG.1/SR.10, Peru E/1984/WG.1/SR.11, Russian Federation E/1984/WG.1/SR.10, Rwanda 
E/1984/WG.1/SR.10, Sweden E/1984/WG.1/SR.14, Spain E/1984/WG.1/SR.12, Spain 
E/1984/WG.1/SR.14, Rwanda E/1984/WG.1/SR.12, Philippines E/1984/WG.1/SR.15, Belarus 
E/1984/WG.1/SR.13, Belarus E/1984/WG.1/SR.14, Belarus, E/1984/WG.1/SR.15, Ukraine 
E/1984/WG.1/SR.13, Ukraine E/1984/WG.1/SR.14, Ukraine E/1984/WG.1/SR.15, Finland 
E/1984/WG.1/SR.17, Denmark E/1984/WG.1/SR.17, Mongolia E/1984/WG.1/SR.16, Yugoslavia 
E/1984/WG.1/SR.16, Sweden E/1984/WG.1/SR.16, Peru E/1984/WG.1/SR.18, Yugoslavia 
E/1984/WG.1/SR.18, Mongolia E/1984/WG.1/SR.18, Cyprus E/1984/WG.1/SR.18, Finland 
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E/1984/WG.1/SR.18, Ecuador E/1984/WG.1/SR.20, Denmark E/1984/WG.1/SR.21, Hungary 
E/1984/WG.1/SR.19, Hungary E/1984/WG.1/SR.21, Norway E/1984/WG.1/SR.19, Philippines 
E/1984/WG.1/SR.20, Norway E/1984/WG.1/SR.22, Cyprus E/1984/WG.1/SR.22, Ecuador 
E/1984/WG.1/SR.22, Colombia E/1984/WG.1/SR.22, Portugal E/1985/WG.1/SR.2, France 
E/1985/WG.1/SR.5, France E/1985/WG.1/SR.7, Portugal, E/1985/WG.1/SR.4, Bulgaria 
E/1985/WG.1/SR.9, Romania E/1985/WG.1/SR.10, Romania E/1985/WG.1/SR.13, Bulgaria 
E/1985/WG.1/SR.11, Australia E/1985/WG.1/SR.17, Nicaragua E/1985/WG.1/SR.15, United Kingdom of 
Great Britain and Northern Ireland E/1985/WG.1/SR.14, United Kingdom of Great Britain and Northern 
Ireland E/1985/WG.1/SR.17,  Australia E/1985/WG.1/SR.18, Australia E/1985/WG.1/SR.21, Hungary 
E/1986/WG.1/SR.9, Austria E/1986/WG.1/SR.4, Zambia E/1986/WG.1/SR.4, Zambia E/1986/WG.1/SR.5 , 
Hungary E/1986/WG.1/SR.6, Iraq E/1986/WG.1/SR.8, Hungary E/1986/WG.1/SR.7, Austria 
E/1986/WG.1/SR.7, Zambia E/1986/WG.1/SR.7, Iraq E/1986/WG.1/SR.11, Poland E/1986/WG.1/SR.26, 
Poland E/1986/WG.1/SR.27, Poland E/1986/WG.1/SR.25, Chile E/C.12/1988/4, Democratic Republic of 
the Congo E/C.12/1988/4, Netherlands E/C.12/1989/5, Netherlands E/C.12/1989/5, Netherlands 
E/C.12/1989/5 paras. 193-228, Trinidad and Tobago E/C.12/1989/5 paras. 267-309, Cameroon 
E/C.12/1989/5 paras. 53-78, Canada E/C.12/1989/5 paras. 79-112, Rwanda E/C.12/1989/5 paras. 162-
192, Netherlands E/C.12/1989/5 paras. 193-228, United Kingdom of Great Britain and Northern Ireland 
(Crown Dependencies) A/44/40 paras. 140-189, Philippines E/C.12/1990/3 paras. 113-133, Argentina 
E/C.12/1990/3 paras. 235-254, Costa Rica E/C.12/1990/8 paras. 159-195, Iran (Islamic Republic of) 
E/C.12/1990/8 paras. 196-212, Dominican Republic E/C.12/1990/8 paras. 213-250, Jordan 
E/C.12/1990/8 paras. 56-86, Afghanistan E/C.12/1991/4 paras. 55-94, Syrian Arab Republic 
E/C.12/1991/4 paras. 158-194, Hungary E/C.12/1992/2 paras. 133-154 Australia, E/C.12/1993/9, Kenya 
E/C.12/1993/6, Iran (Islamic Republic of) E/C.12/1993/7, Viet Nam E/C.12/1993/8, Lebanon 
E/C.12/1993/10, Canada E/C.12/1993/5, Iceland E/C.12/1993/15, New Zealand E/C.12/1993/13, 
Nicaragua E/C.12/1993/14, Senegal E/C.12/1993/18, Mexico E/C.12/1993/16, Germany E/C.12/1993/17, 
Morocco E/C.12/1994/5, Romania E/C.12/1994/4, Iraq E/C.12/1994/6, Uruguay E/C.12/1994/3, 
Mauritius E/C.12/1994/8, Belgium E/C.12/1994/7, Austria E/C.12/1994/16, Argentina E/C.12/1994/14, 
Jamaica E/C.12/1994/15, United Kingdom of Great Britain and Northern Ireland (Crown Dependencies) 
E/C.12/1994/19, United Kingdom of Great Britain and Northern Ireland E/C.12/1994/19, Mali 
E/C.12/1994/17, Suriname E/C.12/1994/18, Philippines E/1995/22(SUPP) paras. 216-220, Austria 
E/1995/22(SUPP) paras. 243-263, Dominican Republic E/1995/22(SUPP) paras. 206-210, Kenya 
E/1995/22(SUPP) paras. 159-164, Argentina E/1995/22(SUPP) paras. 221-242, United Kingdom of Great 
Britain and Northern Ireland (Crown Dependencies) E/1995/22(SUPP) paras. 264-304, United Kingdom 
of Great Britain and Northern Ireland E/1995/22(SUPP) paras. 264-304, Suriname E/C.12/1995/6, 
Sweden E/C.12/1995/5, Philippines E/C.12/1995/7, Republic of Korea E/C.12/1995/3, Portugal 
E/C.12/1995/4, Panama E/C.12/1995/8, Panama E/C.12/1995/8, Panama E/C.12/1995/8, Ukraine 
E/C.12/1995/15, Colombia E/C.12/1995/12, Algeria E/C.12/1995/17, Norway E/C.12/1995/13, Mauritius 
E/C.12/1995/14, Paraguay E/C.12/1/Add.1, Spain, E/C.12/1/Add.2, El Salvador E/C.12/1/Add.4, 
Guatemala E/C.12/1/Add.3, Guinea E/C.12/1/Add.5, Algeria E/C.12/1995/18 paras. 278-305, Colombia 
E/C.12/1995/18 paras. 173-202, Norway E/C.12/1995/18 paras. 203-227, Mauritius E/C.12/1995/18 
paras. 228-247, Belarus E/C.12/1/Add.7/Rev.1, Finland E/C.12/1/Add.8, Dominican Republic 
E/C.12/1/Add.6, Portugal (Macau) E/C.12/1/Add.9, United Kingdom of Great Britain and Northern 
Ireland (Hong Kong) E/C.12/1/Add.10, Dominican Republic E/C.12/1996/6, Zimbabwe E/C.12/1/Add.12, 
Libya E/C.12/1/Add.15, Peru E/C.12/1/Add.14, Russian Federation E/C.12/1/Add.13 Saint Vincent and 
the Grenadines E/C.12/1/Add.21, United Kingdom of Great Britain and Northern Ireland 
E/C.12/1/Add.19, Dominican Republic E/C.12/1/Add.16, Iraq E/C.12/1/Add.17, Luxembourg 
E/C.12/1/Add.22, Azerbaijan E/C.12/1/Add.20, Uruguay E/C.12/1/Add.18, Nigeria E/C.12/1/Add.23, 
Netherlands  E/C.12/1/Add.25 Netherlands (Antilles) E/C.12/1/Add.25, Netherlands (Aruba) 
E/C.12/1/Add.25, Sri Lanka E/C.12/1/Add.24, Poland E/C.12/1/Add.26, Israel E/C.12/1/Add.27, Germany 
E/C.12/1/Add.29, Cyprus E/C.12/1/Add.28, Switzerland E/C.12/1/Add.30, Canada E/C.12/1/Add.31, 
Iceland E/C.12/1/Add.32, Ireland E/C.12/1/Add.35, Denmark E/C.12/1/Add.34 Solomon Islands 
E/C.12/1/Add.33, Tunisia E/C.12/1/Add.36, Argentina E/C.12/1/Add.38, Armenia E/C.12/1/Add.39, 
Bulgaria E/C.12/1/Add.37, Mexico E/C.12/1/Add.41, Georgia E/C.12/1/Add.42, Italy E/C.12/1/Add.43, 
Egypt E/C.12/1/Add.44, Congo E/C.12/1/Add.45, Mongolia E/C.12/1/Add.47, Jordan E/C.12/1/Add.46, 
Kyrgyzstan E/C.12/1/Add.49, Sudan E/C.12/1/Add.48, Australia E/C.12/1/Add.50, Portugal 
E/C.12/1/Add.53, Morocco E/C.12/1/Add.55, Belgium E/C.12/1/Add.54, Finland E/C.12/1/Add.52, Serbia 
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E/2001/22 paras. 496-511(preliminary recommendations), Togo E/C.12/1/Add.61, Venezuela (Bolivarian 
Republic of) E/C.12/1/Add.56, Honduras  E/C.12/1/Add.57, Bolivia (Plurinational State of) 
E/C.12/1/Add.60, China (Hong Kong) E/C.12/1/Add.58, Republic of Korea E/C.12/1/Add.59, Israel 
E/C.12/1/Add.69, Senegal E/C.12/1/Add.62, Japan E/C.12/1/Add.67, Panama E/C.12/1/Add.64, Nepal 
E/C.12/1/Add.66, Germany E/C.12/1/Add.68, Syrian Arab Republic E/C.12/1/Add.63, Ukraine 
E/C.12/1/Add.65, Algeria E/C.12/1/Add.71, France E/C.12/1/Add.72, Sweden E/C.12/1/Add.70, Croatia 
E/C.12/1/Add.73, Colombia E/C.12/1/Add.74, Jamaica E/C.12/1/Add.75, Ireland E/C.12/1/Add.77, 
United Kingdom of Great Britain and Northern Ireland E/C.12/1/Add.79, Trinidad and Tobago 
E/C.12/1/Add.80, United Kingdom of Great Britain and Northern Ireland (Overseas Territory) 
E/C.12/1/Add.79, United Kingdom of Great Britain and Northern Ireland (Crown Dependencies) 
E/C.12/1/Add.79, Czech Republic E/C.12/1/Add.76, Benin E/C.12/1/Add.78, Japan E/C.12/2002/12, 
Poland  E/C.12/1/Add.82, Solomon Islands E/C.12/1/Add.84, Slovakia E/C.12/1/Add.81, Georgia 
E/C.12/1/Add.83, Estonia E/C.12/1/Add.85, Iceland E/C.12/1/Add.89, Brazil E/C.12/1/Add.87, 
Luxembourg E/C.12/1/Add.86, Israel E/C.12/1/Add.90, New Zealand E/C.12/1/Add.88, Russian 
Federation E/C.12/1/Add.94, Republic of Moldova E/C.12/1/Add.91, Guatemala E/C.12/1/Add.93, 
Democratic People's Republic of Korea E/C.12/1/Add.95, Yemen E/C.12/1/Add.92, Ecuador 
E/C.12/1/Add.100, Greece E/C.12/1/Add.97, Kuwait E/C.12/1/Add.98, Lithuania E/C.12/1/Add.96, Spain 
E/C.12/1/Add.99, Chile E/C.12/1/Add.105, Chile E/C.12/1/Add.105/Corr.1, Azerbaijan E/C.12/1/Add.104, 
Denmark E/C.12/1/Add.102, Malta E/C.12/1/Add.101, Italy E/C.12/1/Add.103, China E/C.12/1/Add.107, 
China (Hong Kong) E/C.12/1/Add.107, China (Macau) E/C.12/1/Add.107, Zambia E/C.12/1/Add.106, 
Serbia, E/C.12/1/Add.108, Norway E/C.12/1/Add.109, Bosnia and Herzegovina E/C.12/BIH/CO/1, 
Uzbekistan E/C.12/UZB/CO/1, Austria E/C.12/AUT/CO/3, Libya E/C.12/LYB/CO/2, Slovenia 
E/C.12/SVN/CO/1, Canada E/C.12/CAN/CO/4, Canada E/C.12/CAN/CO/5, Canada E/C.12/CAN/CO/4, 
Canada E/C.12/CAN/CO/5, Mexico E/C.12/MEX/CO/4, Liechtenstein E/C.12/LIE/CO/1, Monaco 
E/C.12/MCO/CO/1, Morocco E/C.12/MAR/CO/3, Morocco E/C.12/MAR/CO/2, El Salvador 
E/C.12/SLV/CO/2, Tajikistan E/2007/22, San Marino E/C.12/SMR/CO/4, Paraguay E/C.12/PRY/CO/3, 
Belgium E/C.12/BEL/CO/3, Costa Rica E/C.12/CRI/CO/4, Ukraine E/C.12/UKR/CO/5, Latvia 
E/C.12/LVA/CO/1, The former Yugoslav Republic of Macedonia E/C.12/MKD/CO/1, Nepal 
E/C.12/NPL/CO/2, Finland E/C.12/FIN/CO/5, Hungary E/C.12/HUN/CO/3, Netherlands (Antilles) 
E/C.12/NLD/CO/3/Add.1, Costa Rica E/C.12/CRI/CO/4/CORR.1, France E/C.12/FRA/CO/3, Benin 
E/C.12/BEN/CO/2, Bolivia (Plurinational State of) E/C.12/BOL/CO/2, India E/C.12/IND/CO/5, Nicaragua 
E/C.12/NIC/CO/4, Sweden E/C.12/SWE/CO/5, Kenya E/C.12/KEN/CO/1, United Nations Interim 
Administration in Kosovo E/C.12/UNK/CO/1, Philippines E/C.12/PHL/CO/4, Cyprus E/C.12/CYP/CO/5, 
Brazil  E/C.12/BRA/CO/2, Cambodia E/C.12/KHM/CO/1, Australia E/C.12/AUS/CO/4, United Kingdom of 
Great Britain and Northern Ireland E/C.12/GBR/CO/5, United Kingdom of Great Britain and Northern 
Ireland (Overseas Territory) E/C.12/GBR/CO/5, United Kingdom of Great Britain and Northern Ireland 
(Crown Dependencies) E/C.12/GBR/CO/5, Poland E/C.12/POL/CO/5, Madagascar E/C.12/MDG/CO/2, 
Chad E/C.12/TCD/CO/3, Democratic Republic of the Congo E/C.12/COD/CO/4, Republic of Korea 
E/C.12/KOR/CO/3, Kazakhstan E/C.12/KAZ/CO/1, Colombia E/C.12/COL/CO/5, Afghanistan 
E/C.12/AFG/CO/2-4, Algeria E/C.12/DZA/CO/4, Mauritius E/C.12/MUS/CO/4, Switzerland 
E/C.12/CHE/CO/2-3, Dominican Republic E/C.12/DOM/CO/3, Uruguay E/C.12/URY/CO/3-4, Netherlands 
(Aruba) E/C.12/NLD/CO/4-5, Netherlands (Antilles) E/C.12/NLD/CO/4-5, Netherlands E/C.12/NLD/CO/4-
5, Sri Lanka E/C.12/LKA/CO/2-4, Netherlands (Antilles) E/C.12/NLD/CO/4-5/CORR.1, Netherlands (Aruba) 
E/C.12/NLD/CO/4-5/CORR.1, Netherlands E/C.12/NLD/CO/4-5/CORR.1, Russian Federation 
E/C.12/RUS/CO/5, Yemen E/C.12/YEM/CO/2 Turkey E/C.12/TUR/CO/1, Germany E/C.12/DEU/CO/5, 
Republic of Moldova E/C.12/MDA/CO/2, Turkmenistan E/C.12/TKM/CO/1, Argentina E/C.12/ARG/CO/3, 
Estonia E/C.12/EST/CO/2, Israel E/C.12/ISR/CO/3, Cameroon E/C.12/CMR/CO/2-3, Peru 
E/C.12/PER/CO/2-4, Ethiopia E/C.12/ETH/CO/1-3, New Zealand E/C.12/NZL/CO/3, Spain 
E/C.12/ESP/CO/5, Slovakia E/C.12/SVK/CO/2, Mauritania E/C.12/MRT/CO/1, Iceland E/C.12/ISL/CO/4, 
Bulgaria E/C.12/BGR/CO/4-5, Equatorial Guinea E/C.12/GNQ/CO/1, United Republic of Tanzania 
E/C.12/TZA/CO/1-3, Ecuador E/C.12/ECU/CO/3, Congo E/C.12/COG/CO/1, Angola E/C.12/AGO/CO/3, 
Togo E/C.12/TGO/CO/1, Azerbaijan E/C.12/AZE/CO/3, Denmark E/C.12/DNK/CO/5, Iran (Islamic Republic 
of) E/C.12/IRN/CO/2, Jamaica E/C.12/JAM/CO/3-4, Japan E/C.12/JPN/CO/3, Rwanda E/C.12/RWA/CO/2-
4, Belarus E/C.12/BLR/CO/4-6, Norway E/C.12/NOR/CO/5, Austria E/C.12/AUT/CO/4, Egypt 
E/C.12/EGY/CO/2-4, Bosnia and Herzegovina E/C.12/BIH/CO/2, Albania E/C.12/ALB/CO/2-3, Kuwait 
E/C.12/KWT/CO/2, Belgium E/C.12/BEL/CO/4, Gabon E/C.12/GAB/CO/1, Djibouti  E/C.12/DJI/CO/1-2, 
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The issuing of concluding observations and recommendations to States parties offers 
guidance on implementation of their obligations under the treaty and can contribute to the 
scope and understanding of the treaty. The concluding observations can also facilitate the 
sharing of best practice through an interactive dialogue.  Therefore, the concluding 
observations are of significance to this research in terms of contributing to the 
understanding of the scope of the right to health and access to medicines, and in 
monitoring states’ compliance with their obligations under Article 12.  The issue of access 
to medicines was raised in 6.6 percent of the concluding observations.  Recommendations 
were made in relation to access to medicines in 3.2 percent of the concluding 
observations, and the CESCR referred to the right to health under Article 12 in all of these 
recommendations.  The majority of the recommendations referred to access to medicines 
in general terms and did not provide a definition of the type of medicines to fall within 
the scope of ‘medicine’. However, 31 percent referred specifically to HIV/AIDS 
medicines. The types of recommendation being made relate to ensuring that intellectual 
property standards in FTAs do not adversely affect access to medicines, facilitating access 
                                                            
Ukraine E/C.12/UKR/CO/6, Uzbekistan E/C.12/UZB/CO/2, China E/C.12/CHN/CO/2, China (Hong Kong) 
E/C.12/CHN/CO/2, China (Macau) E/C.12/CHN/CO/2, El Salvador E/C.12/SLV/CO/3-5, Indonesia 
E/C.12/IDN/CO/1, Monaco E/C.12/MCO/CO/2-3, Czech Republic E/C.12/CZE/CO/2, Lithuania 
E/C.12/LTU/CO/2, Serbia E/C.12/SRB/CO/2, Armenia E/C.12/ARM/CO/2-3, Portugal E/C.12/PRT/CO/4, 
Romania E/C.12/ROU/CO/3-5, Guatemala E/C.12/GTM/CO/3, Nepal E/C.12/NPL/CO/3, Montenegro 
E/C.12/MNE/CO/1, Slovenia E/C.12/SVN/CO/2, Viet Nam E/C.12/VNM/CO/2-4, Finland 
E/C.12/FIN/CO/6, Paraguay E/C.12/PRY/CO/4, Tajikistan E/C.12/TJK/CO/2-3, Gambia E/C.12/GMB/CO/1, 
Kyrgyzstan E/C.12/KGZ/CO/2-3, Mongolia E/C.12/MNG/CO/4, Venezuela (Bolivarian Republic of) 
E/C.12/VEN/CO/3, Chile E/C.12/CHL/CO/4, Uganda E/C.12/UGA/CO/1, Ireland E/C.12/IRL/CO/3, 
Thailand E/C.12/THA/CO/1-2, Burundi E/C.12/BDI/CO/1, Morocco E/C.12/MAR/CO/4, Iraq 
E/C.12/IRQ/CO/4, Greece E/C.12/GRC/CO/2, Sudan E/C.12/SDN/CO/2, Italy E/C.12/ITA/CO/5, Guyana 
E/C.12/GUY/CO/2-4, Canada E/C.12/CAN/CO/6, Namibia E/C.12/NAM/CO/1, Kenya E/C.12/KEN/CO/2-5, 
Honduras E/C.12/HND/CO/2, Burkina Faso E/C.12/BFA/CO/1, France E/C.12/FRA/CO/4, United Kingdom 
of Great Britain and Northern Ireland E/C.12/GBR/CO/6, Sweden E/C.12/SWE/CO/6, The former 
Yugoslav Republic of Macedonia E/C.12/MKD/CO/2-4, Angola E/C.12/AGO/CO/4-5, Costa Rica 
E/C.12/CRI/CO/5, Dominican Republic E/C.12/DOM/CO/4, Lebanon E/C.12/LBN/CO/2, Philippines 
E/C.12/PHL/CO/5-6, Poland E/C.12/POL/CO/6, Cyprus E/C.12/CYP/CO/6, Tunisia E/C.12/TUN/CO/3, 
Liechtenstein E/C.12/LIE/CO/2-3, Netherlands E/C.12/NLD/CO/6, Australia E/C.12/AUS/CO/5, Pakistan 
E/C.12/PAK/CO/1, Uruguay E/C.12/URY/CO/5, Sri Lanka E/C.12/LKA/CO/5, Russian Federation 
E/C.12/RUS/CO/6, Republic of Moldova E/C.12/MDA/CO/3, Republic of Korea E/C.12/KOR/CO/4, 
Colombia E/C.12/COL/CO/6, Mexico E/C.12/MEX/CO/5-6, Bangladesh E/C.12/BGD/CO/1, Spain 
E/C.12/ESP/CO/6, New Zealand E/C.12/NZL/CO/4, Central African Republic E/C.12/CAF/CO/1, Niger 
E/C.12/NER/CO/1, Turkmenistan E/C.12/TKM/CO/2, Argentina E/C.12/ARG/CO/4, Mali 
E/C.12/MLI/CO/1, Germany E/C.12/DEU/CO/6, Cabo Verde E/C.12/CPV/CO/1, South Africa 
E/C.12/ZAF/CO/1, Cameroon E/C.12/CMR/CO/4, Estonia E/C.12/EST/CO/3, Kazakhstan 
E/C.12/KAZ/CO/2, Bulgaria E/C.12/BGR/CO/6, Mauritius E/C.12/MUS/CO/5, Denmark E/C.12/DNK/CO/6, 
Israel E/C.12/ISR/CO/4, Senegal E/C.12/SEN/CO/3, Ecuador E/C.12/ECU/CO/4, Slovakia 
E/C.12/SVK/CO/3, Switzerland E/C.12/CHE/CO/4. 
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to HIV/AIDS medicines for patients, and ensuring health facilities and hospitals have 
supplies of medicines.  Illustrative examples of these trends are discussed below. 
 
(a) Impact of FTAs on access to medicines 
 
The implications of trade agreements on access to medicines, entered into by developing 
countries was highlighted by the CESCR in its recommendations on the state report of 
Costa Rica560. The CESCR recommended that the State party should undertake to take 
steps necessary to assess any potentially adverse impacts of the Central American Free 
Trade Agreement (CAFTA) on the State party’s obligations under the ICESCR in respect 
of access to generic medicines.561  Specific concerns related to the data exclusivity 
provisions which went beyond the minimum standards set out in Article 39(3) TRIPS562, 
and would delay the entry of the generic equivalent to the market. The CESCR 
recommendation illustrates that States are expected to monitor and assess the implications 
of such agreements on the Covenant rights even after the agreements have been entered 
into, as a continuous process of assessment and monitoring of compliance with the 
Covenant obligations.   Costa Rica responded to this recommendation in its subsequent 
state report, confirming that assessments had been undertaken and that current challenges 
in enhancing access to medicines were not as a result of CAFTA. 563  The State’s response 
to this recommendations provides an example of how the concluding observations can 
facilitate a constructive dialogue with states on how they can best discharge their 
obligations under the right to health. 
 Further attention on the impact of FTAs on the right to health was evident in the 
concluding observations of the state report of Peru in 2012564. As with CAFTA, concerns 
                                                            
560 UNCESCR ‘Consideration of Reports Submitted by States Parties under Articles 16 and 17 of the 
Covenant, Costa Rica, Draft concluding observations of the Committee on Economic, Social and Cultural 
Rights’ (4 January 2008) UN Doc E/C.12/CRI/CO/4 
561 ibid 27 
562 P Pusceddu ‘Access to Medicines in Developing Countries and Free Trade Agreements: The Case of 
the US-DR-CAFTA with Focus on Costa Rica’ (2014) 19 JIPR 104, 105, Correa (n 336) 83; G Krikorian and D 
Szymkowiak, 'Intellectual Property Rights in the Making: The Evolution of Intellectual Property 
Provisions in US Free Trade Agreements and Access to Medicine' (2007) 10 J World Intell Prop 388, 402 
563 UNCESCR ‘Consideration of reports submitted by States parties under articles 16 and 17 of the 
International Covenant on Economic, Social and Cultural Rights, Fifth periodic reports of States parties 
due in 2012: Costa Rica’ (30 April 2015) UN Doc E/C.12/CRI/5, 177-178 
564 UNCESCR ‘Concluding observations of the Committee on Economic, Social and Cultural Rights: Peru’ 
(30 May 2012) UN Doc E/C.12/PER/CO/2-4 
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related to the data exclusivity provisions in the US-Peru FTA565, and the impact on 
consumers due to delays in accessing generic medicines.  The CESCR observations 
included recommending that the State party consider the impacts on Covenant rights 
before entering into similar free trade agreements, but went further than requiring the 
State party to merely consider the Covenant rights by recommending that the State party 
take active steps to secure the affordability, accessibility and availability of essential 
medicines, “if necessary through subsidies.”566  This suggests that there is an expectation 
on State parties to take positive steps to ensure that its population has access to affordable 
essential medicines, and if the medicines are not affordable, the State may have an 
obligation under the Covenant to subsidise that cost for its population.  This could be seen 
to be ‘rewarding’ pharmaceutical companies for setting high or excessive prices for 
medicines, which is a controversial proposal as the pharmaceutical companies bear 
responsibility for setting excessive prices.  However, such a bold stance by the CESCR 
might encourage states parties to take other positive actions to address affordability and 
accessibility concerns, for example through public health insurance plans or making full 
use of the TRIPS flexibilities, so that subsidies are not ‘necessary’. 
The CESCR has also provided direction to developed States on their obligations 
under the Covenant with regard to trade agreements, as evidenced in the concluding 
observations to Germany in 2018.567  The CESCR expressed concern at the data 
exclusivity provisions imposed on developing countries by EU FTAs which delay access 
to affordable generic medicines, with harmful impacts on the right to health. The CESCR 
recommended that the State party carry out human rights impact assessments prior to the 
negotiation of FTAs to assess their impact on access to affordable medicines in 
developing countries.568  The State was reminded of their international obligations in 
relation to Article 12, including that States parties have to respect the enjoyment of the 
right to health in other countries569.  
                                                            
565 R Cartagena and A Attaran, 'A Study of Pharmaceutical Data Exclusivity Laws in Latin America: Is 
Access to Affordable Medicine Threatened' (2009) 17 Health LJ 269, 281; Lopert and Gleeson (n 339) 
202; M Jorge ‘The Peruvian Implementation of the US-Peru FTA: A Model for the World with Room for 
Improvement’ (2010) 7(1) Journal of Generic Medicines 40, 43 
566 UNCESCR ‘Concluding observations of the Committee on Economic, Social and Cultural Rights: Peru’ 
(30 May 2012) UN Doc E/C.12/PER/CO/2-4, 25 
567 UNCESCR ‘Concluding observations on the sixth periodic report of Germany’ (27 November 2018) UN 
Doc E/C.12/DEU/CO/6 
568 UNCESCR ‘Concluding observations on the sixth periodic report of Germany’ (27 November 2018) UN 
Doc E/C.12/DEU/CO/6, 14-15 
569 General Comment No. 14 (n 112) 39 
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This recommendation illustrates the CESCR’s interpretation of the scope of 
States’ parties obligations outside of their jurisdiction in relation to FTAs and the right to 
health.  TRIPS outlines a minimum standard of IP rights protection, and so states can 
agree to a higher standard of IP rights protection in FTAs. Implementing a minimum 
standard of IP protection, rather than a maximum standard or a harmonised IP rights 
protection, has been considered in academic literature as a positive measure because of 
the degree of flexibility afforded to states in implementing the TRIPS provisions.570 This 
flexibility is an advantage as it recognises the need to find a balance between the needs 
of developed and developing countries in relation to promoting trade and protecting IP 
rights.  The recommendations of the CESCR highlight that although IP protection in 
TRIPS is not inherently incompatible with human rights, the inclusion of TRIPS-plus 
standards is problematic in relation to states’ treaty obligations under Article 12 ICESCR.   
 
(b) Examples of other key trends 
 
The CESCR expressed concern regarding the number of HIV/AIDS cases in the 
concluding observations on the state reports of Venezuela571 and Burundi572, and 
recommended that the states take the necessary steps to ensure adequate coverage of 
antiretroviral medicines and to make them accessible to persons living with HIV/AIDS573. 
These reports provide guidance that HIV/AIDS medicines are types of medicines 
considered to be ‘essential’ under Article 12.  The concluding observations on the state 
reports of Mali and Cameroon included recommendations to ensure the accessibility, 
availability and quality of health care in all regions, by improving the infrastructure of 
the primary health-care system and ensure that hospitals have a regular supply of 
medicines.574  The CESCR acknowledged that the state party had made efforts to improve 
                                                            
570 P Judd, 'Toward a TRIPS Truce' (2011) 32 Mich J Int'l L 613, 655; M Land, 'Rebalancing Trips' (2012) 33 
Mich J Int'l L 433, 435; Kur and Ruse-Khan (n 252) 26 
571 UNCESCR ‘Concluding observations of the Committee on Economic, Social and Cultural Rights: 
Venezuela’ (7 July 2015) UN Doc E/C.12/VEN/CO/3 
572 UNCESCR ‘Concluding observations of the Committee on Economic, Social and Cultural Rights: 
Burundi’ (16 October 2015) UN Doc E/C.12/BDI/CO/1 
573 See also UNCESCR ‘Concluding observations of the Committee on Economic, Social and Cultural 
Rights: Venezuela’ (7 July 2015) UN Doc E/C.12/VEN/CO/3, 29; and UNCESCR ‘Concluding observations 
of the Committee on Economic, Social and Cultural Rights: Burundi’ (16 October 2015) UN Doc 
E/C.12/BDI/CO/1, 56 
574 UNCESCR ‘Concluding observations on the fourth periodic report of Cameroon’ (25 March 2019) UN 
Doc E/C.12/CMR/CO/4, 56; UNCESCR ‘Concluding observations on the initial report of Mali’ (6 
November 2018) UN Doc E/C.12/MLI/CO/1, 46 
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health care, and the recommendation was for the purpose of addressing the problems 
relating to affordable health care in the State.575  This recommendation shows that states 
are reporting on issues relating to medicines and are using the concluding observations 
process to receive guidance from the CESCR on how to meet their human rights 
obligations, forming a constructive dialogue.576   
The concluding observations can also be used to recognise good practice. For 
example, the CESCR’s concluding observations on Brazil’s state report included 
welcoming measures the State party had taken to adopt compulsory licensing of 
HIV/AIDS antiretroviral drugs in order to make them affordable and enable the extension 
of treatment to all patients.577 Recognition of good practices at international level through 
the concluding observations can provide helpful models to other states in addressing 
similar concerns.  The findings from this review of the concluding observations illustrate 
that the CESCR is giving specific guidance to States parties on measures to enhance 
access to medicines as part of their treaty obligations in relation to the right to health.  The 
limited data means that conclusions must be drawn with caution, but the 
recommendations which have been made are useful in terms of clarifying the scope of 
States’ parties obligations under Article 12 in relation to access to medicines.  The 
findings also highlight that the CESCR views TRIPS-plus provisions as a significant 
challenge to the promotion and protection of the right to health, which is a key theme 
emanating from the work of the UN human rights bodies. 
 
IV. Conclusion 
 
The interplay between the right to access to medicines and TRIPS has been recognised in 
academic literature.578  This chapter has shown that this agenda is still at an early stage.  
The relatively low number of references to access to medicines in state reports and 
recommendation in the UPR shows limited state practice on the right to access to 
medicines within the UN human rights regimes.  A more substantial body of practice is 
                                                            
575 UNCESCR ‘Concluding observations on the initial report of Mali’ (6 November 2018) UN Doc 
E/C.12/MLI/CO/1, 45 
576 Mechlem (n 105) 924; B Toebes 'Towards an Improved Understanding of the International Human 
Right to Health' (1999) 21 Hum Rts Q 661, 666; O'Flaherty (n 524) 36 
577 UNCESCR ‘Concluding observations of the Committee on Economic, Social and Cultural Rights: Brazil’ 
(12 June 2009) UN Doc E/C.12/BRA/CO/2, 3 
578 For example, Helfer and Austin (n 3); Correa (n 336); Hestermeyer (n 72); Chapman (n 72) 
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found within the UN human rights bodies, clarifying that access to medicines is within 
the right to health under Article 12 ICESCR.  This body of practice also clarifies that 
there is no definition of ‘medicines’ or ‘essential medicines’.  Further, there is no prima 
facie conflict between human rights and TRIPS. However, particular challenges have 
been identified with regard to the use of FTAs by states to secure TRIPS-plus provisions.  
Such challenges include data exclusivity provisions going beyond those set out in TRIPS, 
which could lead to delays in generic medicines reaching the market, and have a 
detrimental impact on access to affordable medicines.  The UN human rights bodies have 
also identified measures to promote reconciliation between human rights and WTO 
obligations, such as effective use of the flexibilities within TRIPS.  Examples of good 
practice have also been highlighted, including carrying out impact assessments prior to 
agreeing FTAs. 
The work of the UN human rights bodies highlights that access to medicines has 
been a growing concern for the Charter-based bodies as well as the CESCR.  Although 
the reports are non-binding, and therefore the monitoring of the recommendations in the 
reports may be questioned, these sources provide a valuable contribution to the 
interpretation of the right to health and clear guidance on state obligations to achieve full 
realisation of this right.  The work of the Charter bodies has contributed significantly to 
the normative development of the right to health, while the work of the CESCR illustrates 
that access to medicines is a key element of the right to health under Article 12 and states 
have minimum core obligations to ensure access to essential medicines.  Therefore the 
lack of access to medicines within States parties could give rise to an issue under the 
ICESCR in respect of Article 12.  There is prima facie compliance with UN human rights 
law in respect of the TRIPS Agreement, although challenges exist in relation to the 
TRIPS-plus provisions. These concerns may become more prevalent given the Trump 
administration’s apparent favour towards bilateral trade agreements, and the UK’s need 
to enter into such agreements as an individual State following Brexit, which could 
potentially lead to further TRIPS-plus provisions.   
In particular, the actions of the pharmaceutical industry have been identified as a 
significant challenge.  This has implications for the obligations of states, and the work of 
the Working Group on business and human rights may become more significant.  
Although the influence of the findings of the UN human rights bodies is limited on the 
pharmaceutical companies as they are not parties to, and therefore not bound by, the UN 
human rights instruments, the potential inclusion of business enterprises into National 
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Action Plans operationalizing the UN Guiding Principles would significantly alter this 
position.  There are also implications with regard to the States’ responsibility to seek 
assistance if they cannot comply with their ICESCR obligations due to resource 
constraints, and therefore support for a more collaborative and cooperative approach 
among all States should be encouraged, particularly if failure to uphold access to 
medicines may give rise to an issue under Article 12.  As access to medicines is viewed 
as forming part of the Article 12 right within the UN human rights systems, it must be 
considered how this can be advanced in order to improve access to medicines for all. 
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Chapter 4: Advancing access to medicines as a right 
 
Introduction 
 
The previous chapter discussed how access to medicines has been addressed within the 
UN human rights framework. The chapter focussed in particular on the right to health 
under Article 12 ICESCR, and a key finding was that access to medicines forms part of 
the right to health under Article 12.  It also showed that the access to medicines agenda 
is still evolving.  This chapter explores whether this agenda can be advanced, shifting the 
focus on ICESCR from the Article 12 right to consider whether other ICESCR rights 
could also advance the protection of the right to access to medicines under international 
human rights law.  For the purposes of this research, specific focus will be on Article 15 
ICESCR.  The dual nature of Article 15, in that Article 15 protects the rights of creators 
in their creations, and also protects the right of everyone to benefit from scientific 
progress, is of key relevance to this research.  The importance of science and technology 
in the research and development of new medicines, and the link between Article 15 and 
the progressive realisation of the Article 12 right579 is also relevant to the research.  The 
chapter then moves to explore the actions being taken in the UN human rights framework 
more broadly to promote access to medicines as a right. Key recent developments will be 
considered, to examine how these developments advance the access to medicines agenda. 
Also, whether recommendations emanating from these developments could help states to 
meet their obligations under the right to access medicines. 
Article 15 ICESCR outlines the right to take part in cultural life, the right to 
benefit from scientific progress and the rights of creators to the protection of the moral 
and material interests resulting from scientific, literary or artistic production.580  Given 
the significance of TRIPS in relation to accessing medicines and the importance of the IP 
rights enshrined in TRIPS to global trade, the chapter will address the issue of whether IP 
rights are rights that form part of human rights under Article 15 ICESCR.  This chapter 
will focus primarily on original documents of the UN human rights bodies to analyse how 
these bodies are addressing this provision, to evaluate the nature of rights of creators. The 
chapter will also draw on relevant academic literature in the analysis of the findings from 
                                                            
579 A Müller, ‘Remarks on the Venice Statement on the Right to Enjoy the Benefits of Scientific Progress 
and its Applications (Article 15(1)(b) ICESCR)’ (2010) 10(4) HRLR 765, 766 
580 International Covenant on Economic, Social and Cultural Rights (n 2) Article 15 
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this research.  If IP rights did amount to human rights under Article 15, this could amount 
to a potential obstacle to the enjoyment of the right to access medicines. Issues could also 
arise in relation to the potentially incompatible obligations under Article 15 and Article 
12, and how these could be reconciled within the UN human rights framework.   
Given the dual nature of Article 15, the chapter will also explore whether Article 
15 could contribute to advancing access to medicines through the right to benefit from 
scientific progress. The purpose of this research is to explore whether Article 15 could 
promote the creation of knowledge in a way that enhances access to medicines. The focus 
will primarily be on primary sources from the UN human rights framework, including the 
work of the relevant Special Rapporteurs, which elucidate the background and purpose 
of such a right.  The purpose of this is to provide an understanding of the normative 
content of Article 15, to explore the interpretative guidance in relation to this right and its 
relevance to advancing access to medicines.  This chapter will also refer to the emerging 
discussions581 of this right in academic literature in the analysis.   
The chapter then changes focus to explore key developments to promote access 
to medicines across the UN human rights framework. In particular, the discourse 
emanating from the recent expert consultation on access to medicines and the 
recommendations of the Secretary General’s High Level Panel on Access to Medicines 
on how to improve the facilitation of access to medicines will be examined, and outcomes 
of such developments.  The purpose of this is to explore whether the recommendations 
emanating from these developments promote enhanced understanding of how states can 
effectively meet their human rights obligations to enhance access to medicines under the 
ICESCR and TRIPS. Responses to the proposals will also be examined, in order to assess 
the utility of the work of the UN human rights bodies in furthering the access to medicines 
agenda. 
 
I. The dual focus of Article 15 
 
While the right to the highest attainable standard of health is a significant provision under 
the ICESCR in relation to securing access to medicines, the ICESCR also includes rights 
that are intended to protect the rights of creators under Article 15.  Academic literature 
                                                            
581 Lee notes that Article 15 ICESCR has received relatively little attention in academic literature.  See JY 
Lee,  A Human Rights Framework for Intellectual Property, Innovation and Access to Medicines, (Ashgate 
2015) 155 
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has considered that these rights can conceivably have a significant impact on access to 
medicines as they can be utilised to protect the creators of works usually protected by IP 
legislation582, including creators of new medicines.  Consequently, the rights of creators 
must be considered as well as the rights of individuals with regard to accessing new 
medicines, an issue which may present difficulties for the Member States responsible for 
upholding the respective rights.  Therefore it is important to examine the content of rights 
that protect creators, and how this affects the issue of securing access to medicines.  
Article 15 ICESCR583 states: 
 
“1. The States Parties to the present Covenant recognize the right of everyone: 
 
(a) To take part in cultural life; 
 
(b) To enjoy the benefits of scientific progress and its applications; 
 
(c) To benefit from the protection of the moral and material interests resulting from any 
scientific, literary or artistic production of which he is the author. 
 
2. The steps to be taken by the States Parties to the present Covenant to achieve the full 
realization of this right shall include those necessary for the conservation, the 
development and the diffusion of science and culture. 
 
3. The States Parties to the present Covenant undertake to respect the freedom 
indispensable for scientific research and creative activity. 
 
4. The States Parties to the present Covenant recognize the benefits to be derived from 
the encouragement and development of international contacts and co-operation in the 
scientific and cultural fields.” 584 
 
                                                            
582 Helfer and Austin (n 3) 171; R Okediji 'Does Intellectual Property Need Human Rights ' (2018) 51 NYU 
J Int'l L & Pol 1, 35-36; Yu (n 9) 1424-1427; D Matthews ‘Intellectual Property Rights, human rights and 
the right to health’ in W Grosheide (ed), Intellectual Property and Human Rights: A Paradox (Edward 
Elgar, Cheltenham 2010), 119; Chapman (n 72) 877 
583 International Covenant on Economic, Social and Cultural Rights (n 2) Article 15 
584 ibid 
 127 
 
Article 15(1) sets out the normative content of the right while Articles 15(2) to (4) set out 
the obligations of Member States.   There are three components to the right comprised in 
Article 15(1), with the right of authors to benefit from the protection of the moral and 
material interests in their scientific productions under Article 15(1)(c) being the most 
significant in relation to consideration of the status of IP rights over medicines.  However, 
the right to enjoy the benefits of scientific progress under Article 15(1)(b) is also an 
important provision with regard to the creation of new medicines which must also be 
considered.  Article 15 ICESCR is a legally binding norm, so it is important to analyse 
the scope of these rights and how they have been interpreted in light of the work of the 
UN human rights bodies, to provide an enhanced understanding of the nature of these 
rights and their impact on enhancing access to medicines. 
 
(a) Article 15(1)(c): The rights of authors of creative works 
 
The right to benefit from protection of moral and material interests under Article 15(1)(c) 
ICESCR protects those who are responsible for authoring creative works in the form of a 
human right.  This creates a potential complication regarding enhancing access to 
medicines as the recognised obstacles such as the pricing of essential medicines set by 
pharmaceutical companies may be seen to result from a right to receive the benefit of 
creating new medicines.  Given the nature of IP rights of allowing pharmaceutical 
companies to benefit financially from the scientific progress in developing new 
medicines, it may be considered that IP rights are human rights under the wording of 
Article 15(1)(c).585 Academic literature generally supports the view that protecting the 
interests of authors in their creative works is also a right which is protected within IP 
                                                            
585 This thesis does not explore the status of intellectual property rights under the European Convention 
on Human Rights, or the Charter of Fundamental rights of the European Union, but it is pertinent to 
note that the status of intellectual property rights is different than under the ICESCR. There is protection 
for IP holders under the right to property under Article 1, Protocol 1 ECHR, and Article 17(2) of the 
Charter of Fundamental Rights provides the intellectual property shall be protected.  See Convention for 
the Protection of Human Rights and Fundamental Freedoms (European Convention on Human Rights, as 
amended) (ECHR), Article 1 of the First Protocol  and Charter of Fundamental Rights of the European 
Union, [2000] OJ C 364/01, Article 17(2). For discussion on the status of IP rights under these 
instruments, see also W Grosheide (ed), Intellectual Property and Human Rights: A Paradox (Edward 
Elgar, Cheltenham 2010), 14, 18-19; Cullet (n 61) 410-411; L Helfer, 'The New Innovation Frontier - 
Intellectual Property and the European Court of Human Rights' (2008) 49 Harv Int'l LJ 1; A Plomer, 'After 
Brustle: EU Accession to the ECHR and the Future of European Patent Law' (2012) 2 Queen Mary J Intell 
Prop 110, 130-1, 134; M Husovec, 'The Essence of Intellectual Property Rights under Article 17(2) of 
the EU Charter' (2019) 20 German LJ 840, 844-846. 
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provisions, but that Article 15(1)(c) protects the personal link between author and 
creation, while IP rights protect corporate interests586.  This view suggests that such a 
distinction has been drawn because of the diverging purposes of Article 15(1)(c) and the 
wider human rights regime, and IP instruments.  Therefore, whereas private companies 
derive significant benefit from the system of intellectual property law, this is not the case 
under the ICESCR where the core of the right is the link between the individual author 
and their creation. 
General Comment 17587 provides authoritative guidance on the scope and 
interpretation of Article 15(1)(c). It highlights that the right under Article 15(1)(c) derives 
from the dignity of persons, emphasising that human rights are fundamental, permanent 
rights and therefore distinct from the temporary rights under IP systems which can be 
assigned or retracted.588 It explicitly states that IP rights are not to be equated with the 
Article 15(1)(c) human right589,  providing unequivocal confirmation that IP rights are 
not human rights under this provision.  This is confirmed by the drafting history of Article 
15 which demonstrates that the inclusion of the protection of authors’ rights under Article 
15 was due to the fact that they were linked to the realisation of other rights.590  Therefore 
the rights of authors should facilitate rather than restrict benefits of scientific progress591.  
It suggests that the UN human rights bodies and Member States never sought to enshrine 
this form of IP right as a distinct human right.  This argument is persuasive as Article 
15(1)(c) does not specify any method by which the moral and material interests of authors 
should be protected, and does not require that such rights should be protected by IP law.592 
Therefore it would be difficult to claim that this provision can be used to strengthen IP 
rights.  In addition, General Comment 17 also states that the scope of protection provided 
                                                            
586 Joseph (n 198) 215; P Yu ‘Ten Common Questions about Intellectual Property and Human Rights’ 
(2007) 23(4) Georgia State University Law Review 709, 730; Matthews (n 582) 124; HM Haugen, 
'Intellectual Property -Rights or Privileges' (2005) 8 J World Intell Prop 445, 451; A Plomer, 'The Human 
Rights Paradox: Intellectual Property Rights and Rights of Access to Science' (2013) 35 Hum Rts Q 143, 
151 
587 UNCESCR ‘General Comment 17 (2005) The right of everyone to benefit from the protection of the 
moral and material interests resulting from any scientific, literary or artistic production of which he or 
she is the author (article 15, paragraph 1 (c), of the Covenant)’ (12 January 2006) UN Doc E/C.12/GC/17 
588 ibid 1 
589 ibid 3 
590 Helfer and Austin (n 3) 179-180 
591 Helfer and Austin (n 3) 179-180 
592 Yu argues that this right could be protected by other means, including open source drug discovery, 
patent pools, and public-private partnerships. See Yu (n 9) 1421 
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for under Article 15 (1)(c) does not necessarily accord with intellectual property rights 
within intellectual property law.593 
General Comment 17 also clarifies the normative content of Article 15(1)(c), 
which further distinguishes that Article 15(1)(c) is not intended to be relied upon by 
producers of medicines to protect their capacity to financially exploit their products.  It 
affirms that only natural persons, and not legal entities such as pharmaceutical companies, 
are protected at the level of human rights.594 Joseph argues that General Comment 17 of 
the CESCR clearly distinguishes IP rights from those protected under Article 15(1)(c).595  
The position under the European Convention on Human Rights (ECHR)596 may be 
contrasted as legal persons can invoke rights under the ECHR597.  It shows that Article 
15(1)(c) is not intended to be relied upon by producers of medicines to protect their 
capacity to financially exploit their products.  Also, there is a public interest in the 
products of pharmaceutical companies which should be duly contemplated, from which 
it may be argued that the public have a right under Article 15(1)(c) to benefit from the 
scientific progress in the creation of new medicines, by having access to them and 
benefitting from their effects.  It is also established that the level of protection afforded 
to authors under Article 15(1)(c) is of a lower level than that which is enjoyed under IP 
protection regimes598, further highlighting the differences in the content of the Article 
15(1)(c) in comparison to the content of IP rights in national and international IP 
instruments.   
The responsibilities placed on Member States include that States should prevent 
the use of the Article 15(1)(c) right for purposes contrary to human rights, including the 
right to health599. General Comment 17 also explicitly states that States parties have a 
duty to prevent unreasonably high costs for access to essential medicines.600 This is a 
crucial statement as it makes explicit that States have a positive obligation to ensure that 
essential medicines are available at a reasonable cost.  Academics have taken the view 
that General Comment 17 provides that States have an obligation to prevent uses of IP 
                                                            
593 UNCESCR General Comment 17 (n 587) 2 
594 UNCESCR General Comment 17 (n 587) 7 
595 Joseph (n 198) 215 
596 Convention for the Protection of Human Rights and Fundamental Freedoms (European Convention 
on Human Rights, as amended) (ECHR) 
597 An example of this is evident in the case of The Sunday Times v The United Kingdom App. no. 
6538/74 (ECtHR 26 April 1979) 
598 UNCESCR General Comment 17 (n 587) 10 
599 ibid 35 
600 ibid 35 
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that result in socially damaging effects601. It suggests that, rather than having a duty to 
uphold IP rights as human rights, States have a duty to restrict IP rights of creators where 
the exercise of such rights could be detrimental to the rights of others.  Furthermore, 
General Comment 17 states that although States parties are accountable for upholding the 
Covenant rights, they are urged to consider regulating the responsibilities on the private 
business sector, private research institutions and other non-state actors to respect the 
rights recognised in Article 15(1)(c).602  This is consistent with the UN Guiding Principles 
developed by John Ruggie, and General Comment 24 on State obligations under the 
ICESCR in the context of business activities, which were discussed in the previous 
chapter.   
A consistent view emanating from the academic literature is that, while Article 
15(1)(c) protects the author’s material interests in the scientific production such as a new 
medicine, this right must be balanced in view of the benefit to the public to access the 
creation, as well as the other rights within the ICESCR603.  Therefore, Article 15(1)(c) 
does not prioritise the interference of IP law including patents with the right to health and 
the enhancement of access to medicines.  This is significant as if IP rights were construed 
to be human rights then this would produce a potential conflict between the human rights 
of creators of medicines and patients needing access to the medicines.  Challenges could 
also have arisen for states in interpreting TRIPS in light of the right to access medicines, 
because of the human rights implications relating to the IP rights set out in TRIPS.  
However it is clear from the guidance of the UN human rights bodies that the Article 
15(1)(c) right does not raise intellectual property law to a human right. Therefore, this 
removes one potential obstacle to advancing access to medicines. 
 
(b) Article 15(1)(b): Right to enjoy the benefits of scientific progress 
 
As IP rights do not amount to human rights under Article 15, and given the dual focus of 
Article 15, it is important to examine whether the provision can be used to promote access 
to medicines. In addition to the rights of authors under Article 15(1)(c), the right of 
everyone to enjoy the benefits of scientific progress under Article 15(1)(b) is also an 
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important provision in relation to accessing medicines, particularly new medicines.  This 
right indicates that there is a human right for all to enjoy advancements in science 
including scientific productions resulting from such advances, without limitations based 
on economic reasons.  This suggests that if a medicine exists but is not widely available 
to those who need it, they have a human right to enjoy benefits from it and therefore there 
is a duty on States to facilitate access to that medicine as part of their obligations to uphold 
the right.  It is only relatively recently that the academic literature has examined the 
Article 15(1)(b) right.604  The drafting history demonstrates that the drafters viewed all of 
the provisions under Article 15 as being interrelated and provides that intellectual 
property law must assure that intellectual property protection respects and promotes other 
components of Article 15, so that the rights of authors and creators should facilitate rather 
than restrain scientific progress and access605.  It indicates that the drafters intended that 
Article 15(1)(b) should be supported by national intellectual property provisions, 
although they did not elaborate on the relationship between protecting the rights of 
creators and facilitating access to scientific developments.  Several of the UN human 
rights bodies have sought to fill this gap and to develop understanding of how the Article 
15(1)(b) right should be interpreted by states. 
 
(i) Venice Statement 
 
The United Nations Educational, Scientific and Cultural Organization (UNESCO) 
convened a number of expert meetings in 2009 aimed at elaborating the normative content 
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of the Article 15(1)(b) right.  It acknowledged that the right is intrinsically linked to other 
human rights including the Article 12 right to heath, and that the realisation of numerous 
social, economic, cultural and political human rights is dependent on the sharing of 
scientific progress.606  This led to the drafting of the Venice Statement on the Right to 
Enjoy the Benefits of Scientific Progress and its Applications607.  The Statement 
considered four concerns with regard to the Article 15(1)(b) right, namely, the neglect of 
the Article 15(1)(b) right, the elucidation of the core content, State obligations and 
international cooperation608.  The content of the Venice Statement is based on the views 
of the participating experts, and not those of UNESCO or any other intergovernmental 
organisation, and such views are not intended to be binding upon such organisations609.  
Therefore, the Statement was not intended to be legally binding.  However, given that the 
meetings included experts from WTO, WIPO, UN human rights bodies including the 
CESCR610, the Venice Statement provides important guidance on the meaning of the right 
to enjoy the benefits of scientific progress. 
 The Venice Statement noted that the acceleration of scientific progress had led to 
growing inequalities between States including in the development of medicines.611 The 
Statement noted that advances were driven by market considerations that did not 
correspond with health needs of all, therefore affecting the right to health.612  It was 
observed that although private actors are primarily responsible for scientific progress, the 
right of the individual to enjoy the benefits of his scientific production must be balanced 
with the rights of the population to share in the benefits.613 It was further suggested that 
sharing of such benefits was not based on participation in the progress614, so individuals 
and communities have a right to enjoy the benefit regardless of whether they have played 
a role in generating a benefit.  The proposed normative content of the right included the 
freedom of sharing of information for the development of science or technology, equal 
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access and participation of all public and private actors and non-discriminatory access to 
the benefits of scientific progress and its applications615.  It suggests that the Article 
15(1)(b) right could be a useful tool in allowing pharmaceutical companies and generic 
manufacturers to secure access to research and development into new medicines to treat 
the most prevalent diseases, as well as gaining information on scientific progress in 
developing new medicines to treat neglected diseases. 
 The view that Article 15(1)(b) could be used to further other rights, such as the 
right to health, is also supported in the literature.616  The right to health includes access to 
essential medicines617, and so the Article 15(1)(b) right could potentially take this further. 
Academics have suggested that essential medicines need to be ‘created’ through scientific 
research and development, in addition to being made ‘accessible’618.  Improving physical 
accessibility in terms of the development of new medicines is a key issue emanating from 
this research, distinct from reducing cost of medicines.  However, the current absence of 
clarification from the CESCR on the content of the Article 15(1)(b) right and the 
obligations of states undermines its utility in being employed alongside the right to 
health.619  This could be addressed in a General Comment by the CESCR on the normative 
content of the Article 15(1)(b) right and the obligations of states, which would be useful 
in order to provide the necessary clarity.  Müller argues that although the Venice 
Statement made non-binding proposals as to the content of the Article 15(1)(b) right, the 
reporting process to the CESCR could be helpful in clarifying the obligations on States 
under this right620.  
 The Venice Statement also made proposals with regard to the obligations on 
States, considering that a State duty to protect should include taking measures to prevent 
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third parties from utilising science and technology to the detriment of human rights621. It 
was also proposed that the duty to fulfil should include the adoption of frameworks to 
promote the development of science and technology in a manner consistent with human 
rights, and to provide opportunities for public engagement in decision-making about 
science and technology and their development622.  Admittedly, these proposals are de lege 
ferenda, but indicate that the Article 15(1)(b) right could develop so as to oblige States to 
facilitate the dissemination of research and information between pharmaceutical 
companies to further the development of a particular medicine, benefitting the wider 
population by potentially providing a required medicine reaches the market more 
expeditiously. Donders argues that although the issue of limited resources affects 
investment in R&D, the development of medicines to treat widespread diseases has done 
much to improve life expectancy so it is crucial that states invest in scientific 
developments and share the benefits623. This view suggests that states should take a more 
balanced approach to the protection of knowledge and the development of new medicines, 
and should commit to more publicly funded R&D facilities.  This could address 
challenges around the development of medicines for ‘neglected’ diseases, and benefit the 
wider population by potentially providing a required medicine reaches the market more 
expeditiously. However, a state’s budgetary constraints may be an obstacle to such a 
proposal, particularly for developing states that do not have sufficient domestic 
manufacturing capacity and therefore would need greater investment to develop this. The 
proposals also indicate that States have a duty to allow the public to actively participate 
in determining the course of progression. This could provide that advances in medicine 
will not be primarily driven by market considerations, but by the collective assessments 
of need by a range of public and private actors. 
The Venice Statement also recognised tensions between the Article 15(1)(b) right 
and IP regimes, but asserted that there is a collective responsibility to ensure that profit 
for private business enterprises is not prioritised over benefit for all624.  McBeth argues 
that the interests under Article 15(1)(c) are balanced with the right of everyone to enjoy 
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the benefits of scientific progress under Article 15(1)(b), and the ordering of these 
provisions in Article 15 emphasises that public benefit outweighs proprietary interests.625  
Plomer also argues that UNESCO’s work was aimed at limiting the impact of IP rights 
on access to essential goods.626  These views suggest that Article 15(1)(b) may be relied 
on to counteract an assertion that a scientific advancement, such as the development of a 
new medicine, should be subject to the protection of authors rights under Article 15(1)(c).  
This does accord with the guidance on Article 15(1)(c) in General Comment 17, discussed 
above, that States parties have a duty to prevent unreasonably high costs for access to 
essential medicines.627  It also reflects that no tension should exist in relation to states 
discharging their obligations under Article 15(1)(b) and Article 15(1)(c), as Article 
15(1)(b) should be prioritised. 
Article 15(1)(b) has been described as a “neglected right”628, suggesting that it 
could be utilised more effectively by individuals and communities to gain enjoyment of 
scientific advancements, and the Venice Statement is significant as a first step in 
understanding the normative content of the right.629  This point is supported by the fact 
the General Comment 17 only applies to Article 15(1)(c). However, Müller notes that 
promoting realisation of this right may be challenging for countries that do not have the 
resources to comply with the obligations proposed in the Venice Statement630. Although 
individuals may assert a right to access to a medicine, it is the State which is obligated to 
uphold this right and therefore bear the associated costs of doing so. This would not 
provide a solution to ensuring that medicines are affordable for all unless States were to 
implement legislative frameworks which involved engagement with the scientific 
community, pharmaceutical enterprises and other relevant private actors to address cost 
implications in securing the right to enjoy the benefits of scientific progress, such as 
medicines.  As has been noted in the literature, a major challenge is the fact that 
developments in science and medicines are generally undertaken by private companies 
that are directed by commercial interests631.  However, the discussion in the previous 
chapter of the Guiding Principles developed by John Ruggie, and General Comment 24 
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highlights that States parties do have extraterritorial obligations to take steps to prevent 
and remedy infringements of ICESCR rights due to the activities of business entities, 
including pharmaceutical companies.   
There is a need to clarify the Article 15(1)(b) right and the obligations of states at 
national level, to provide further guidance to states on how to meet their obligations under 
this provision and how it fits with other obligations under the ICESCR. The expansive 
approach adopted in the Venice Statement, particularly in relation to states’ obligations 
around the development of science and technology, may call into question the viability 
of the Statement. However, it could offer a useful starting point to contribute towards the 
drafting of a General Comment to clarify the normative content of the Article 15(1)(b) 
right. This could be particularly useful as the debate in the academic literature and the 
work of the UN human rights bodies to date reflects that the relevance of this right to 
enhancing access to medicines is increasing. 
 
(ii) 2012 Report of Special Rapporteur in the field of cultural rights 
 
Further guidance on the scope of the Article 15(1)(b) right was produced by the Special 
Rapporteur in the field of cultural rights632. Taken together with the Venice Statement, 
these reports make an important contribution to the discourse on the content of this 
right633.  The Special Rapporteur’s report aimed to mobilise dialogue between States and 
other stakeholders to clarify the Article 15(1)(b) right634.  It set out the normative content 
of the right as having four elements; (1) access to the benefits of science by everyone, 
without discrimination; (2) opportunities for all to contribute to the scientific enterprise 
and freedom indispensable for scientific research; (3) participation of individuals and 
communities in decision-making; and (4) an enabling environment fostering the 
conservation, development and diffusion of science and technology.635 These elements 
echo those proposed in the Venice Statement and in clarifying the content of the Article 
15(1)(b) right. It affords an authoritative elucidation of the norms inherent in the right.   
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The report recognises that there may be a conflict between the Article 15(1)(b) 
right and IP rights, particularly TRIPS, but reiterates the statement in General Comment 
17 that the rights of authors are not to be equated with IP rights, and authors’ rights and 
IP rights can be limited in order to uphold other human rights636.  The report indicates 
that the right of authors under Article 15(1)(c) must be balanced with the Article 15(1)(b) 
right.  This is echoed in the literature. For example, Shaver argues that the development 
of IP law, particularly through TRIPS, has undermined the dissemination of knowledge 
as a global public good outlined in Article 15.637 Eide argues that the Special Rapporteur 
has adopted a similar argument, which is reflected in the recommendations in the 
report.638  The report focuses on the benefits of scientific progress for all as a key element 
of the right, and contends that there was no evidence to support the supposition that 
scientific inventiveness is only stimulated by legal protection639.  This calls into question 
the argument that there is a need for strong IP protection in pharmaceuticals in order to 
encourage research and development, and that scientific creativity in relation to medicines 
can be stimulated in other ways.   
 The report made a number of recommendations relating to medicines, notably that 
States ensure that innovations essential for a life with dignity reach everyone and identify 
priority needs of marginalised populations640; that States and other stakeholders develop 
incentives to disconnect research and development from the price of products and 
encourage companies to join the Medicines Patent Pool641; and that States safeguard 
against encouraging privatisation of knowledge and explore a minimalist approach to IP 
protection, as well as developing creative mechanisms for protecting the financial 
interests of creators and the human rights of individuals642.  The recommendations also 
suggest that there should be a change in approach to promoting innovation and sharing of 
information emanating from such innovation, rather than protecting this information and 
therefore restricting its use and benefit for all.  The report also made recommendations to 
UN human rights bodies including that the CESCR to comprehensively review Article 15 
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and consider adopting a new General Comment covering all of the rights under Article 
15643.  
 Significantly, the report was welcomed by the Human Rights Council, which 
adopted a resolution644 in July 2012 to request the OHCHR to convene a seminar in 2013 
to discuss the scope of Article 15(1)(b), and the relationship with Article 15(1)(c).  The 
resolution was adopted without a vote at the thirty first meeting645, reflecting consensus 
by States.  This suggests that some of the proposals outlined in the Venice Statement 
could be more viable than first thought.  The report on the seminar646 was published in 
2014, which highlighted that the participants had provided examples of initiatives and 
good practice to improve global access to the benefit of IP647.  Examples included open 
access repositories for the sharing of scientific information.648  The report noted that the 
WHO had turned its attention to new innovation models which separated the costs of 
research and development from the price of the product649.  The report concluded that 
significant adjustments were needed in the international IP system to ensure a balanced 
system which aligns with human rights standards650.  This suggests that the current IP 
system prioritises the interests of the IP creators and owners to the detriment of the human 
rights of the individual.   
 
(iii) 2015 Report of Special Rapporteur in the field of cultural rights 
 
The Special Rapporteur in the field of cultural rights developed the discourse from the 
2012 report in a 2015 report which focused on patent policy and Article 15 rights651.  It 
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reiterated that although the ICESCR provides for the progressive realisation of rights, 
States do have an immediate obligation to ensure that legal provisions do not 
inappropriately encumber the enjoyment of human rights652. It demonstrates that States 
must act immediately to address patents legislation which restricts enjoyment of human 
rights such as the right to health, and access to medicines.  The report also restated that 
Article 15(1)(c) does not recognise a human right to protection of IP to the same standard 
as set out in international IP treaties653. Although ‘author’ does include inventors, a strong 
personal link must exist between the inventor and the invention, as the right cannot be 
relied upon to challenge patent provisions providing adequate protection of financial 
interests654.  It clearly designates the parameters of the Article 15(1)(c) right by 
confirming that the right cannot be relied upon by inventors to seek strengthened IP 
protection. This is particularly relevant in relation to inventors within pharmaceutical 
enterprises that will not be able to use Article 15(1)(c) to seek strengthened legal 
protection over its patented pharmaceuticals.  Furthermore, the report clarified that the 
right to the protection of moral and material interests cannot be relied upon by States to 
defend patent laws that inadequately respect the Article 15(1)(b) right. 
 The report highlighted that where patent protection is so robust as to prevent a 
compulsory licence being issued, there is potentially a human rights infringement. The 
report also stated that the human rights system requires that patents do not extend so far 
as to interfere with an individual’s dignity or wellbeing, giving the example of when a 
patent holder’s right is so strong as to make compulsory licensing unfeasible655. 
Compulsory licensing is an important exception to patent protection in TRIPS, and this 
statement proposes that the obligations of states Article 15(1)(b) means that the State must 
take appropriate measures to enhance equitable access to scientific progress, including by 
supporting the use of compulsory licensing.  This also reflects that compulsory licensing 
is viewed within the UN human rights framework and by the WTO as an important tool 
to enhance access to medicines, and that the Article 15(1)(b) right could be relied upon 
to promote the use of compulsory licensing.   
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A significant conclusion emanating from the report was that there is no human 
right to patent protection under Article 15.656  This is an important statement as it would 
preclude pharmaceutical enterprises from seeking to strengthen IP protection in 
medicines in the form of a human right which Member States are obligated to uphold, 
such as through FTAs and other international IP legislative instruments.  The report also 
recommended that States ensure that there is transparency in the negotiations of 
international IP agreements657. States must also ensure that pharmaceutical companies 
benefitting from patents disclose information on costs of developing medicines, as well 
as the sums reinvested in research and development658.  This would ensure that 
pharmaceutical companies are held publicly accountable for the efficiency of their 
spending on developing medicines, and would also either prove or disprove the argument 
that patent protection is necessary to protect the large sums of money invested in research 
and development.  However, it may be challenging for states to monitor the cooperation 
and participation of pharmaceutical companies in the sharing of this information. 
 The report stated that patent legislation should not place limitations on the right 
to health unless the State complies with the Article 4 ICESCR659 exception660.  It also 
noted that States have a human rights obligation not to adopt or support IP provisions 
which would prevent them from utilising the TRIPS flexibilities and therefore reconciling 
patent protection with human rights661.  This is an important conclusion as it indicates 
that States which accept TRIPS-plus provisions in international agreements could be in 
breach of their human rights obligations.  The report also recommended that the UN 
convene an independent, high-level body to review proposals for a new IP regime for 
pharmaceutical products that would be consistent with international human rights law and 
safeguard inventors’ rights662. Any proposals for a new IP regime for pharmaceutical 
products are unlikely to gain support, and are likely to meet resistance from 
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pharmaceutical companies in particular. However, the recommendation to convene a 
high-level panel was followed in 2015 with the convening of the High-Level Panel on 
Access to Medicines, discussed below. 
 The 2012 and 2015 reports of the Special Rapporteur are not binding on states, 
and it remains to be seen how these reports will influence IP law at national level. 
However, the Human Rights Council, and hence States, took note of the work of the 
Special Rapporteur and did not raise any objections to the content of the reports663. 
Academics have noted the role of international NGOs in ensuring positive domestic 
action is taken following a Special Rapporteur’s report, particularly in relation to access 
to medicines664.  The reports have also contributed to the discourse on the scope within 
TRIPS for states to balance social, intellectual, and economic objectives, through 
effective utilisation of the TRIPS flexibilities665, as well as contributing to clarification of 
the normative content of Article 15. 
 
II. Expert consultation on access to medicines 
 
In seeking to clarify IP rights in the context of human rights, the work of the Special 
Rapporteur in the field of cultural rights has evidently added to the work of the Special 
Rapporteur on the right to health on the human rights issues relating to access to 
medicines.  In 2009 the Human Rights Council666 endorsed the recognition that access to 
medicines is a fundamental element in achieving progressive realisation of the right to 
the highest attainable standard of health.667 It invited the OHCHR to convene an expert 
                                                            
663 See UNHRC ‘Report of the Human Rights Council on its twentieth session’ (14 November 2013) UN 
Doc A/HRC/20/2, 10, 81-85; UNHRC ‘Report of the Human Rights Council on its twenty-eighth session’ (8 
July 2015) UN Doc A/HRC/28/2, 160 
664 D Matthews ‘NGO Coalitions and the Global Access to Medicine Campaign: The Impact of Intellectual 
Property Rights on Developing Countries’ in J Howell (ed), Global Matters for Non-Governmental Public 
Action (Palgrave 2012), 68; Okediji (n 582) 22; Hein and Moon (n 637) 10 
665 R Cooper Dreyfuss ‘Patents and Human Rights: The Paradox Reexamined’ in C. Geiger (ed.), 
Intellectual property and access to science and culture: conflict or convergence?, CEIPI-ICTSD Publication 
Series on Global Perspectives and Challenges for the Intellectual Property System, Issue 3, Geneva/ 
Strasbourg, 2016 (Forthcoming); NYU School of Law, Public Law Research Paper No. 15-35, 8-9 
666 UNHRC Res 12/24 (12 October 2009) UN Doc A/HRC/RES/12/24. The resolution was adopted without 
a vote.  The draft resolution was sponsored by Brazil and co-sponsored by Bolivia (Plurinational State 
of), Bosnia and Herzegovina, Colombia, Cuba, the Dominican Republic, Ecuador, Egypt, India, Kyrgyzstan, 
Nicaragua, South Africa and Venezuela (Bolivarian Republic of). Subsequently, Algeria, Angola, 
Argentina, Bangladesh, Belarus, Burkina Faso, Chad, Chile, Guatemala, Kyrgyzstan, Maldives, Mexico, 
Nigeria, Pakistan, Panama, Peru, the Philippines, Thailand and Viet Nam joined the sponsors. (See UN 
Doc A/HRC/12/50, 167-171) 
667 ibid 7 
 142 
 
consultation to exchange views on human rights considerations relating to this issue.668  
It shows that the issue of access to medicines had become a significant concern which the 
Human Rights Council viewed as an obstacle to the realisation of achieving the highest 
attainable standard of health for all669.     
 In 2011 the Special Rapporteur on the right to health reported on the expert 
consultation to the Human Rights Council670, stating that the “right to health requires a 
company that holds a patent on a lifesaving medicine to make use of all the arrangements 
at its disposal to render the medicine accessible to all”671.  The expert consultation was 
convened by the OHCHR and participants included representatives from Member States, 
international organisations, non-governmental organisations and independent experts, 
although it was noted that no representatives from pharmaceutical companies attended 
the consultation672. The objective of the consultation was to facilitate a discussion on 
“human rights considerations relating to the realisation of access to medicines as one of 
the fundamental elements in achieving progressively the full realization of the right of 
everyone to the enjoyment of the highest attainable standard of physical and mental 
health”673.  It provides further confirmation that access to medicines is a core part of the 
right to health674. 
 The consultation comprised two panels, with the first panel discussing access to 
medicines as a fundamental component of the right to health.  Stephen Marks of the 
Harvard School of Public Health noted that access to medicines derived from Article 
15(1)(b) as well as Article 12675.  Chandrashekhar Dasgupta of the CESCR highlighted 
                                                            
668 ibid 7 
669 The resolution was adopted without a vote.  The draft resolution was sponsored by Brazil and co-
sponsored by Bolivia (Plurinational State of), Bosnia and Herzegovina, Colombia, Cuba, the Dominican 
Republic, Ecuador, Egypt, India, Kyrgyzstan, Nicaragua, South Africa and Venezuela (Bolivarian Republic 
of). Subsequently, Algeria, Angola, Argentina, Bangladesh, Belarus, Burkina Faso, Chad, Chile, 
Guatemala, Kyrgyzstan, Maldives, Mexico, Nigeria, Pakistan, Panama, Peru, the Philippines, Thailand and 
Viet Nam joined the sponsors. (See UN Doc A/HRC/12/50, 167-171) 
670 UNHRC ‘Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest 
attainable standard of physical and mental health, Expert consultation on access to medicines as a 
fundamental component of the right to health’ (16 March 2011) UN Doc A/HRC/17/43 
671 ibid 47 
672 ibid 1-2. It was noted that Novartis had submitted a letter in which it regretted not being available to 
participate in the consultation. 
673 ibid 1 
674 Hein and Moon (n 637) 4; CF Wu 'Transnational Pharmaceutical Corporations' Legal and Moral 
Human Rights Responsibilities in Relation to Access to Medicines' (2012) 7 Asian J WTO &Int'l Health L & 
Pol'y 77, 91 
675 UNHRC ‘Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest 
attainable standard of physical and mental health, Expert consultation on access to medicines as a 
fundamental component of the right to health’ (16 March 2011) UN Doc A/HRC/17/43, 9 
 143 
 
the obligations of states to achieve full realisation of the right to health, including through 
international assistance stemming from Article 2(1) and Article 12, while also noting that 
TRIPS-plus standards that prevented use of the TRIPS flexibilities were unacceptable if 
they restricted access to medicines676.  Richard Laing of the WHO noted that in most 
countries public sector procurement obtained medicines at a reasonable cost, however 
this was not the case in the private sector, although the availability of generic medicines 
was lower in the public sector compared with the private sector677.  Laing recommended 
that governments adopt a rights-based approach to national health policies, specify their 
obligations with regard to access to medicines, and establish monitoring and 
accountability mechanisms678.  Representatives of some unnamed states expressed 
concerns about developing countries being pressured into entering into TRIPS-plus 
standards and not using the TRIPS flexibilities, the impact of poverty and pricing, as well 
as research that prioritises diseases which predominantly affect developed countries679.  
State representatives also noted concern over counterfeit medicines and how they may 
undermine IP regimes, with states requesting to be part of talks between WHO and WIPO 
on IP680.  It highlights the differing objectives of certain states which have strong IP 
regimes and those states which have to rely on the research and manufacturing capacity 
of other states to produce the medicines they require.   
The discussions of the first panel reflect common themes emanating from the 
literature681, with participants with a human rights and health perspective advocating a 
rights-based approach to enhancing access to medicines. The recommendation to states 
to introduce more rigorous accountability and monitoring in relation to the cost of 
medicines proposes that state could do more to effectively regulate the cost of medicines 
at national level.  The responses of state participants highlight problems with regard to 
resources as well as pressure to accept TRIPS-plus standards, reflecting the wider factors 
which impact upon access to medicines beyond simply high pricing. Establishing 
monitoring and accountability mechanisms at national level could improve the 
monitoring of pricing set by pharmaceutical companies, but state responses highlight the 
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complexities in addressing the issue of access to medicines. Stricter regulation of pricing 
does not address all of the concerns the states have raised. It is also significant to note 
that states responses did not dispute that access to medicines is a fundamental part of the 
right to health. This supports Hein and Moon’s view that by 2011 there was widespread 
acceptance that access to medicines should be universal, and not arbitrarily blocked by 
patent protection682.  It is evident that states want to be part of the discussion on how to 
improve access to medicines, and state responses indicate that they would welcome 
support and substantive advice on how to address the key challenges they face at national 
level.  Therefore, the establishment of an expert body on medicines and health innovation, 
comprised of experts including those who participated in the consultation, would be 
useful to provide a regular forum to take forward this discourse. 
 The second panel discussed the emerging issues and existing obstacles to 
providing access to medicines as a fundamental component of the Article 12 right. Key 
obstacles were stated to be inadequate supply chains, inequitable pricing, poor 
information on access to medicines and weak accountability for failing to secure access 
to medicines683.  The discussion showed that there was consensus that negotiations on 
TRIPS-plus standards should be closely monitored, and that more guidance should be 
provided to states on the legitimate use of the TRIPS flexibilities684.  The contribution 
from Médécins Sans Frontières noted that the WHO Global Strategy and Plan of Action 
was positive, but its effectiveness depended on the inclination of states in 
implementation685.  Representatives of unnamed states expressed concern that too much 
responsibility was placed on governments, particularly developing states, asserting that 
international organisations and pharmaceutical companies should have more 
responsibility in relation to removing obstacles to access to medicines686.  A growing, 
urgent need to ensure that multinational companies adopt a corporate social responsibility 
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approach was also articulated687.  It indicates the significance of the UN Guiding 
Principles on Business and Human Rights688, discussed in the previous chapter.   
The report noted that while States have primary responsibility for enhancing 
access to medicines, numerous actors also have a role, including pharmaceutical 
companies689.  The report made a number of suggestions directed at States including that 
States should establish a competent legal framework in order to realise the right to access 
to medicines; ensure that medicine-related health priorities are not weakened in favour of 
business priorities; take measures to ensure equality for all individuals and groups, such 
as disadvantaged minorities; and establish accountability and monitoring mechanisms for 
access to medicines.690  However, there is little to encourage the States and the private 
business sector to take positive actions to progressively realise access to medicines, which 
was identified as a concern in previous reports. Also, although the report stated that the 
expert consultation identified the need for a reliable system for the supply of medicines 
that are affordable for all691, the report did not go far enough so as to propose the 
substantive details of such a system.  It places the onus on the States to take the proposed 
steps to enhance access to medicines in order to comply with their human rights 
obligations.  However, as the report itself observed, the responsibility to improve access 
to medicines for all is collective.  Therefore, it would have been useful for the consultation 
to have made suggestions which related to the responsibilities of non-State actors and 
other stakeholders, particularly those participating in the consultation, to assist States to 
achieve this goal, in order to fulfil the objective of the consultation. 
 
United Nations Secretary-General’s High-Level Panel on Access to Medicines 
 
In November 2015 the then UN Secretary-General Ban Ki-moon convened a High-Level 
Panel on Access to Medicines with the aim of reviewing and finding solutions for 
resolving policy incoherence between the rights of inventors, public health, international 
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human rights law and trade rules with regard to health technologies.692 This is a significant 
development in advancement of access to medicines as the Panel included a range of 
stakeholders with a remit to find more extensive and viable solutions to enhance access 
to medicines and medical technologies.693  Therefore it is important to examine the 
findings of the Panel to explore the efficacy of the recommendations made in helping 
states to interpret and implement their obligations under TRIPS and the ICESCR to 
enhance access to medicines.  
The Panel comprised fourteen members and two co-chairs from developed and 
developing countries, including representatives from non-governmental organisations, 
the pharmaceutical industry, and experts in law, domestic government policy, IP trade 
and development694.  The mandate of the Panel was to look at the competing interests of 
health and trade and to find a solution within the parameters of the existing international 
legal frameworks on human rights and trade respectively695.  A background paper 
recognised that there have been substantial efforts by various actors696 to address the 
issues with regard to particular diseases or access issues specific to low income countries.  
However, more radical proposals were needed to modify the current incentive systems 
for innovation.697  It suggests that the UN Secretary-General viewed that the work done 
to date had been ineffective in tackling this global issue due to a lack of coordinated 
efforts between the various actors, with such efforts being relatively low level, as well as 
a reactive approach to challenges that arose in specific areas.  The paper also emphasised 
                                                            
692 United Nations Secretary-General’s High-Level Panel on Access to Medicines , United Nations 
Secretary-General’s High-Level Panel on Access to Medicines: Terms of Reference (2015) 
<http://www.unsgaccessmeds.org/reports-documents/> (accessed 27/04/2020), 3 
693 United Nations Secretary-General’s High-Level Panel on Access to Medicines, Background Paper: 
Existing and prior work, initiatives and proposals to improve innovation and access to health 
technologies, prepared by Brook Baker, with the High-Level Panel Secretariat at UNDP in collaboration 
with UNAIDS (2015) <http://www.unsgaccessmeds.org/reports-documents/> (accessed 27/04/2020), 40 
694 United Nations Secretary-General’s High-Level Panel on Access to Medicines, ‘The Panel’, 
<http://www.unsgaccessmeds.org/new-page/> (accessed 27/04/2020) 
695 United Nations Secretary-General’s High-Level Panel on Access to Medicines, Background Paper: 
International legal norms: the right to health and the justifiable rights of inventors, prepared by Richard 
Elliott, with the High-Level Panel Secretariat at UNDP in collaboration with UNAIDS (2015) 
<http://www.unsgaccessmeds.org/reports-documents/> (accessed 27/04/2020), 22 
696The paper reviewed the initiatives of a wide range of organisations on supporting innovation and 
access to health technologies, including the work of the WHO Commission on Intellectual Property 
Rights, Innovation and Public Health and the work of the WTO resulting in the Doha Declaration. ibid 
697 United Nations Secretary-General’s High-Level Panel on Access to Medicines, Background Paper: 
Existing and prior work, initiatives and proposals to improve innovation and access to health 
technologies, prepared by Brook Baker, with the High-Level Panel Secretariat at UNDP in collaboration 
with UNAIDS (2015) http://www.unsgaccessmeds.org/reports-documents/ (accessed 27/04/2020), 39 
 147 
 
that innovators must be rewarded.698  It highlights that the UN human rights system 
recognises that a balancing of these competing interests has been undertaken, although 
Okediji argues that, despite considerable political pressure regarding the right to health, 
this balance has not been successful to date699.  A second background paper also 
considered the competing obligations under international human rights law and 
international trade law and confirmed that as part of its mandate the Panel had to consider 
the “recognised and entrenched legal intellectual property rights under international or 
domestic laws, but also the foundational position of human rights in the international legal 
system.”700  The final report was to be submitted to the Secretary-General in June 2016, 
with the intention of making the report available to the General Assembly to take 
appropriate action on the findings of the report. 
The Panel’s final Report was released on 14 September 2016701.  It noted the 
importance of Sustainable Development Goal 3702 as a device in realising the right to 
health, stating that while medical innovation has contributed to improving health for 
millions of people, the current health innovation model was inadequate to respond to the 
growing emergence of communicable diseases.703  The Report discussed the effect of 
TRIPS and FTAs, arguing that several contributions to the Panel indicated a gradual 
departure from human rights in the implementation of IP law and policy, both under 
TRIPS and in recent trade agreements.704  It asserted that the necessary balance between 
the human right to health and trade and IP law would be met if the provisions under 
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TRIPS and the Doha Declaration were properly followed, and significantly it noted that 
more recent FTAs had included dispute resolution mechanisms which permitted private 
enterprises to challenge national legislation that would deny them of future profit.705 It 
highlights the particular difficulties for states to comply with human rights 
responsibilities when the actions of private enterprises which are not bound by such 
obligations, have a major influence in trade agreements and policy.  The Report also 
observed that the Member States that are parties to TRIPS have not implemented the 
flexibilities that protect health as vigorously as they have enforced the provisions that 
protect IP rights706.  It reaffirms the importance of TRIPS and its flexibilities707, and 
suggests that States have not done enough to ensure that the health rights of individuals 
are upheld in the same manner as the IP rights of private businesses.  However, there may 
be several reasons for this.  The more robust enforcement mechanisms within the WTO 
forum compared with enforcement of human rights norms may greatly influence the 
actions of States. Issues such as resource constraints are also relevant.  
The Report noted gaps in innovation and access particularly in relation to 
neglected diseases, which predominantly affect developing countries, and encouraged the 
further development of mechanisms which incentivise health innovation while delinking 
the cost from the price of the final product.708  The Report stated that States have a 
significant responsibility in respect of funding research and development of medicines 
because of their obligations to their citizens to progressively realise the right to health 
under Article 12.709 Bagley argues that the Report shows that the global community is not 
getting the best mix of medicines needed.710  This view highlights that despite significant 
developments in science and health technologies in recent decades, such developments 
are not translating into greater access to medicines.  The Report stated that States have a 
significant responsibility in respect of funding research and development of medicines 
because of their obligations to their citizens to progressively realise the right to health 
under Article 12.   It was also noted that ensuring State accountability is impeded by the 
lack of transparency in trade negotiations, as well as a lack of coordination with non-
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government agencies and international organisations.   An additional difficulty is that 
there is a lack of accountability for private enterprises.  Although some companies have 
corporate social responsibility policies, there is no obligation to do so.  The Report also 
commented on the lack of transparency in relation to funding costs and clinical trial data, 
which may also impede the development of new medicines as well as the sharing of data 
and information promptly for the benefit of all. 
 
(a) Recommendations of the Panel 
 
The Report made several recommendations aimed at resolving inconsistencies between 
policies encouraging innovation and access.  Recommendations relating to improving 
physical access to medicines included that States should reinforce the current legal 
position by facilitating the use of compulsory licensing through legislation, and to support 
the use of TRIPS flexibilities by WTO Member States711.  Houston and Beall argue that 
the Report concludes that the Paragraph 6 system should be revised, but fails to provide 
specific guidance on steps that could be taken to increase the use of the system.712  This 
suggests that the panel missed the opportunity to progress the discourse on how the 
Paragraph 6 system might be improved so that it can be utilised more effectively for the 
benefit of developing states.  Solovy argues that while the Report recognises the 
flexibility in issuing a compulsory licence, it ignores the limitations and requirements in 
relation to compulsory licences set out in Article 30 TRIPS713. This assumes that the 
Report took the view that it should be relatively easy to obtain a compulsory licence, and 
did not take into account the limitations on the issuing of a compulsory license in Article 
30, which protect the rights of the IP holder.  Solovy further argues that from a policy 
perspective, the overuse of compulsory licensing could undermine the credibility of a 
state’s patent system.714  This rather expansive view appears to contradict the point that 
the limitations under Article 30 do not make it ‘easy’ for states to obtain a compulsory 
licence. To utilise compulsory licensing under Article 30 would also be a legitimate use 
                                                            
711 United Nations Secretary-General’s High-Level Panel on Access to Medicines, final report (n 72) 27 
712 A Houston and R Beall, 'Could the Paragraph 6 Compulsory License System Be Revised to Increase 
Participation by the Generics Industry: Lessons Learned from a Unheralded and Unsuccessful Attempt to 
Use Canada's Access to Medicines Regime' (2018) 12 McGill JL & Health 227, 231 
713 E Solovy and P Krishnamurthy, 'TRIPS Agreement Flexibilities and Their Limitations: A Response to the 
UN Secretary-General's High Level Panel Report on Access to Medicines' (2017) 50 Geo Wash Int'l L Rev 
69, 121 
714 ibid 122 
 150 
 
of an exception to patent protection under TRIPS that has been agreed by Members.  
Therefore, states should not be subject to external pressure not to utilise Article 30, and 
should be able to seek recourse through the WTO DSB if subjected to such pressure from 
another Member. 
The Report also recommended that States that are subject to pressures, from other 
States or the private sector, which undermine their use of the TRIPS flexibilities should 
report such practices to WTO.715  This suggests that the Panel wished to encourage States 
that seek to promote access to health, including medicines, through international 
agreements such as TRIPS that, should they be challenged by other States or other private 
enterprises, they would be supported by the UN human rights bodies and WTO.  It also 
indicates that States that may attempt to undermine their commitments under international 
agreements, such as TRIPS, through FTAs may be subject to challenge.  The Report also 
recommended that the WHO maintain an international database of prices of patented and 
generic medicines in countries where they are registered716, highlighting that in order to 
improve the inconsistencies in policy with trade and health, international organisations 
and non-governmental organisations have responsibilities to assist States in achieving this 
objective.  However, this could also raise the issue of transparency, as accurate and quality 
data on pricing would need to be provided consistently for such a database to be effective. 
The Report also made recommendations relating to promoting innovation in the 
development of new medicines.  It recommended that additional funding models should 
be implemented which would stimulate innovation where there is no market incentive to 
develop particular medicines717, such as public-private partnerships and prizes for 
innovators.  This would delink the research and development costs from the price of the 
end product, which could lead to more equitable prices for medicines so that they are 
more widely available for the population.  Further recommendations included that States 
increase government funding for health innovations, particularly in developing and least 
developed countries718, and that the UN Secretary-General should establish an 
independent review body to assess progress on health technology innovation and access, 
as well as monitoring implementation of the recommendations of the Panel and progress 
on the 2030 Agenda for Sustainable Development719.  This would further increase 
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accountability of States with regard to their obligations under the right to health, and may 
strengthen the current accountability and enforcement mechanisms within the UN human 
rights systems. 
The Report also made recommendations with regard to the monitoring of 
biomedical and pharmaceutical companies, recommending that they should be required 
to report on actions they have taken to promote access to health technologies720, and 
governments should require the disclosure of all costs relating to the production and 
distribution of medicines.  This would add a measure of accountability for private 
companies, and may also compel them to justify their expenditure on research and 
development, particularly if they wish to take advantages of the more innovative funding 
schemes proposed.  Yu notes that the Report is an example that the issue of sharing test 
data is becoming more significant, and that the right to health has been used to justify the 
disclosure of data on pharmaceuticals in academic literature.721  Greater transparency over 
research and development costs may also give an indication of the efficiency of the 
process, as well as the return on public investment in medicine development722. The 
reporting obligations may have the added effect of showing that the pharmaceutical 
industry is not only of commercial interest but delivers a valuable contribution to society.  
Reporting obligations on pharmaceutical companies could also form part of the regulation 
of such companies by states under the Guiding Principles, discussed in the previous 
chapter. 
While the recommendations in the Report were welcomed by the outgoing 
Secretary-General Ban Ki-moon723, it was evident that the recommendations were 
reached by consensus, and due to the diverse backgrounds of the contributors it is clear 
from the individual commentaries724 annexed to the Report that diverging views over the 
recommendations remain. Following the publication of the Report, the Secretary-General 
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encouraged all stakeholders to review the recommendations and to develop a way forward 
in appropriate fora to ensure access to medicines for all725.   
The commentaries highlight that there was a lack of consensus over a number of 
themes considered by the Panel, with members Jorge Bermudez (former UNITAID 
Executive Director, Unit Chief for Medicines, Vaccines and Health Technologies Unit at 
PAHO/WHO), Winnie Byanyima (Executive Director of Oxfam International and former 
MP, Uganda) and Shiba Phurailatpam (formerly with United Nations Development 
Programme and ActionAid International) stating that the Report should have been bolder 
to include recommendations such as a new IP regime for pharmaceutical products and 
calling for sanctions on TRIPS-plus provisions in FTAs.726  Persad argues that these Panel 
members would have gone further and eliminated rights over certain subsets of 
medicines.727  Their position that IP and costs of medicines are crucial barriers to access 
echoes a core issue in the discourse, but ignores wider factors such as inadequate health 
care infrastructures and states’ resource constraints.728  Conversely, a dissenting 
commentary from Andrew Witty asserted that the Report overstates the use of the TRIPS 
flexibilities and cautioned against implementing an alternative system without a thorough 
risk assessment of potential negative consequences in doing so.729  Cadillo Chandler has 
argued that implementing another IP system may lead to overlap with the current system 
and may not address the problems that have been experienced with attempts to adapt and 
amend TRIPS.730 Implementing another IP system also may not position the issue of 
securing access to medicines in a rights-based framework.   
Andrew Witty further argued that delinking product prices from development 
costs may be difficult as the costs of research and development are not always evident at 
the outset731, which may suggest that increasing publicly funded research could lead to 
increases in national debt.  However it is important to note that the Panel’s Report was to 
address policy incoherencies and stimulate debate on the issue in a high-level forum, and 
                                                            
725 United Nations Press Release, 22 November 2016 (n 723) 
726 United Nations Secretary-General’s High-Level Panel on Access to Medicines, final report (n 72) 
Annex 1: Commentaries, Jorge Bermudez, Winnie Byanyima and Shiba Phurailatpam, 53 
727 Persad (n 707) 162 
728 Persad (n 707) 163 
729 United Nations Secretary-General’s High-Level Panel on Access to Medicines, final report (n 72) 
Annex 1: Commentaries, Andrew Witty, 57 
730 D Cadillo Chandler, ‘The never-ending story of access to medicines’ (2016) 8(1) World Intellectual 
Property Organization Journal 54, 62 
731 United Nations Secretary-General’s High-Level Panel on Access to Medicines, final report (n 72) 
Annex 1: Commentaries, Andrew Witty, 56 
 153 
 
therefore some points may need further exploration and development in order to advance 
an efficacious response to the issue of enhancing access to medicines for all.  While it is 
pertinent to appreciate that the precise expertise of the respective commentators may 
influence their views, the divergence of opinion in the various commentaries highlights 
the difficulties the Panel experienced in finding consensus in achieving recommendations 
to secure access to medicines, reiterating the complex nature of the issue.  It also indicates 
that the Report may have the support of civil society organisations732, but is less likely to 
be supported by the pharmaceutical industry. 
Prior to the publication of the Panel’s final report, concerns as to the scope of the 
Panel’s remit were expressed by biotechnology and biopharmaceutical enterprises733. 
Concerns included that the Panel should not only focus on IP but should take a broader 
approach to consider other factors that affect access to medicines, such as trade barriers.734 
The submission also commented that international IP systems have contributed to 
improving global health735.  This indicates apprehension among the biotechnology 
industries that the Panel report would recommend a reconstruction of the international IP 
system which could lead to international pressure to modify the existing operation of their 
enterprises.  Persad argues that the report focused its analysis and criticism on holders of 
IP rights when other stakeholders, including civil society organisations, and national 
governments, have a role to play in improving access to medicines.736  Although this is a 
reasonable view, it is important to note that the mandate of the Panel was to address 
tension between rights of inventors, human rights law, trade rules and public health, rather 
than a wide-ranging review of all reasons for which medicines and health technologies 
are unaffordable. Solovy argues that the report does not afford sufficient credit for the 
role of patent protection in the creation of medicines.737  However, the report does 
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explicitly recognise the vast contribution of the pharmaceutical and biotechnology 
industries, and that such contributions have been largely stimulated by incentives 
underpinned by IP.738  The Panel also included representation from the pharmaceutical 
industry, as noted above, to provide a measure of balance and to represent the interest of 
rights holders. 
Forman argues that the Panel report “offered an important testing ground for 
promoting an intellectual property system that didn’t simply enhance protection of the 
public interest as an externality to its ethos of advancing trade interests, but that located 
this system within the broader system of international law”.739  Therefore, the Panel could 
have taken the opportunity to address the fragmentation of international law specifically 
in relation to trade law, human rights and access to medicines. However, Forman argues 
that the report added little to what were already existing policy proposals, and so the Panel 
missed this opportunity to progress the issue of access to medicines.740  The Panel did 
make some innovative proposals including those relating to delinking of product prices 
from research and development costs, although the Report did not propose wide 
reform741.  This could be viewed as a missed opportunity, considering the range of 
participants and their relative expertise. Kirby argues that the global community needs to 
find a solution to enhance access to medicines, and this will be achieved by finding 
consensus among the relevant stakeholders, rather than through combative steps742. It is 
also important to note that the Panel had a relatively narrow mandate, so it may not have 
been feasible to make assertions which could exceed the specific mandate of the Panel. 
 
(b) WHO, WTO and WIPO Responses to the Panel’s recommendations 
 
The WHO has outlined its support for the Panel report, with the Director-General stating 
that the work of the Secretariat covers many of the recommendations in the Panel report 
in his report on access to medicines in March 2018743.  Examples are provided in 
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Appendix 3 of the Director-General’s report which outlines recommendations of the 
report of the High-Level Panel and the WHO’s activities, including that the WHO is 
providing technical support to countries on the use of the TRIPS flexibilities744, and is 
advocating for increased transparency on costs of R&D745.  Following from the report of 
the Director-General, a roadmap on access to medicines and vaccines has been drafted746 
in consultation with Member States, which outlines the programming of WHO’s work on 
access to medicines and vaccines for the period 2019-2023, including specific actions and 
key deliverables for each of the strategic areas prioritised in the roadmap747.  The 
document notes that the WHO will take the report of the High-Level Panel into account 
when addressing the area of application and management of intellectual property to 
contribute to innovation and promote public health748.  The work of the WHO indicates 
that it is implementing recommendations of the report relevant to its mandate.  The fact 
that the roadmap has been drafted in consultation with states demonstrates that states are 
engaging in commitments to enhance access to medicines as outlined in the document.   
 The Panel’s report was also discussed within the WTO Council following a 
request by Member States Brazil, China, India and South Africa to place it on the 
agenda749.  In the report to the Council on the annual review of the implementation of 
paragraph 6 of the Doha Declaration750, India restated concerns that the paragraph 6 
process was too burdensome and supported the Panel’s recommendation to revise TRIPS 
to include a distinct compulsory licence mechanism for pharmaceutical products751.   
Brazil also highlighted the report’s recommendations that national governments should 
implement legislation that incorporates an efficient and accessible compulsory licensing 
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provision for medicines752, while South Africa also underlined this recommendation753.  
The WTO General Council took note of the report of the TRIPS Council and the 
accompanying statements in its annual report754.  It remains to be seen whether any of the 
Panel’s recommendations will be adopted by the WTO755.  However given the fact that 
the first amendment to TRIPS emanating from the Doha Decision entered into force on 
23 January 2017756, just three months after the Panel’s report was published, the WTO 
may decide that real progress in securing access to medicines can be made through this 
amendment, rather than seeking to make further amendments which may take a similar 
length of time to agree and to implement. 
The Panel’s report was discussed in the WIPO Standing Committee on Law of 
Patents in December 2016.  The EU statement was critical of the narrow mandate of the 
Panel, suggesting that it ignored more common issues that affect lack of access to 
medicines757. It also highlighted that none of the recommendations were supported by all 
members of the Panel and declined to support some of the recommendations including 
the proposals for revision of TRIPS758.  This opposition to the findings of the report was 
also reflected in the US, with the US Chamber of Commerce asserting that the report 
failed to consider issues such as excessive tariffs and weak distribution systems which 
affect access to medicines, and commented that the recommendations would place the 
UN itself above national governments in administering IP rights759.  However, Moon 
argues that the real concern over the recommendations could be because the report 
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requires broad modifications to the current model of research and development for the 
benefit of all countries, where previously the issue of securing access to medicines has 
centred on lower pricing for developing countries760.  It suggests that the Panel’s report 
underlined a shift in approach to the problem of enhancing access to medicines to viewing 
it as an issue which affects all countries, not only developing and least developed 
countries, and therefore a global response is needed to advance solutions that are 
constructive in all countries. 
The response of the UN General Assembly was the adoption of a resolution761 
including a request to the UN Secretary-General to promote discussion among Member 
States and relevant stakeholders on policies to promote access to medicines, innovation 
and health technologies, while considering relevant reports including the Panel’s report762 
and also the trilateral report of WTO, WIPO and WHO763.  In December 2017 the UN 
General Assembly adopted a further resolution in which it decided to hold a high-level 
meeting on universal health coverage in 2019764, and stated that universal health coverage 
implies that all people have equal access to essential, affordable, effective and quality 
medicines.765 The resolution was adopted without a vote, and Thailand and the US made 
statements emphasising the importance of equitable access to safe, effective medicines.766  
Following the meeting the General Assembly adopted a resolution committing to 
achieving universal health coverage by 2030767.  The resolution also committed to several 
actions relating to medicines which echo the Panel’s recommendations, including 
increased transparency of pricing768, delinking R&D costs from prices769 and appropriate 
incentives in development of new medicines770.  The resolution was also adopted without 
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a vote,771  reflecting consensus by States on the resolution.  A statement from the EU 
stated the need for a comprehensive outlook, working towards access to affordable 
medicines772, and Switzerland stated its commitment to a system that encourages R&D 
in the area of innovative medicines.773 
 
Other recent developments concerning access to medicines 
 
(a) High-level meeting on ending HIV/AIDS 
 
The General Assembly held a high-level meeting on ending HIV/AIDS in June 2016774 
which included discussion of the issue of ensuring access to medicines for all persons 
living with HIV/AIDS.  The summary report by the Human Rights Council for 
consideration at the high-level meeting included the recommendation that IP rights should 
not take precedence over public health as there is also a right for everyone to enjoy the 
benefits of scientific progress775.   The report also stated that IP rights should not be 
allowed to take precedence over the right of all persons living with HIV/AIDS to have 
access to life-saving medicines776.  This statement from the Human Rights Council 
indicates that the right to benefit from scientific progress should be balanced with the 
author’s rights under Article 15 ICESCR and also emphasises that there exists a right to 
access to essential medicines, specifically for treating HIV/AIDS in the context of this 
report.  This position is in line with the position taken by the Panel777, as well as the 
position of other UN human rights bodies. 
The report of the Secretary-General also highlighted the importance of supporting 
research and development for health technologies, as well as ensuring affordability by 
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aligning public health aims and trade policies under a human rights framework778, 
suggesting that affordability may be regulated effectively within a rights-based agenda.  
The General Assembly also adopted a political declaration on HIV/AIDS to commit to 
measures to ensure access to medicines, including generic medicines and health 
technologies, and noted the convening of the High-Level Panel on Access to Medicines 
by the Secretary General779.  
 
(b) Human Rights Council Resolution 32/15 
 
The thirty-second session of the Human Rights Council held in July 2016 resulted in the 
adoption of a resolution on access to medicines780, which reiterated the request for States 
to collaborate on proposals to support delinking new research and development costs from 
the prices of medicines that predominantly affect developing countries781.  This is a 
similar request to the recommendation on delinkage in the High-Level Panel’s subsequent 
Report, indicating a measure of overlap between the work of the Human Rights Council 
and the High-Level Panel, and highlights an important trend in the work of the UN human 
rights bodies.  The resolution also includes the Human Rights Council decision to 
convene a panel discussion at its thirty-fourth session to discuss good practices and key 
challenges relevant to access to medicines as one of the fundamental elements of the right 
to health, inviting the United Nations High Commissioner for Human Rights to liaise with 
states and other stakeholders regarding the panel discussion and to prepare a report on the 
panel discussion to be submitted to the Human Rights Council782.  The panel discussion 
suggested by the Human Rights Council appears to have a broader mandate than the High-
Level Panel, and therefore may add to the discussion on securing access to medicines for 
all as a fundamental element of the right to health under Article 12 ICESCR.  Panellists 
reiterated the call for the Secretary-General to establish an inter-agency taskforce on 
health technology innovation and access783. This could potentially be significant in order 
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to provide a platform for discourse on a key recommendation of the High-Level Panel, 
although such a taskforce may not have a mandate to consider broader issues that affect 
access to medicines. 
 The report of the panel discussion noted that most States supported the Report of 
the High-Level Panel, and explicitly encouraged countries to implement its 
recommendations784.  This is very significant as it indicates that States are willing to 
engage with the recommendations in the Report and to take actions to implement the 
recommendations.  The need for improved transparency of costs and pricing was also 
highlighted785, as well as the need to gather the views of stakeholders, including 
governments and pharmaceutical companies, on the fundamental changes that needed to 
be made to the current innovation model786.  This highlights the importance of the 
availability of data on R&D costs to assess the pricing of medicines, and also that an 
effective collaboration on delinking costs and prices needs to include not only States but 
all other relevant stakeholders, including pharmaceutical companies.  To get 
pharmaceutical companies to agree to disclose their R&D costs could be challenging.  
Disclosing this data could be a condition of receiving funding or a grant, for example if 
the company was receiving public funding for a particular project and was required to 
account for how the money was spent.  This could raise the question of whether there is 
a role for competition law to regulate anti-competitive conduct or excessive pricing787, 
although this question is beyond the scope of this thesis788.   
To envisage how pharmaceutical companies could be compelled to disclose such 
data, the US provides an example.  State legislatures have passed laws on medicines 
pricing, including measures to increase pricing transparency and disclosure of costs in 
states including Vermont in 2016, and Nevada, California and New York in 2017.789  
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Provisions include requiring a manufacturer to report to a state body on financial and non-
financial factors that contributed to the increase in price of a medicine.790 Remedies for 
violations include injunctive relief and fines of $10,000 USD for each violation.791  
However, these laws are subject to challenge by the pharmaceutical industry for 
constitutional violations, infringement of trade secrets and patent law.792 Further criticism 
of the legislation is that only some of the relevant information on pricing is required to be 
disclosed, and pricing of newly introduced medicines is not covered.793 While it is clear 
that the pharmaceutical industry does not favour this approach, the passing of this 
legislation shows that at national level governments are pursuing price transparency to 
redress excessive pricing as a legitimate policy goal.794  Other States could learn from, 
and build upon, the experiences of the US states and the challenges faced in seeking to 
address the issues of excessive pricing of medicines at national level.  
 
Measuring the success of the UN human rights bodies’ work 
 
The UN human rights bodies have appreciated that there are a number of issues which 
have a detrimental effect on securing access to essential medicines, as evidenced by the 
thematic issues addressed by these bodies above.  The work carried out by the various 
bodies has clarified that the human right to the highest attainable standard of health under 
Article 12 is potentially infringed by the failure to remove barriers to access to essential 
medicines.  In addition, the clarification of the scope of the rights under Article 15, 
particularly the right of everyone to enjoy the benefits of scientific progress, has 
elucidated another dimension to the access to medicines debate.  The focus has shifted 
from the content of creators’ rights and instead highlighting the right of everyone to 
benefit from scientific creations and technologies, including new medicines795.   
Furthermore, the convening of the expert consultation on access to medicines and 
the Secretary-General’s High-Level Panel on Access to Medicines demonstrates an 
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elevation of the discourse to a position of principal concern within the UN human rights 
system and a central human rights issue for Member States to address in order to comply 
with their human rights obligations.  The Panel’s report also identified gaps in the practice 
of states with regard to the types of new medicines that are being developed, and in the 
funding of research and development of new medicines.796  This highlights the report’s 
utility in demonstrating discontinuities between the states’ methods of attempting to 
improve access to medicines domestically, and may also indicate that a more 
collaborative approach between states could be useful. 
The ability to monitor states parties’ compliance with their international human 
rights obligations and the authority to make them accountable for violations of such 
obligations is fundamental to ensuring that the rights of all are upheld.  Sellin asserts that 
“to be truly effective human rights must be justiciable and enforceable”797.  However, the 
international human rights framework does not have an effective mechanism to enforce 
human rights obligations.798  Sellin suggests that enforceability can and should be dealt 
with in states parties’ domestic courts799, and this would be a less costly and more 
expedient course of action for claimants. Self-administration of states’ obligations by 
their courts is also beneficial as such obligations may be enforced at national level 
consistent with the highest attainable standard of that state.  It could also be useful to have 
an international mechanism of enforcement to ensure a uniform recognition of the 
applicable UN human rights principles.  This could also assist the domestic courts when 
applying these principles, although interpretation of such principles would still be the role 
of the courts, where the specific application of such principles may vary across 
jurisdictions. In Member States which have problems with regard to corruption within the 
court system, such litigation may be unsatisfactory, particularly if it involves trade 
concerns.  Therefore, it raises the question of how the UN human rights framework can 
effectively compel states parties to comply with the conclusions and recommendations of 
its bodies without an effective system of enforcement.  This applies to all human rights, 
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not only the issue of access to medicines.  The Optional Protocol to the ICESCR800, which 
came into force in May 2013, includes procedures for the CESCR to receive 
communications from individuals on violations of ICESCR rights by States parties801, 
and also includes an inquiry procedure where the CESCR can investigate violations, make 
recommendations and receive responses by States parties.802  This provides a mechanism 
for individuals to hold states to account for infringements of ICESCR rights. Due to the 
relatively low number of states which have ratified the Optional Protocol803, it remains to 
be seen how effective this complaints mechanism will be. However, it could promote 
cooperation and dialogue between the CESCR and States parties, which could strengthen 
the protection of ICESCR rights at national level.804 
 
III. Conclusion 
 
The work of the UN human rights bodies shows that access to medicines is a core element 
of the right to health, and it is also important in relation to rights to enjoy scientific 
progress.  It is evident that human rights of creators do not trump the right to health, and 
the rights of creators cannot be expanded to encompass associated IP rights in IP 
agreements and mechanisms805.  It is also clear that IP rights do not amount to human 
rights under Article 15(1)(c) ICESCR.  Therefore, there is no conflict between Article 15 
and Article 12 in relation to access to medicines and IP, and Article 15 does not present 
an obstacle to advancing access to medicines. The work of the UN human rights bodies 
shows that the rights of creators should not be unduly favoured and must be balanced with 
the public interest the products of scientific progress, such as new medicines.  This aligns 
with the position in relation to the right to health under Article 12.   
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Further, the UN human rights systems have promoted the linked right of all to 
enjoy the benefits of scientific progress, including access to new medicines under Article 
15(1)(b).  The growing discourse on Article 15(1)(b) is also constructive in promoting 
access to medicines as a right.  It supports the findings in the previous chapter that 
individuals have a right to access to essential medicines.  It challenges the position that 
medicines created by private pharmaceutical enterprises should be subject to strong IP 
protection over their products.  It also places emphasis on the responsibility of Member 
States to fulfil their obligations to individuals under this right, alongside the right to 
health, in respect of ensuring access to medicines for all. Some of the proposals in relation 
to the scope of the right could be viewed as expansive, but the consensus among States 
in the subsequent resolutions could indicate some viability.  The drafting of a General 
Comment on Article 15(1)(b) would provide further clarification on the scope and content 
of the right. 
Recent developments emanating from the UN human rights framework also add 
to the understanding of how states can interpret their human rights obligations in a manner 
that enhance access to medicines at national level.  A key theme is that a balance between 
the IP system and human rights has not been successfully achieved, which accords with 
the findings in earlier chapters.  Themes also include the delinking of R&D costs from 
pricing of medicines, increased transparency on costs and the importance of utilising the 
TRIPS flexibilities.  Promoting the use of compulsory licensing is also a key theme which 
is consistent with findings in earlier chapters.  The findings from this chapter indicate that 
Article 15(1)(b) right could be relied upon to promote the use of compulsory licensing.  
Recommendations emanating from these developments, including the UN Secretary 
General’s High-Level Panel on Access to Medicines, have found support at 
intergovernmental level, and broad consensus among States on subsequent resolutions 
incorporating some of the recommendations, is significant in terms of advancing the 
access to medicines agenda. 
The work of the UN human rights bodies infers that a cohesive, uniform, 
international strategy is required to address the issue of securing access to essential 
medicines.  The UN human rights system, with primary responsibility for upholding 
international human rights, has focused its recommendations on modifications to the 
current international IP system, including a new framework for research and development 
into new medicines.  Therefore, the responses of the relevant stakeholder organisations 
and Member States to these recommendations will be critical in developing the proposals 
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of the UN human rights bodies in a positive manner.  A collaborative approach among 
principal stakeholders at international level will be key.  It is evident that states may 
experience challenges in implementing the recommendations at national level, including 
measures to improve pricing transparency and the disclosure of test data by 
pharmaceutical companies. Therefore, more practical guidance on how states could 
effectively implement specific measures to enhance access to medicines could be helpful, 
to help states ensure that they effectively meet their human rights obligations as well as 
their obligations under TRIPS. 
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Chapter 5: Case Study – Canada 
 
Introduction 
 
The previous chapters have explored the issues arising from the international trade forum 
and the UN human rights systems specifically in relation to the enhancement of effective 
access to medicines.  These include that access to medicines is part of the right to health 
under Article 12 ICESCR. Secondly, although the patent protection under TRIPS can 
impact on access to medicines, there are exceptions to this protection which can be 
utilised to enhance access to generic medicines. There is no inherent conflict between 
TRIPS and human rights, but the implementation of TRIPS-plus standards of IP rights 
protection creates tension. The role and responsibilities of private pharmaceutical 
companies in enhancing access to medicines is also a key challenge.  The country case 
studies will explore how the state has complied with its obligations to implement TRIPS 
standards and its obligations to enhance access to medicines as part of the right to health.   
The subject of the first study will be Canada.  The methodology for selecting the 
States that will be the subject of a case study involved identifying the States which are 
WTO Members and have ratified the ICESCR, and applying a series of indicators in the 
form of a table, set out in Annex II.  After identifying the States that were both WTO 
Members and had ratified the ICESCR806, the first indicator applied was which countries 
were classified as developed or developing807.  All States that were also EU Member 
States were excluded as the States are subject to EU law as well as their domestic laws.  
Providing a discussion on EU law and its implications in addition to the legal rules of the 
UN human rights mechanisms and the WTO trade forum would present the need for 
additional analysis that would extend beyond the scope of the case studies and this thesis.  
The next step involved identifying the countries that were net importers of 
                                                            
806 This information was extracted from the official websites of the respective organisations as at March 
2017; see also World Trade Organization, ‘Understanding the WTO: The Organization; Members and 
Observers’ <https://www.wto.org/english/thewto_e/whatis_e/tif_e/org6_e.htm> (accessed 
27/04/2020) and United Nations Office of the High Commissioner for Human Rights, ‘Status of 
Ratification Interactive Dashboard’ (n 539) 
807 Data obtained from UN, World Economic Situation and Prospects 2015, (United Nations, New York 
2015), 139-140 
<http://www.un.org/en/development/desa/policy/wesp/wesp_archive/2015wesp_full_en.pdf> 
(accessed 27/04/2020) 
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pharmaceuticals and which were net exporters of pharmaceuticals808, which highlighted 
that a low number of developed countries are net importers.  Of the four developed States; 
Australia, Canada, Japan and New Zealand, New Zealand was eliminated because it was 
the only one of those States not to have received a visit from the Special Rapporteur on 
the right to health.  There are several compelling reasons why Canada was chosen as a 
case study, including the fact that it is a net importer of medicines yet pharmaceuticals is 
a major export with the State being the tenth largest pharmaceutical market, the fact that 
it is a federal State and the issues this can raise in terms of implementing transnational 
norms.  Also, the fact that the State has demonstrated some willingness to act on its 
international commitments in relation to developing States by adopting some national 
measures which aim to improve access to medicines. 
The purpose of these studies is to explore whether states appreciate the interaction 
between their human rights obligations and their obligations under TRIPS at national 
level, and to evaluate how states are addressing possible tensions in order to discharge 
their obligations simultaneously under TRIPS and the ICESCR. This study will primarily 
focus on reviewing national legislation, policy documents and related case law, and will 
refer to relevant academic literature in the analysis of the findings.  The first section of 
the study will examine the constitutional and legislative framework of the State to explore 
the extent to which the State has complied with its human rights obligations in relation to 
access to medicines, and the extent to which the State has implemented the patent 
provisions under TRIPS. The second section of this study will examine the health policy 
measures on access to medicines, to evaluate whether these measures effectively address 
possible tensions between the State’s obligations under TRIPS and the ICESCR. The third 
section evaluates Canada’s regulatory response to the impact of the private 
pharmaceutical industry, which has a crucial role in producing medicines, on its 
obligations to enhance effective access to medicines.  The fourth section will conclude 
by evaluating the findings from this study. 
 
I. Canada’s Constitutional and legislative framework 
 
                                                            
808 Data on net importation and net exportation of pharmaceutical products by states was taken from 
UN COMTRADE Database; United Nations, Department of Economic and Social Affairs, Statistics 
Division, Trade Statistics, UN COMTRADE Database <https://comtrade.un.org/data/> (accessed 
27/04/2020) 
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(a) Constitutional landscape regarding a right to health and medicines 
 
Canada is a federal jurisdiction, with the ten provinces also having separate legislative 
powers over matters relating to the individual province809.  Federal and provincial 
legislative powers are set out in the Constitution Act 1867, providing that the federal 
government has exclusive powers over national matters such as health, finance and the 
military, while provincial governments have exclusive power over matters local to that 
province810.  Canada has federal legislation relating specifically to patents under the 
Patent Act 1985811, and also has federal legislation on human rights, with the Canadian 
Charter of Rights and Freedoms forming part of the Constitution Act 1982812, as well as 
the Canadian Human Rights Act813 which principally covers discriminatory practices.   
Canada is a dualist state, and so international treaties to which it is a party have to 
be incorporated into national legislation.814  Therefore TRIPS and the ICESCR treaties 
have to be translated into national law to become enforceable.  As noted above, the 
Canadian Charter of Rights and Freedoms forms part of the State’s Constitution. However 
this does not include economic or social rights.815  At national level, Canadian courts have 
adopted a conservative approach to recognising socio-economic rights, including a right 
to health care.816  Section 7 of the Canadian Charter of Rights and Freedoms protects the 
right to life, liberty and security of the person817, providing scope to argue that social 
                                                            
809 Government of Canada, Department of Justice, ‘Where our legal system comes from’ 
<http://www.justice.gc.ca/eng/csj-sjc/just/03.html> (accessed 27/04/2020)  
810 Constitution Act 1867, 30 & 31 Victoria, c. 3 (U.K.), S.91-S.92. 
811 Patent Act 1985 (R.S.C., 1985, c. P-4) (CA007) 
812 Constitution Act 1982 (80) 1982, c. 11 (U.K.), Schedule B <http://laws-
lois.justice.gc.ca/eng/Const/page-15.html#h-38> (accessed 27/04/2020)  
813 Canadian Human Rights Act 1985 (R.S.C., 1985, c. H-6) <http://laws-lois.justice.gc.ca/eng/acts/H-
6/page-1.html> (accessed 27/04/2020)  
814 K Glover, 'The Supreme Court in Canada's Constitutional Order' (2016) 21 Rev Const Stud 143, 155; G  
Remillard, 'Constitution Act, 1982: An Unfinished Compromise' (1984) 32 Am J Comp L 269, 280; C 
Dauvergne, 'How the Charter Has Failed Non-Citizens in Canada: Reviewing Thirty Years of Supreme 
Court of Canada Jurisprudence' (2013) 58 McGill L J 663, 685; L White, 'Understanding Canada's Lack of 
Progress in Implementing the UN Convention on the Rights of the Child; The Intergovernmental 
Dynamics of Children's Policy Making in Canada' (2014) 22 Int'l J Child Rts 164, 165 
815 C Jung, R Hirschl and E Rosevear, 'Economic and Social Rights in National Constitutions' (2014) 62 Am 
J Comp L 1043, 1053; Constitution Act 1982 (n 812)  
816 B Thomas and C Flood ‘Putting Health To Rights: A Canadian View on Global Trends in Litigating 
Health Care Rights’ (2015) 1 CJCCL 49, 58-59; M Jackman ‘Charter Review as a Health Care 
Accountability Mechanism in Canada’ (2010) 18 Health Law Journal 1, 27; B Porter ‘A right to health care 
in Canada: Only if you can pay for it’ (2005) 6(4) ESR Review 8, 10 
817 Section 7 states: Everyone has the right to life, liberty and security of the person and the right not to 
be deprived thereof except in accordance with the principles of fundamental justice. See: Canadian 
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rights including access to medicines should be recognised under the Charter.818  However, 
this argument has not found favour with the national courts.  For example, in Chaoulli v 
Quebec819 the Supreme Court stated that the Canadian Charter of Rights and Freedoms 
does not confer a free standing right to health care.820  In Canadian Doctors for Refugee 
Care v Canada821 the Federal Court concluded that Section 7 did not include a positive 
right to health care.822   
Academics have taken the view that the courts have avoided rigorous review of 
health care decision-making partly by construing Section 7 as protecting only negative 
rights.823 In relation to access to medicines, Section 7 has been successfully relied upon 
only to the extent that restrictions to access to medical marijuana under the Controlled 
Drug and Substances Act 1996824 have been found to be incompatible with Section 7.825  
Thomas and Flood argue that courts have avoided oversight of health care resource 
allocation in deference to government policy, because of concerns about overstretching 
government budgets on health care.826  An example of this concern is evident in Allen v 
Alberta827, where the Court of Appeal concluded that as there is no free standing right to 
health care, spending priorities have to be taken into account, a decision which is outside 
the reach of the Constitution.828  Ries argues that there are examples of deference where 
government decisions are affected by limited resources, but the Supreme Court has 
acknowledged that to simply accept Parliament’s view in all such cases would diminish 
                                                            
Charter of Rights and Freedoms, s 7, Part 1 of the Constitution Act, 1982, being Schedule B to the 
Canada Act 1982 (UK), 1982, c 11. 
818 A Gross ‘Is There a Human Right to Private Health Care?’ (2013) 41(1) The Journal of Law, Medicine & 
Ethics 138, 140; Thomas and Flood (n 816) 58-59; Jackman (n 816) 27; Porter (n 816) 10 
819  Chaoulli v Quebec (AG) [2005] 1 S.C.R. 791, 2005 SCC 35.  This case concerned a challenge to 
legislation prohibiting private health care insurance for services covered by public health care insurance. 
820 ibid 104 
821 Canadian Doctors for Refugee Care v Canada (Attorney General), 2014 FC 651 
822 ibid 570; V Sinha, L Sossin and J Meguid 'Charter Litigation, Social and Economic Rights & Civil 
Procedure' (2017) 26 Journal of Law and Social Policy 43, 62 
823 C Flood and  B Chen 'Charter Rights & Health Care Funding: A Typology of Canadian Health Rights 
Litigation' (2010) 19 Annals Health L 479, 482-483; Thomas and Flood (n 816) 67; Jackman (n 816) 15; C 
Flood and A Gross ‘Litigating the Right to Health: What Can We Learn from a Comparative Law and 
Health Care Systems Approach’ (2014) 16(2) Health and Human Rights Journal 62, 66 
824 Controlled Drugs and Substances Act (S.C. 1996, c. 19) 
825 See examples: R v Parker (2000), 49 OR (3d) 481 (CA); Hitzig v. Canada, 2003 CanLII 30796 (ON CA); 
Allard v. Canada, 2016 FC 236 
826 Thomas and Flood (n 816) 61 
827 Allen v Alberta, 2015 ABCA 277 
828 ibid 52 
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the role of the courts in upholding constitutional rights.829  The restrained approach of the 
courts emphasises the need for policy coherence on health care and medicines among 
government departments. The courts should provide an avenue for rigorous judicial 
review of government spending on health care including medicines in light of the 
fundamental rights set out in Section 7 of the Charter.830 Academics have observed that 
the wording in Section 7 is almost identical to Article 21 of the Indian Constitution831, 
and that Indian courts have interpreted the right to life as imposing a positive duty on the 
State, incorporating health rights into the fundamental rights to life and liberty.832  For 
example, in Paschim Banga Khet Samity v State of West Bengal833 the Indian Supreme 
Court concluded that lack of provision of adequate medical facilities for emergency 
treatment amounted to a breach of the claimant’s fundamental right to life under Article 
21.834  Therefore, the Canadian courts are not restricted to a narrow interpretation of 
health rights by the wording of the Charter. 
Currently, the approach of the national courts means it is unlikely that individuals 
will be able to rely on their national charter of rights to claim a right to access to health 
care including essential medicines. The courts should also provide an avenue for 
accountability in relation to the State’s positive obligations to progressively realise the 
right to health including access to essential medicines under Article 12 ICESCR.835 
Article 12 does provide that states must take action as far as their resources allow, but as 
discussed in Chapter 3 of this thesis, states do have immediate obligations to take concrete 
steps towards full realisation of this right.836  What is not evident is the state being 
challenged over this approach in relation to access to medicines.  A broader recognition 
of health rights including access to medicines could be achieved if the courts were to 
interpret the Charter rights in light of the State’s obligations under the Article 12 ICESCR 
right to health.837  Jackman argues that the lack of justiciability in ensuring health care 
                                                            
829 N Ries, 'Legal Rights, Constitutional Controversies, and Access to Health Care: Lessons from Canada' 
(2006) 25 Med & L 45, 54. Ries refers to the Supreme Court decision in RJR-MacDonald Inc. v. Canada 
(Attorney General), [1995] 3 Supreme Court Reports 199 [136] 
830 Jackman (n 816) 27 
831 The Constitution of India,  26 January 1950 <https://www.india.gov.in/my-government/constitution-
india/constitution-india-full-text> (accessed 27/04/2020). Article 21 states: ‘No person shall be deprived 
of his life or personal liberty except according to procedure established by law.’ 
832 Jung, Hirschl and Rosevear, (n 815) 1050-1; Thomas and Flood (n 816) 59 
833 Paschim Banga Khet Samity v State of West Bengal [1996] 4 SCC 37 (Indian Supreme Court) 
834 ibid 4, 9 
835 Jackman (n 816) 27 
836 General Comment No. 14 (n 112) 30 
837 Thomas and Flood (n 816) 59; Gross (n 818) 140; Porter (n 816) 10-11 
 171 
 
decision-making complies with Canada's constitutional or international human rights 
obligations is a major deficiency in the State’s approach to accountability.838  However, 
given the current approach of the courts in applying the state’s Charter to health care, 
such claims might see little chance of success.839 This highlights the importance of 
embedding rights at national level, to ensure that there is alignment with the obligations 
and responsibilities that the State has committed to at international level. This would also 
provide a means for individuals to hold the State to account in the national courts where 
their rights have been infringed. 
 
(b) Canada’s Access to Medicines Regime 
 
Canada was one of the first countries840 to amend its patent law following the 
Implementation Decision relating to paragraph 6 of the Doha Declaration, resulting in 
Canada’s Access to Medicines Regime (CAMR)841. The Government of Canada passed 
An Act to amend the Patent Act and the Food and Drugs Act (The Jean Chrétien Pledge 
to Africa)842, in May 2004. The Act, along with a supporting set of regulations, established 
the legal framework for Canada's Access to Medicines Regime, which aimed to make it 
easier to provide essential medicines to developing states.  This legal provision was only 
relied upon once, when a batch of generic antiretroviral medicines was exported to 
Rwanda in 2008.  The introduction of this legislation in Canada is an illustration of how 
the State has taken measures to implement the Doha Declaration and its interpretation of 
the provisions in TRIPS for the promotion of access to medicines.  Therefore it could be 
viewed that the State was trying to uphold its obligations under the international trade 
rules and its UN human rights obligations under the ICESCR, including its extraterritorial 
obligations, and it is important to see a developed State taking this action for the purpose 
of improving access to medicines in developing States. However, the fact that this 
provision has only be used once shows that it is not achieving its intended objectives.  
                                                            
838 M Jackman, 'The Future of Health Care Accountability: A Human Rights Approach' (2016) 47 Ottawa L 
Rev 441, 455 
839 Flood and Chen (n 823) 482-483, 494 
840 As of July 2015, 51 WTO Members had adopted specific implementation provisions into national law 
at varying levels of detail. See Kampf, (n 316) 6 
841 J Cohen-Kohler, L Esmail and A Perez Cosio, ‘Canada’s Implementation of the Paragraph 6 Decision: is 
it Sustainable Public Policy?’ (2007) 3 Globalization and Health 12, 1 
842 An Act to amend the Patent Act and the Food and Drugs Act (The Jean Chrétien Pledge to Africa) (S.C. 
2004, c. 23) <http://laws-lois.justice.gc.ca/eng/AnnualStatutes/2004_23/page-1.html> (accessed 
27/04/2020)  
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Criticisms of CAMR include the limited list of pharmaceutical products that were subject 
to compulsory licensing for export843, the limit of two years on the term of the compulsory 
licence844, and additional conditions imposed on non-WTO Member developing countries 
that wish to be added to the schedule of eligible importing countries.845  It is important to 
analyse the criticisms of CAMR to evaluate whether the regime could work more 
effectively to enhance access to medicines. 
 
(i) Limited list of pharmaceutical products 
 
During the parliamentary debate on the Bill, it was stated that the decision to include the 
limited list “represents a compromise solution between those who wanted a narrow list of 
eligible medicines and those who wanted no list at all”846. It was also stated that the list’s 
utility was as a “tool to expedite the process of acquiring a compulsory licence for those 
products that have been found to be safe, effective and of high quality”.847  This outlines 
that the list was meant to be for guidance and was intended to be flexible, so that other 
medicines could be subject to a compulsory licence once they had satisfied safety and 
quality standards.  However, during the debate, it was argued that the list should not be 
expanded to include two more medicines, for reasons including that they did not appear 
on the WHO list of essential medicines848.  Therefore the list could potentially have a 
limiting effect on the scope of the Act, as the reference to the WHO list may narrow the 
possibility of new medicines being added to the CAMR list if they do not appear on the 
WHO list.   
Since the enactment of this legislation, two more medicines have been added to 
the list, although this process was fairly lengthy, taking up to seven months rather than a 
matter of days as anticipated during the parliamentary debate.849  Therefore although it is 
                                                            
843 R Elliott, ‘Pledges and pitfalls: Canada’s legislation on compulsory licensing of pharmaceuticals for 
export’ (2006) 1 Int J Intellectual Property Management 94, 100 
844 ibid 107 
845 P Goodwin, ‘Right Idea, Wrong Result – Canada’s Access to Medicines Regime’ (2008) 34 American 
Journal of Law & Medicine 567, 581 
846 HC Deb 28 April 2004, vol 139, col 1705, Hon. Joe Fontana (Parliamentary Secretary to the Prime 
Minister (Science and Small Business), Lib.), (CAN) 
847 HC Deb 28 April 2004, vol 139, col 1705, Hon. Joe Fontana (Parliamentary Secretary to the Prime 
Minister (Science and Small Business), Lib.), (CAN) 
848HC Deb 28 April 2004, vol 139, col 1715, Hon. Larry Bagnell (Parliamentary Secretary to the Minister 
of Indian Affairs and Northern Development, Lib.), (CAN) 
849 Goodwin (n 845) 579 
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possible to update the list to include medicines to meet the specific needs of developing 
countries that wish to acquire a compulsory licence under this regime, it appears to be a 
protracted and inefficient process, which could deter developing countries from utilising 
this regime to acquire medicines that do not already appear on the list. Goodwin has 
argued that pressure from branded pharmaceutical companies was a factor in retaining 
such a list, because of their view that it would provide a way of ensuring that compulsory 
licences were not used for commercial purposes.850  However, this goes beyond what was 
agreed within the WTO, where there was no requirement for a list included under the 
paragraph 6 system851.  Therefore this may serve as an example to other developed States 
considering implementing a regime modelled on CAMR that their branded 
pharmaceutical industries may seek to influence the development of such a regime, 
asserting their IP rights in their medicines.  As it is the government’s responsibility to 
ensure that the State is meeting its international human rights commitments, it is 
important that governments do not prioritise the views of the branded pharmaceutical 
industry over other considerations when developing such a regime. 
 
(ii) Two-year limit on the term of the compulsory licence 
 
The reasoning for placing a two-year limit was so that the purchasers were not committed 
to a long-term contract for a particular medicine and should have the flexibility to take 
advantage of obtaining newer, more effective medicines852.  This suggests that such a 
limit was for the benefit of the developing States, to ensure that they were not committed 
to purchase a medicine from a specific manufacturer without the opportunity to make a 
more cost-effective agreement in the market.  However, Elliott argues that the limit has 
the effect of restricting the generic pharmaceutical manufacturers’ ability to compete in 
the market853, as the relatively short term of the licence may limit the ability of the 
manufacturers to recoup the initial costs of producing the generic medicine854.  Placing 
such a time limit may protect the parties involved from being committed to a long-term 
commitment which may not amount to an advantageous agreement. However, having a 
                                                            
850 ibid 580 
851 Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health (n 
287) 
852 Elliott (n 843) 107 
853 ibid 
854 ibid 
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limit of just two years may not provide generic manufacturers that obtain a compulsory 
licence with enough time to build a market or profile for their generic medicines before 
their licence expires.  If they decided to apply for another compulsory licence, going 
through the process would delay the ability of the generic producers to continue to sell 
their products.  There would also be a possibility that they were unsuccessful in obtaining 
another compulsory licence, which would mean that they could no longer take advantage 
of any market profile that they had previously built.   
The reasoning behind paragraph 6 is to find an efficient solution to the problem 
of access to available, affordable medicines in developing countries, particularly in 
emergency situations.855  The primary goal of CAMR is to promote access to medicines 
in developing countries.856  Therefore, this raises the question of whether there is a need 
for generic manufacturers to build a commercial market, and whether this is a relevant 
consideration where the compulsory licence is issued to address an emergency need for a 
specific medicine.  However, there does need to be an incentive for generic manufacturers 
to take part in the regime.  The lack of commercial incentives for generic manufacturers 
has been identified as an issue with CAMR, as it is difficult for the generic manufacturer 
to recoup the investment for producing the generic version of the medicine where it is 
produced for one country for a limited period.857  Therefore, to make CAMR more 
functional, the commercial motivations of generic manufacturers need to be taken into 
account in order to encourage them to engage in the regime. This echoes the 
recommendation of the UN Secretary-General’s High-Level Panel on Access to 
Medicines, to find a solution to make the objective of paragraph 6 more achievable in 
practice.858 
 
(iii) Additional conditions on non-WTO Members 
 
The additional conditions on non-WTO Members include a declaration of the adoption 
of measures to prevent diversion of the products to unintended markets and the 
                                                            
855 M Abbas and S Riaz ‘WTO “Paragraph 6” system for affordable access to medicines: Relief or 
regulatory ritualism?’ (2018) 21 J World Intellect Prop 32, 45 
856 Houston and Beall (n 712) 242 
857 Abbas and Riaz (n 855) 41; H Mathur ‘Compulsory licensing under section 92A: Issues and concerns’ 
(2008) 13(5) Journal of Intellectual Property Rights 464, 467; Cohen-Kohler, Esmail and Perez Cosio, (n 
841) 3-4; Houston and Beall (n 712) 242-243 
858 United Nations Secretary-General’s High-Level Panel on Access to Medicines, final report (n 72) 9 
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requirement that the pharmaceutical products under the compulsory licence are not used 
for commercial purposes859.  The schedules of countries eligible to import medicines 
under CAMR are organised according to level of development and WTO membership, 
with non-WTO members able to be added upon request and subject to satisfaction of these 
additional conditions.860  The Canadian government’s review of CAMR noted that the 
branded pharmaceutical industry supported such specifications with the view that this 
would ensure that medicines were only exported to countries with genuine public health 
needs861.  However, Elliott argues that these conditions were included with the aim of 
restricting potential competition for such medicines being generated within the importing 
country’s market862. Such competition could contribute to reducing prices and improving 
access in that country, and therefore the conditions appear contrary to the spirit and 
purpose of the legislation.  Elliott also highlights that such conditions may also be difficult 
to satisfy for non-WTO members without comprehensive public healthcare schemes and 
where medicines are predominantly accessed through private pharmacies863, and so could 
limit the number of non-WTO States that can satisfy the eligibility conditions under 
CAMR.  Therefore it appears difficult to justify why non-WTO members should be 
subject to conditions that WTO Members do not have to satisfy, particularly as this 
distinction is not a requirement of the WTO.   
 
(iv) Proposals for reform 
 
Given the criticism of CAMR, and the fact that the regime has not been utilised since 
2008, it is pertinent to explore whether the State is considering reform of the regime, to 
address the challenges in using the regime to enhance access to medicines for developing 
countries. In 2009 a Bill864 was presented in the House of Commons proposing several 
                                                            
859 Goodwin (n 845) 581 
860 Government of Canada, Report on the Statutory Review of Sections 21.01 to 21.19 of the Patent Act, 
(Industry Canada, Ottawa 2007), ISBN 978-0-662-05338-5, 7-8 
<http://publications.gc.ca/site/eng/322851/publication.html> (accessed 27/04/2020) 
861 ibid 8 
862 Elliott (n 843) 105 
863 ibid 105-106 
864 Parliament of Canada, House of Commons, Bill C-393, An Act to amend the Patent Act (drugs for 
international humanitarian purposes) and to make a consequential amendment to another Act, 40th 
Parliament, 3rd Session (March 3, 2010 - March 26, 2011) 
<http://www.parl.ca/DocumentViewer/en/40-2/bill/C-393/first-reading/page-24> (accessed 
27/04/2020) 
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amendments to CAMR. However the Bill did not pass a second reading in the Senate865, 
with the dissolution of the government following a no confidence vote in March 2011866, 
and the Bill was not proceeded with by the new government867. As at March 2020, there 
has been no further action taken by the government to make CAMR more workable.  
Kohler et al argue that legislative reform of CAMR is needed, and for it to be a workable 
provision it needs to be combined with other initiatives.868  Tsai also argues that greater 
incentives for generic pharmaceutical manufacturers should be introduced869.  The 
objective of this legislation was to enhance effective access to medicines for developing 
states in Africa870, so the purpose was not primarily to ensure that generic manufacturers 
derive a profit as a result of their participation.  However, in realistic terms if there is little 
incentive in participating then it could be difficult to attract the interest of pharmaceutical 
companies in participating in the scheme. Esmail and Kohler also argue that further input 
from the developing countries may lead to improved policies to achieve affordable access 
to medicines871.  This view conveys that for such a scheme to work there needs to be a 
multilateral approach to ensure that the needs of all stakeholders are considered, so that 
there is a less unbalanced outcome.  
While the Canadian government has expressed its commitment to engaging in 
initiatives to enhance the provision of medicines to developing countries, particularly 
through monetary donations to NGOs872, there appears to be little evidence from the 
government that the above proposals would gain sufficient support to ensure their 
adoption.  Therefore, it is difficult to assess whether such proposals would be workable 
                                                            
865 Parliament of Canada, ‘LegisInfo’, ‘Bill C-393, An Act to amend the Patent Act (drugs for international 
humanitarian purposes) and to make a consequential amendment to another Act’, ‘Status of the Bill’, 
<http://www.parl.ca/LegisInfo/BillDetails.aspx?Bill=C393&Language=E&Mode=1&Parl=40&Ses=3> 
(accessed 27/04/2020)  
866 BBC News, US and Canada, ‘Canadian government falls after no-confidence vote’, 25 March 2011, 
<http://www.bbc.co.uk/news/world-us-canada-12865339> (accessed 27/04/2020)  
867 Parliament of Canada, ‘LegisInfo’, ‘Senate Public Bill’, ‘S-208, An Act to amend the Patent Act and the 
Food and Drugs Act (drugs for international humanitarian purposes)’, 41st Parliament, 1st Session (2 
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(2010) 5(3) Healthcare Policy 40, 46 
869 G Tsai, ‘Canada's Access to Medicines Regime: Lessons for Compulsory Licensing Schemes under the 
WTO Doha Declaration’(2009) 49 Virginia Journal of International Law 1063, 1081-1083 
870 ibid 1089 
871 L Esmail and J Kohler, ‘The politics behind the implementation of the WTO Paragraph 6 Decision in 
Canada to increase global drug access’ (2012) 8(7) Globalization and Health, 11-12 
872 Government of Canada, Report on the Statutory Review of Sections 21.01 to 21.19 of the Patent Act 
(n 860) 39 
 177 
 
for other states considering implementing a similar model.  Also, the State may need to 
be reminded of its obligations with regard to the right to health under Article 12 ICESCR, 
to ensure that achieving effective access to medicines for all is prioritised.   
 
(c) Patent Law 
 
The constitutional landscape has been discussed above to consider how the State is 
interpreting and implementing its human rights obligations into national law in relation 
to access to medicines. Canada has provided for pharmaceutical patents in its national 
law since 1993873. S.79 of Canada’s Patent Act 1985874 covers patented medicines and 
although there were few major impacts on the Act resulting from the implementation of 
TRIPS, there were two significant challenges to the Canadian patent legislation under the 
WTO dispute resolution mechanism, which are discussed in Chapter 2 of this thesis.  The 
term of patent protection was challenged in Canada - Term of Patent Protection875 which 
resulted in an extension of the term from seventeen to twenty years, contrary to the views 
of the Canadian generic pharmaceutical industry.  The provisions relating to stockpiling 
and the regulatory review exceptions were challenged with partial success in Canada – 
Patent Protection for Pharmaceutical Products876, the outcome being the stockpiling of 
generic medicines in anticipation of the expiration of the patent was not consistent with 
Article 30 of TRIPS and the provision was repealed from the Patent Act. The outcomes 
of both cases can be seen to most significantly impact upon the State’s generic 
pharmaceutical industry.  In both cases the effects of the decisions were to extend the 
period of time for which generic manufacturers had to wait to legally enter generic 
medicines into the market, compared to the legal position prior to the implementation of 
TRIPS in Canada.   
Two recent cases presented significant challenges to the State’s patent law and to 
enhancing access to medicines; Eli Lilly and Company v. Government of Canada877 and 
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AstraZeneca Canada Inc v. Apotex Inc878.  Given their importance to access to medicines 
in Canada, these decisions will be analysed to evaluate the impact on access to medicines, 
and to consider whether the State is responding to potential tensions between patent law 
protection and the right to health arising from the cases. 
 
(i) Eli Lilly and Company v. Government of Canada 
 
The case of Eli Lilly and Company v. Government of Canada879 has been described as a 
case of “immense importance”880 in relation to pharmaceutical patents.  The claimant 
sought to challenge the ‘promise’ doctrine, a Canadian law doctrine applied by Canadian 
courts when deciding upon usefulness in determining patentability881 under Section 2 of 
the Patent Act 1985. The ‘promise’ doctrine was advantageous for generic pharmaceutical 
companies as they could apply to the court for the annulment of a patent granted to another 
pharmaceutical company, if the evidence of the patented medicine’s utility did not fulfil 
its promise in the patent application.  The claimant argued that the interpretation and 
application of the utility criteria under Canada’s Patent Act by the Canadian courts, 
through the ‘promise’ doctrine, was a violation of Canada’s obligations under NAFTA882.  
The claimant asserted that the ‘promise’ doctrine contravenes Canada’s intellectual 
property obligations in Chapter Seventeen of NAFTA, because the ‘promise’ doctrine 
imposed a significantly higher burden on the patentee than the standard of utility required 
by NAFTA.883  It was argued that the revocation of the patents was in breach of Canada’s 
Chapter Eleven obligations under NAFTA to protect investors of other State parties to 
NAFTA from expropriation of their investments under Article 1110 and to guarantee their 
fair and equal treatment under Article 1105.  Therefore, it was argued that Canada had 
failed to protect the claimant’s intellectual property rights and had failed to protect the 
company’s investment. 
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This case provides an example of the wider criticism of investor-state dispute 
resolution.884  The reliance on Chapter Eleven of NAFTA by the investor claimant is 
significant because such an outcome would indicate that the State has an obligation to 
protect the patents of private pharmaceutical companies as an investment where they are 
unsuccessful in arguing they have the right to protection of their intellectual property by 
the State.  The claim was ultimately unsuccessful, with the tribunal finding that the 
invalidation of the Zyprexa and Strattera patents through application of the ‘promise’ 
doctrine did not violate the claimant’s legitimate expectations under Article 1110 or 1105.  
The tribunal determined that the claimant was not able to demonstrate that the ‘promise’ 
doctrine was a radical departure from the traditional utility doctrine applied by the other 
States parties to NAFTA885.  However the case is an example of an intellectual property 
dispute being heard within the investor-state dispute settlement mechanism in NAFTA, 
indicating that pharmaceutical companies may seek to rely on the terms of a free trade 
agreement to try to achieve a more favourable outcome in terms of protecting their IP 
rights in their products than they may obtain in a national court.  
This case also provides an example of the impact that FTAs can have on national 
measures to improve access to medicines.  Although the claim was unsuccessful, this case 
highlights that the Canadian courts had developed the ‘promise’ doctrine to ensure that a 
pharmaceutical patent could not be enforced unless the product matched the description 
contained in the patent application.  However, the patent holding pharmaceutical 
company concerned attempted to circumvent this legal doctrine under the terms of 
NAFTA for the purpose of extending the patent to a product that the patent was not 
originally issued to cover. This highlights that holding pharmaceutical companies to 
account for failing to respect measures to promote access to medicines may present a 
challenge for states, which is a key theme emanating from previous chapters. 
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Against ISDS Abuses and Protect Host-State Sovereignty’ (2017) 26 MINN. J. INTL. L. 273, 302; S Puig and 
G Shaffer ‘Imperfect Alternatives: Institutional Choice and the Reform of Investment Law’ (2018) 112 
AM. J. INT'L L. 361, 408  
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(ii) AstraZeneca Canada Inc v. Apotex Inc 
 
Following the decision in the Eli Lilly and Company v. Government of Canada886, which 
found that the medicines in question did not satisfy the utility requirement under Section 
2 of the Patent Act 1985, the decision by the Canada Supreme Court in AstraZeneca 
Canada Inc v. Apotex Inc887 may be of concern to Canadian generic manufacturers.  While 
the former claim concerned Canadian legislation but was heard by an ICSID arbitral 
tribunal, the latter case concerned similar issues over the ‘promise’ doctrine as in the Eli 
Lilly claim, but was heard by the Canada Supreme Court.  Therefore, AstraZeneca 
Canada Inc v. Apotex Inc is a case which concerned the application and interpretation of 
this Canadian legal norm by the Canadian courts. The decision of the Canada Supreme 
Court in this case is particularly significant for both branded and generic pharmaceutical 
companies because it offers an authoritative interpretation of this doctrine, which may 
have implications in relation to the validity of several pharmaceutical patents granted in 
Canada.   
The Federal Court held that AstraZeneca’s patent on the medicine Esomeprazole 
was invalid under the ‘promise’ doctrine, as the utility requirement for an “invention” 
under Section 2 of Canada’s Patent Act was not met, because the patent only fulfilled one 
of the two promises of utility that were made to obtain the patent.888  However, the 
Supreme Court overturned this decision on the basis that the ‘promise’ doctrine was not 
the correct method of determining whether the utility requirement under Section 2 of the 
Patent Act 1985 had been satisfied889.  It was stated that the doctrine was an interpretation 
of the utility requirement that was incompatible with the Patent Act because the doctrine 
determines the standard of utility that is required by reference to the promises stated in 
the patent, and if there are several promises of utility, all promises have to be fulfilled for 
a patent to be valid.890  In delivering the judgement, Rowe J stated that this was 
“excessively onerous”891, and inconsistent with the wording of the Patent Act.892  It was 
held that where there are multiple promises of utility, they should not all need to be 
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fulfilled, as Section 2 requires a ‘useful’ subject-matter and “a single use makes a subject-
matter useful”893.  The Act did not specify the degree of usefulness required so “a scintilla 
of utility will do”894.  This amounts to a high level of IP protection, which could reduce 
the latitude for generic versions of medicines. 
This decision is worrying as Canada has so recently been successful in the 
investor-state dispute resolution arbitration in the Eli Lilly895 case on similar arguments 
to this case.  The ‘promise’ doctrine developed by the Canadian courts sought to prevent 
the extension of patent protection, by ensuring that the patented product matches the 
utility promised in the patent application under the criteria for patentability under Section 
2 of the Patent Act 1985.  However, this decision could lead to the widening of the scope 
of patents to products with little utility.  It may now be more difficult for the validity of a 
pharmaceutical patent to be challenged following this decision and it may also be argued 
that this approach differs from the purpose of the patent legislation, which is to protect 
inventions that are new and useful.  The decision could also have a detrimental impact on 
access to more affordable generic medicines in the State. 
This case an example of the tension that can exist between IP and access to 
medicines at national level. The decision indicates that the Canadian judicial authorities 
are prioritising the interests of patent holders over the rights of the population to have 
access to medicines under Article 12 ICESCR.896 It is important to note that the Canadian 
Supreme Court did not give any consideration to the rights of Canadian citizens in relation 
to access to medicines as part of their Article 12 ICESCR right to health.  This decision 
strengthens the position of patent holding pharmaceutical companies, and the 
interventions in the case by numerous intellectual property organisations show the 
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pressure that the courts were under to reach this decision897. It is also concerning to note 
this decision since it was made after the publication of the final report of the UN 
Secretary-General’s High-Level Panel on Access to Medicines, which recommended that 
governments should only award patents when “genuine innovation” has occurred898.   
 
(d) Conclusions from Section I 
 
The review of the State’s national and legislative framework has highlighted that the State 
has an appreciation of the tension which can arise between IP rights protection and access 
to medicines in developing countries, as it has taken legislative measures to implement 
the Doha Declaration. While this is commendable, CAMR has not provided an effective 
measure to enhance access to medicines, and there appears to be little appetite for reform 
to make the regime more workable.  The State could do more at national level to enhance 
access to medicines, as the recent AstraZeneca decision could lead to extension of patent 
protection for medicines and therefore a lack of affordable access to generics.  By taking 
full account of the right to health under Article 12 ICESCR and interpreting Charter rights 
in light of the ICESCR, the State may be able to address possible tensions more 
effectively in order to discharge their obligations under TRIPS and ICESCR.  
 
II. National healthcare provision and medicines 
 
In addition to examining the State’s legislative framework, health policy measures on 
enhancing access to medicines will also be examined.  The purpose of this review is to 
evaluate whether the State is effectively enhancing access to medicines in order to meet 
their obligations under TRIPS and the ICESCR, through government commitments at 
national level. 
 
(a) Healthcare provision across provinces within the State 
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Canada has a health care system funded by the federal government known as Medicare.  
However, instead of a single national plan within this system there are 13 provincial and 
territorial health care insurance plans, with the provincial governments being responsible 
for the delivery of health care services for their citizens899.  These plans are funded by the 
federal government and cover basic services, but citizens who require prescription 
medicines would have to obtain private health insurance to cover these costs, or pay for 
the medicines directly900.   This could lead to disparities in access to medicines across 
provinces as not every citizen may be able to purchase private health insurance to cover 
their prescription medicines needs, or bear the costs themselves and therefore the 
medicines they require may be unobtainable. As the provincial governments are 
responsible for purchasing medicines, they have a key role in enhancing access to 
medicines within their province. The provincial governments have taken steps to address 
potential disparities in access to medicines across provinces through collaborative efforts 
to achieve greater value for pharmaceuticals for publicly funded medicine programmes 
through the pan-Canadian Pharmaceutical Alliance (pCPA).901   
The pCPA aims to increase access to medicines, achieve lower pricing, and 
improve consistency of coverage across provinces by utilising the collective negotiating 
power across the provinces.902   The pCPA has reported that, as of April 2018, these 
collaborative efforts have resulted in over two hundred completed joint negotiations on 
brand name medicines and price reductions on over sixty generic medicines.903  This 
suggests that the pCPA has had a notable impact on attaining more cost effective 
medicines for public medicines plans, which may help to make more generic as well as 
branded medicines accessible for patients. Milliken et al argue that the work of the pCPA 
has not yet made a significant impact on the overall proportion of new medicines listed 
across provinces, although it was noted that only a relatively low number of medicines 
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had been the subject of the pCPA negotiation process.904  This view explains that while 
the pCPA’s work to reduce the cost of medicines may mean that those medicines are more 
accessible, there has not yet been a notable improvement in the availability of new 
medicines to patients across the State, and therefore accessibility to new medicines has 
not been enhanced.  The federal drug plans are participating in the pCPA, and the support 
of the federal government for the pCPA may illustrate that it can have a meaningful 
impact on enhancing access to new and existing branded and generic medicines across 
the State. However, following a visit to Canada in 2018, the Special Rapporteur on health 
stated that the efforts of the pCPA remain insufficient to benefit uninsured persons or 
those who are privately insured.905 
The introduction of a national medicines benefit programme could potentially be 
beneficial to ensure all Canadians are afforded the same level of access to medicines. This 
may be a more equitable system, because this implies that such a strategy would provide 
more reliable supplies of essential medicines which would be available across the whole 
State, and therefore discrepancies in availability between provinces may be minimised. 
The funding of provincial health insurance plans by the federal government and the 
outcomes of these plans in terms of lack of coverage for prescription medicines also 
highlights that to enhance access to medicines there needs to be effective implementation 
of measures to enhance access as well as available funding to invest in improvements to 
health care.  However the work of the pCPA, including collective negotiating resulting in 
savings in medicines costs and aims to continue developing the alliance, provides 
evidence of the utility of cross-province strategies for enhancing access to medicines. In 
2019, the Advisory Council on the Implementation of National Pharmacare 
recommended that the Canadian government implement a national pharmacare 
programme and outlined a plan to implement this between 2019 and 2027.906 This is an 
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important step, although it highlights that the political will of the government is crucial 
to the implementation of the plan.  This is an important factor for consideration for other 
states in relation to making provision for national medicines programmes.  It will be 
interesting to note the actions of the Canadian government in relation to the proposals of 
the Advisory Council, and whether the plan is adopted in the State.  
 
(b) National Pharmaceuticals Strategy 
 
The National Pharmaceuticals Strategy was designed to improve access to affordable 
medicines including by improving access to new medicines, enhancing cost-effectiveness 
in purchasing medicines, and achieving consistency over pricing for generic medicines907.  
Key elements of the Strategy included ensuring increased access to generic medicines at 
prices which were consistent with other states, improved purchasing strategies and 
enhanced access to new medicines for neglected diseases and unmet health needs908.  The 
implementation of this Strategy as part of the wider scheme to improve health equality 
could suggest that the federal government recognised that the issue of providing effective 
access to medicines for all Canadians was an important element of the wider issue of 
improving health, as reflected in Article 12 ICESCR.  However, the recognition of the 
State obligations with regard to the right to health including medicines is not explicitly 
stated. This lack of vertical and horizontal policy coherence is a key concern which has 
been highlighted by John Ruggie in several of his reports to the UN on the human rights 
harm that can be caused by business and the State’s duty to protect all human rights from 
corporate-related human rights abuses.909 
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In 2009 the Health Council of Canada conducted a review of the National 
Pharmaceuticals Strategy.910 The review highlighted that there is a need for a consistent 
approach among the provinces and territories in implementing the Strategy so that it is a 
more effective device for enhancing access to medicines nationally.  The review noted 
that some provinces had made advances in implementing parts of the Strategy.  For 
example, provinces such as Ontario and Newfoundland made legislative changes to 
amend their approach to purchasing medicines, and British Columbia and Alberta 
explored the option of purchasing medicines together911. The report concluded that 
although some of the individual provinces and territories had taken steps to implement 
some of the key objectives, there was also a need for collective measures to ensure that 
Canadian citizens benefited from the Strategy912.   
A review of the federal government’s 10-Year Plan to Strengthen Health Care913 
was published in 2012 by the Standing Senate Committee on Social Affairs, Science and 
Technology914, which included a review of the National Pharmaceuticals Strategy.  This 
review illustrated that although the National Pharmaceuticals Strategy set out key 
objectives to be met in order to improve access to medicines for Canadians, advancing 
the Strategy has been problematic due to disparities in implementing the objectives across 
the provinces. The review observed that the progress of the Strategy had been mixed, with 
inequities in the provision of medicines still existing across the State and the cost of new 
specialised medicines was also problematic915.  The review also noted that although some 
provincial jurisdictions had made progress in pursuing generic medicine pricing and 
purchasing strategies which were leading to some savings, there was still a funding gap 
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with regard to the cost of pharmacy services to provide the medicines to the population916. 
The review recommended that the federal, provincial and territorial governments work 
together to develop a national programme to ensure access to medicines for all, including 
price controls and frameworks to ensure improved quality of medicines, and working with 
private health insurance companies on strategies regulating costs917.  This also 
demonstrates that a comprehensive collective national strategy could be more effective in 
achieving these goals.  Calls for a pan-Canadian strategy have been made by stakeholders 
including the Canadian Medical Association918.  This suggests that there is national 
support for such a scheme from the medical profession, although it appears that such a 
strategy would need to be implemented and regulated by the federal government in order 
to seek to achieve the desired improvements in attaining affordable medicines.   
The outcome of this review highlights findings which accord with the key 
concerns relating to access to medicines emanating from the UN human rights bodies, 
discussed in Chapter 3 of this thesis.  The finding that deficiencies in funding for 
pharmacy services suggested a lack of physical accessibility to these medicines 
emphasises the linkage between affordability and accessibility of medicines, and the 
importance of ensuring that affordable medicines can be readily obtained by patients.  It 
also highlights that it is important to ensure that funding is allocated appropriately to 
support the facilitation of supply of medicines to patients.  The findings of the review also 
highlighted that where cross-provincial alliances are formed, the utility of such alliances 
may be enhanced by advancing an effective, overarching strategy to incorporate 
facilitating the supply of medicines to citizens in addition to the acquisition of medicines 
at more affordable cost. 
 
(c) Indigenous Peoples 
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A key theme emerging from the measures taken in Canada to enhance effective access to 
medicines is ensuring that the specific health needs of the indigenous peoples are 
identified and addressed.  This is particularly significant as in addition to the reference to 
rights of indigenous peoples in UN human rights instruments such as the ICESCR, the 
United Nations Declaration on the Rights of Indigenous Peoples (UNDRIP)919 was 
adopted by the UN General Assembly in 2007920 for the purpose of protecting the 
individual and collective rights of indigenous peoples.  In 2010 Canada endorsed the 
principles in the UNDRIP and in May 2016 confirmed full support of the UNDRIP921.  
Specific issues relate to access to prescription medicines, and secondly that intellectual 
property law may be utilised to appropriate traditional medicines and materials, and 
indigenous peoples may require legal measures in order to protect their culture and 
resources. 
 
(i) Access to prescription medicines  
 
Health concerns regarding indigenous peoples in Canada were noted during the first visit 
of the Special Rapporteur on the rights of indigenous peoples in 2004922, with rates of 
HIV/AIDS, diabetes and tuberculosis considerably higher than among other 
Canadians923.  One of the recommendations of the Special Rapporteur was that the 
Canadian Government should intensify measures to close the gap between aboriginal and 
                                                            
919 UNGA Res 61/295 ‘United Nations Declaration on the Rights of Indigenous Peoples’ (2 October 2007) 
UN Doc A/RES/61/295  
920  UNGA Res 61/295 (2 October 2007) UN Doc A/RES/61/295 was adopted by the UN General Assembly 
without reference to a Main Committee. See UNHRC ‘United Nations Declaration on the Rights of 
Indigenous Peoples’ (12 September 2007) UN Doc A/61/L.67 and Add.1 
921 Government of Canada, ‘United Nations Declaration on the Rights of Indigenous Peoples’  
<http://www.aadnc-aandc.gc.ca/eng/1309374407406/1309374458958> (accessed 27/04/2020); B 
Gunn, 'Overcoming Obstacles to Implementing the UN Declaration on the Rights of Indigenous Peoples 
in Canada' (2013) 31 Windsor YB Access Just 147, 173-174 
922 As part of the thematic Special Procedures, a Special Rapporteur on the rights of indigenous peoples 
was first appointed in 2001 by the Commission on Human Rights.  The mandate of the Special 
Rapporteur includes the examining of ways to overcome existing obstacles to the full and effective 
protection of the rights of indigenous peoples, and to formulate recommendations and proposals on 
appropriate measures to prevent and remedy violations of the rights of indigenous peoples.  See also 
UNCHR ‘Indigenous Issues, Human rights and indigenous issues, Report of the Special Rapporteur on the 
situation of human rights and fundamental freedoms of indigenous people, Rodolfo Stavenhagen; 
Addendum: Mission to Canada’ (2 December 2004) UN Doc E/CN.4/2005/88/Add.3 
923 ibid 40 
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non-aboriginal peoples in relation to health care provision924. Several initiatives have 
been introduced and supported by the Canadian government for the purpose of improving 
the health of indigenous peoples.  These measures and initiatives demonstrate that the 
Canadian government appreciates that the disparities between access to appropriate health 
care services between indigenous and non-indigenous peoples in Canada needs to be 
addressed.  However, while there are some examples of enhanced relationships leading 
to improved understanding of the specific needs of indigenous peoples, there appears to 
be little evidence of significant improvement in the availability of medicines to treat 
diseases which need the most urgent attention in these communities.   
Health Canada925, the federal department for health in Canada, oversees a health 
programme for indigenous peoples, the First Nations and Inuit peoples, which provides 
access to prescription medicines as well as policies to transfer to the indigenous peoples 
greater administrative responsibilities over their health care programmes926.  Health 
Canada has provided eligible indigenous groups with supplementary health benefits for 
particular services such as prescription medicines that would not otherwise be available 
to them927.  However an evaluation of the health planning activities for indigenous 
peoples undertaken by Health Canada928 in 2016 highlighted that there were still problems 
including limited resources to address immediate need and a lack of qualified 
professionals providing pharmacy care929. This suggests that the federal government was 
engaging with the recommendations of the Special Rapporteur to bridge the gap in non-
indigenous health care provision between indigenous and non-indigenous peoples, but 
that there may still be limitations on the accessibility of resources including essential 
medicines.  Therefore the benefits of the strategic plan could be restricted due to resource 
                                                            
924 ibid 101 
925 Government of Canada, ‘Health Canada – a partner in health for all Canadians’ 
<https://www.canada.ca/en/health-canada/corporate/about-health-canada/activities-
responsibilities/partner-health-canadians.html> (accessed 27/04/2020) 
926 Health Canada, First Nations and Inuit Health Strategic Plan: A shared path to improved health, 
(Minister of Health, Health Canada, Ottawa, 2012) ISBN: 978-1-100-21186-2, 11-18, 
<http://publications.gc.ca/collections/collection_2013/sc-hc/H34-258-2012-eng.pdf>  (accessed 
27/04/2020) 
927 ibid 11-18, 7 
928 Health Canada and the Public Health Agency of Canada, Office of Audit and Evaluation, ‘Evaluation of 
the First Nations and Inuit Health Branch’s Health Planning and Quality Management Activities 2010-
2011 to 2014-2015’, 26 September 2016, <https://www.canada.ca/content/dam/hc-
sc/documents/corporate/transparency/corporate-management-reporting/evaluation/2010-2011-2014-
2015-first-nations-inuit-health-planning-quality-management-activities/hpqm-psgq-eng.pdf> (accessed 
27/04/2020)  
929 ibid P.28 
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constraints and an evaluation of the reasons for this may help to inform the objectives and 
implementation of the strategy.  The lack of expertise in pharmacies may also be 
detrimental to enhancing understanding of the benefits that prescription medicines can 
offer to indigenous peoples, which could in effect limit access to effective medicines for 
these peoples. 
There is evidence of the introduction of measures to facilitate the participation of 
indigenous peoples in the province of British Columbia, where the British Columbia 
Tripartite Framework Agreement on First Nation Health Governance930 was introduced 
in 2011 with the purpose of ensuring that indigenous peoples in the province could fully 
participate in decision-making and delivery of health services and programmes931.  In 
October 2013, as part of this framework agreement Health Canada transferred its 
responsibilities regarding health services delivery to the First Nations Health Authority 
(FNHA), the first pan-province health authority for indigenous peoples in Canada932.  The 
FNHA provides a health benefits programme which funds approved medicines for 
eligible indigenous peoples933.  The implementation of the FNHA demonstrates that the 
importance of engagement with the indigenous peoples is a key factor in improving health 
care for indigenous peoples, as well as the importance of inter-government collaboration 
in order to facilitate a framework for the purpose of achieving this aim.  This framework 
is still developing934 but if there is clear evidence that it has enhanced access to medicines 
then the framework could offer an example for other provinces to follow to improve 
access to medicines for their indigenous peoples.  This also highlights that disparities 
exist in relation to the health services available to indigenous peoples as well as non-
indigenous peoples across the provinces. 
 
(ii) Traditional resources and medicinal knowledge 
 
                                                            
930 British Columbia Tripartite Framework Agreement on First Nation Health Governance, 13 October 
2011, <https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fniah-
spnia/alt_formats/pdf/pubs/services/tripartite/framework-accord-cadre-eng.pdf> (accessed 
27/04/2020) 
931 ibid Section 2.1 
932 First Nations Health Authority, ‘About the FNHA’, <http://www.fnha.ca/about/fnha-overview> 
(accessed 27/04/2020)  
933 First Nations Health Authority, ‘Pharmacy’, <http://www.fnha.ca/benefits/pharmacy> (accessed 
27/04/2020) 
934 First Nations Health Authority, Annual Report 2018-2019, <https://www.fnha.ca/Documents/FNHA-
Annual-Report-2018-2019.pdf> (accessed 27/04/2020) 
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Intellectual property rules can be used to further human rights goals for indigenous 
peoples, in relation to protecting their traditional knowledge.  This particular human rights 
objective is to further their right to self-determination935, to freely pursue their economic, 
social and cultural development, which comprises having control over their indigenous 
natural resources, such as traditional medicines and medicinal resources.  Therefore it is 
pertinent to examine how the State is utilising intellectual property rules to further this 
human rights objective for the benefit of its indigenous population and to satisfy its 
obligations with regard to upholding the right to self-determination of its indigenous 
peoples.  It is also pertinent to identify any issues experienced within the State when 
trying to achieve these objectives, which could be informative to other states which also 
have indigenous populations.  The recognition of the rights of indigenous peoples in 
relation to their traditional medicines is evident in Article 12 ICESCR, with General 
Comment 14 providing guidance to states with indigenous peoples to implement the 
provisions under Article 12 ICESCR936.  The ICESCR also recognises the rights of 
indigenous peoples with regard to their traditional knowledge and resources, such as 
medicinal resources, under Article 15.937  Therefore government and health services need 
to ensure that indigenous peoples have access to non-traditional medicines as well as 
supporting the use of traditional medicines as part of the State’s obligations under the 
ICESCR.   
  The CESCR’s concluding observations for Canada published in 2006 addressed 
concerns over the protection of indigenous culture including traditional knowledge938, 
and recommended that Canada adopted a strategy in the area of intellectual property for 
the protection of traditional knowledge of its indigenous peoples939.  The recommendation 
has implications for the issue of access to medicines as it highlights that there may be 
                                                            
935 United Nations Declaration on the Rights of Indigenous Peoples (n 919) Article 3 
936 General Comment No. 14 (n 112) 27 
937 General Comment 21 provides that as part of the right of everyone to take part in cultural life under 
Article 15(1)(a), States parties must take measures to recognise the rights of indigenous peoples to 
develop and control their natural resources. General Comment 17 also provides that as part of the 
protection of the author’s moral and material interests under the Article 15(1)(c) right, States parties 
should adopt measures to ensure the effective protection of the interests of indigenous peoples relating 
to their productions, which are often derived from traditional knowledge.  See UNCESCR ‘General 
Comment No. 21: Right of everyone to take part in cultural life (art. 15, para. 1 (a), of the International 
Covenant on Economic, Social and Cultural Rights)’ (21 December 2009) UN Doc E/C.12/GC/21, 36; 
UNCESCR General Comment 17 (n 587) 32 
938 UNCESCR ‘Concluding observations of the Committee on Economic, Social and Cultural Rights: 
Canada’ (22 May 2006) UN Doc E/C.12/CAN/CO/4-E/C.12/CAN/CO/5 
939 ibid 67 
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issues within the State relating to the misappropriation of traditional knowledge including 
traditional medicines and resources.  Therefore, there could be a need for the State to 
introduce sustainable measures to ensure that these peoples do have access to their 
indigenous medicines, as part of their human right to health under Article 12 ICESCR.  
Gervais argues that IP law in Canada generally does not deal with customs and practices 
of indigenous peoples.940  This raises the question of whether the State should address 
this concern by introducing specific IP protection for traditional knowledge.941  The 
participation of the indigenous peoples in the development of health services to meet their 
specific needs could facilitate the inclusion of provisions to protect and enhance the use 
of traditional medicines by these peoples so that their cultural practices and traditions are 
preserved and upheld.942  This also illuminates how the human rights of indigenous 
peoples could serve as a catalyst for the expansion of the existing IP regime so that IP 
protection effectively protects the collective rights of indigenous peoples and that 
indigenous peoples can assert and enforce their legal rights against infringers. 
Although there does not appear to be a formal process in place to offer the 
indigenous peoples a forum to seek protection from the exploitation of their traditional 
knowledge and resources by private enterprises, the Canadian Network on Corporate 
Accountability943 may offer an example of such a process.  The Canadian Network on 
Corporate Accountability is a civil society organisation which advocates for regulations 
to ensure that Canadian extractive companies working abroad944 respect human rights, 
including the rights of indigenous peoples, and the withdrawal of government support for 
companies that are non-compliant945.  The Network also advocates that those who have 
had their rights infringed by a Canadian extractive company should have access to 
Canadian courts as well as access to a human rights Ombudsperson in order to seek a 
                                                            
940 D Gervais, 'Spiritual But Not Intellectual - The Protection of Sacred Intangible Traditional Knowledge' 
(2003) 11 Cardozo J Int'l & Comp L 467, 493 
941 S Kaur Verma, 'Protecting Traditional Knowledge: Is a Sui Generis System an Answer' (2004) 7 J World 
Intell Prop 765, 797, 803-5 
942 N Adelson ‘The Embodiment of Inequity: Health Disparities in Aboriginal Canada’ (2005) 96(2) Can J 
Public Health S45, S59 
943 Canadian Network on Corporate Accountability <http://cnca-rcrce.ca> (accessed 27/04/2020) 
944 This organisation does not advocate for the respect of human rights by Canadian extractive 
companies over ancestral lands of indigenous peoples in Canada. 
945 Canadian Network on Corporate Accountability, ‘What we do’ <http://cnca-rcrce.ca/about-us/what-
we-do/> (accessed 27/04/2020) 
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remedy946.  While this organisation specifically advocates in the extractive industry, some 
of the principles upheld by the organisation in relation to corporate social responsibility 
could be applied to the pharmaceutical industry, and the protection of traditional 
knowledge and resources from use without appropriate permission.  The proposals for a 
human rights Ombudsperson as well as regulations to ensure appropriate compensation 
may help to preserve the traditional knowledge and medicines of indigenous peoples, and 
provide a formal process for holding pharmaceutical companies accountable if they 
believe that their rights in relation to these resources have been infringed.947  It is 
important to note that these proposals remain as such, and therefore it is uncertain how 
successful such a regulatory system would be.  However, some of the principles could be 
transferable to the pharmaceutical industry and provide a formal process that the 
indigenous peoples could engage with and participate in, to secure their rights over the 
use of their traditional medicines.   
Concerns have also been raised by UN human rights bodies in relation to how 
TRIPS-plus provisions in FTAs can negatively affect the protection of indigenous 
peoples’ traditional medicines and resources.948  As a result the Special Rapporteur on the 
rights of indigenous peoples stated an intention to place a focus on several issues which 
could include access to culturally appropriate health care and traditional medicines as part 
of her investigations over a three year period to 2017949.  This is potentially a significant 
statement with regard to the protection of traditional medicines as it demonstrates a 
concentrated effort to ensure that indigenous peoples have control over, and therefore 
access to, their traditional medicines when States enter into such agreements, in a human 
rights context.  This could be particularly significant for Canada given the trend towards 
TRIPS-plus provisions under FTAs such as NAFTA.  This also suggests that the standards 
of IP protection under TRIPS may not be the most appropriate degree of protection to 
                                                            
946 Ibid. See also P Simons, 'Canada's Enhanced CSR Strategy: Human Rights Due Diligence and Access to 
Justice for Victims of Extraterritorial Corporate Human Rights Abuses' (2015) 56 Can Bus LJ 167, 177, 
191-192 
947 L Shipton ‘Canada’s Mining Industry in Guatemala and the Right to Health of Indigenous Peoples’, 
Health and Human Rights Journal; Perspectives, August 2017, 
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afford to traditional knowledge.950  International human rights law specifically in relation 
to indigenous peoples has the potential to act as a catalyst for impacting on the IP regime, 
although it does not appear that this has occurred in the State.  However the outcome of 
such focus following the end of the three year review period outlined by the Special 
Rapporteur has not been explicitly outlined.  This would be helpful as guidance for other 
states regarding their human rights responsibilities specifically to indigenous peoples and 
their health needs.  
 
(d) Conclusions from Section II 
 
The review of the State’s national commitments in relation to health provision show that 
some measures have been implemented to improve access to medicines nationally 
through addressing cost, such as the National Pharmaceuticals Strategy.  Challenges 
include meeting the specific needs of minority groups which may be more particularly 
affected by lack of access to medicines.  Addressing the challenges affecting indigenous 
peoples in relation to access to medicines and protecting traditional medicines could be 
made more prominent in government policy. Therefore, the national policies could go 
further to secure a collective, collaborative response to enhancing access to medicines at 
national level in line with the State’s international obligations.  
 
III. Regulating the pharmaceutical industry 
 
A key challenge for states in implementing health policies to enhance access to affordable 
medicines is the role of pharmaceutical companies in the research and development, and 
pricing of medicines. This section will analyse regulatory provisions implemented in 
Canada with regard to the cost and development of medicines, to evaluate how the State 
is responding to the impact of a private industry, which has a crucial role in producing 
medicines, on its obligations to enhance effective access to medicines while also 
appropriately protecting the IP rights of that industry in accordance with its obligations 
under TRIPS . The purpose of this review is to examine whether the State is effectively 
addressing possible tensions between protecting the IP rights of pharmaceutical 
                                                            
950 R Barsh, 'A Social Theory of Fair Trade, with Special Reference to Indigenous Peoples' (2002) 96 Am 
Soc'y Int'l L Proc 279, 280 
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companies and its human rights obligations in relation to enhancing access to medicines. 
There is a strong presence of both branded and generic pharmaceutical industries in 
Canada, and so the conflicting demands of these industries have to be balanced951.  This 
highlights some of the complexity of the issues facing States in discharging their 
obligations simultaneously under TRIPS and ICESCR.  The findings from this review 
could also inform understanding of the interaction between IP rights and the right to 
health at national level, and provide lessons to other states in effectively meeting their 
obligations under TRIPS and the ICESCR. 
 
(a) Patented Medicine Prices Review Board 
 
The Canadian government has implemented provisions relating to the monitoring and 
regulation of pharmaceuticals and their costs for the population of Canada.  The Patented 
Medicine Prices Review Board (PMPRB) is a quasi-judicial body952 created in 1987 and 
acts for the purpose of regulating the price of patented medicines to ensure that the prices 
paid by consumers are not “excessive”953 under Section 85 of the Patent Act 1985.  As a 
governmental body the PMPRB has a responsibility to comply with the State’s UN human 
rights obligations although the language used to describe the citizens as ‘consumers’954 
implies that the Board carries out its regulatory actions from a clear economic standpoint, 
which may detract from viewing the issues of affordable medicines in a rights-based 
context.  While the PMPRB has a responsibility to citizens in terms of consumer rights, 
it could be beneficial to appoint a member of the Board with an understanding of the 
State’s international and national human rights obligations, to include a more rights-based 
perspective in the exercise of its functions.   
This expenditure on patented pharmaceuticals highlights that there is a notable 
gap between the sales of patented medicines and generic medicines.  The 2017 report of 
the PMPRB noted that 61.5 percent of the total medicines sales in Canada were of 
                                                            
951 IBP Inc, Canada Investment, Trade Strategy and Agreements Handbook Volume 1 Strategic 
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952 Patented Medicine Prices Review Board, Strategic Plan 2015-2018, ISBN: 978-0-660-03054-8, 6 
<http://www.pmprb-cepmb.gc.ca/CMFiles/Publications/StrategicPlan/Strategic_Plan_2015-
2018_en.PDF> (accessed 27/04/2020) 
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patented medicines, an increase from 60.8 percent in 2016955.  Consumers were spending 
more on patented medicines in 2017 compared to the previous year, although it was 
contended that this increase was not necessarily due to rising prices, with suggested other 
factors including an increase in the overall population, and increases in health problems 
requiring medicines956.    The report also noted that in 2017, the Patented Medicines Price 
Index (PMPI) measured that the increase in patented medicines prices was, on average, 
less than the rate of inflation957.  This portrays that in Canada the costs of patented 
pharmaceuticals are increasing, although the price of pharmaceuticals had risen at a lower 
rate than the prices of other goods and services.  Therefore, such a rise in prices may not 
be prohibitive, although for vulnerable and minority groups any price increase in their 
essential medicines could be unaffordable.  This demonstrates the need for greater 
alignment when addressing the issue of enhancing access to medicines.  Key issues are 
not just lower prices and accessibility generally, but also include marginalised groups 
within the States and the specific measures that may be required to ensure their rights are 
also protected. This is also an important consideration for other states contemplating the 
advancement of a national mechanism based on the framework implemented in Canada. 
Questions have been raised over the effectiveness of the current regime to meet 
its objective of ensuring pharmaceutical companies do not utilise their IP rights to charge 
excessive prices958, due to the relatively high prices of patented medicines and low 
investment into research and development959.  Morgan and Cunningham argue that the 
empirical evidence does not support the view that IP protection is an important 
determinant in investment in pharmaceutical research and development, with other 
factors including scientific innovation and access to clinical trials emerging as more 
important factors960.  This view contradicts an accepted rationale of IP protection, being 
that strong IP rights encourage creators of medicines to research and develop new 
products because they can rely on their private legal rights to prevent their ideas from 
being utilised without permission.  Lexchin argues that Canada’s domestic position has 
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seen increased emphasis on IP rights to encourage investment in research and 
development by pharmaceutical companies961.  However, Lexchin also notes that 
“between 2010 and 2013 seven major multinational pharmaceutical companies have 
closed research facilities in Canada with a loss of over 1000 jobs”962.  This suggests that 
the promise of strong IP rights protection is not itself enough to attract pharmaceutical 
companies to invest in research and development of medicines in the State, and other 
incentives need to be offered in order to stimulate the required investment.   
The PMPRB is taking measures to adapt its framework for the purpose of 
enhancing its efficacy for consumers. The PMPRB has developed new strategic 
objectives for the period 2015 to 2018963.  These objectives include consumer-focused 
regulation, enhancing public awareness of its mandate and reviewing its regulatory 
framework964. Therefore, although Canada has implemented a mechanism for monitoring 
of the pricing of patented pharmaceuticals, the variety of factors which affect pricing 
appear to make it difficult to develop a clear pricing strategy to regulate the pricing for 
the population. In 2019 Health Canada announced amendments to the Patented Medicines 
Regulations, which provide the framework by which the PMPRB regulates prices965.  
Amendments include new price regulatory factors allowing the PMPRB to assess the cost 
of a patented medicine against the health benefit, and added reporting requirements 
relating to these new factors966. The amendments aim to address the increasing cost of 
medicines, improve their affordability and could be an important development in the 
regulation of patented medicines pricing.  They are intended to come into force on 1 July 
2020967, although as of March 2020 the amendments are subject to challenge by the 
pharmaceutical industry968. 
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  It is significant that the Patented Medicines Regulations amendments recognise 
that affordability is a major concern in relation to ensuring access to medicines.  However, 
affordability of medicines is a broader issue than price regulation.  Alignment with other 
organisations, intergovernmental bodies and other stakeholders is needed to address the 
complex nature of the issue of affordability.  There is evidence that Canada has taken 
measures to try to make the cost of medicines more affordable. However, in order to fully 
meet its UN human rights obligations the State should prioritise the human rights of its 
population when entering into agreements or making policy decisions that directly or 
indirectly affect the right of its people to have effective access to medicines. 
 
(b) The significance of the pharmaceutical industry  
 
Canada is a net importer of pharmaceutical products969, with pharmaceutical imports at a 
value of approximately $12.5 billion (USD) compared to pharmaceutical exports at a 
value of approximately $8 billion (USD) in 2018970.  This trend appears to be less 
common in developed countries, as depicted in the table in Annex II.  Key issues that 
underline Canada’s position as a net importer of pharmaceutical products are the effect 
of regulatory obstacles in the development of new medicines and the availability of 
cheaper overseas imports, in addition to high demand for pharmaceuticals to meet the 
evolving needs of the population971.  Regulation of medicines is important to ensure the 
safety and quality of new medicines for patients.  However, to promote access to new 
medicines it may be useful to provide additional incentives for pharmaceutical 
manufacturers to encourage them to pursue the manufacturing and development process 
including taking the appropriate measures as far as possible to meet the requisite 
regulatory standard in order to market their product.  It is also important for other states 
to understand the changing needs of the population for reasons such as health concerns 
related to ageing or other emerging factors affecting health.  By doing so the state could 
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take measures such as implementing procedures to address these needs to ensure that 
medicines are available in the state to treat long term conditions, in addition to serious 
diseases. 
 The pharmaceutical industry is of importance to the Canadian economy in terms 
of international trade and therefore medicines production in Canada may be targeted 
towards the needs of these markets.  Between 2011 and 2016 the export of 
pharmaceuticals increased by 132.2 percent, and grew by 12.8 percent in 2016, making 
pharmaceuticals Canada’s ninth biggest export and 2.2 percent of Canada’s total 
exports.972  Over half of Canada’s pharmaceutical production is exported, and this is 
primarily to the US973.  The needs of the overseas market could potentially contrast with 
the needs of the domestic market and may mean that the Canadian pharmaceutical 
industry does not primarily aim to meet the health needs of the Canadian population, but 
those of the export market instead.  Lexchin argues that pharmaceutical companies gain 
a clear economic advantage in getting their products to the market as soon as possible974, 
so it is in the interests of the companies and their shareholders to produce products that 
are the most marketable and lucrative.  However these products may not necessarily 
address the key health needs of Canadian citizens.  Also, only one of the top ten leading 
pharmaceutical companies in Canada, accounting for half of total Canadian 
pharmaceutical sales in 2017, is under Canadian ownership975.  Ownership of the 
companies might have an impact on target markets for these companies, as non-Canadian 
owned pharmaceutical companies may not primarily focus on the health needs of 
Canadian citizens with regard to their research and development models.  However other 
factors such as the commercial objectives of the companies and the demands of the 
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<https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/h_hn01703.html> (accessed 27/04/2020) 
974 J Lexchin, Private Profits Versus Public Policy: The Pharmaceutical Industry and the Canadian State, 
(University of Toronto Press, Buffalo, 2016), ISBN: 978-1-4426-4917-0, 59 
975 Government of Canada, ‘Pharmaceutical Industry Profile’ > ‘Canada’s Pharmaceutical Sector’ > 
‘Leading Companies’ <https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/h_hn01703.html> (accessed 
27/04/2020) 
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international, not only domestic markets, may have significant impacts on the innovation, 
research and development structures of these companies. 
 
(c) The branded pharmaceutical industry 
 
As noted above, both the branded and generic pharmaceutical industries have strong 
presence in the State. A key tension in between IP rights and access to medicines is that 
patented medicines are sold at a high price, which makes them unaffordable for those 
who need them.  Therefore, it is pertinent to explore the impact of the branded industry 
on access to medicines, and whether access to medicines could be enhanced in the State 
through the branded industry976. A 2013 government report on Canada’s pharmaceutical 
industry977 observed that the Canadian pharmaceutical industry had to transform in order 
to deal with global pressures on the industry including the expiration of patents for many 
lucrative medicines978.  The report stated that the pace of growth of the Canadian 
pharmaceutical industry has slowed since its peak in 2001979, with suggested reasons 
being restrictive pricing for branded and generic pharmaceuticals, and low usage in public 
medicines plans in the Canadian market980 due to the level of benefit that such new 
medicines would provide.  This could provide an example of why the cost of medicines 
is still considered to be excessive for Canadians by the PMPRB and also why there were 
difficulties in implementing pricing and purchasing strategies under the National 
Pharmaceuticals Strategy.  The report also stated that Canada’s market growth in the 
global pharmaceutical industry would be affected by competition from new emerging 
markets981 and suggested that the government should implement tax incentives and 
subsidies in order to encourage growth982.  This highlights that enhancing the availability 
of new, quality medicines is an important factor in improving access to medicines in the 
                                                            
976 In 2012, seven of the top ten leading pharmaceutical companies in Canada in terms of sales were 
branded pharmaceutical companies. See J Lexchin, ‘Drug pricing in Canada’ in ZUD Babar (ed), 
Pharmaceutical Prices in the 21st Century, (Springer, Switzerland 2015), 28 
977 Industry Canada, Government of Canada, ‘Canada’s Pharmaceutical Industry and Prospects’, 2013, 
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978 ibid 5  
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980 ibid 9-10  
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State. Other incentives, in addition to the protection of IP rights, may also be needed to 
stimulate innovation and development of new medicines in the State. 
Proposals to engage in collaborative efforts to improve access to medicines have 
emerged from the pharmaceutical industry, but there appears to be little evidence of real 
commitment to implementing measures that promote access to medicines for all.  
Innovative Medicines Canada is an association of over fifty research-based 
pharmaceutical companies, and a key aim is to enhance access to new, innovative 
medicines for Canadian citizens, which is balanced with the aim of ensuring that 
innovators can rely on the legal protection of their ideas through an enterprising IP 
system.983  As part of the objective to develop associations Innovative Medicines Canada 
together with other stakeholders created the Canadian Consensus Framework for Ethical 
Collaboration984, which states that it is intended to promote patients’ best interests 
including by forging effective collaborations between health providers, researchers and 
the pharmaceutical industry with regard to innovation and knowledge transfer.  This also 
includes developing codes and principles for ethical collaboration, as well as systems for 
reporting breaches of such standards, to ensure accountability of the respective 
stakeholders985.   
Leading pharmaceutical companies in Canada such as Apotex and Novartis 
Canada986 have corporate social responsibility statements. However, they do not appear 
to include explicit commitments on promoting or enhancing access to medicines for all.  
They are also not parties to the UN Global Compact987, a voluntary initiative of the UN 
to support companies to adopt social responsibility policies to advance societal aims, such 
as the UN Sustainable Development Goals988.  These statements are not binding and there 
                                                            
983 Innovative Medicines Canada, 2016 Annual Report, <http://innovativemedicines.ca/wp-
content/uploads/2015/05/2016_Annual-Report_Web_EN_Final.pdf> (accessed 27/04/2020), 22 
984 Canadian Consensus Framework for Ethical Collaboration <http://innovativemedicines.ca/wp-
content/uploads/2016/06/IMC_CONCENSUS_2016_HR_nobleed.pdf> (accessed 27/04/2020) 
985 ibid 3-4 
986 See also Apotex, ‘Corporate Responsibility’ <http://www1.apotex.com/global/about-us/corporate-
responsibility>; and Novartis Canada, ‘Ethical Business Conduct’ <https://www.novartis.ca/en/ethical-
business-conduct> (accessed 27/04/2020) 
987 United Nations Global Compact, ‘Our Participants’ <https://www.unglobalcompact.org/what-is-
gc/participants> (accessed 27/04/2020); JP Therien and V Pouliot, 'The Global Compact: Shifting the 
Politics of International Development' (2006) 12 Global Governance 55, 55; J Ruggie ‘Reconstituting the 
Global Public Domain — Issues, Actors, and Practices’ (2004) 10(4) European Journal of International 
Relations 499, 516; J  Cohen-Kohler and Laura C Esmail, 'Scientific Misconduct, the Pharmaceutical 
Industry, and the Tragedy of Institutions' (2007) 26 Med & L 431, 444 
988 United Nations Global Compact, ‘Who We Are’ > ‘Our Mission’ 
<https://www.unglobalcompact.org/what-is-gc/mission> (accessed 27/04/2020) 
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appears to be little by way of engagement with the Canadian government and relevant 
stakeholders to develop frameworks to enhance access to medicines through more 
affordable purchasing structures, or through enhanced accessibility to medicines which 
are most needed.  This highlights difficulties for the State, in seeking to comply with its 
human rights obligations, to impose obligations on private pharmaceutical companies to 
promote access to medicines through their business activities.  The CESCR also 
recognised the impact of private business enterprises on the rights enshrined in the 
ICESCR, expressing concern over the conduct of corporations, particularly as it was 
difficult to seek access to a judicial remedy as a result of such conduct, and existing 
accountability mechanisms were not always considered to work efficiently989.  This 
highlights the importance of coherence between state actions at national and international 
level in relation to meeting the State’s obligations on medicines under international 
human rights law.  There is evidence of pharmaceutical companies engaging with the 
issue in relation to voluntary associations, but there appears to be little evidence of these 
measures resulting in effective outcomes for the promotion of access to medicines, which 
may be because of their voluntary nature.   
The members of Innovative Medicines Canada agree to be bound by its code of 
ethical practices990, and the guiding principles of the Code state that the members are 
expected to be held accountable for their business practices991.  However the Code also 
outlines that it “provides a mechanism for Members to establish and maintain an ethical 
culture through a committed, self-regulated approach”992, which does not suggest an 
objective and effective accountability mechanism as envisaged by the UN human rights 
bodies.  The Canadian Generic Pharmaceutical Association (CGPA), which represents 
manufacturers and distributors of generic pharmaceuticals, has claimed that the 
Innovative Medicines Canada members, the branded pharmaceutical companies, are 
failing to meet their commitments on investment in research and development.  The 2015 
annual report of the PMPRB shows that branded pharmaceutical companies spent around 
4.9 percent of their annual revenue on research and development, less than half of the 
                                                            
989 UNCESCR ‘Concluding observations on the sixth periodic report of Canada’ (23 March 2016) UN Doc 
E/C.12/CAN/CO/6, 15 
990 Innovative Medicines Canada, 2018 Code of Ethical Practices, <http://innovativemedicines.ca/wp-
content/uploads/2018/06/Code-Formatted_Regular_EN-2.pdf> (accessed 27/04/2020) 
991 ibid 5 
992 Ibid. See also R Habibi, L Guénette, J Lexchin, E Reynolds, M Wiktorowicz, and B Mintzes ‘Regulating 
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agreed commitment of 10 percent promised when the Patent Act was amended in 1987993.  
Therefore, an effective strategy to incentivise branded pharmaceutical companies to reach 
their commitment to research and development investment needs to be developed. 
There also appears little evidence of proposals for a framework to incorporate the 
UN Guiding Principles on Business and Human Rights994.  This points to a lack of 
effective engagement with the recommendations and guidance from UN human rights 
bodies in relation to the actions of private pharmaceutical companies in the State.  
Therefore it may be beneficial for Canada to consider the implementation of a National 
Action Plan in accordance with the Guiding Principles in order to develop policy 
coherence across the provincial jurisdictions and with the pharmaceutical industry.  As of 
March 2020, twenty-three states995 have produced a National Action Plan, and another 
twenty-four states996 are either in the process of developing a National Action Plan or 
have committed to doing so.  Therefore it could be informative for Canada to learn from 
the experiences of these states in considering whether to implement a National Action 
Plan in Canada. 
 
(d) The generic pharmaceutical industry 
 
The generic pharmaceutical industry is of key significance for Canadian health services, 
and the benefits of generic medicines as cost effective alternatives to branded medicines 
are recognised within the State.  Therefore, it is also important to explore the impact of 
the generic pharmaceutical industry on access to medicines in the State, and whether 
                                                            
993 Canadian Generic Pharmaceutical Association, The Real Story; Research and Development Spending 
by Brand-Name Drug Companies in Canada 1987-2015, 1 <http://canadiangenerics.ca/wp-
content/uploads/2016/10/TheRealStory_2016_Eng_Web.pdf> (accessed 27/04/2020) 
994 United Nations Office of the High Commissioner for Human Rights, Guiding Principles on Business and 
Human Rights: Implementing the United Nations “Protect, Respect and Remedy” Framework (n 494).  
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access to generic medicines could be enhanced.  The pricing of generic medicines in the 
State is a barrier to access.  In 2018 generic medicines were used to fill 71.8 percent of 
all prescriptions in Canada997.    Law et al note that Canadians pay the second highest 
medicines prices998 and a key issue is that the State does not have a uniform medicines 
pricing strategy for medicines.  However, there is further disparity in relation to the 
pricing of generic medicines.  While the PMPRB regulates price increases of patented 
medicines999, in the case of generic medicines provincial governments pay a percentage 
of the cost of the original patented medicine1000.  In 2010 an amendment to the pricing of 
generic medicines was also introduced in Ontario1001 to reduce the price of generic 
medicines from 50 percent to 25 percent of the cost of the branded version, and Law et al 
argue that despite initial concerns from the pharmaceutical sector the measure has reduced 
expenditure on generic medicines1002.  Law et al suggest that by moving away from 
pricing based on the patented medicine to a more competitive market-based system would 
lead to further reductions in the cost of generic medicines in the province, and across the 
State1003. This could potentially provide an example of the importance of delinking the 
cost of patented medicines from the cost of generic medicines in order to make generic 
medicines more accessible for a wider range of people.  However this would only be 
effective if there is more than one generic manufacturer of a particular medicine in 
demand, in order to generate the competition in the market to keep the costs at an 
accessible level. 
In addition to the cost of generics, maintaining effective availability and 
accessibility of generic medicines also present challenges to enhancing access to 
medicines in the State. The CGPA has reported on some of the issues it sees as acting as 
                                                            
997 Canadian Generic Pharmaceutical Association, ‘Sustainable Healthcare’ > ‘Market Trends’ 
<http://canadiangenerics.ca/sustainable-healthcare/market-trends/> (accessed 27/04/2020) 
998 M Law, A Ystma and S Morgan ‘The Short-Term Impact of Ontario’s Generic Pricing Reforms’, (2011) 
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barriers to getting generic medicines to the Canadian markets, such as pressure to reduce 
costs of generics and Canadian patent laws potentially preventing new generics reaching 
the market1004.  This is particularly pertinent in Canada given the data on the usage of 
generic medicines to fill prescriptions.  The CGPA highlighted that Health Canada has an 
obligation to improve the existing regulatory framework to encourage the introduction of 
new generic medicines into the Canadian market and “to help ensure that they stay on the 
market based upon patient demand”1005. The CGPA also called on Health Canada to work 
together to align Canada’s regulations on generic medicines with those of other states in 
order to facilitate global product development1006 which would in turn benefit generic 
manufacturers by enabling them to introduce more generic medicines into the market, 
resulting in lower prices for patients and the Canadian healthcare system.  This suggests 
that the federal government needs to take positive measures to enhance continued access 
to new generic medicines, and that a change in approach as well as greater collaboration 
with stakeholders globally could have a positive impact on the accessibility and usage of 
generic medicines.  It could ensure that the State is discharging its national and 
extraterritorial obligations in relation to enhancing access to medicines under the 
ICESCR. 
A key concern highlighted by the work of the UN human rights bodies in relation 
to access to medicines is the inclusion of TRIPS-plus standards of patent protection in 
FTAs, which have a detrimental impact on access to generic medicines. El Said argues 
that Canada has been “active in perusing an international TRIPS-plus agenda” through its 
participation in a number of international TRIPS-plus arrangements.1007 Pursuing such an 
agenda would be cause for concern in light of the national policy measures discussed 
                                                            
1004 Canadian Generic Pharmaceutical Association, Ensuring a Consistent Supply of Safe, Effective and 
High Quality Generic Medicines for Canadians, (Deloitte, 17 October 2016), 22 
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1007 M El-Said, 'TRIPS-plus, Public Health and Performance-Based Rewards Schemes Options and 
Supplements for Policy Formation in Developing and Least Developed Countries' (2016) 31 Am U Int'l L 
Rev 373, 422 
 206 
 
above which focus on health of citizens, in particular on access to medicines, and would 
cause tension with the State’s obligations under the right to health.  Canada is a party to 
two high-profile FTAs.  The Comprehensive Economic and Trade Agreement (CETA)1008 
provisionally came into force on 21 September 20171009, and the Trans-Pacific 
Partnership (TPP)1010 renamed the Comprehensive and Progressive Agreement for Trans-
Pacific Partnership (CPTPP)1011 came into force on 30 December 20181012.  The State has 
been criticised for failing to comply with the recommendations of the UN human rights 
bodies1013 to undertake a human rights impact assessment on the impact of the TPP on 
access to generic medicines.1014  National reports on the benefits and challenges of the 
TPP did not make specific reference to the impact of the TPP on access to medicines.1015  
The intellectual property chapter in the TPP caused considerable debate during the 
                                                            
1008 Government of Canada, ‘Text of the Comprehensive Economic and Trade Agreement – Table of 
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drafting and negotiations, with sustained criticism from academics and civil society 
organisations.1016 Concerns were raised over data exclusivity provisions in Article 18.50 
which would have the effect of delaying the entry into the market of generic medicines. 
For example, exclusivity on undisclosed test data on small-molecule medicines of at least 
5 years for new pharmaceutical products plus either 3 years for new indications, 
formulations or methods of administration or 5 years for combination products containing 
a chemical entity that has not previously been approved1017.  Concern was also expressed 
over wide-ranging civil and criminal penalties for IP rights infringements which go 
beyond TRIPS1018.  Several of the IP provisions in the chapter were subsequently 
suspended1019.  These provisions include articles on patentable subject matter, test data 
protection and technological protection measures.1020  Médécins Sans Frontières argue 
that the trade ministers negotiating the agreement have “suspended many of the damaging 
provisions that would have restricted access to medicines and vaccines, a victory for 
millions of people who rely on affordable medicines worldwide.”1021  The suspension of 
the provisions is a positive outcome in relation to access to generic medicines.  However, 
by engaging with the recommendations of the UN human rights bodies to undertake 
impact assessments on health including medicines, before agreeing terms in FTAs, the 
State could ensure that it is fulfilling its obligations with regard to furthering access to 
medicines as part of the right to health under Article 12 ICESCR.  This also highlights 
the importance of policy coherence across government departments in relation to 
enhancing access to medicines.   
 The text of CETA, an agreement between Canada and the EU, has also produced 
difficulties in relation to access to generic medicines.  Petersen argues that CETA will 
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 208 
 
require Canada to implement stricter IP protection which will have an impact on the 
generic pharmaceutical industry, and bring Canada’s IP protections into line with other 
leading economies, in order to continue investment with the EU1022.  This appears 
contrary to the recommendations of the UN human rights bodies, including the UN 
Secretary-General’s High-Level Panel, that states should resist the implementation of 
TRIPS-plus provisions in FTAs1023. Bill C-301024 which would become the Act to 
implement CETA into Canadian law, received Royal Assent on 16 May 2017, and 
contains amendments to the Patent Act which will have an impact on access to medicines.  
Section 59 of the Bill provides for patent holders to apply for certificates of 
supplementary protection in order to extend the patent term for a medicinal product1025 
for a maximum of two years1026. The purpose of the new system of patent term restoration 
is to compensate pharmaceutical companies for time lost between the filing of the patent 
application and receiving approval.1027  The eligibility criteria for applying for a 
certificate is fairly wide1028 and a broad range of medicines under patent may qualify for 
supplementary protection. This may lead to particular medicines marketed at a higher 
price for a longer period of time, and delay the entry of generic copies of such medicines 
to the market by up to two years.1029  Lexchin and Gagnon argue that the introduction of 
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an extended term of patent protection could increase the total annual cost of patented 
medicines by 6.2 percent1030.  Although Lexchin and Gagnon note that the Canadian 
federal government has stated that it will compensate provinces for the rise in medicine 
costs for their public medicines plans, they argue that the increased cost is still borne by 
the Canadian taxpayer, and people who pay for their medicines privately will not benefit 
from any compensation1031.  Therefore, the government may be attempting to achieve a 
balance between implementing the more robust patent rights protection as part of its 
obligations under CETA, and ensuring that medicines are affordable.  However it appears 
that this strategy will not adequately protect or fulfil the rights of all Canadian citizens in 
relation to accessing medicines. 
There is evidence that the government recognises the concerns of the generic 
pharmaceutical industry and is attempting to introduce reforms to make it easier for 
generic manufacturers to produce copies of required medicines, which should benefit 
citizens as the generic product should be more affordable.  Canada and the EU had 
intended for CETA to be in place provisionally in July 2017. However, a reason for the 
delay relates to the Canadian government providing clarification on regulatory 
amendments promised to generic manufacturers, intended to appease the industry as 
measures in CETA relating to extension of pharmaceutical patent terms would benefit the 
branded pharmaceutical industry1032.  Although it has been stated that such regulatory 
change would occur outside of CETA itself, the pressure from the generic pharmaceutical 
industry for assurances of an end to ‘dual litigation’1033, had contributed to a delay in 
meeting the planned implementation date.  This highlights a key problem faced by generic 
manufacturers in the production of generic medicines, and is an example of a potential 
conflict with branded pharmaceutical companies which could continue over a prolonged 
period of time.1034  This also highlights that the government is trying to balance the 
interests of the branded and generic pharmaceutical industries at national level.  However, 
a more central focus on the needs of patients, and greater alignment of national health and 
                                                            
1030 Lexchin and Gagnon (n 1027) 4 
1031 ibid 5 
1032 J McGregor, ‘CBC News: More trouble for Canada-EU trade deal, as drug changes delay 
implementation’ 28 June 2017 <http://www.cbc.ca/news/politics/ceta-provisional-application-
pharmaceutical-litigation-1.4179676>  (accessed 27/04/2020) 
1033 ‘Dual litigation’ is a system which allows two proceedings between the same parties over the same 
patent and medicine. 
1034 A Falconi ‘CETA: An Opportunity to Fix Canada's Broken Pharmaceutical Patent Linkage System’ 
(2015) 27(3)  Intellectual Property Journal 325, 328-329; Grootendorst and Hollis (n 1029) 88 
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trade policies, could ensure that the State takes full account of its human rights obligations 
in relation to access to medicines when negotiating such agreements. 
 
(e) Conclusions from Section III 
 
The review of the pharmaceutical industry in the state highlights that the high prices of 
branded and generic medicines is a key issue in the State.  This means that ensuring 
consistent access and availability of medicines could present a challenge.  The PMPRB 
is an important mechanism to promote access to medicines. However, the agreeing of 
TRIPS-plus measures in FTAs reflects a lack of consistency across government 
departments on policies relating to medicines. The State should ensure that its 
international obligations on health and access to medicines are taken into account when 
developing policy and decision-making impacting on access to medicines, to achieve a 
more balanced approach in line with its obligations under TRIPS and the ICESCR. 
 
IV. Conclusion 
 
In Canada, there are several federal and provincial government measures to try to reduce 
the cost of medicines to try to improve access to medicines within the State, and also in 
developing states.  Good practices in relation to improving affordability of medicines 
include the PMPRB, which regulates pricing of patented medicines, to protect consumers 
from excessive pricing.  The State also introduced legislation resulting in CAMR, which 
intended to improve access to medicines for developing states in Africa.  Although these 
measures may not conclusively be described as successful, they demonstrate that the State 
has understood its responsibilities with regard to the implementation of TRIPS and the 
Doha Declaration.  These measures also demonstrate that the State has recognised its 
human rights obligations on health, including access to medicines, by introducing 
standards to address some key problems affecting access.  The practices of this State could 
also prove informative for other states that may consider implementing similar regimes 
and could learn lessons from Canada’s experiences. 
 Canada is a net importer of pharmaceuticals and therefore strong IP rights 
protection may incentivise business enterprises to innovate and manufacture new 
medicines in Canada to grow domestic production, while increased competition from 
imports may contribute to lower prices of medicines.  However, the cost of medicines 
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means that they are not accessible to all.  There is no accountability mechanism which 
could be utilised by the State to hold companies accountable in relation to their social 
responsibility to enhance access to medicines, in compliance with the State’s UN human 
rights obligations.  Promotion of generic medicines is the main policy to improve 
affordability, but appropriate pricing strategies are needed to enhance access to generic 
medicines.  It is evident that TRIPS-plus provisions have an adverse effect on the 
accessibility of cheaper generic medicines, although it appears that Canada and the other 
state parties to the CPTPP have addressed this concern by suspending several TRIPS-plus 
provisions in the CPTPP.  The study also highlights the need for states to consider specific 
issues relating to access to medicines affecting minority groups, such as the gaps in the 
provision of services of prescription medicines for indigenous peoples and a specific need 
to protect traditional knowledge and medicines.  Therefore, the position of social and 
economic rights in the Canadian legal system could be strengthened to take full account 
of the State’s obligations under the right to health, and access to medicines. 
 The issues experienced in Canada highlight that enhancing effective access to 
medicines in Canada is a cross-jurisdictional issue with the federal government and the 
provincial governments all having significant roles. This has led to some disparities and 
inconsistencies in the level of provision of medicines across Canada, with variations in 
accessibility in different provinces.  It could be argued that this reflects global disparities 
in securing access to medicines for all.  While a single solution may not be suitable to 
address a complex issue, there may be a need for international collaboration between 
states on policy development, and an enhanced understanding of states’ obligations in the 
context of rights in order to further improve access to medicines within their own state, 
and also extraterritorially. Despite the lack of an enforcement mechanism at international 
level, states have made commitments to uphold the rights within the ICESCR. Translating 
those commitments into effective national policy is crucial to further the enhancement 
access to medicines in a rights-based context. 
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Chapter 6: Case Study – Peru 
 
Introduction 
 
The subject of the second case study in this thesis will be Peru.  As in the previous case 
study on Canada, this chapter will examine whether the State appreciates the interaction 
between its human rights obligations and obligations under TRIPS at national level, and 
evaluate how the State is addressing possible tensions in order to discharge its obligations 
simultaneously under TRIPS and the ICESCR. This study will primarily focus on 
reviewing national legislation, policy documents and related case law, and will refer to 
relevant academic literature in the analysis of the findings.  Issues including the nature of 
Member States’ human rights obligations on access to medicines, TRIPS-plus provisions 
and the impact of the private pharmaceutical sector, will be examined.  The study will 
evaluate how state practice at national level might inform understanding of key issues on 
reconciling obligations under TRIPS and ICESCR.  The study will also consider if there 
are examples of good practice to other states in effectively meeting their obligations. 
As with the first case study, the methodology for selecting the state that will be 
the subject of this case study involves identifying the states which are WTO Members 
and have ratified the ICESCR, and applying the series of indicators in the form of the 
table set out in Annex II. The first indicator was which countries were classified as 
developed or developing1035, and EU Member States were excluded as in the 
methodology in the previous case study1036.  As is evident from the table in Annex II, 
there were a high number of states that are classified as developing.  The next step 
involved identifying the countries that were net importers of pharmaceuticals and which 
were net exporters of pharmaceuticals1037, which highlighted that most of the developing 
countries are net importers. Therefore, in order to narrow the field of potential states, 
further indicators had to be applied. The next indicator applied was states that had 
received a visit from the Special Rapporteur on the right of everyone to the highest 
attainable standard of physical and mental health.  This indicator was selected because by 
engaging with the relevant stakeholders and primary sources, the Special Rapporteur may 
have identified specific issues with regard to access to medicines in that State.  Therefore 
                                                            
1035 Data obtained from UN, World Economic Situation and Prospects 2015 (n 807) 139-140 
1036 See Chapter 5, Introduction 
1037 UN COMTRADE Database (n 808) 
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the Special Rapporteur’s report may be informative to other developing States to ensure 
that they meet their human rights obligations.  By applying this indicator, the potential 
states were narrowed considerably.  Peru was then selected as a case study because the 
State has adopted a range of measures to give effect to the right to health at national level, 
such as the inclusion of the right to health in its Constitution1038.  Peru’s participation in 
the Medicines Transparency Alliance project, which aimed to address challenges in 
accessing essential medicines, also highlights the validity of selecting this State as a case 
study, particularly as the State was selected due to its willingness to enhance access to 
medicines. 
The first section of this study will examine the constitutional framework of the 
State to explore the extent to which the State has complied with its human rights 
obligations in relation to the right to health and access to medicines.  The second section 
of this study will analyse specific measures implemented by the State to address the 
pricing of medicines, to evaluate whether they could enhance access to medicines. The 
third section will explore specific challenges in relation to access to generic medicines in 
the State and whether possible tensions may arise between the State’s obligations under 
TRIPS and the ICESCR. The fourth section will examine the health policy measures on 
access to medicines, particularly for the most marginalised groups, to evaluate whether 
state policy is addressing wider issues which need to be considered to enhance access to 
medicines for these groups within the State. The fifth section will conclude by evaluating 
the findings from this study.     
 
I. National Constitutional measures impacting upon access to medicines 
 
The Constitution of Peru1039 and its interpretation by the Constitutional Court provides an 
important example of the State’s political commitment to enhancing access to medicines 
and its engagement in measures to promote this.  The current Political Constitution of 
Peru1040 came into force in 1993 and sets out the rights and duties of citizens.  The right 
                                                            
1038 The right to health is included in the Political Constitution of Peru.  See also: Political Constitution of 
Peru 1993, <http://www.wipo.int/wipolex/en/details.jsp?id=6544> (accessed 27/04/2020); (English 
translation <http://www.congreso.gob.pe/Docs/files/CONSTITUTION_27_11_2012_ENG.pdf> (accessed 
27/04/2020)) 
1039 ibid 
1040 ibid 
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to protection of health is recognised in Article 7 of the Constitution1041, which states that 
there is also a duty on citizens to contribute to its protection.  Article 7 states that:  
 
“Everyone has the right to protection of his health, his family environment, and his 
community, just as it is his duty to contribute to their development and defense. Any 
individual unable to care for himself due to physical or mental disability has the right to 
respect for his dignity and to a regime of protection, care, rehabilitation, and 
security.”1042   
 
A literal interpretation of this provision indicates that the right does not amount to a right 
to good health, but a right to achieve the highest level of health possible in the State, and 
have access to appropriate services to do so. This is comparable with the guidance on the 
normative content of Article 12 ICESCR1043, set out in General Comment 141044, 
indicating that the State has understood the nature and content of the right to health under 
Article 12 ICESCR and this is reflected in the Constitution.  Therefore, the national right 
to health is in line with international standards.  Article 9 of the Constitution1045 provides 
that the State is responsible for determining national health policy to provide equal access 
to all health services, and Article 11 provides that free access to health benefits is 
guaranteed by the State, through public, private or mixed entities1046.  These articles do 
not explicitly include reference to medicines, although there is reference to health 
services, which include the provision of medicines. 
The State has constitutional obligations to ensure that the right to health of the 
population is fulfilled.  Sanchez-Moreno argues that the rights within the Constitution 
have not been embedded1047, and due to the unstable political landscape1048 of the State, 
                                                            
1041 ibid Article 7 
1042 ibid 
1043 The ICESCR was ratified by Peru in 1978.  See also United Nations Office of the High Commissioner 
for Human Rights, ‘Status of Ratification Interactive Dashboard’(n 539) 
1044 General Comment No. 14 (n 112) 8 
1045 Political Constitution of Peru 1993 (n 1038) Article 9 
1046 Political Constitution of Peru 1993 (n 1038) Article 11 
1047 Peru is a dualist State.  M Sanchez-Moreno, ‘When a “Constitution” is a Constitution: Focus on Peru’ 
(2001) 33(2) New York University Journal of International Law and Politics 561, 564 
1048 K Weyland, The Politics of Market Reform in Fragile Democracies: Argentina, Brazil, Peru and 
Venezuela, (Princeton University Press, Princeton and Oxford, 2002), 12-13; Congressional Research 
Service Report for Congress, ‘Peru: Political Situation, Economic Conditions and U.S. Relations’, RS22715, 
6 September 2007, 1 <http://www.dtic.mil/dtic/tr/fulltext/u2/a472693.pdf> (accessed 27/04/2020)  
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the Constitution does not occupy a stable and authoritative position1049.  Sandoval and 
Cáceres also state that the right to health is treated as a national aspiration rather than an 
entitlement that can be enforced against the State.1050 The right to health is not contained 
in the first chapter of fundamental rights, but in the second chapter of social and economic 
rights1051, which highlights that the status of the right to health within the Constitution 
does not amount to a fundamental right.  Therefore, this suggests that the status of this 
principle is that it is not legally enforceable, but is instead a directive principle of State 
policy.  However, the manner in which these provisions have been interpreted by the 
national courts provides authoritative guidance on the status of the right to health, and 
access to medicines in the State.  The Constitution establishes a Constitutional Court 
which has a duty to hear writs of unconstitutionality1052. Several key decisions of the 
Constitutional Court in relation to the constitutional right to health have been instructive 
in clarifying the State’s obligations in relation to the health of the population under the 
Constitution.  
 
(a) Azanca Alhelí Meza García [2003] 02945-2003-AA/TC 
 
When adjudicating on a petition against the Ministry of Health to provide medical care to 
an HIV/AIDS patient in Azanca Alhelí Meza García [2003] 02945-2003-AA/TC1053, the 
Court considered whether the State had an obligation to provide comprehensive medical 
care for the protection of health, under Article 7 and Article 91054 of the Constitution. 
 
(i) Access to medicines as part of the right to health in the Constitution 
                                                            
1049 Sanchez-Moreno (n 1047) 593.  A recent example of the political landscape in Peru is that in March 
2018 the sitting President Pedro Pablo Kuczynski resigned amid allegations of corruption, and divisions 
in the government.  See also BBC News, ‘Peru political turmoil: President Martín Vizcarra sworn in’, 23 
March 2018, <https://www.bbc.co.uk/news/world-latin-america-43523076> (accessed 27/04/2020) 
1050 C Sandoval and CF Cáceres, ‘Influence of health rights discourses and community organizing on 
equitable access to health: the case of HIV, tuberculosis and cancer in Peru’ (2013) 9:23 Globalization 
and Health, doi:10.1186/1744-8603-9-23, 2 
1051 Political Constitution of Peru 1993 (n 1038) Chapters 1 – 2  
1052 Political Constitution of Peru 1993 (n 1038) Articles 201-205 
1053 Azanca Alhelí Meza García [2003] 02945-2003-AA / TC, Lima, Peru, (English translation  
<http://www.globalhealthrights.org/wp-content/uploads/2013/08/2945-2003-AA-TC-ENGLISH.pdf> 
(accessed 27/04/2020)  
1054 Article 9 states that ‘The State determines the national health policy. The Executive Branch sets 
standards for and oversees its enforcement, and it is responsible for drafting and directing it in a 
pluralistic, decentralizing manner to facilitate equal access for everyone to health services. See Political 
Constitution of Peru 1993 (n 1038) 
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In this case, the Court took the approach of protecting the right to health by way of its 
connection with the fundamental right to life.  The case involved a patient diagnosed with 
HIV/AIDS who argued that since her diagnosis she had not received comprehensive 
medical care, including appropriate medicines.  It was also argued that in this case the 
State was not fulfilling its obligations to care for the health of the population, as compared 
with the treatment provided to patients with other diseases such as tuberculosis, in 
accordance with Article 71055.    In reaching its decision, the Constitutional Court stated 
that the right to health is not considered to be a fundamental right, but when the violation 
of the right to health compromises other fundamental rights, such as the right to life, this 
right acquires the character of a fundamental right1056.  The Court stated that the right to 
health has an inseparable relationship with the right to life, so the State must protect this 
by strengthening health services1057, and that the Article 7 right includes medical 
assistance, to the level allowed by public resources1058.    This is a key statement as it 
indicates that the State is obliged to take positive measures to fulfil the right to health, 
and that this right includes provision of medical services, such as medicines.  This also 
provides that treating life limiting or serious diseases such as HIV/AIDS including 
through provision of antiretroviral drugs, is an example of the situations where the Court 
will consider that if the non-fundamental right to health has been infringed, this provides 
an indicator that a fundamental right has been breached. 
 The Court’s approach to treating the right to health as fundamental in this case 
also raises the issue of clarity around terminology. The Court is applying a specific 
meaning to “fundamental rights” in this case by categorising the right to health as a 
fundamental right due to the proximity to the right to life, which is a fundamental right. 
Problems with justiciability of social and economic rights include that such rights are too 
vaguely worded to be justiciable and the realisation of such rights depends on government 
policy1059.  Therefore such rights are normally placed in a different section to fundamental 
                                                            
1055 Azanca Alhelí Meza García (n 1053) Background 
1056 ibid 6 
1057 ibid 28 
1058 ibid 30 
1059 See also M Ssenyonjo, Economic, Social and Cultural Rights in International Law, (Hart Publishing, 
Oxford and Portland, Oregon, 2009), 5; Office of the High Commissioner for Human Rights, ‘Key 
concepts on ESCRs - Can economic, social and cultural rights be litigated at courts?’, 
<https://www.ohchr.org/en/issues/escr/pages/canescrbelitigatedatcourts.aspx> (accessed 27/04/2020) 
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rights in national constitutions, with Peru’s national Constitution an example of this1060.  
This case illustrates the interdependence and indivisibility of rights and how the linking 
of rights can deliver tangible benefits for the individual when deployed by national courts.  
However it also highlights the uncertainty around the characterisation of the right to 
health as a fundamental right, as this right can only be enforced if the right to life has 
been infringed.  Therefore the fragility of the enforceability of the right to health is evident 
as it is dependent on the degree of proximity to the right to life in each case.  This presents 
difficulties for patients to identify whether they will be able to seek a remedy for a breach 
of their right to health in their national court.  The ability of patients to pursue a remedy 
in their national court is significant as this would be more effective due to time and cost 
concerns. 
The Special Rapporteur on the right to health observed that Peru was one of only 
four states parties that recognised access to essential medicines as a fundamental right1061.  
This suggests that the Court’s interpretation of the right to health to include access to 
essential medicines, and the interpretation of the right to health as a fundamental right 
because of its close link to the right to life, has elevated access to essential medicines to 
the level of a fundamental right in specific cases.  It is important to reiterate that access 
to essential medicines is not explicitly detailed in the Constitution, so this statement on 
the national position in Peru by the Special Rapporteur merits some qualification.  
However, the Court’s interpretation of the right to health indicates that there is scope for 
the treatment of the issue of access to essential medicines as forming part of a national 
constitutional right.  Therefore the recognition of this position by the Special Rapporteur 
highlights positive actions by the national court to enhance access to essential medicines 
in a rights-based context, and could provide an example to other states that have 
obligations under the ICESCR. 
 The Constitutional Court also appreciated the interaction between IP rights under 
TRIPS and human rights in relation to access to medicines at national level.  The Court 
noted the State’s commitments under TRIPS as a WTO Member1062, observing that 
                                                            
1060 Political Constitution of Peru 1993 (n 1038) 
1061 The other States being Mexico, the Philippines and the Syrian Arab Republic.  See also UNHRC 
‘Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable 
standard of physical and mental health, Expert consultation on access to medicines as a fundamental 
component of the right to health’ (16 March 2011) UN Doc A/HRC/17/43, 14 
1062 World Trade Organization, ‘Understanding the WTO: The Organization; Members and Observers’ (n 
806) 
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although IP protection is important for the development of new medicines, there are 
obvious concerns about the effect of such protection on prices1063.  To address this 
tension, the Court called on the State to utilise the TRIPS flexibilities to fulfil its national 
objectives, including the transitional provisions.1064  This demonstrates the value of 
embedding rights into national law, and also demonstrates the interplay between national 
and international mechanisms.  This also indicates that securing access to new essential 
medicines in the State is a key concern, and that the pricing of such medicines may be 
prohibitive in terms of securing access to such medicines for the whole population.     
 
(ii) The State’s obligations under the constitutional right to health 
 
The Court also set out the parameters of the State’s obligations under the right to health.  
The Court emphasised that the economic and social rights within the Constitution are not 
to be considered as merely a declaration of good intentions, but as a commitment to clear 
and realistic goals1065.  This highlights that although the right to health, including access 
to medicines, is not enforceable as a fundamental right under the Constitution, it is not 
enough to treat such rights as mere aspirations and the State must set genuine and 
achievable objectives for the fulfilment of this right.  The Court recognised that as a 
developing country it is difficult to provide immediate policies for the benefit of the whole 
population, as such social rights depend on the means and resources available to the 
State1066.  This is consistent with General Comment 14 which states that the ICESCR 
provides for the progressive realisation of the right to health1067, further highlighting the 
comprehension of the normative content of the Article 12 right to health by the national 
court.  This supports the embedding of international standards into national law so that 
they can provide effective remedies.  However, the Court also stated that this is only a 
valid justification when the State does take positive actions to achieve fulfilment of this 
right as far as possible, such as care for low-income and poverty groups1068, and that 
prolonged inaction cannot be justified as this would result in a constitutional omission1069.  
                                                            
1063 Azanca Alhelí Meza García (n 1053) 40 
1064 ibid 41-42 
1065 ibid 38 
1066 ibid 39, 49 
1067 General Comment No. 14 (n 112) 30-31 
1068 Azanca Alhelí Meza García (n 1053) 39 
1069 ibid 49 
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Therefore this highlights that although the State’s level of development may cause 
limitations to the measures that the State is capable of implementing to achieve the highest 
attainable standard of health for the whole population, this is not a justification for taking 
no action.  Such inaction would be contrary to the Constitution itself, and the State will 
be accountable for such failure to take steps to fulfil this right. 
The outcome of this case was that the Court recommended that the State take 
tangible actions to achieve the patient’s right to health, such as ensuring essential 
HIV/AIDS treatment, including medicines.  Noriega argues that this is a significant case 
as the Court fully adopted the approach of protecting the right to health through its linkage 
with other fundamental rights, and in doing so the Court is developing a norm for the 
legal protection of the right to health through the protection of related constitutional 
fundamental rights1070.  In this case the Court is setting a precedent for the legal 
enforceability of the right to health, through its link to other fundamental rights such as 
the right to life, under the national Constitution.  The decision also emphasises that the 
right to health includes the provision of essential medicines, and therefore this case may 
also provide scope for legal enforceability of access to essential medicines as part of the 
right to health under the Constitution. 
 
(b) RJSA Vda. of R. [2007] 03081-2007-PA/TC 
 
In RJSA Vda. of R. [2007] 03081-2007-PA/TC1071, which related to the care of a patient 
diagnosed with a mental health condition, the Court reiterated that the constitutional right 
to health did not amount to a right to be healthy, but guarantees access to adequate, quality 
health services, as far as public resources allow.1072  This interpretation is consistent with 
the Court’s interpretation in the Azanca Alhelí Meza García case1073.  The Court stated 
that the enforceability of a social right always depends on three factors: the seriousness 
and reasonableness1074 of the case; its connection with other fundamental rights; and 
budget availability.1075  This suggests that there are qualifications to the constitutional 
                                                            
1070 AI Noriega, ‘Judicial review of the right to health and its progressive realisation: the case of the 
Constitutional Court of Peru’ (2012) 1(1) UCL Journal of Law and Jurisprudence 166, 180 
1071 RJSA Vda. of R. [2007] 03081-2007-PA/TC, Lima, Peru 
1072 ibid 19 
1073 Azanca Alhelí Meza García (n 1053) 
1074 The Court did not outline the meaning of the term “reasonableness” in this context. 
1075 RJSA Vda. of R. (n 1071) 23 
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right to health being framed as a fundamental right, and the seriousness of each particular 
case would have to be justified in order to be able to enforce the right to health.   
This test stemmed from the Azanca Alhelí Meza García case1076, where the Court 
outlined that social and economic rights are how individuals can achieve full self-
determination, and that the realisation of socio-economic rights and civil and political 
rights are interrelated and interdependent.1077  Therefore, the Court stated that the State 
must establish basic public services as a minimum of action.1078 Further, the Court stated 
that social rights must be interpreted as genuine claims of the citizen against the State if 
the legal effectiveness of the Constitutional mandates, and therefore the validity of the 
Constitution, is to be recognised.1079  Although social rights are to be progressively 
realised the State is required to take concrete and quantifiable steps to implement public 
policies that ensure their realisation.1080  The Court recognised that social rights cannot 
be demanded in the same way in all cases, due to budget constraints, and so judicial 
enforceability of social rights will depend on factors such as the seriousness and 
reasonableness of the case; its connection with other rights and the budgetary availability 
of the State, as long as concrete actions on its part can be verified.1081   
The Court in RJSA Vda. of R.1082 took this further, stating that the three factors 
outlined above must be taken into account, notwithstanding the progressive nature of the 
right to health in terms of budgetary considerations.1083 Therefore, this test has evolved 
from examples of factors which should be considered, to factors that must be taken into 
account. Florian is critical of this approach, arguing that there are ambiguities regarding 
the determination of how social rights can be claimed in judicial proceedings.1084 Florian 
argues that challenges could arise where there is no specific protection of a social right, 
or where such a right has not been recognised in any budget.1085  These cases did not 
                                                            
1076 Azanca Alhelí Meza García (n 1053) 
1077 ibid 10-11 
1078 ibid 12 
1079 A Oquendo, 'The Solitude of Latin America: The Struggle for Rights South of the Border' (2008) 43 
Tex Int'l L J 185, 199-200; Azanca Alhelí Meza García (n 1053), 13 
1080 A Jenkins and S Ardalan, 'Positive Health: The Human Right to Health Care under the New York State 
Constitution' (2008) 35 Fordham Urb LJ 479, 509; Oquendo (n 1079) 200 
1081 Azanca Alhelí Meza García (n 1053), 32-33 
1082 RJSA Vda. of R. (n 1071) 
1083 ibid 23 
1084 F Florian ‘The right to health in jurisprudence of the Peruvian Constitutional Court’ (2014) 
19Constitutional Thought 389, 407-408 
1085 ibid 408 
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elaborate on how this test should be applied, and the Court in RJSA Vda. of R.1086 also did 
not elaborate on its reasoning for adopting the factors set out in the Azanca Alhelí Meza 
García case1087 as a legal test.  Therefore, it could be said that the Constitutional Court 
has not addressed all issues which could arise when applying this test. However, these 
cases do show that the Court has taken positive steps in achieving more comprehensive 
protection of health challenges, including access to medicines, and in cases where 
vulnerable individuals were affected. 
As noted in the Azanca Alhelí Meza García case1088, the Court highlighted that 
the right to health was to be protected because of its intrinsic connection with the right to 
life in that case.  It is important to appreciate that the right to life is distinct from a patient’s 
quality of life, which although important to the patient, is a subjective standard of 
wellbeing and cannot be described as a fundamental right.  Therefore, as the right to health 
is not fundamental, it can only be protected in specific cases which have a strong right to 
life element, underlining the fragility of the protection of the right to health determined 
by the Court. 
 
(i) The State’s obligations v. resource constraints 
 
The Court also observed that the close connection between life and health is recognised 
in domestic law and in international human rights law, to the extent that budget constraints 
cannot amount to a legitimate argument for denying a person health benefits, in such a 
way that their right to life is put at risk.1089  Therefore a state’s failure to comply with its 
obligations under the right to health due to lack of resources is not justifiable where this 
could result in a potential violation of the right to life.  The patient’s life could potentially 
have been at risk in this case as her antipsychotic medication was associated with a 
potentially life-threatening condition1090.  The patient therefore required regular 
monitoring and a person with capacity to be in control of her medication1091.  Therefore 
the Court recognised the State’s international human rights law obligations in relation to 
resource availability, and is consistent with the position in General Comment 14.  The 
                                                            
1086 RJSA Vda. of R. (n 1071) 
1087 Azanca Alhelí Meza García (n 1053) 
1088 Azanca Alhelí Meza García (n 1053) 
1089 RJSA Vda. of R. (n 1071) 23 
1090 ibid 59-60 
1091 ibid 65 
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right to health also has real and meaningful content even though it is not a fundamental 
right. 
General Comment 14 emphasises that if it is impossible for a State to comply fully 
with its obligations under Article 12 due to resource constraints, it has to justify that every 
effort has been made to use all available resources at its disposal in order to satisfy its 
obligations.1092  Therefore if the State potentially has not fulfilled its obligations under 
Article 12, the burden of proof is on the State to show that it has taken positive actions to 
fulfil its obligations as far as possible, and utilised the maximum resources available to 
do so1093.  This is also consistent with the recommendation of the Special Rapporteur that 
the State should develop a “pro-poor equity-based health policy”1094 and allocate greater 
financial resources to the health sector in line with such a policy1095, and the health 
national policy measures taken by the State as discussed above.  General Comment 14 
also goes further, stating that a State which is unwilling to use its maximum available 
resources for the realisation of the right to health is in violation of its obligations under 
Article 12.1096  This indicates that if a State cannot discharge this burden, and therefore 
cannot justify the failure to utilise its available resources to fulfil its obligations under the 
Article 12 right to health, it could be in breach of those obligations.  The Court’s 
interpretation of the State’s duty to utilise maximum resources available to meet its 
obligations under the right to health in national and international law, is therefore 
consistent with the State’s UN human rights obligations. 
 
(ii) The State’s obligations in relation to medicines 
 
This case outlined that lack of access to essential medicines is a concern in the State, in 
this case particularly for mental health conditions. In addition to outlining the State’s 
responsibilities under the right to health, the Court also noted that the Ministry of Health 
                                                            
1092 General Comment No. 14 (n 112) 47 
1093 General Comment 14 also goes further, stating that a State which is unwilling to use its maximum 
available resources for the realisation of the right to health is in violation of its obligations under Article 
12.   This indicates that if a State cannot discharge this burden, and therefore cannot justify the failure 
to utilise its available resources to fulfil its obligations under the Article 12 right to health, it could be in 
breach of those obligations.  See also General Comment No. 14 (n 112) 47 
1094 UNCHR ‘Report submitted by the Special Rapporteur on the right of everyone to the highest 
attainable standard of physical and mental health, Paul Hunt, Addendum Mission to Peru’ (4 February 
2005) UN Doc E/CN.4/2005/51/Add.3, 28 
1095 ibid 38 
1096 General Comment No. 14 (n 112) 47 
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Ministerial Resolution No. 0943-2006-MINSA1097 identified one of the main problems 
affecting mental health care in relation to the State’s response as being limited access to 
health services and medicines1098.  The inclusion of this statement in a ministerial 
resolution of the national health department reflects that securing access to medicines 
does form part of the provision of adequate health services, in accordance with the State’s 
responsibilities under the constitutional right to health, as well as its UN human rights 
commitments.   
The Court stated that the Ministry of Health should consider an expansion to the 
free delivery of medicines to ensure equitable access to medicines and taking into account 
limited resources1099.  This reinforces that the cost of medicines is an issue identified as a 
potential barrier to accessing medicines in the State. This also identifies that the delivery 
of medicines should be a priority in the national budget, providing an example of how the 
Court applied the third factor of the enforceability test outlined above, being budget 
availability, in relation to medicines.  The reference to equitable access underlines that 
the poorer regions may be particularly affected by lack of access, and that providing 
equitable access is particularly important where the State, as a developing country, has 
limited resources. As noted above, the Court identified that although the State may take 
into account its budget and resources constraints, this cannot amount to a justification not 
to fulfil the right to health.  Therefore, the State should take actions to fulfil its national 
and international human rights obligations by securing access to essential medicines as 
far as the maximum available resources permit.   
The Court also stated that for people who do not have economic capacity, the 
Ministry of Health must develop policy that allows access to medicines through adequate 
prices, as well as sufficient regulation of medicines to guarantee effective and quality 
medicines1100.  This is consistent with the recommendation of the Special Rapporteur on 
health to develop a “pro-poor equity-based health policy”1101, and suggests that equitable 
access to quality medicines should be a key element of such policy, to secure access for 
poor and vulnerable groups.  This also highlights the importance of ensuring the 
                                                            
1097 Ministerio de Salud/Ministry of Health Ministerial Resolution No. 0943-2006-MINSA, 6 October 
2006, <ftp://ftp2.minsa.gob.pe/normaslegales/2006/RM943-2006.pdf> (accessed 27/04/2020) 
1098 RJSA Vda. of R. (n 1071) 42.  See also Ministerial Resolution No. 0943-2006-MINSA (n 1097) P.21 
1099 RJSA Vda. of R. (n 1071) 43.F 
1100 ibid 
1101 UNCHR ‘Report submitted by the Special Rapporteur on the right of everyone to the highest 
attainable standard of physical and mental health, Paul Hunt, Addendum Mission to Peru’ (4 February 
2005) UN Doc E/CN.4/2005/51/Add.3, 28 
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availability of medicines of appropriate quality in the State, which can be achieved 
through regulatory mechanisms.  The outcome of the case was that the patient was granted 
indefinite medical care, including the provision of essential medication for the treatment 
of her mental health condition. The decision of the Court indicates that, in fulfilment of 
its obligations in relation to the patient’s constitutional right to health, the State has a duty 
to provide the essential medicines required by the patient as part of her ongoing mental 
health care.   
This is a significant decision as the Court held that the patient had a right to access 
medicines necessary to her care, as part of her constitutional right to health.  Also, her 
constitutional right to health was enforced against the State, requiring the State to take 
positive measures to fulfil its obligations to her.  This could potentially be a useful 
decision in terms of clarifying the State’s constitutional responsibilities on ensuring 
access to essential medicines, and highlighting that the Constitutional Court’s 
interpretation of this right in this case was consistent with the State’s international human 
rights commitments.  This is also an important decision as it demonstrates the tangible 
benefits of Peru’s approach to interpreting the right to health for the patient.  The decision 
resulted in the necessary medicines being secured for the patient’s care, and the test for 
enforceability of a social right applied by the Court was therefore effective in enhancing 
access to medicines in this case. Therefore this test could be a useful tool for courts in 
other jurisdictions to utilise when adjudicating on access to medicines and the competing 
obligations of the state with regard to the right to health and TRIPS. 
 
(c) Other relevant decisions of the Constitutional Court 
 
The Constitutional Court has also emphasised the significance of the link between the 
right to health and other fundamental rights in subsequent cases.  In Teofanes Ronquillo 
Cornelio [2007] 06057-2007-PHC/TC1102, where the appellant was not transferred to the 
favoured hospital to receive the optimum treatment for the diagnosed condition, the Court 
referred to the Azanca Alhelí Meza García case1103, and highlighted that the right to health 
is inseparable from the right to life, so it is a fundamental right.1104  The Court also stated 
that the State has a duty to guarantee the right to health, including by taking positive 
                                                            
1102 Teofanes Ronquillo Cornelio [2007] 06057-2007-PHC/TC, Lima, Peru 
1103 Azanca Alhelí Meza García (n 1053) 
1104 Teofanes Ronquillo Cornelio (n 1102) 8 
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actions to promote the right.1105  This position was also stated in Carlos Gonzales La 
Torre [2010] 03425-2010-PHC/TC1106 where, although the case related to the 
hospitalisation of a prisoner and did not present a direct right to life or right to health 
issue, the Court outlined that the right to health is necessary for the exercise of the right 
to life itself, and has an inherent connection to the right to life, right to personal integrity 
and other fundamental rights that forms the right to health as an undeniable fundamental 
right.1107 These decisions emphasise the importance of the right to health in terms of 
fulfilling the right to life, and also indicate that the close connection between the two 
rights elevates the right to health to the status of a fundamental right through the 
interpretation of these constitutional rights by the Constitutional Court.  This 
interpretation is also consistent with the Azanca Alhelí Meza García [2003] 02945-2003-
AA/TC1108case, suggesting that a body of jurisprudence on this issue has emerged in 
relation to the content and interpretation of the State obligations in relation to the 
constitutional right to health.  This indicates that citizens can enforce their right to health 
against the State, in circumstances where they can show that there is a risk to their right 
to life if their right to health is not fulfilled.  Therefore if the State fails to secure access 
to essential medicines in accordance with the constitutional right to health of its citizens, 
this delivers an accountability mechanism in addition to the State’s UN human rights 
obligations1109. 
 The Constitutional Court has sought to ensure the close alignment of national 
Constitutional rights with international human rights norms in cases involving human 
rights arguments.  This has been observed by the CESCR, which has noted that Peru “had 
made huge advances in the constitutional interpretation of human rights”1110.  This is a 
key statement which emphasises the importance of the national courts in interpreting the 
national and international human rights obligations of the State.  The CESCR’s 
concluding observations in 2012 noted that the Constitutional Court had issued several 
                                                            
1105 ibid 12 
1106 Carlos Gonzales La Torre [2010] 03425-2010-PHC/TC, Lima, Peru 
1107 ibid 6 
1108 Azanca Alhelí Meza García (n 1053)  
1109 See also Chapter 2, (iii) State obligations in relation to the actions of pharmaceutical companies; and 
III. United Nations Human Rights Treaty Monitoring Bodies; and Chapter 3, II. Expert consultation on 
access to medicines; and United Nations Secretary-General’s High-Level Panel on Access to Medicines, (a) 
Recommendations of the Panel. 
1110 UNCESCR ‘Summary record of the 6th meeting; Consideration of reports (a) Reports submitted by 
States parties in accordance with articles 16 and 17 of the Covenant (continued), Combined second to 
fourth periodic reports of Peru’ (9 May 2012) UN Doc E/C.12/2012/SR.6, 19 
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innovative judgements that had enriched constitutional law, and recognised that 
international human rights treaties were of immediate application1111.  The concluding 
observations further noted that the Constitutional Court had on several occasions applied 
an expanded interpretation of the Article 12 right to health set out in General Comment 
141112.  This is evident in several of the cases discussed above, and highlights that the 
Constitutional Court is engaging with the guidance of the UN human rights bodies on the 
State obligation in relation to the right to health, including access to medicines. This also 
highlights that this engagement has been recognised and supported by the relevant UN 
Treaty Monitoring Body, and provides an example of good practice to other Member 
States in the interpretation of international human rights commitments on health at 
domestic level.  The State representative stated that the right to health care was guaranteed 
under the Constitution and the ICESCR and other international human rights treaties had 
been invoked in health-related cases before the Constitutional Court1113.  This statement 
further reinforces that the national Constitutional Court provides recourse for citizens to 
enforce their human rights against the State domestically, and provides accountability and 
a remedy where the State has infringed their rights.  
 
(d) Conclusions from Section I 
 
The jurisprudence of the Constitutional Court shows that the Court is taking full account 
of the right to health under the Constitution in cases relating to access to medicines, and 
its interpretation of the right is in line with the State’s obligations under Article 12 
ICESCR right to health. These cases show the advantages of taking a rights-based 
approach to access to medicines, as this approach did enhance access to medicines for the 
patients concerned. The RJSA case also demonstrates the value of embedding rights from 
an international source into the national legal landscape.  This jurisprudence also provides 
a good example of individuals enforcing their human rights at national level, providing a 
measure of accountability for the State to uphold its national and international obligations 
in relation to the right to health and access to medicines. 
 
II. Measures to address the pricing of medicines 
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(a) The Medicines Transparency Alliance 
 
There is evidence that Peru is willing to engage with concerns over the accessibility and 
affordability of medicines, with its participation in the Medicines Transparency Alliance 
project1114.  The project “aimed to redraw the landscape of the pharmaceutical market – 
changing policies, behaviour and the balance of power”1115 to address the challenges in 
ensuring that essential medicines are available to all.  This statement indicates that the 
project had compelling aims to improve access to medicines through challenging the 
private pharmaceutical companies to adapt policies on pricing and marketing, and 
therefore it is important to evaluate the success of the project in achieving its objectives. 
The Medicines Transparency Alliance (MeTA) was established in 2008 by the 
UK’s Department for International Development (DfID) and supported by the WHO and 
the World Bank1116, with the aim of enabling the sharing of information regarding 
medicine supply chain between governments, manufacturers and civil society 
organisations, to gain a better understanding of the problems, increase accountability and 
to facilitate changes to increase access to medicines1117.  DfID invited seven countries, 
Ghana, Jordan, Kyrgyzstan, Peru, Philippines, Uganda and Zambia to participate in a 
pilot, that were chosen because access to medicines was limited but there was also an 
apparent willingness to address the problem in these countries1118.  The MeTA Councils, 
which oversee the implementation of each State’s programme, are made up of 
representatives from various stakeholder groups including government, civil society 
organisations, academics and business enterprises1119.  Therefore, the pilot promoted a 
participative process among the various actors involved in the issue of enhancing access 
to medicines, which could be useful for furthering understanding of specific problems 
related to enhancing access to medicines, and for promoting collaboration and sharing of 
ideas between stakeholders to identify solutions. 
                                                            
1114 World Health Organization, ‘Essential medicines and health products’ > ‘Medicines Transparency 
Alliance (MeTA) Initiative’ <http://www.who.int/medicines/areas/coordination/meta/en/> (accessed 
27/04/2020) 
1115 Medicines Transparency Alliance (MeTA), Medicines Transparency Alliance: A review of the pilot, 
(MeTA London, 2010), 5  
1116 ibid 
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A significant lesson from the pilot is the importance of collecting data, including 
from pharmaceutical companies.  All of the pilot countries established a MeTA Council 
to facilitate sharing of information and gathering of evidential data, although it is noted 
that the models implemented by each of the countries varied1120.  The pilot proposed that 
each stakeholder disclosed information relating to the availability, price and quality of 
medicines, including medicine prices, manufacturing prices, health budgets and 
quantification and trade statistics1121.  A review of the pilot carried out by DfID did note 
that the level of private sector engagement has varied from state to state1122.  This suggests 
that there were issues in relation to ensuring that private companies disclosed the 
necessary data, although specific data on levels of engagement was not provided in the 
review to elaborate on this statement.  The reluctance of pharmaceutical companies to 
disclose data due to its potential value or due to privacy concerns, was recognised in the 
DfID review which sought to address this through incremental disclosure of information 
which may be sensitive, or the holding of such information by a third party1123.    As this 
is presented as a proposal to address difficulties in information sharing during the pilot, 
rather than a clear solution, further evidence of the utilisation of such a method would be 
useful in order to assess its potential efficacy for other states.   
Another important lesson from the pilot is not only that the collection of data is 
important, but also how the data is collected and utilised. The United Nations 
Development Programme noted that MeTA led to increased participation in policy 
dialogue in the Philippines, as well as pricing and other transparency measures in Uganda, 
Zambia and Peru1124, although inclusion of data to demonstrate the level of engagement 
with the private sector, and how this was facilitated, would be useful in order to provide 
an example of good practice to other states.  However, Wirtz et al also argue that the 
Medicines Transparency Alliance was not as successful as many had hoped, with lessons 
learned including the length of time to engage stakeholders, and that careful disclosure of 
                                                            
1120 ibid 13  
1121 ibid 18-19  
1122 ibid 19 
1123 ibid 
1124 United Nations Development Programme, Fighting Corruption in the Health Sector: Methods, Tools 
and Good Practices, (Democratic Governance Group, Bureau for Development Policy, New York, October 
2011), 19 
<https://www.undp.org/content/dam/undp/library/Democratic%20Governance/IP/Anticorruption%20
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data was essential.1125  This suggests that this type of project may take a prolonged period 
of time to implement.  Other states considering participating in a similar project would 
need to appreciate the commitment needed in terms of financial support and building 
relationships with the pharmaceutical sector, civil society organisations, and other 
participants.  Stedman-Bryce et al further noted that transparency and information sharing 
between all stakeholders was needed, as well as consistent engagement1126, which 
highlights that a level of trust between all of the stakeholders, including pharmaceutical 
companies, civil society organisations and governmental bodies needs to develop, in 
order to ensure the necessary data is disclosed, and that real transparency can be achieved.  
This also indicates that voluntary participation in such a project may create 
inconsistencies which impact on the efficacy of the project and therefore future projects 
may need to be underpinned by more rigorous participatory obligations. 
The legacy of the MeTA pilot in Peru is the development of the Peruvian 
Observatory of Pharmaceutical Products1127. The MeTA pilot led to the drafting of 
legislation establishing the Observatory nationally and requiring all medicine 
manufacturers to publish their prices.1128 The implementation of this type of observatory 
was also proposed in the health impact assessment by the Ministry of Health prior to the 
conclusion of the US-Peru FTA1129, discussed further below.  The purpose of the 
Observatory is to provide a public database of medicines prices, to allow the population 
to make an informed choice about where to purchase their medicines from, with the aim 
that this will help to lower prices of essential medicines.1130 It has been stated that the 
Observatory is a useful tool for the population to be able to compare the prices of a range 
of pharmaceutical manufacturers, with around five thousand hits per day1131.  This 
                                                            
1125 V Wirtz et al, ‘Essential medicines for universal health coverage’, The Lancet Commissions, 7 
November 2016, http://dx.doi.org/10.1016/S0140-6736(16)31599-9, 46 
1126 e-Pact (G Stedman-Bryce et al), Medicines Transparency Alliance (MeTA) Evaluation: Testing MeTA’s 
underlying intervention logic, December 2015, P.28 <http://itad.com/wp-
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1127 Peruvian Observatory of Pharmaceutical Products 
<http://observatorio.digemid.minsa.gob.pe/?over=1> (accessed 27/04/2020) (translated) 
1128 Medicines Transparency Alliance (MeTA, Medicines Transparency Alliance: A review of the pilot (n 
1115) 26  
1129 Ministerio de Salud del Peru, ‘Evaluacion de los Potenciales Efectos Sobre Acceso a Medicamentos 
del Tratado de Libre Comercio Que Se Negocia Con Los Estados Unidos de America’, Abril 2005, P. 253  
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1130 Medicines Transparency Alliance (MeTA), Medicines Transparency Alliance: A review of the pilot (n 
1115) 26 
1131 World Health Organization, ‘Medicines Transparency Alliance (MeTA): Pathways to Transparency, 
Accountability and Access; Cross-Case Analysis and Review of Phase II’, 25 May 2016, P.64 
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indicates that this is a tool which is used regularly, although does not provide evidence 
that those who have used the tool have found a lower cost medicine as a result of the 
Observatory.  It also does not indicate who has been accessing the information, which 
could be significant as DfID noted that under the MeTA pilot in Uganda a similar website 
was created, but the real users were private sector manufacturers and importers for the 
purpose of identifying gaps in the market1132.  Therefore it is important for other states 
considering implementing such an observatory, to consider the users to whom the 
information is targeted, and the best way to ensure access to the data for them.  Another 
potential issue is the level of access to the internet across the State, in order to ensure that 
patients can use the database.   
The decision of the Peruvian government to address the issue of improving access 
to existing medicines indicates that pricing of patented and generic medicines in Peru has 
been identified as a barrier to access to medicines in Peru.  This is a concern that has been 
recognised at international level and highlights a commitment by the national government 
to implement policy measures to combat this issue.  All medicine sellers are required to 
enter their information into the database1133, to ensure that the database provides an 
accurate reflection of medicines pricing across Peru.  The WHO noted that around six 
thousand institutions report to the Observatory1134, although the number of institutions 
required to comply was not stated.  This data would have been useful in order to assess 
the level of compliance among the relevant institutions.  
Peru has successfully established legislation to require the disclosure of 
information on pricing of medicines1135.  This is an important provision to support the 
effectiveness of the Observatory, as it places a legal requirement on pharmaceutical 
manufacturers and sellers to provide the requisite information for the Observatory.  
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(accessed 27/04/2020)  
1132 DfID Human Development Resource Centre, Evaluation of the Medicines Transparency Alliance 
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1133 Medicines Transparency Alliance Peru, Working Together for Better Access to Medicines, (World 
Health Organization 2015), WHO/EMP/PAU/2015.7, 5 
<http://www.who.int/medicines/areas/coordination/country_activity_brochure-Peru.pdf?ua=1> 
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Accountability and Access; Cross-Case Analysis and Review of Phase II (n 1131) P.64  
1135 UK Department for International Development annual review 2015, 13 
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 231 
 
Article 1 of the Ministry of Health Ministerial Resolution No. 040-2010/MINSA states 
that all pharmaceutical establishments, public and private, operating in the country, must 
register with the National Price Information System for Pharmaceutical Products under 
the Directorate General of Medicines, Supplies and Drugs (DIGEMID), as well as supply 
information about the prices of the commercial offer of its pharmaceutical products.1136  
Article 6 provides that the information will be made available in the Observatory1137, and 
Article 7 provides that institutions that fail to comply will be subject to sanctions1138.  
However, the enforcement of this provision also needs to be effective for the purpose of 
promoting and securing compliance.  The 2015 DfID report1139 which reported on the 
legislation does not provide information or data on the level of compliance or whether 
sanctions have been issued to companies for non-compliance, which would be useful to 
evaluate the efficacy of the Resolution in ensuring that private companies disclose the 
necessary data. 
A key challenge is that although there are publicly funded health services in Peru 
and health insurance coverage available1140, underfunding has led to patients purchasing 
medicines themselves1141.  The DfID report further noted that the Observatory had 
highlighted price inequalities between public and private providers1142.  This is significant 
as the MeTA Peru report noted that 87 percent of private health spending was paid out of 
pocket by consumers1143, highlighting that there is a cost burden on patients in the State.  
The WHO has stated that the Observatory has highlighted that medicine prices are 
typically higher in private clinics1144.  This suggests that the Observatory database was 
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making a positive impact on enhancing effective access to medicines by highlighting the 
issue of the varying pricing strategies for medicines, which impacts on affordability of 
medicines for all.  This also suggests that the Observatory is fulfilling its objective of 
providing information on pricing of medicines, so that patients can identify and obtain a 
cheaper version.  This reiterates the importance of making accurate and comprehensive 
data on medicines pricing publicly available so that patients can make an informed 
decision on where to obtain their medicines, and further highlights the importance of 
ensuring that pharmaceutical companies disclose the necessary data, to underpin the 
efficacy of the Observatory.  It also indicates the importance of the availability of 
medicines by publicly funded providers, as these appear to be cheaper for patients.   
However, the reports do not indicate whether the highlighting of such disparities 
had led to a reduction on prices in the private sector, which could also enhance access to 
medicines by providing a greater choice of affordable medicines.  It is also not indicated 
whether there are specific medicines, or medicines to treat particular diseases which are 
notably higher, which could highlight whether there are any issues around access to 
particular medicines or groups of patients which need to be addressed in the State.  As 
noted above the objective of the Observatory is to provide information on medicines 
pricing in the State, therefore although this data would be useful to provide a more 
comprehensive picture of the situation in relation to medicines costs, this may be beyond 
the scope of the Observatory. 
 
(b) Participation and accountability of pharmaceutical companies 
 
A key issue emanating from earlier chapters is securing the accountability of private 
pharmaceutical companies.  Private companies are not parties to the UN human rights 
treaties and therefore do not have direct obligations in relation to the right to health of 
patients.  The DfID review stated that transparency and disclosure are key elements of 
the pilot, and by making information on data including pricing, manufacturing costs 
available in the public domain, this increases accountability because it highlights where 
the problems in terms of barriers to access to medicines exist1145.  In addition, it is stated 
that by engaging all of the stakeholders, including the national government, private 
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enterprises and civil society organisations at the outset to define the objectives, there is a 
level of mutual accountability to attain the agreed goals1146.  This highlights the 
importance of greater calibration of a legal, structural and policy nature in order to 
improve access to medicines within states.  It also highlights that this level of 
accountability is linked to the level of disclosure by the actors, including pharmaceutical 
manufacturers, on costs of R&D and pricing of medicines.  As the Observatory model 
has a monitoring function with the objective of protecting the population from prohibitive 
costs, it does not directly facilitate the accountability or regulation of pharmaceutical 
companies that set high prices for medicines.  This may highlight bad practice of 
particular pharmaceutical companies, but does not necessarily ensure that they are 
accountable for that practice.  However, there is the issue that these companies could be 
subjected to the courts of public opinion, for failing to meet their responsibilities to 
respect human rights including the right to health.1147 
Vian et al argue that the success of MeTA in promoting accountability by the 
government and stakeholders in the pharmaceutical sector will depend on how well such 
measures are continued and sustained1148.  Increased transparency of pricing is useful, but 
requires a voluntary commitment from the pharmaceutical sector as well as the other 
stakeholders to engage in this participatory process and the level of accountability that is 
involved, to ensure that accurate data can be obtained consistently and published. MeTA 
reported that there was little data available from the domestic pharmaceutical 
manufacturing sector1149 or in relation to pharmacist dispensing fees1150 in order to 
undertake a price comparison between the public and private sector.  The quality of the 
data that is collected is also important, in order to achieve transparency so that MeTA has 
a credible accountability function in publicising inequitable pricing. A further issue that 
is highlighted is that private companies do not appear to have been issued with sanctions 
or other punitive measures for non-disclosure, which could strengthen the effectiveness 
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of the project and improve disclosure of information.  However if they were compelled 
to disclose information this could impact negatively on the working of the body, as for 
example competitors could potentially utilise the information when setting their own 
R&D and pricing strategies. Pharmaceutical companies that are setting high prices for 
medicines in comparison to cheaper alternatives may be “named and shamed” by their 
prices being made public.  This may provide negative publicity which could impact on 
sales and persuade the companies concerned to revisit their pricing strategies.  However 
if there is no cheaper alternative then patients have no choice as to where to purchase their 
essential medicines and would have to pay the high price.  Therefore this type of 
accountability may only be effective in specific circumstances. 
 The Observatory has provided more effective monitoring of medicine prices, 
being a useful source of information for policy makers and the health system1151.  
Therefore it does provide a useful function for patients.  MeTA Peru stated that the 
implementation of the concept of the Peruvian Observatory of Pharmaceutical Products 
has led to the development of a medicines quality observatory and a medicines availability 
observatory.1152 Therefore this recognises that there are other factors in addition to cost 
that may restrict access to medicines in Peru, which also need to be considered when 
developing a national strategy to enhance access to medicines.  In addition to affordable 
medicines, such medicines need to be of good quality and they need to be available to all, 
in order to effectively enhance access to medicines.  These are also key elements of the 
Article 12 ICESCR right to health, as stated in General Comment 141153, which the State 
has an obligation to fulfil.  The replication of the Peruvian model to cover the availability 
and quality of medicines indicates that data on quality and availability, in addition to 
pricing, is useful to the government and civil society organisations when identifying 
measures to address barriers to access in Peru.  The model implemented in Peru may 
therefore provide a suitable example to other States on the utility of gathering national 
data on the range of factors that affect access to medicines which can then be used to 
inform national strategies on ensuring access to medicines.   
 
(c) Conclusions from Section II 
 
                                                            
1151 Medicines Transparency Alliance Peru, Working Together for Better Access to Medicines (n 1133) 5 
1152 ibid  
1153 General Comment No. 14 (n 112) 12 
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The creation of the Observatory to address price inequalities is a positive measure, as 
patients have access to pricing information to help them find the medicines they require 
at the most affordable price.  The Observatory provides a tool for monitoring medicines 
prices and may also add a form of accountability by highlighting disparities in pricing by 
pharmaceutical companies. The effectiveness of the Observatory relies on the cooperation 
of pharmaceutical companies to provide their data, which could present challenges in 
providing complete information to patients.  The State’s engagement in such measures to 
promote access to affordable medicines shows the appetite for enhancing access to 
medicines in Peru. However, this also highlights the wider challenge of addressing the 
role of private pharmaceutical companies in setting high prices for medicines, in order 
for states to meet their obligations simultaneously under TRIPS and the ICESCR. 
 
III. Challenges in securing access to generic medicines 
 
(a) Physical accessibility of generic medicines 
 
In addition to concerns over pricing of medicines, physical accessibility to generic and 
biosimilar medicines is also a key concern1154.  In 2009 the Law of Pharmaceutical 
Products, Medical Devices and Sanitary Products1155 was introduced in Peru, covering 
the regulation of these products, including the safety and quality requirements for 
medicines and the performance of persons involved in the manufacturing, sale and 
export1156.  The Act provides that the National Health Authority has the power to apply 
                                                            
1154 UNCHR ‘Report submitted by the Special Rapporteur on the right of everyone to the highest 
attainable standard of physical and mental health, Paul Hunt, Addendum Mission to Peru’ (4 February 
2005) UN Doc E/CN.4/2005/51/Add.3, 48 
1155 Law No. 29459 on the Law of Pharmaceutical Products, Medical Devices and Sanitary Products, 26 
November 2009 
<http://www.leyes.congreso.gob.pe/DetLeyNume_1p.aspx?xNorma=6&xNumero=29459&xTipoNorma=
0> (accessed 27/04/2020). The Directorate General of Medicines, Supplies and Drugs (DIGEMID), an 
agency of the Ministry of Health , is responsible at national level for ensuring the quality and efficacy of 
pharmaceuticals, including duties such as registering, and monitoring the registrations and marketing 
authorisations listed in the Law of Pharmaceutical Products, Medical Devices and Sanitary Products. See 
Ministry of Health, Directorate General of Medicines, Supplies and Drugs, ‘What do we do?’ 
<http://www.digemid.minsa.gob.pe/Main.asp?Seccion=641> (accessed 27/04/2020) (translated) 
1156 V Dongo, ‘Law N° 29459 of pharmaceutical products, medical devices and sanitary products’ (2009) 
26(4) Peruvian Journal of Experimental Medicine and Public Health 517, 517 
<http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-
46342009000400014&lng=en&nrm=iso>. (accessed on 27/04/2020) (translated) 
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the limitations and exceptions set out in TRIPS and the Doha Declaration1157 for the 
purpose of improving access to essential medicines1158.  The 2009 regulations were 
introduced1159 for pharmaceutical products for a market which was previously 
unregulated, including the regulation of generic medicines1160.  In May 2014 the National 
Association of Pharmaceutical Laboratories (ALAFARPE), the representative 
organisation of the pharmaceutical industry in Peru1161, filed a petition in the Peruvian 
courts seeking to prevent the sale of biosimilar medicines that were similar to products of 
the ALAFARPE companies where the quality and safety had not been verified1162.  Torres 
López argues that the motive of this action was that the pharmaceutical companies under 
ALAFARPE, several of which were foreign companies, intended to prevent the 
commercialisation of generic medicines in Peru1163.  This suggests that the 
pharmaceutical companies under ALAFARPE were seeking to protect their investment 
in their branded medicines and to ensure that generic alternatives did not provide 
competition for those products in the Peruvian markets, which may have had the effect of 
driving down the prices of those products.  The court noted that in the first instance, the 
petition was upheld for reasons including the risk to the right to health of patients who 
choose biosimilar products which have not been proven to be safe and effective through 
pre-clinical and clinical studies which are comparable to those carried out on the original 
branded product1164.  Therefore, DIGEMID was unable to grant registrations of these 
                                                            
1157 Law No. 29459 on the Law of Pharmaceutical Products, Medical Devices and Sanitary Products (n 
1155) Article 27 
1158 ibid 
1159 ibid 
1160 All medicines require marketing authorisation under Article 8 of Law No. 29459, although DIGEMID 
does provisionally authorise the use of medicines in limited circumstances, including where an 
emergency situation has been declared, and in public health situations where the need and 
unavailability of the medicines nationally is demonstrated. See also A Ehlers (ed), Getting the Deal 
Through – Life Sciences 2017, (Law Business Research London 2016), ISSN: 2042-4329, 74; C Rochette, 
‘The Impact Of Regulation On Market Access for Pharma Companies In Peru’, 17 June 2015, 
<https://pharmaboardroom.com/article/the-impact-of-regulation-on-market-access-for-pharma-
companies-in-peru/> (accessed 27/04/2020)  
1161 National Association of Pharmaceutical Laboratories (ALAFARPE), ‘About Us’ 
<http://alafarpe.org.pe/nosotros/> (accessed 27/04/2020) (translated) 
1162 F Torres López, ‘The legal battles of the pharmaceutical monopoly’, 11 March 2015, <http://ojo-
publico.com/36/las-batallas-legales-del-monopolio-farmaceutico> (accessed 27/04/2020) (translated)   
1163 ibid 
1164 Corte Superior de Justicia de Lima, Cuarta Sala Especializada en lo Civil, Expediente Numero 8612-
2014, Resolucion Numero Veintiuno, Lima 17 de Octubre 2016/ Superior Court of Justice of Lima, Fourth 
Specialized Chamber in Civil Matters, Case Number 8612-2014, Resolution Numero Veintiuno, Lima 
October 17, 2016, 3.11-3.12 (translated) 
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biosimilar medicines1165.  This decision identified potential challenges relating to the 
accessibility of cheaper generic copies which existed but which had not been authorised 
by DIGEMID to be marketed in Peru.   
In March 2016 the Peruvian government addressed this issue by introducing new 
regulations on generic medicines1166, including clinical data requirements for biosimilar 
products1167, to promote the use of generic medicines and to ensure their quality and 
safety.  Subsequently the Superior Court of Justice revoked the ruling in favour of 
ALAFARPE, noting that the new regulations were focused on the guidelines of the WHO, 
and there was no decisive evidence that the management and supervision undertaken by 
DIGEMID was insufficient and did not comply with the legal provisions1168.  The result 
of this decision is that DIGEMID is able to approve authorisations for biosimilar 
medicines, and therefore potentially enhance access to such medicines of appropriate 
quality and safety in Peru1169.  In addition, this decision highlights the potential for 
promoting increased competition between branded and generic products in Peru, for the 
purpose of securing more affordable medicines for patients.  The regulation of generic 
medicines to ensure their safety is a positive measure for the benefit of the health of 
Peruvian citizens, and can improve accessibility and availability of biosimilar and generic 
medicines of adequate quality, even if this was not the real motive of the pharmaceutical 
companies behind the ALAFARPE action.  However, this situation does highlight 
potential problems with obtaining the appropriate authorisations to market medicines, 
such as administrative delays.  This could lead to delays in getting these medicines to the 
market efficiently in Peru and providing physical access to generic and biosimilar 
medicines, although it does appear that the government is trying to address issues relating 
to physical access, and quality control, as well as time delays resulting from quality 
control procedures. 
                                                            
1165 María del Carmen Alvarado Bayo et al, ‘Peru’, in R Kingham (ed), The Life Sciences Law Review, (5th 
ed, The Law Reviews, April 2017), VIII 
1166 Decreto Supremo No. 013-2016-SA, (March 1st, 2016) 
<http://www.digemid.minsa.gob.pe/UpLoad/UpLoaded/PDF/Normatividad/2016/DS_013-2016.pdf> 
(accessed 27/04/2020); See also Ana Maria Agueda Chura Tito, Peru Ministerio de Salud, Recent Trends 
in the Regulation of Biotechnological Products in Peru, 
<https://cdn.ymaws.com/www.casss.org/resource/resmgr/cmc_euro_speaker_slides/2018_cmce_Chur
aAna.pdf> (accessed 27/04/2020) 
1167 Chura (n 1166) 16 
1168 Superior Court of Justice of Lima, Fourth Specialized Chamber in Civil Matters, Case Number 8612-
2014 (n 1164) 14 
1169 María del Carmen Alvarado Bayo et al (n 1165) VIII 
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(b) Quality of medicines 
 
The availability of generic medicines as an affordable alternative to branded medicines is 
particularly important to the health care services in the State.  In 2012 the CESCR 
reported that 98 percent of the medicines marketed in Peru were generic1170.  A report by 
the Oxford Business Group in 2014 noted that due to the costs of production of medicines 
in Peru, the Ministry of Health chiefly purchased generic medicines1171.  The General 
Law of Health states that medical practitioners should always prescribe a generic product 
if possible, and the patient should always be informed of the availability of a generic 
version of the required medicine where it exists1172.  This provides an example of good 
practice to other states of the potential to increase the use of existing generic medicines 
if patients are given the appropriate information by health care providers, on the quality 
and use of generic medicines as a more affordable alternative to the branded version of 
the medicine.  However, a challenge is ensuring that the affordable alternatives are of 
good quality. 
 The Oxford Business Group report suggested that patients may favour buying 
branded medicines at a higher cost than the generic equivalent because they believed that 
generic versions of medicines were of inferior quality1173.  A reason for this could be the 
circulation of counterfeit medicines in the State.  Counterfeit medicines are a major public 
health concern in Peru, and Medina et al argue that considerable efforts are needed in 
order to control this problem1174.  A counterfeit medicine is described as an improperly 
manufactured product, in a deliberate and fraudulent manner, and may include products 
with incorrect ingredients or which have falsified labelling1175.  Therefore counterfeit 
                                                            
1170 UNCESCR ‘Summary record of the first part (public) of the 8th meeting; Consideration of reports (a) 
Reports submitted by States parties in accordance with articles 16 and 17 of the Covenant (continued); 
Combined second to fourth periodic reports of Peru (continued)’ (14 May 2012) UN Doc 
E/C.12/2012/SR.8, 3 
1171 Oxford Business Group, The Report: Peru 2014, (Oxford Business Group, 2014), ISBN: 
9781907065941, 215 
1172 General Law of Health (Law No. 26842 of 1997), 20 July 1997, Article 26 (Digital Archive of the 
Legislation of Peru) 
<http://www.leyes.congreso.gob.pe/LeyNume_1p.aspx?xEstado=2&xTipoNorma=0&xTipoBusqueda=4&
xFechaI=&xFechaF=&xTexto=&xOrden=0&xNormaI=26842&xNormaF=> (accessed 27/04/2020) 
1173 Oxford Business Group, The Report: Peru 2014 (n 1171) 215 
1174 E Medina, E Bel and J María Suñé, ‘Counterfeit medicines in Peru: a retrospective review (1997-
2014)’ (2016) BMJ Open 6, doi:10.1136/bmjopen-2015-010387, 1 
1175 ibid 2 
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medicines can relate to branded and generic medicines.  Medina et al state that a real 
concern over counterfeit medicines is that the highest rates of counterfeit medicines were 
found in pharmacies1176, which suggests an issue with the supply of legitimate medicines 
to pharmacies.  This further affects the population’s access to effective medicines and 
may result in a lack of confidence in health services to provide safe, reliable and 
efficacious treatments.  This could also lead to patients seeking other methods of 
obtaining the medicines that they require, which could also be harmful if they acquire 
medicines without receiving adequate medical advice, or where the quality of such 
products is unclear.  This would be particularly concerning where such patients are in 
need of essential, life-saving medicines.   
Counterfeit medicines were shown to be most prevalent among national brands as 
opposed to imported medicines, and the counterfeiting of life saving medicines signifies 
a serious public health threat1177. The supply of counterfeit medicines being widely 
circulated in Peru restricts access to medicines as patients are not receiving the medicines 
that they need, and they may also not be aware of the health risks associated with these 
products, particularly if they are purchasing these medicines from legitimate sources such 
as pharmacies.  In 2013 the OECD noted that ALAFARPE reported the measure of 
counterfeit medicines to be around $46 million1178.  Therefore, the Peruvian government 
should take steps to prevent such products from reaching pharmacies, to ensure that 
patients are not purchasing or consuming potentially dangerous products.  The right to 
health has several elements including that health goods must be of sufficient quality, 
requiring scientifically approved medicines,1179 and also includes the specific legal 
obligation on the State to refrain from marketing unsafe medicines1180.  Therefore, the 
Peruvian government has to take positive actions to address this concern as part of its 
obligations under Article 12 ICESCR.  
A further benefit of the Peruvian Observatory of Pharmaceutical Products is that 
it has helped to counteract the entry into the market of counterfeit medicines, by alerting 
reporting authorities to informal suppliers who have tried to enter unregistered products 
                                                            
1176 ibid 6 
1177 OECD, Overview of global counterfeit medicines, 2013, P.20 
<http://globalforumljd.com/new/sites/default/files/documents/virtualLibrary/OECD%202014%20Overvi
ew%20of%20global%20counterfeit%20medicines.pdf> (accessed 27/04/2020) 
1178 ibid 
1179 General Comment No. 14 (n 112) 12(d) 
1180 ibid 34 
 240 
 
into the system1181.  This is an important contribution to enhancing access to medicines 
of sufficient quality as such counterfeit medicines could have an adverse effect on health, 
and indicates that the model can be utilised to address other factors that impede access to 
medicines, in addition to cost.  However, it would be useful for these observatories to 
collate full evidential data on the impact of this monitoring to be able to analyse the 
practical effects of these monitoring mechanisms. 
 
(c) Data exclusivity and development of local generic medicines 
 
Peru is reliant on importation of medicines1182, which may impact on the State’s ability 
to develop new medicines domestically to meet the specific needs of its population.  The 
Special Rapporteur on health identified specific concerns relating to the right to health 
and access to medicines as including the potential impact of the US-Peru FTA on access 
to essential medicines in Peru1183.  The CESCR also expressed concern that the State 
concluded the US-Peru Free Trade Agreement in December 2005, because it included 
TRIPS-plus provisions severely restricting future access to new and affordable generic 
medicines, which was particularly concerning in Peru as it was noted that the population 
relied heavily on affordable generic medicines.1184  The inclusion of TRIPS-plus 
provisions in FTAs is a key concern emanating from the work of the UN human rights 
bodies in relation to access to medicines1185.  Particular concerns included terms which 
have the effect of providing data exclusivity for pharmaceutical products1186 as well as 
                                                            
1181 World Health Organization, ‘Essential medicines and health products’ > ‘Making medicine prices 
transparent in Peru’, 
<http://www.who.int/medicines/areas/coordination/medprice_transparent_peru/en/> (accessed 
27/04/2020)  
1182 Between 2011 and 2015 Peru’s pharmaceutical imports increased from a value of approximately 
$586 million (USD) to approximately $802 million (USD), falling in 2016 to approximately $772 million 
(USD).  By comparison, the pharmaceutical exports increased from approximately $36 million (USD) in 
2011 to approximately $52 million in 2013, falling over the following two years to approximately $41 
million (USD) in 2016.  This indicates that Peru relies on importing medicines in order to meet the 
demands of the population and the fall in the value of pharmaceutical exports suggests that Peru does 
not have a large established pharmaceutical manufacturing industry. (See UN COMTRADE Database (n 
808)) 
1183 UNCHR ‘Report submitted by the Special Rapporteur on the right of everyone to the highest 
attainable standard of physical and mental health, Paul Hunt, Addendum Mission to Peru’ (4 February 
2005) UN Doc E/CN.4/2005/51/Add.3, 47 
1184 UNCESCR ‘Concluding observations of the Committee on Economic, Social and Cultural Rights: Peru’ 
(30 May 2012) UN Doc E/C.12/PER/CO/2-4, 25 
1185 As discussed in Chapter 3 of this thesis. 
1186 World Trade Organization, ‘RTA database > United States-Peru’, Article 16.10(2)(a)-(c) 
<http://rtais.wto.org/UI/PublicShowMemberRTAIDCard.aspx?rtaid=180> (accessed 27/04/2020) 
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the extension of the patent term for the marketing approval process1187.  These terms 
amount to TRIPS-plus provisions that could delay the development of local generic 
medicines1188, could lead to a delay in getting new, essential medicines to patients, and 
therefore potentially contravenes the statements made on the promotion of access to 
medicines in the agreement1189.  This highlights that states need to ensure greater 
consistency with regard to national policy on regulation and monitoring of medicines and 
international policy regarding terms in bilateral trade agreements, which may impact on 
access to medicines.   
Cartagena and Attaran argue that the US-Peru FTA marked a change in the 
language used to define the data exclusivity provisions for pharmaceuticals, compared 
with earlier FTAs entered into by the US1190, with Article 16.10(2)(b) providing that the 
exclusivity period shall “normally mean five years from the date on which the Party 
granted approval to the person that produced the data for approval to market its 
product”1191.  Cartagena and Attaran argue that this wording provides unlimited scope to 
vary the term of data exclusivity1192, which could lead to a longer period of data 
exclusivity being implemented.  The inclusion of the word “normally” does suggest that 
there is some flexibility over the length of term, although the parties have agreed this term 
so the drafting of the term does indicate that the parties have agreed the five year period, 
as opposed to there being unlimited scope for varying the term1193.  The term “normally” 
is also largely interpreted as setting out a general rule in a treaty.  As such, the burden of 
departing from the general rule lies with the party wishing to depart from it, and this is 
usually a difficult burden to discharge.  An example of this is evident in US – Clove 
Cigarettes1194, where the Panel agreed that the inclusion of the term “normally” qualifies 
the length of an interval1195.  On appeal, the Appellate Body stated that this meant that the 
burden was on the responding Member to make a prima facie case that the departure from 
                                                            
1187 ibid Article 16.9(6)(c) 
1188 L Araujo and M Montagne, ‘Effect of the US-Peru Free Trade Agreement on Peruvian New Drug 
Policies and the Registration of Pharmaceutical Products’ (2013) 11(24) International Society for 
Pharmacoeconomics and Outcomes 
1189 World Trade Organization, ‘RTA database > United States-Peru’ (n 1186) Article 16.13(2)(a) 
1190 Cartagena and Attaran (n 565) 280 
1191 ibid 281 
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1193 The treaty does not provide specific guidance on when parties can derogate from the five year term. 
1194 United States – Measures Affecting the Production and Sale of Clove Cigarettes, WT/DS406/R, 
adopted 2 September 2011 
1195 ibid 7.580 
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the general rule where the interval is “normally” a specified period is justified1196.  In this 
case the Appellate Body found that the responding Member, the US, had failed to do 
so1197.  Therefore, it is difficult to justify the argument that there would be unlimited scope 
for the variance of the term of data exclusivity. 
In addition to the terms of data exclusivity in the US-Peru FTA, other terms within 
the FTA have also been highlighted as potentially being TRIPS-plus terms.  It is pertinent 
to note that Article 16.9(2) explicitly recognises the flexibility contained in Article 27 of 
TRIPS, which allows WTO Members to exclude methods of medical treatment from 
patentability.  This highlights that the Agreement supports an important flexibility in 
terms of production of new medicines.  The inclusion in Article 16.9(6)1198 of terms 
requiring patent authorities to monitor whether pharmaceutical products which form the 
subject matter of marketing approval applications are covered under existing patents, has 
been described as patent linkage1199.  This is because the process would notify patent 
holders of competitors’ products, and may also require that states deny marketing 
approval for products such as cheaper generic medicines if the approval is sought on the 
basis of data submitted by the patent holder for its products1200.  This could be problematic 
in terms of developing a competitive market for medicines in Peru, given that currently 
the pharmaceutical market is relatively small.  Hsu argues that such terms effectively 
create another layer of patent protection which clearly exceeds TRIPS, as this requirement 
creates a link between the marketing approval process for generic medicines and the status 
of the patented original medicines.1201  This indicates that the state’s marketing approval 
authority must not grant approval for a generic medicine if it is believed that the medicine 
may infringe an existing patent.  This would essentially provide that the marketing 
approval authority is responsible for patent enforcement, which appears to be outside of 
the authority of the regulatory body.  The effect of this could be to limit the physical 
accessibility to generic medicines as a cheaper alternative to the branded product.  This 
further highlights the issue of the importance of national coherence across government to 
ensure consistency in policy on enhancing access to medicines.  This is a key concern 
                                                            
1196 United States – Measures Affecting the Production and Sale of Clove Cigarettes, WT/DS406/AB/R, 
adopted 4 April 2012, 289 
1197 ibid 296-297 
1198 World Trade Organization, ‘RTA database > United States-Peru’ (n 1186) Article 16.9(6)  
1199 L Hsu, ‘Regulatory flexibilities and tensions in public health and trade – an Asian perspective’ (2015) 
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which is recognised generally in the human rights arena, with an example being John 
Ruggie’s 2008 report on business and human rights, in which he highlighted the adverse 
effects of domestic policy incoherence1202. 
The FTA states that, notwithstanding the data exclusivity terms under Article 
16.10(2), a party “may take measures to protect public health”1203 in accordance with the 
Doha Declaration and subsequent Implementation Decision, suggesting that the parties 
are entitled to take positive steps for the benefit of public health including access to 
medicines.  Article 16.13 expands on this by outlining the states’ commitments in relation 
to public health1204.  Article 16.13(2)(a) states that the obligations under the agreement 
should not prevent the state parties from taking measures to protect public health by 
promoting access to medicines, in particular to treat epidemic diseases or a national 
emergency1205.  In addition Article 16.13(2)(a) states that the provisions under Chapter 
16 can and should be implemented in a way that supports each Party’s right to protect 
public health, in particular, to promote access to medicines for all1206.  This implies a 
positive duty on the states to interpret and apply the provisions in a way which promotes 
access to medicines, and also frames this as the state party’s right, rather than obligation, 
to protect public health and to promote access to medicines.  A dispute settlement tribunal 
would have to respond to any arguments made by the respondent State in reliance on 
Article 16.13.  This is different from the situation, for example, of a trade law or 
investment law tribunal being asked to engage with a human rights norm which is external 
to the treaty under interpretation. 
 
(d) Conclusions from Section III 
 
The State’s reliance on generic medicines makes it particularly important to have physical 
access to generic medicines of good quality. The implementation of regulations which 
include specific provision to utilise TRIPS and the Doha Declaration to enhance access 
                                                            
1202 UNHRC ‘Promotion and Protection of all Human Rights, Civil, Political, Economic, Social and Cultural 
Rights, including the Right to Development: Protect, Respect and Remedy: a Framework for Business 
and Human Rights: Report of the Special Representative of the Secretary-General on the issue of human 
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1205 ibid Article 16.13(2)(a) 
1206 ibid 
 244 
 
to essential medicines provides an example of the State taking positive actions to meet its 
obligations simultaneously under TRIPS and the ICESCR.  However, the possibility of 
extended patent protection in the US-Peru FTA, and the potential impact on access to 
generic medicines does present a possible tension between the State’s obligations under 
TRIPS and the ICESCR, and highlights the importance of coherence on policy on 
medicines across government departments.  
 
IV. Health policy measures for access to medicines for marginalised groups 
 
(a) Access to medicines by the most marginalised groups 
 
Improving access to medicines specifically for marginalised groups is a key concern in 
the State, and has been highlighted by UN human rights bodies1207.  In April 2005 the 
Ministry of Health published a health impact assessment on the impact of the US-Peru 
FTA on medicines1208, as noted above.  Although this was not a human rights impact 
assessment, it does highlight that the national government recognised that there was a 
need to assess the effect of the FTA specifically on access to medicines in the State.  The 
assessment concluded that the FTA would affect access to generic medicines, and that in 
the first five years of the FTA, between 700,000 and 900,000 people per year would be 
left without medicines if the national health budget or the incomes of the poorest 
households did not change.1209  This emphasises the need for greater calibration when 
addressing access to medicines, to include not just lower costs and broad-scale 
accessibility, but also wider concerns including access to resources, quality of health 
services and the specific needs of minority and marginalised groups to ensure that their 
rights are protected.  The assessment made several recommendations, including the 
creation of an observatory of prices made available to the public, to pressure the market 
to lower prices, and establishing norms to oblige companies to disseminate pricing 
                                                            
1207 See examples: UNCHR ‘Report submitted by the Special Rapporteur on the right of everyone to the 
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information1210.  As discussed above, an observatory of prices has been established in the 
State, which indicates that the State did engage with the recommendations of the health 
impact assessment, and provides an example of good practice to other states in relation 
to undertaking impact assessments prior to agreeing FTAs.   
To enhance access to medicines for marginalised groups, it is not only important 
for the national government to increase spending on health care and medicines, but also 
to ensure that resources are allocated appropriately according to need.  Other 
recommendations from the health impact assessment included the promotion of TRIPS 
flexibilities, strengthening of health insurance initiatives, and increasing the Ministry of 
Health budget to cope with additional spending on medicines.1211  The Special Rapporteur 
on health also reported that the government devoted inadequate resources to the health 
sector, and that budget allocations for health care were inequitable1212.  Such inequality 
could have a significant impact on marginalised groups, including the poorest of the 
population.    The Special Rapporteur recommended that the State developed a ‘pro-poor 
equity-based health policy’ and allocated greater financial resources to the health sector 
in line with such a policy1213. 
The national government has implemented several measures to improve access to 
health care and medicines for marginalised groups.  For example, in November 2019 the 
government introduced urgent measures to close the gap in the population without health 
insurance and introduce universal health coverage1214.  The emergency decree states that 
this measure was introduced to guarantee protection of the Constitutional right to health, 
demonstrating the value of a rights-based approach to health care and medicines1215.  The 
measure will be subject to progressive entry into force, and it will be important to assess 
the efficacy of the measure in improving access to medicines. However, it could provide 
a direct benefit to the poor and marginalised groups who would have been unable to afford 
health insurance. 
                                                            
1210 ibid P.253  
1211 ibid 
1212 UNCHR ‘Report submitted by the Special Rapporteur on the right of everyone to the highest 
attainable standard of physical and mental health, Paul Hunt, Addendum Mission to Peru’ (4 February 
2005) UN Doc E/CN.4/2005/51/Add.3, 36 
1213 ibid 28, 38 
1214 Decreto de Urgencia Nº 017-2019 Decreto de Urgencia Que Establece Medidas para la Cobertura 
Universal de Salud/Decree of Emergency No. 017-2019 Emergency Decree Establishing Measures for 
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(accessed 27/04/2020) 
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The national government has also implemented policy measures to improve 
access to health care and medicines for marginalised groups, and this has been highlighted 
through the UN human rights framework.  In 2007 the Special Rapporteur recognised that 
Peru had implemented a National Plan of Human Rights (2006-2010)1216, which included 
implementing a national drug policy guaranteeing the population access to quality generic 
medicines1217. Other initiatives included la Cruzada Nacional por los Derechos y 
Responsabilidades Ciudadanas en Salud (National Crusade for the Quality of Health 
Services)1218, with the aim of the formulation of a comprehensive health policy based on 
the right to health and equity.  Peru’s engagement with the recommendations of the UN 
human rights bodies in the development of a national rights-based health policy was 
recognised during the peer review process of the UPR.1219 The evaluation of the policy 
by the Special Rapporteur also suggests that this measure provides an instructive example 
for other States seeking to implement a health policy in compliance with their obligations 
under the right to health.   
The UPR has given Peru the opportunity to highlight measures that the State had 
taken to improve health standards for marginalised groups in accordance with the right to 
health. During the first cycle, Peru stated that the State was engaging with participative 
programmes to address poverty, including designing social support programmes with 
significant resources for poor and marginalised communities 1220.  This also provides an 
example of the utility of the UPR in providing a reporting and review process for states 
to evidence measures taken to comply with their international human rights obligations.  
During the second cycle of UPR Peru highlighted that significant budget increases had 
been provided in the area of health, as well as an increase in the proportion of people 
enjoying health insurance1221. This may indicate an improvement in standards of health 
                                                            
1216 UNHRC ‘Compilation prepared by the Office of the High Commissioner for Human Rights, in 
accordance with paragraph 15(b) of the annex to the Human Rights Council Resolution 5/1: Peru’ (9 
April 2008) UN Doc A/HRC/WG.6/2/PER/2, 7 
1217 Ministerio de Justicia, Consejo Nacional de Derechos Humanos, Plan Nacional de Derechos Humanos 
2006-2010, Anexo – Decreto Supremo No 017-2005-JUS, Dicembre 2005, P.305970, 3.2.3, R1, A8 
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1219 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Peru’ (28 May 2008) UN Doc 
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1220 ibid 48 
1221 UNHRC ‘Report of the Working Group on the Universal Periodic Review: Peru’ (27 December 2012) 
UN Doc A/HRC/22/15, 36 
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services, however academics have argued that although promising measures had been 
taken to improve health standards through a rights-based approach, the pace of this 
progress has slowed, in part due to the political landscape1222.  This highlights the impact 
of the political will of the national government on compliance with the State’s duties 
under the right to health, including enhancing access to medicines.  Sandoval and Cáceres 
argue that advancing a practical health rights agenda has been difficult in Peru as although 
high-level policy statements have addressed health as a right, this has not been the case 
in the formulation of specific health policies.1223  This indicates a need for greater 
coherence at national level on how to incorporate a rights-based approach in the 
development of health policies for specific issues.  Haley et al also argue that another 
reason for the slowing of such progress is that the State’s health care infrastructure is not 
currently adequately equipped to deal with the changing burdens on the health services, 
and that this created a barrier to primary health care.1224  Therefore, in addition to an 
increase in resources, there is a need to use the resources effectively in combination with 
improvements to the health infrastructure in order for the State to fulfil its obligations 
under the right to health.  This further highlights the need for greater alignment of the 
issues affecting health and access to medicines, to include these wider concerns. 
An important and distinct issue in terms of the State’s core minimum obligations 
under Article 2 ICESCR is that the State should take measures to secure efficacious access 
to generic medicines for the benefit of the whole population, including the poorest 
patients1225. General Comment 3 outlines that where any significant number of 
individuals is denied access to essential primary health care, the State is failing to fulfil 
its obligations1226, and underlines that vulnerable members of society must be protected 
even where a State has severe resource constraints1227.  This further highlights the 
complex nature of the issues surrounding access to medicines, with the need to enhance 
                                                            
1222 A Frisancho, ‘The right to health in Peru’ in J Zuniga, S Marks and L Gostin (eds), Advancing the 
Human Right to Health, (Oxford University Press, Oxford, 2013), ISBN: 9780199661619, P.189. Since July 
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access for marginalised groups including the poorest sections of the population.  The 
CESCR’s concluding observations in 2012 noted the efforts of the State in promoting 
economic, social and cultural rights1228, but expressed concern over inadequate access to 
and quality of health services, especially in remote areas1229.  The CESCR recommended 
that the State take steps to improve access to and quality of health services, including 
addressing barriers to access1230.  It is pertinent to note that the State reported that it had 
implemented a Coordinated National Health Plan (PNCS), based on a participative 
process and which set health objectives for the period 2007-20111231. This highlights that 
the State did engage with the observations of the CESCR with regard to the provision of 
health services in the State and had taken positive measures to adopt a national health 
policy. The implementation of such measures was also reflected during the first cycle of 
UPR, as noted above.  The CESCR also requested that the State provide disaggregated 
data on access and quality of health services in the State in its next report1232, indicating 
that the CESCR required evidence of the efficacy of such measures in terms of enhancing 
access to quality health services for all sections of the population, including marginalised 
groups.  This would allow for a more detailed examination of such measures by the 
CESCR, and therefore could produce examples of good practice for other jurisdictions to 
follow. It has not been reported whether the State provided the data requested by the 
CESCR1233, although this could be included in the next state report. 
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record of the 6th meeting; Consideration of reports (a) Reports submitted by States parties in 
accordance with articles 16 and 17 of the Covenant (continued), Combined second to fourth periodic 
reports of Peru’ (9 May 2012) UN Doc E/C.12/2012/SR.6; UNCESCR ‘Summary record of the first part 
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(b) Indigenous peoples and access to medicines 
 
As also noted in the case study on Canada, there are issues for indigenous peoples in Peru 
relating to access to prescription medicines and the protection of traditional medicines 
from appropriation.  Underpinning these issues includes the rights of indigenous peoples 
to self-determination, including their rights to control their indigenous natural resources, 
such as traditional medicines.  Sem argues that the pharmaceutical industry derives great 
benefit from traditional medicines, with Peru being a particularly abundant source of 
traditional medicines1234.  Approximately 45 percent of the Peruvian population is 
indigenous1235.  Williamson et al note that Peru’s national health statistics are estimated 
by geographical area rather than ethnic group1236.  This could result in inaccurate 
representations of the health needs of indigenous populations.  Therefore, it is important 
to examine how these issues are addressed in Peru, and whether any lessons can be 
learned from the experiences of these States which could inform the development of 
indigenous rights and policy in other states.   
 
(i) Access to prescription medicines 
 
There is a need to bridge the gap between indigenous peoples and non-indigenous services 
by enhancing the understanding of the services that the national government can provide 
for the benefit of the indigenous peoples.  The concluding observations of the CESCR1237 
in 2012 expressed concern about the high percentage of the population, particularly in 
                                                            
(public) of the 8th meeting; Consideration of reports (a) Reports submitted by States parties in 
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1234 D Sem, ‘Co-Developing Drugs with Indigenous Communities: Lessons from Peruvian Law and the 
Ayahuasca Patent Dispute’ (2016) 23 Richmond Journal of Law & Technology 1, 10 
1235 Central Intelligence Agency, ‘The World Factbook: South America: Peru’, ‘People and Society: Peru’ 
<https://www.cia.gov/library/publications/the-world-factbook/geos/pe.html> (accessed 27/04/2020) 
1236 J Williamson et al, ‘Health, Healthcare Access, and Use of Traditional Versus Modern Medicine in 
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1237 UNCESCR ‘Concluding observations of the Committee on Economic, Social and Cultural Rights: Peru’ 
(30 May 2012) UN Doc E/C.12/PER/CO/2-4 
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remote areas, that does not benefit from health care coverage and recommended that the 
State take steps to address economic, social and cultural barriers to access to health care 
services1238.  This suggests that marginalised groups including indigenous peoples in Peru 
do not have appropriate health facilities1239 and services available to them, as required 
under the Article 12 right to health.  This also suggests that there are several factors which 
have created such barriers, including that indigenous peoples may be failing to engage 
with necessary health services if they are available, because they are not culturally 
appropriate.  Dongo states that in Peru the right to access medicines also involves 
acceptability of health services including the need to take into account the cultures of 
populations and their perceptions of health and disease1240.  Therefore, meeting the needs 
of indigenous peoples and their cultural position on medicines and diseases is an 
important obligation of the State under the right to access medicines, and ensuring that 
specific health services and support are available and accessible to those groups forms 
part of the right of all citizens to have access to essential medicines in Peru.  Such 
provisions would require consultation with indigenous peoples as part of their right to 
self-determination1241 in order to achieve a collaborative relationship to facilitate the 
effective and appropriate treatment of the health needs of indigenous peoples.   
 Gianella et al argue that weaknesses in the health system, including the lack of 
timely diagnosis1242 have a negative impact on treatment of indigenous peoples 
particularly in tuberculosis cases.  Gianella et al also argue that there is a need to address 
low investment in health services, and poverty in order to address the risk of tuberculosis 
in indigenous peoples1243.  This indicates that there is a direct link between the level of 
investment in services for indigenous peoples by the Peruvian government and quality of 
                                                            
1238 ibid 20 
1239 In the consideration of the State report prior to the CESCR’s Concluding Observations in 2012, it was 
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treatment for a disease known to be a specific risk to indigenous groups. This also 
underlines the importance of the facilitation of services for indigenous peoples who have 
specific needs and also are susceptible to specific risks to their health collectively. The 
issue of poverty also reiterates that the cost of medicines may act as a barrier to 
prescription medicines particularly for indigenous peoples, and suggests that the public 
health plans and health insurance programmes may not be accessible to, or suitable for, 
indigenous peoples. 
Brierley et al state that there is some evidence of improved healthcare access for 
indigenous peoples in Peru over the last decade, although ongoing challenges with access 
to basic medical care still remain, including poverty, infrastructure and low education 
levels1244.  Improvements were noted to result from factors including developing links to 
urbanised areas, and improved transportation reducing the length of time taken to travel 
to these groups1245.  This highlights that a challenge in ensuring access to necessary health 
services and medicines for indigenous peoples in developing countries include addressing 
physical inaccessibility, such as improving the State infrastructure and links to health care 
services. It is also important that such services are culturally appropriate, so that 
indigenous peoples participate in the development of programmes to provide education 
on indigenous health care. However, Brierley et al argue that although these groups are 
situated in largely remote locations, financial constraints may be a greater barrier to health 
care, including medicines, than the distance from urbanised regions1246.  Therefore, 
although indigenous peoples may have experienced some improvement in health services 
from stronger links to non-indigenous urban regions, this was not enough to address the 
combination of complex issues which restrict indigenous peoples from accessing health 
services including prescription medicines.  Poverty is a significant concern in relation to 
indigenous peoples which can also act as a barrier to access to essential medicines.  This 
emphasises the importance of greater alignment of these multifaceted and wide-ranging 
issues which impact on access to medicines. 
 Measures have been introduced which indicate that the government is taking 
positive actions to comply with its obligations regarding the rights of indigenous peoples 
to participate in the promotion of health services that affect them.  The Directorate of 
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Indigenous Issues1247 is a unit of the Ministry of Health which is responsible for 
promoting the development of health policies in coordination with the indigenous peoples 
and in consideration of their culture1248.  Further, in 2016 the Sectoral Policy on 
Intercultural Health was adopted with the purpose of aligning indigenous and non-
indigenous health systems, involving recognising indigenous medicines and an 
intercultural approach at all levels of care1249.  Gianella et al argue that the State has a 
central role in developing policies and in the allocation of resources to improve access to 
health services, and therefore the focus should be on the State actions and making the 
State accountable for complying with its UN human rights obligations under the ICESCR 
Article 12 right to health1250.  It would be useful for the State to monitor the 
implementation of these measures to evaluate their effectiveness in improving the level 
of health care, including access to essential medicines, for indigenous peoples.  This could 
provide useful evidential data for other states considering implementing measures to 
further the rights of indigenous peoples nationally, in accordance with their international 
human rights obligations.  
 
(ii) Traditional resources and medicinal knowledge 
 
Several national legislative provisions recognise that supporting the use of traditional 
medicines is also part of the right of indigenous peoples to access essential medicines. 
Sem observes that although the Constitution of Peru does not directly protect the rights 
of its indigenous peoples, Article 68 does contain a provision to promote the conservation 
of biological diversity1251, which includes traditional medicines and indigenous natural 
resources.  The Peruvian government implemented the General Law of Health1252 in 1997, 
which states that the promotion of traditional medicine is a key interest of the State1253.  
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In 2002 the Peruvian government also implemented the Law No. 27811, introducing a 
Protection Regime for the Collective Knowledge of Indigenous Peoples derived from 
Biological Resources1254, to ensure the protection of the IP and traditional knowledge of 
indigenous peoples.  The introduction of national legislation to enshrine indigenous rights 
over their traditional resources, protecting their access to their traditional medicines, 
reflects the State’s recognition of the rights to protection of traditional knowledge and 
medicinal resources in Peru.  Boza argues that this law also recognises that “traditional 
intellectual property rights are not fully effective in addressing the traditional knowledge 
problem”1255. This highlights that the State has taken positive action to address possible 
tensions in relation to IP rights and protecting the rights of indigenous peoples to their 
traditional medicines, in order to meet its obligations under TRIPS and the ICESCR.  It 
also highlights the importance of careful calibration across government departments in 
order to address these complex issues. 
The implementation of Law No. 27811 is an important development as it 
recognises that indigenous peoples have collective rights over their resources and creates 
legal obligations for the government to uphold those rights.  Objectives of the Law No. 
278111256 were to avoid patents being granted on the basis of indigenous knowledge 
without the appropriate recognition of the same1257, to promote equitable distribution of 
the benefits derived from the use of the indigenous knowledge1258, and to promote the use 
of the traditional knowledge for the benefit of not only the indigenous peoples, but for the 
benefit of everyone1259.  The Law recognises the collective knowledge rights of 
indigenous peoples, and their authority to make decisions on the use of their traditional 
knowledge1260.  Legislation introduced in 20041261 went further, to implement measures 
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of Peru 
<http://www.leyes.congreso.gob.pe/LeyNume_1p.aspx?xEstado=2&xTipoNorma=0&xTipoBusqueda=4&
xFechaI=&xFechaF=&xTexto=&xOrden=0&xNormaI=27811&xNormaF=> (accessed 27/04/2020); English 
translation sourced from WIPO Lex <http://www.wipo.int/wipolex/en/details.jsp?id=3420> (accessed 
27/04/2020)) 
1255 RT Boza, ‘Protecting Andean Traditional Knowledge and biodiversity Perspectives Under the U.S.-
Peru Trade Promotion Agreement’ (2006) 16 Currents: Int'l Trade L.J. 76, 77 
1256 Law No. 27811 of 24 July 2002 (n 1254) 
1257 ibid Article 5(f)  
1258 ibid Article 5(b) 
1259 ibid Article 5(c) 
1260 ibid Article 1  
1261 Law No. 28216 on the Protection of Access to Peruvian Biological Diversity and Collective Knowledge 
of Indigenous Peoples, 30 April 2004, (English translation sourced from WIPO Lex 
<http://www.wipo.int/wipolex/en/details.jsp?id=5752> (accessed 27/04/2020))  
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on the protection of biological resources and traditional knowledge1262, and included the 
composition of a National Commission1263 to oversee such protection, with functions 
comprising the tracking of applications for patents filed or granted abroad that related to 
biological resources or collective knowledge of the indigenous peoples of Peru1264.  This 
could be a significant measure in protecting the use of traditional knowledge including 
traditional medicines from appropriation without consent in domestic patent applications 
and also extraterritorially, although seeking enforcement outside of national territory may 
be difficult and require the cooperation of the State in which the patent is filed.   In 
practice, the legislation functions well to protect traditional knowledge, and is considered 
to be a model for other countries to protect their traditional knowledge.1265  Peru also has 
considerable means of enforcement at domestic level, but a key challenge is using 
sanctions effectively against parties located outside of Peru.1266  Enhanced international 
cooperation among states to protect traditional knowledge could be useful to support the 
measures implemented at national level. 
Although there are legislative measures for the protection of the collective rights 
of indigenous peoples over their traditional resources including medicines, in practice 
there may be gaps in the efficacy of these legal measures.  In 2012 the CESCR expressed 
concern that consultation and consent of indigenous peoples was not systematically 
sought in decision making processes relating to the exploitation of their traditional natural 
resources1267.  The right to self-determination under UNDRIP includes participation in 
measures to determine their health measures, which include measures relating to 
traditional medicines and medicinal resources1268. This further indicates that states need 
to ensure greater coherence between their international human rights commitments and 
their domestic legislative provisions to enhance human rights nationally.  The Special 
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Rapporteur on the right to health stated that the Peruvian government should ensure that 
training courses including training in the medical practices and traditions of indigenous 
groups should be provided, to help preserve the collective knowledge of the indigenous 
peoples1269. This could help to promote the specific rights of indigenous peoples with 
regard to their rights of access to medicines including traditional medicines. However, it 
would be important that any such provisions were developed in consultation with 
indigenous peoples as part of their right to self-determination, including the right to 
participate in development of health programmes affecting them. This may also further 
help the State to facilitate the building of relationships between the indigenous peoples 
and non-indigenous health services.  
During the second cycle of UPR the national report of Peru1270 disclosed that, in 
order to preserve the collective knowledge of indigenous peoples that is tied to biological 
resources, regulations were developed to provide for the functioning of a fund for the 
development of indigenous peoples that was set up under Law No. 278111271.  This 
indicates that, in addition to consultation, the protection of indigenous resources requires 
appropriate financial support from the government to protect the collective knowledge of 
indigenous peoples, and this had not initially been provided for under the legislation.  This 
also provides an example of the State engaging with the work of the UN human rights 
bodies to improve protection of and access to traditional medicines for indigenous 
peoples, in line with their international obligations in relation to access to medicines.  
As noted above, a key concern of UN human rights bodies is the inclusion of 
TRIPS-plus terms in FTAs.  Sem argues that bilateral free trade agreements may lead to 
higher protection for IP rights and less protection for traditional knowledge as such rights 
are conceded by developing countries in return for other trade benefits1272 in Peru.  This 
suggests that the bargaining position of developing States during negotiations may result 
in disengagement with the international human rights of indigenous peoples and the 
obligations of States emanating from these rights.  Although there are examples of 
TRIPS-plus terms being included in bilateral trade agreements, it is also evident that such 
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agreements may be negotiated to include terms which may promote access to medicines.  
Academics have argued that Peru’s position with regard to the US-Peru FTA has been 
assisted by participation in the Andean Community, a transnational South American 
organisation comprising the governments of Bolivia, Colombia, Ecuador and Peru1273 as 
a voluntary alliance for purposes including the enhancement of their bargaining power in 
trade negotiations.   
The Andean Community has law-making powers, which are adopted nationally 
by the member states.  Sem contends that the member governments have used the political 
influence afforded to them through participation in the Andean Community, operating as 
a regional group with enhanced political bargaining power, to benefit from the TRIPS 
flexibilities to enhance public health and to collectively resist pressure from States with 
a stronger bargaining position1274.  Sem argues that this was central to securing protection 
for traditional medicines knowledge in the US-Peru FTA, with the result being that any 
medicines co-development enterprise with Peru must recognise the correlative traditional 
medicinal knowledge protections that have been created at national, regional and 
international levels, despite the original position of the US being that such protections 
should be administered through WIPO1275.  This provides an example of developing 
States utilising a regional trade bloc to further the protection of the human rights of 
indigenous peoples over their traditional medical knowledge.  
However, the International Institute for Environment and Development has 
argued that the protection of traditional knowledge has been undermined in the FTA due 
to the lack of provision to ensure that patents are not granted over traditional knowledge 
without the authorisation of the traditional knowledge holders1276.  This could lead to 
increases in the number of patents being granted over traditional knowledge without the 
consent of the rights holders.  This issue could be addressed by the inclusion of specific 
provisions in such agreements to require authorisations, to protect against the 
misappropriation of traditional knowledge of indigenous peoples.  This also indicates that 
                                                            
1273 See also S Bucher,  ‘The Protection of Genetic Resources and Indigenous Knowledge — Disclosure of 
Origin on the International and Latin-American Agenda’ (2008) 39(1) IIC 35, 47; Sem (n 1234) 38; and 
Comunidad Andina, ‘What is the Andean Community?’, 
<http://www.comunidadandina.org/Seccion.aspx?id=%20189&tipo=QU&title=somoscomunidad-
%20andina> (accessed 27/04/2020) (translated) 
1274 Sem (n 1234) 43 
1275 ibid 40 
1276 International Institute for Environment and Development, Protecting Indigenous Knowledge against 
Biopiracy in the Andes, (December 2006, IIED), 3 
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it is possible to uphold international human rights law in bilateral trade agreements, 
although the substantive realisation of this may depend on the relative political landscape 
and negotiating strengths of the respective parties.  This also highlights that issues of a 
political as well as legal nature are significant to enhancing access to medicines, and 
therefore there is a need for greater alignment when addressing issues of protecting 
traditional medicines, and the wider issue of enhancing access to medicines. 
 
(c) Conclusions from Section IV 
 
The State’s engagement with the recommendations of the UN human rights bodies 
highlights that it has taken measures to implement a rights-based approach to improving 
access to medicines for marginalised groups and indigenous peoples. There is evidence 
that the State appreciates the interaction between IP rights and human rights in relation to 
access to medicines at national level through the implementation of legislation to protect 
the rights of indigenous peoples over their traditional medicines.  However, disparities 
still exist, with challenges including resources, health infrastructure and the political 
landscape.  Therefore, consistency and coherence in policy across government 
departments is particularly important to address the wider issues impacting on access to 
medicines in relation to these groups. 
 
V. Conclusion 
 
This case study has evidenced several core issues in relation to enhancing access to 
medicines in Peru.  These issues include ensuring physical accessibility to existing 
branded and generic medicines, and ensuring available medicines of appropriate quality.  
State has implemented several measures to address key issues, including the creation of 
the Peruvian Observatory of Pharmaceutical Products to highlight pricing inequalities 
This provides an important monitoring function, although challenges exist in providing 
accountability for inequitable pricing. Developing jurisprudence on the constitutional 
right to health and access to medicines in the Constitutional Court shows the value of a 
rights-based approach in relation to access to medicines, providing an accountability 
mechanism for individuals, and an example of good practice to other states. There is 
evidence of the State engaging with the recommendations of the UN Charter bodies, and 
the relevant Treaty Monitoring Body, the CESCR, and that this engagement is translating 
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into the development of national health policies to address health issues including access 
to medicines. 
There are also specific issues relating to access for marginalised groups and 
indigenous peoples, including inequitable spending on health care and the need for 
culturally appropriate medical services.  Broader concerns also include access to 
resources, the need for adequate infrastructure, and the connection with rights of self-
determination and participation in decisions relating to health care for indigenous peoples.  
The study highlights that these factors also need to be taken into account by states when 
devising national health policy in relation to medicines.  Wider issues impacting on access 
to medicines have also emerged, including the significance of transparency and disclosure 
of data by pharmaceutical companies on pricing of medicines, and securing accountability 
of pharmaceutical companies for obstructive pricing and costs.  Potential restrictions to 
access to generic medicines as a result of TRIPS-plus terms in FTAs, as well as the 
circulation of counterfeit medicines, is a significant problem which needs to be addressed 
by the State, give the significance of generic medicines to the national health system.  
These findings also present key lessons for other states. 
It is also evident that challenges exist in relation to weaknesses in the national 
health service, the cost of public services and health insurance initiatives. This emphasises 
how national political, structural and legal factors have an impact on state actions to 
enhance access to medicines, which is crucial for states to take account of when 
implementing domestic measures to enhance access to medicines. It highlights the 
importance of coherence across national government departments when implementing 
policy which impacts upon access to medicines. However, it is important to recognise 
that the Peruvian government is making positive steps to address the key issues, which 
indicates cause for optimism in terms of the potential to further enhance access to 
medicines for all sections of the population. 
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Chapter 7: Conclusion 
 
This thesis explores whether a tension exists between the distinct regulatory frameworks 
of World Trade Law and UN Human Rights Law in relation to enhancing access to 
essential medicines.  Specifically, tension between TRIPS and the ICESCR was explored.  
TRIPS sets out a minimum standard of patent protection to be implemented nationally by 
WTO Members, and a key concern is that such patent protection can contribute to higher 
pricing of patented medicines and restrict access to generic medicines.  TRIPS also 
contains exceptions to patent protection which states can rely upon to promote public 
health.  The UN human rights bodies have produced considerable guidance on the content 
of economic, social and cultural rights, including the right to health under Article 12 
ICESCR.  This has led to the clarification of the obligations of states as well as the rights 
of individuals, including that access to medicines forms part of the right to health. Key 
factors and challenges facing states in meeting their obligations under WTO law and their 
human rights obligations were examined. Examples include inconsistent interpretation 
and implementation of IP standards at national level, TRIPS-plus standards of patent 
protection in FTAs and ensuring that the pharmaceutical companies are accountable for 
practices, including high prices, which act as a barrier to access to medicines.  This 
chapter will evaluate the outcomes of the research, raising questions relating to states’ 
policy and measures on medicines and to suggest possible actions to improve the position.  
This chapter will also discuss several factors for consideration for states to address the 
wide-ranging issues affecting access to medicines, and to comply with their international 
obligations under TRIPS and the ICESCR. 
 
I. Evaluating the outcomes of this research 
An important finding from this research is that access to essential medicines forms part 
of the right to health under Article 12 ICESCR.  The ICESCR is a legally binding treaty 
and the guidance from the UN human rights framework, in particular the CESCR, on the 
interpretation of this right is that access to essential medicines is a core part of the Article 
12 right1277.  The guidance in the form of reports of the UN human rights bodies is non-
binding but is authoritative, as there is evidence that states are engaging with the 
                                                            
1277 UNGA ‘Right of everyone to the enjoyment of the highest attainable standard of physical and mental 
health’ (16 July 2019) UN Doc A/74/174, 55 
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recommendations of the CESCR in relation to enhancing access to essential medicines as 
part of their obligations under the Article 12 right.  This research sought to address the 
question of whether patent law provisions under TRIPS could be interpreted so as to 
enhance access to medicines.  Possible tension between TRIPS and the ICESCR and the 
manner that these agreements address access to medicines could present challenges to 
states, if complying with their obligations to implement patent provisions under TRIPS 
nationally may lead to a failure to discharge their obligations under the ICESCR.  The 
discussion in Chapter 1 outlined that it is not possible to conclude that the right to health 
has primacy over trade norms in international law. A way of resolving tension between 
TRIPS and UN human rights law is by interpreting TRIPS in a manner that promotes the 
right to health, including access to essential medicines.  Public health concerns can be 
taken into account by WTO Panels and the Appellate Body, and also national courts and 
policy makers, in the interpretation of TRIPS as part of its object and purpose, under 
Articles 7 and 8. This interpretative flexibility means that TRIPS could be interpreted in 
a manner conducive to public health, such as to enhance access to essential medicines.  
Where tension exists between states’ obligations under TRIPS and the ICESCR, the 
general rule of treaty interpretation under Article 31 VCLT, in particular that any relevant 
rules of international law applicable in the relations between the parties shall be taken 
into account under Article 31(3)(c) VCLT1278, could facilitate the Article 12 right to 
health being taken into account when interpreting TRIPS. 
As discussed in Chapter 1, the WTO Appellate Body has confirmed that WTO 
agreements, and therefore TRIPS, cannot be read in isolation from international law.  
Therefore, the WTO panel or Appellate Body could take into account human rights law 
as tools for the interpretation of TRIPS, if this could be justified with reference to the 
object and purpose of TRIPS.  However, it is evident from the decisions of WTO Panels, 
such as the Canada – Patent Protection for Pharmaceuticals1279  case, that this approach 
is not being taken.  It is noted that other key provisions have been interpreted in isolation 
from Articles 7 and 8 which provide interpretive context, and speak to the object and 
purpose of TRIPS, and so greater attention from the WTO DSB is merited due to the 
potential to provide a basis for a pro-development interpretative approach to TRIPS.1280  
                                                            
1278 VCLT (n 47) Article 31(3)(c)  
1279 Canada – Patent Protection for Pharmaceutical Products, WT/DS114/R, adopted 7 April 2000 
1280 P Yu, ‘TRIPS Enforcement and Developing Countries’ (2011) 26 American University International 
Law Review 727, 768-772; D Harris, 'TRIPs after Fifteen Years: Success or Failure, as Measured by 
Compulsory Licensing' (2011) 18 J Intell Prop L 367, 382 
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Greater engagement with Articles 7 and 8 when interpreting other provisions would 
facilitate the balancing of rights under the respective international law frameworks.1281  
This is also consistent with the Doha Declaration, which stated that TRIPS should be 
interpreted and implemented in a manner supportive of WTO Members’ right to protect 
public health.1282  This interpretative approach would be important in the dispute 
settlement practice in the WTO, and should also inform the actions of national courts and 
policy makers. 
The outcomes from the case studies include that states can reconcile their 
competing obligations at national level in a manner that enhances access to essential 
medicines by taking a rights-based approach.  The UN human rights bodies have done 
much work to clarify the content of the right to health under Article 12 ICESCR as 
including access to medicines.  These bodies have also provided guidance to states as to 
how to effectively meet their human rights obligations.  The case studies in this thesis 
show that the degree of protection of the Article 12 right to health differs across states.  
This is most clearly seen in the approach of the national courts in the respective states to 
upholding human rights principles.  The national courts of Canada have taken a restrictive 
approach to upholding the right to health, whereas in Peru the more expansive approach 
of the Constitutional Court in interpreting the right to health has resulted in access to 
essential medicines for the patient in several cases.  
The value of a human rights approach by the national courts is evident in the 
Peruvian cases discussed in this thesis as it provides a measure of accountability for states 
in relation to their international human rights obligations.1283  The test applied by the 
Peruvian Constitutional Court in RJSA Vda. of R1284 when adjudicating on cases 
concerning access to essential medicines is a mechanism which provides an example of 
good practice to other states.  In this case, the Constitutional Court outlined that that the 
enforceability of a social right always depends on three factors: the seriousness and 
reasonableness of the case; its connection with other fundamental rights; and budget 
availability1285.  This test provides flexibility in terms of enforcing a social right to help 
                                                            
1281 Frankel (n 200) 22; Slade (n 200) 414 
1282 Doha Declaration (n 92) 
1283 K Perehudoff, N Alexandrov and H Hogerzeil ‘Legislating for universal access to medicines: a rights-
based cross-national comparison of UHC laws in 16 countries’ (2019) 34 Health Policy and Planning 48–
57, 48 
1284 RJSA Vda. of R. (n 1071) 
1285 ibid 23 
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patients requiring access to medicines, while also taking into account the arguments 
relating to resource constraints.  The outcome of the case was a positive one for the patient 
concerned, and highlights the importance of individuals having a course of action at 
national level to call for the state to discharge its obligations in relation to essential 
medicines. 
  A related concern is additional pressures on the national health care systems, if 
access to medicines is awarded regardless of the cost1286. Increased burdens on the health 
budgets could have detrimental impact on the provision of other health services, which 
could also undermine health equity.  Employing a test such as the one outlined by the 
Peruvian Constitutional Court above could address such concerns. Kapczynski argues 
that the national courts upholding the right to health and granting access to medicines has 
had important indirect effects, including triggering responses from other government 
departments that have improved the health care system, such as stronger price control 
measures.1287 Although this litigation does not directly address the issue of costs of 
medicines, it could be part of a solution in terms of influencing changes in government 
policy towards accessibility and affordability of medicines within a state.  This approach 
can also promote a dialogue between the courts and the government on finding solutions 
to the issue of protecting human rights and the economic factors regarding medicines1288, 
as seen in the Azanca Alheli Meza Garcia case, where the Peruvian Constitutional Court 
invited the government to consider utilising tools such as compulsory licensing.1289   
Patients in other Latin American states, including Colombia and Brazil, have been 
largely successful in litigation on access to medicines as part of the right to health, through 
an expansive interpretation of the right to health in the national constitution1290.  
Therefore, through the upholding of human rights principles by the national courts, 
                                                            
1286 O Ferraz ‘The Right to Health in the Courts of Brazil: Worsening Health Inequities?’ (2009) 11(2) 
Health and Human Rights 33, 33–34; O Ferraz ‘Moving the Debate Forward in Right to Health Litigation’ 
(2016) 18(2) Health and Human Rights 265, 265-7 
1287 A Kapczynski ‘The Right to Medicines in an Age of Neoliberalism’ 10(2) Humanity 79, 85; H Brennan, 
R Distler, M Hinman and A Rogers, ‘A Human Rights Approach to Intellectual Property and Access to 
Medicines’, Yale Law School and Yale School of Public Health Global Health Justice Partnership Policy 
Paper No. 1. (August 2013), http://dx.doi.org/10.2139/ssrn.2323144, 22 
1288 Kapczynski (n 1287) 93 
1289 Azanca Alhelí Meza García (n 1053) 40 
1290 A Kapczynski (n 1287) 80 & 83-84; J Biehl, M Socal, and J Amon ‘The Judicialization of Health and the 
Quest for State Accountability: Evidence from 1,262 Lawsuits for Access to Medicines in Southern Brazil’ 
(2016) 18(1) Health and Human Rights Journal 209, 218; D Landau, 'The Reality of Social Rights 
Enforcement' (2012) 53 Harv Int'l LJ 189, 214; M Prado, 'The Debatable Role of Courts in Brazil's Health 
Care System: Does Litigation Harm or Help' (2013) 41 JL Med & Ethics 124, 125 
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patients have been afforded access to medicines. These illustrative examples reflect the 
value of a human rights approach to enhance access to medicines, and could be a useful 
example to other states in meeting their human rights obligations in relation to the Article 
12 right to health.  Litigation on medicines in Latin American states has led to greater 
access to medicines in response to individual cases1291. Questions have been raised over 
whether the right to health litigation adequately addresses the issue of health inequity, if 
only those who can afford to litigate would benefit.1292    However, the results of a study 
of cases in Brazil showed that the poorest patients were to an extent benefiting from 
greater access to medicines in such cases.1293 Therefore, poor patients have had a measure 
of success in holding the state accountable to their medical needs, although the study was 
only conducted in one state of Brazil1294, therefore some caution should be taken in 
relation to evaluating how it reflects the position across Brazil. 
It is evident from this research that a key policy for improving affordability of 
medicines is making generic versions of essential medicines available.  The case studies, 
in particular the experience in Canada, highlights the importance of implementing 
appropriate pricing policies for generic medicines, to ensure that they are accessible for 
patients.  The experience in Peru shows that making information on prices widely 
available could have a positive impact in terms of ensuring that patients have data on the 
most affordable versions of the medicines they require. The effectiveness of such a 
measure largely depends on the quality and accuracy of such data, which may in turn 
require the cooperation and participation of pharmaceutical companies.   Also, having 
information on pricing is useful if there are alternatives to choose from. If only one 
version of the required medicine is available, then there is no choice over the price to be 
paid.   
A related issue affecting the availability and accessibility of generic medicines in 
particular, is concern over the impact of potentially ‘TRIPS-plus’ terms in FTAs.  It is 
evident from the work of the UN human rights bodies that while there is no inherent 
conflict between TRIPS and the Article 12 right to health, the agreeing of TRIPS-plus 
terms is problematic. The agreeing of higher standards of IP protection that go beyond 
TRIPS causes an imbalance in terms of states’ ability to discharge their obligations 
                                                            
1291 J Biehl, J Amon, M Socal and A Petryna ‘Between the court and the clinic: Lawsuits for medicines and 
the right to health in Brazil’ (2012) 14(1) Health and Human Rights Journal 36, 50 
1292 Kapczynski (n 1287) 80; Ferraz (n 1286) 
1293 Biehl, Amon, Socal and Petryna (n 1291) 48 
1294 ibid 38 
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simultaneously under TRIPS and the ICESCR.  A challenge is the pressure placed on 
developing states to agree such measures as a trade-off, with the US being a developed 
state which has employed such a strategy1295.  The undertaking of impact assessments on 
the effect of such terms on the right to health and access to medicines, prior to agreements 
being formalised have been proposed, and would show recognition of the states’ 
obligations under the right to health. This would require a political commitment from 
states to undertake such an assessment, and to act on the outcomes of assessments if there 
was found to be a significant adverse impact on access to medicines.  
 
II. Factors for consideration in addressing issues affecting access to medicines 
 
States could do more to achieve a balance between their obligations under TRIPS and 
their human rights obligations by making more effective use of the exceptions to patent 
protection set out in TRIPS, under Articles 30 and 31. The criticism of the Canada – 
Patent Protection for Pharmaceuticals1296  case and the interpretation of Article 30 
advanced in this thesis could provide scope for use of Article 30 to permit a generic 
pharmaceutical manufacturer to use the patented medicine before the expiry of the patent 
in order to obtain regulatory approval. The generic manufacturer could then market the 
generic copy of the medicine immediately once the patent expires.  This would prevent 
an extended term of patent protection for the patent holder, and therefore an extension of 
monopoly in the market. However, the patent holder would still retain monopoly for the 
full patent term, and so would not address the issue of monopoly pricing during this term. 
More effective use of compulsory licensing under Article 31 TRIPS could also 
form part of the solution to enhance access to essential medicines. On 11th March 2020, 
the WHO declared the 2020 Coronavirus outbreak a pandemic.1297  As part of the response 
to this global health crisis, several states including Chile, Ecuador, Germany and Canada 
have issued or proposed compulsory licenses relating to patented Covid-19 medicines, 
vaccines and other medical tools.1298  Using compulsory licensing to facilitate entry of 
                                                            
1295 J Watal, Intellectual Property Rights in the WTO and Developing Countries, (Springer Netherlands, 
2001), 24, 42 
1296 Canada – Patent Protection for Pharmaceutical Products, WT/DS114/R, adopted 7 April 2000 
1297 BBC, ‘Coronavirus confirmed as pandemic by World Health Organization’ 
<https://www.bbc.co.uk/news/world-51839944> (accessed 27/04/2020) 
1298 E ‘t Hoen ‘Covid-19 and the comeback of compulsory licensing’, 23 March 2020, Medicines Law and 
Policy <https://medicineslawandpolicy.org/2020/03/covid-19-and-the-come-back-of-compulsory-
licensing/> (accessed 27/04/2020) 
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generic competitors into the market will only be effective if the process is simple and 
user-friendly.  The amendment to TRIPS to introduce Article 31bis was intended to 
address concerns that least developed countries could not utilise the compulsory licensing 
provision under Article 31 because of the domestic use requirement.   The experience of 
Canada and Rwanda in utilising the compulsory licensing system under Article 31, and 
the difficulties in using it, was explored in Chapter 5. Criticisms included that the length 
of the process and administrative conditions required to be met obstructed use of the 
system for the purpose it was intended.1299  The experience of Canada also shows that 
there needs to be effective legal infrastructure at national level to implement the 
system.1300  Proposals for reform have been suggested, but there does not appear to be the 
political will in Canada to amend the national legislation.  
In addition, fear of trade sanctions has been highlighted in the academic literature 
as a reason developing states have not made extensive use of the system.1301  However, 
the threat of use of the system can also be a useful tool in terms of agreeing a voluntary 
licence, as this could increase developing states’ bargaining power during 
negotiations.1302  As it is the only amendment to TRIPS, having been accepted by the 
requisite number of WTO Members, encouraging use of the system should not meet 
significant criticism or challenge from states. Another concern relating to compulsory 
licensing is the potentially detrimental impact on innovation.1303 However, where there is 
a need for R&D in medicines to treat diseases prevalent in developed and developing 
countries, the incentive to innovate remains, as the primary market would be the 
developed country.1304 Where diseases are most prevalent in developing countries, there 
is already a lack of innovation in relation to medicines to treat neglected diseases. This is 
not the result of compulsory licensing1305. However, compulsory licensing would also not 
address this particular concern in relation to access to medicines to treat neglected 
diseases. A related point is that generic medicines are not free, so even if they are 
                                                            
1299 Tsai (n 307) 1090 
1300 E Ng and J Kohler, 'Finding Flaws: The Limitations of Compulsory Licensing for Improving Access to 
Medicines - An International Comparison' (2008) 16 Health LJ 143, 171-172 
1301 T Manu, 'Assessing the Potential Impact of Intellectual Property Standards in EU and US Bilateral 
Trade Agreements on Compulsory Licensing for Essential Medicines in West African States' (2015) 23 Afr 
J Int'l & Comp L 226, 229 
1302 A McBeth ‘When Nobody Comes to the Party: Why Have No States Used the WTO Scheme for 
Compulsory Licensing of Essential Medicines?‘ (2006) 3 NZYIL 69, 97; D Harris (n 1280) 395 
1303 Abbott and Reichman (n 70) 953  
1304 Reichman (n 163) 250; Lee (n 581) 234 
1305 Bagley (n 710) 2481; Manu (n 1301) 228-229 
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marketed at a lower price than the patented medicine, the lower price may not be enough 
to facilitate access if they are still unaffordable to the poor.1306  Incentives for generic 
manufacturers could be provided to generate interest, as these are also private companies 
with the objective of making a profit, including being able to renew the compulsory 
licence without going through the whole process again.1307 
Although not an exception to patent protection, states could also utilise the 
flexibility in TRIPS in relation to parallel importing of medicines.  Parallel importation 
involves the importation of a patented medicine without authorisation of the patent holder 
from a country where the patent holder has marketed the medicine at a lower price. The 
exhaustion principle operating within IP law is that the patent holder’s rights are 
exhausted once the patented product is placed on the market.1308  The product can be 
purchased from a low cost market for resale within a market where the cost of the product 
is higher, which has the effect of increasing competition and lowering of the cost of the 
pharmaceutical product in that market.  This may result in the patent holder reducing the 
cost of the product across all markets in order to compete with parallel imports. TRIPS 
provides under Article 6 that Members are free to determine their own way of addressing 
the issue of exhaustion of IP rights.1309  TRIPS does not set out standards for the 
application of the exhaustion principle and therefore Members have the flexibility of 
adopting exhaustion regimes1310 in national law for patented pharmaceuticals to achieve 
national public health needs.   
                                                            
1306 McBeth (n 1302) 92 
1307 Ng and Kohler (n 1300) 171 
1308 F Abbott ‘The TRIPS-Legality of Measures Taken to Address Public Health Crisis: Responding to USTR-
State Industry Positions  that Undermine the WTO’ in D Kennedy and J Southwick (eds) Political 
Economy of International Trade Law: Essays in Honor of Robert E. Hudec,( Cambridge University press, 
Cambridge 2002) 311; C Correa, Trade Related Aspects of Intellectual Property Rights: A Commentary on 
the TRIPS Agreement (Oxford University Press, Oxford 2007) P.108; O Owoeye, ‘Access to medicines and 
parallel trade in patented pharmaceuticals’ (2015) 37(6) EIPR 359, 360 
1309 Article 6 states that “For the purposes of dispute settlement under this Agreement, subject to the 
provisions of Articles 3 and 4 nothing in this Agreement shall be used to address the issue of the 
exhaustion of intellectual property rights.” 
1310 WIPO has summarised the type of exhaustion regimes as follows: “The concept of national 
exhaustion does not allow the IP owner to control the commercial exploitation of goods put on the 
domestic market by the IP owner or with his consent. However, the IP owner (or his authorized licensee) 
could still oppose the importation of original goods marketed abroad based on the right of importation. 
In the case of regional exhaustion, the first sale of the IP protected product by the IP owner or with his 
consent exhausts any IP rights over these given products not only domestically, but within the whole 
region, and parallel imports within the region can no longer be opposed based on the IP right. Where a 
country applies the concept of international exhaustion, the IP rights are exhausted once the product 
has been sold by the IP owner or with his consent in any part of the world.” See World Intellectual 
Property Organization, ‘International Exhaustion and Parallel Importation’ 
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A potential challenge in using this flexibility is that pressure on developing 
countries to agree provisions to negate parallel importation and exhaustion of rights has 
meant that developing countries could not take advantage of this flexibility.1311  The Doha 
Declaration explicitly stated that Members are free to establish their own exhaustion 
regimes without challenge,1312 as an attempt to clarify the flexibility for Members and to 
counteract such political pressure.  If developing countries adopt a regional exhaustion 
regime, this could help develop competition which would then help in ensuring access to 
medicines in many poor countries.1313  
These measures within TRIPS could be utilised more effectively by states, to 
discharge their obligations under TRIPS and the right to health. However, it must also be 
recognised that these measures alone will not address the challenges for states to meet 
their obligations in relation to enhancing access to medicines.  There are disparities 
among states in their capacity to address issues affecting access to medicines. This thesis 
has highlighted two key issues in relation to intellectual property law and access to 
medicines.  One issue is where intellectual property, specifically patents enable monopoly 
pricing of medicines which creates a barrier to access to affordable essential medicines.  
Another issue is where intellectual property does not act as sufficient incentive for 
innovation in medicines to treat neglected diseases which are unlikely to generate a 
significant profit for the producers. In addition to addressing prohibitive and inequitable 
costs of essential medicines, there is also a need to encourage innovation, and research 
and development in neglected diseases. The case study of Peru provides an example that 
some developing states do not have the manufacturing capacity to produce affordable 
generic medicines and rely on imports.  This presents challenges where medicines to treat 
diseases prevalent in a state do not exist.  Therefore, at intergovernmental level, for 
example through the WHO, WIPO, WTO Trilateral Cooperation on Public Health, IP and 
Trade1314, greater efforts could be made to explore ways in which research and 
development in neglected diseases could be promoted at national and international level.   
                                                            
<http://www.wipo.int/sme/en/ip_business/export/international_exhaustion.htm> (accessed 
27/04/2020) 
1311 K Balasubramanian, ‘Access to Medicines and Public Policy Safeguards under TRIPS’ in C Bellman, G 
Dutfield and R Meléndez Ortiz (eds) Trading in Knowledge: Development Perspectives on TRIPS, Trade 
and Sustainability (ICTSD, Earthscan London 2003), 140; Joseph (n 75) 242 
1312 Doha Declaration (n 92) [5d] 
1313 Owoeye (n 1308) 368 
1314 WTO ‘Trilateral cooperation on intellectual property and public health’ 
<https://www.wto.org/english/tratop_e/trips_e/who_wipo_wto_e.htm> (accessed 27/04/2020) 
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The current patent model does not operate to effectively promote innovation in 
this area, so new incentives apart from IP protection could be useful.  Incentives could 
include prize or grant systems, which reward innovators for meeting objectives to develop 
a new medicine for a specified disease.  Such schemes were recommended by the UN 
Secretary-General’s High-Level Panel on Access to Medicines, and find support in 
academic literature1315. These incentives could be useful because of the delinking of the 
cost of the medicine with the research and development costs. Promoting global health 
innovation is important in terms of securing the right to health, and initiatives that 
encourage health innovation to address the needs of developing countries could have a 
positive impact on access to medicines.  Also, global social impact funds such as the 
Global Health Investment Fund1316, which facilitates investments in innovative global 
health companies, could also be part of the solution to promoting development of new 
medicines to treat neglected diseases.  In addition to supporting innovation, funds such as 
the Fund for Global Health1317 also have a role in advocating for increased funding for 
global health. Therefore, such initiatives can also place political pressure on governments 
to meet their obligations under the right to health. As access to medicines is a global issue, 
the importance of international assistance and cooperation is increasing, and under Article 
2 ICESCR states parties have a duty to take steps to progressively realise Covenant rights, 
including through international cooperation.  Therefore, increasing recognition of states 
parties’ extraterritorial human rights obligations under the ICESCR is of growing 
importance. 
The political will to implement effective measures to address challenges in 
securing access to medicines is also a key issue, which has been identified in this research. 
Examples include the lack of appetite to amend CAMR in Canada, and the issue of 
effectively addressing challenges of resource constraints in relation to providing adequate 
health services including medicines.  This research has highlighted that minority groups, 
and indigenous peoples may have specific issues which impact on their ability to access 
                                                            
1315 United Nations Secretary-General’s High-Level Panel on Access to Medicines, final report (n 72) 59. 
See also A Kapczynski ‘Commentary: Innovation Policy for a New Era’ 37 Journal of Law, Medicine and 
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82 Chi-Kent L Rev 1519; F Suleman, M Low, S Moon and S Morgan ‘New business models for research 
and development with affordability requirements are needed to achieve fair pricing of medicines’ (2020) 
BMJ 368 doi: 10.1136/bmj.l4408 
1316 Global Health Investment Fund, ‘About’ <http://www.ghif.com/> (accessed 27/04/2020) 
1317 The Fund for Global Health, ‘About us’ <http://www.fundforglobalhealth.org/> (accessed 
27/04/2020) 
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medicines that need to be addressed.  As noted above, concerns have also been expressed 
around the use of FTAs to agree TRIPS-plus standards of IP protection, and international 
political pressure on developing states not to use the flexibilities within TRIPS.  These 
are a range of complex issues which require robust government policy to effectively 
address the multifaceted challenges presented.  There is a need to ensure that the policies 
of one government department do not adversely affect the policies of another government 
department in relation to medicines.  Therefore, there is a need for consistency between 
government departments and policy in relation to commitments to enhance access to 
medicines.  
It is the responsibility of states to comply with their respective obligations under 
TRIPS and the ICESCR to enhance access to medicines. However, the challenge of 
overcoming the impact of the private pharmaceutical companies on medicines pricing and 
research and development costs is a key issue emanating from this research.  The UN 
human rights bodies have also recognised this issue, and the UN Guiding Principles on 
business and Human Rights, adopted by the Human Rights Council1318, is an important 
development in setting out the human rights responsibilities of private companies, in 
addition to the obligations of states.  The Guiding Principles have gained support from 
states, as discussed in Chapter 3, which reflects that there is a commitment at the 
international and national level to address actions of businesses that infringe human 
rights.  The responsibility of states to implement regulatory regimes for businesses where 
human rights concerns arise, and therefore to regulate pharmaceutical companies, 
recognising their responsibilities in relation to the right to health, should be promoted1319. 
Intellectual property serves social objectives and is not an end in itself, so ensuring access 
for all to the benefits of scientific progress is in line with Article 15 ICESCR.  Therefore, 
a rights-based approach could help to achieve a more even balance between commercial 
interests and public health objectives. 
Patients being unable to obtain essential medicines due to cost and lack of 
availability is a global problem.  This research makes a contribution to the academic 
literature by elaborating on the content of the right to health, and access to medicines as 
a legally binding norm that flows from the right to health.  This research contributes to 
                                                            
1318 UNHRC Res 17/4 (6 July 2011) UN Doc A/RES/17/4 
1319 J Ruggie ‘The construction of the UN "protect, respect and remedy" framework for business and 
human rights: the true confessions of a principled pragmatist’ (2011) 2 EHRLR 127; E Oke ‘Defining the 
right to health responsibilities of patent-owning pharmaceutical companies’(2019) 1 IPQ 43 
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the academic debate on how TRIPS could be interpreted and implemented more 
effectively to enhance access to medicines, for states to discharge their obligations under 
TRIPS and their human rights obligations under the ICESCR. The research also adds to 
the academic discussion of how UN human rights bodies have elaborated on the scope of 
states parties’ obligations and evaluates the guidance from UN human rights bodies on 
how states can meet their human rights obligations in relation to medicines.  The research 
also contributes to the developing discourse on the key features of the right to benefit 
from scientific progress and how this right could support enhancing access to medicines.  
The case studies fill gaps in the literature on how states might reconcile their obligations 
under TRIPS and the ICESCR by addressing the issue from an international and national 
viewpoint, exploring the challenges faced by states in meeting their obligations under 
TRIPS and the ICESCR respectively.  The studies also fill gaps in the literature in relation 
to how the complexities around enhancing access to medicines impact upon marginalised 
groups, which need to form part of the discourse on enhancing access to medicines for 
everyone, and make proposals as to how states may resolve tensions between their 
respective obligations under TRIPS and the ICESCR at national level.  This chapter also 
outlines considerations to help inform initiatives at the national level and at the 
intergovernmental or international level to promote effective access to medicines, for the 
benefit of patients across all states. 
This global concern is continuing to receive growing attention, particularly from 
UN human rights bodies, with the convening of the UN Secretary-General’s High-Level 
Panel on Access to Medicines being a key example.  This concern is likely to be magnified 
when a medicine is found to treat Covid-19.  Knowledge of the issues affecting access to 
medicines is continuing to evolve.  States have committed to the rights set out in TRIPS 
and the ICESCR and they have to meet their respective legal obligations under these 
international agreements.  The primary responsibility to enhance access to medicines lies 
with states, but international cooperation and the regulation of pharmaceutical companies 
is also crucial, to prevent people from dying from treatable diseases due to lack of access 
to medicines.  A rights-based approach can ensure a more balanced outcome so that the 
rights of individuals are promoted, protected and fulfilled. 
 
 
 
